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Abstract
In 2013, EFSA published a literature review on epidemiological studies linking exposure to pesticides and
human health outcome. As a follow up, the EFSA Panel on Plant Protection Products and their residues
(PPR Panel) was requested to investigate the plausible involvement of pesticide exposure as a risk factor
for Parkinson’s disease (PD) and childhood leukaemia (CHL). A systematic literature review on PD and
CHL and mode of actions for pesticides was published by EFSA in 2016 and used as background
documentation. The Panel used the Adverse Outcome Pathway (AOP) conceptual framework to deﬁne
the biological plausibility in relation to epidemiological studies by means of identiﬁcation of speciﬁc
symptoms of the diseases as AO. The AOP combines multiple information and provides knowledge of
biological pathways, highlights species differences and similarities, identiﬁes research needs and
supports regulatory decisions. In this context, the AOP approach could help in organising the available
experimental knowledge to assess biological plausibility by describing the link between a molecular
initiating event (MIE) and the AO through a series of biologically plausible and essential key events (KEs).
As the AOP is chemically agnostic, tool chemical compounds were selected to empirically support the
response and temporal concordance of the key event relationships (KERs). Three qualitative and one
putative AOP were developed by the Panel using the results obtained. The Panel supports the use of the
AOP framework to scientiﬁcally and transparently explore the biological plausibility of the association
between pesticide exposure and human health outcomes, identify data gaps, deﬁne a tailored testing
strategy and suggests an AOP’s informed Integrated Approach for Testing and Assessment (IATA).
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Summary
The European Food Safety Authority (EFSA) asked the Panel on Plant Protection Products and their
Residues (PPR Panel) to develop a Scientiﬁc Opinion investigating experimental toxicological properties of
plant protection products having a potential link to Parkinson’s disease (PD) and childhood leukaemia
(CHL).
Following a signiﬁcant association between pesticide exposure, PD and CHL as reported in an external
scientiﬁc report of EFSA (Ntzani et al., 2013), the PPR Panel analysed the involvement of pesticides
exposure as a risk factor in the pathogenesis of these two diseases. This task is required due to the
intrinsic weakness of epidemiological studies that do not allow ﬁrm conclusions on causal relationships,
but still raise a concern and open a question on suitability of regulatory studies to inform on speciﬁc and
complex human health outcomes.
In addition to epidemiological studies, experimental data, although performed at toxicologically
relevant doses, have also provided evidence for neurotoxic effects and biologically plausible
mechanisms linking pesticides to PD. Scarce experimental and mechanistic evidence, however, also
supports the association between pesticide exposure and paediatric leukaemia.
The deﬁnition of biological plausibility in relation to epidemiological studies, if any, was achieved by
organising and analysing systematic literature reviews, diseases knowledge and the available
experimental data of tool compounds in the Adverse Outcome Pathway (AOP) conceptual framework
according to the OECD criteria (OECD 2013, 2014).
An AOP describes the chain of events leading from the ﬁrst interaction of any chemical with a
target (molecular initiating event (MIE)) to an adverse outcome (AO), generally an apical endpoint in
accepted regulatory toxicity testing. As such, AOPs are not chemical speciﬁc and will not be used to
speciﬁcally address the issue of linking exposure to a pesticide found to be associated to PD or
paediatric leukaemia in epidemiological studies. Rather, the AOP framework will assess the mechanistic
plausibility – if any – that pesticides pose a hazard contributing to the pathogenesis of PD or paediatric
leukaemia (i.e. CHL and infant leukaemia (IFL)) and therefore represent potential risk factors.
According to the OECD guidelines, MIE and AO are sequentially linked by a series of biologically
plausible and essential key events (KEs) and their relationship (key event relationships (KERs)) should
be concordant on dose–response, temporality and incidence. The availability and robustness of
quantitative experimental data classiﬁes the strength, in a codiﬁed assembly of weight of evidence, of
the developed AOP. Putative AOPs are based on a hypothesised sequence of KE and KERs supported
by biological plausibility and/or statistical inference; qualitative AOPs include assembly and evaluation
of the supporting weight of evidence; quantitative AOPs are supported by quantitative relationships
and/or computational models that allow quantitative translation of key event measurements into
predicted probability or severity of AO.
The Panel adopted the AOP framework to assess biological plausibility of epidemiological studies
(i.e. that a plausible mechanism exists linking the cause to the effect). The starting point was the
identiﬁcation of a sequence of events able to (i) link a MIE to an AO, in this case, a relevant complex
disease through a series of key events and (ii) describe the KER on the basis of biological plausibility,
essentiality and empirical support. It should be noted that biological plausibility in the context of KERs
is deﬁned by an established question (i.e. is there a mechanistic relation between KEup and KEdown
consistent with established biological knowledge?). The most relevant requisite was to identify a
deﬁned symptom for each disease equivalent to an AO for toxicants, reproducible in animal models,
and possibly associable to a deﬁned and measurable regulatory apical endpoint also triggered by
chemicals in the regulatory or investigative studies. For PD, the application of the above rationale led
to the identiﬁcation of parkinsonian motor symptoms, i.e. the typical motor deﬁcit observed in humans
and in experimental conditions, associated with a decrease in number of dopaminergic neurons as a
representative AO.
The empirical support for KER was provided by tool compounds (i.e. chemical stressors), which
were selected from the literature:
1) 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a street drug contaminant, supported by
human poisoning data, as well as experimental animal data.
2) The piscicide/insecticide rotenone, supported by epidemiological and experimental animal data
and a well characterised molecular target; the mitochondrial complex I for which human
evidence of the involvement in PD exists.
3) The herbicide paraquat, supported by epidemiological studies and for which experimental data
exist.
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In line with the selected AO and chemicals and based on the literature retrieved, two qualitative AOPs
relevant for PD were built. Two MIEs, binding to mitochondrial complex I and initiation by a chemical of a
redox cycling process, were deﬁned. Those MIEs lead to parkinsonian motor deﬁcit converging in a
sequence of consequent KEs (summarised as mitochondrial dysfunction, impaired proteostasis and
degeneration of dopaminergic neurons of the nigrostriatal pathway). Through a detailed analysis of the
KERs, the strength of association was judged by a weight of evidence approach based on modiﬁed
Bradford–Hill criteria (i.e. based on biological plausibility, essentiality and empirical support of linkage,
quantitative understanding of the linkage, evidence supporting taxonomic applicability and evaluation of
uncertainties and inconsistencies). The overall weight of evidence indicates a strong link between the
identiﬁed MIEs and the AO, i.e. parkinsonian motor symptoms.
For CHL, the Panel adopted the same rationale as used for PD, supported both by a systematic
literature review commissioned by EFSA (EN-955, 2016) and expert knowledge. In this case, it became
apparent that the term ‘childhood leukaemia’ used in epidemiological studies is general and does not
distinguish between infant and childhood leukaemia or other forms of paediatric leukaemia. Although
both diseases share in utero exposure to relevant environmental risk factors for the development of
the disease, they display distinct pathological pathways. Furthermore, while for CHL, the Panel was not
able to identify tool chemicals that were able to induce the disease in the experimental models, for IFL
enough evidence supported the applicability of the anticancer drug etoposide as a tool. Symptoms and
signs of overt paediatric leukaemia were chosen as AO, although the disease as such is not an apical
endpoint in the regulatory toxicity studies. Taking into account the above limitations, it has been
considered scientiﬁcally acceptable to develop a qualitative AOP relevant for IFL and to design only a
putative AOP for CHL. The development of these two different AOPs, also in comparison to AOPs
relevant for PD, allowed evaluating the ﬂexibility of such an approach. In line with the selected AO and
the prototype chemical etoposide for IFL, a MIE ‘in utero topoisomerase II poisoning’ was deﬁned. It
was linked to the selected AO through a single KE summarised as ‘in utero MLL chromosomal
rearrangement’. The overall weight of evidence suggests that the link between the MIE and the AO is
strong and that the proposed events can be used to explore the IFL-triggering hazard of chemicals. As
stated, the AOP developed for CHL is based on weaker biological plausibility. However, a hypothetical
biological plausibility could exist but cannot be convincingly formulated with the currently available
circumstantial information. Although epidemiological observations suggest that the association of the
disease to in utero exposure to pesticides, complexities in deﬁning a deﬁnite MIE and involvement of
modulating factors as well as limitations in the standard design of regulatory studies for the
exploration of tumour-related endpoints following in utero exposure prevent building a convincing
qualitative AOP. In addition, the Panel recognises that an animal model recapitulating the disease is
not available and this is also weakening the assessment.
Based on the results obtained, the Panel supports the use of the AOP framework to scientiﬁcally
and transparently explore the biological plausibility of the epidemiological association between
pesticide exposures and human health outcomes. Moreover, pesticides triggering the MIEs of the
proposed AOPs should be considered as potential risk factors with respect to the development of
analysed diseases, considering the power of the AOP framework, at its best, to provide quantitative
knowledge of biological pathways leading to an AO on a weight of evidence basis.
The Panel also identiﬁed a number of uncertainties regarding the three major areas explored during
the development of this Scientiﬁc Opinion, i.e. epidemiological studies, experimental studies and AOP
development.
Although the AOPs developed in the present Scientiﬁc Opinion only explain a small fraction of the
supposed interactions of pesticides, PD and paediatric leukaemia risk, the Panel considered
the outcome of this approach promising. Thus, a multitude of AOPs might be developed to investigate
the potential link of various pesticides to the different symptoms of the considered diseases. Beside
this very relevant point, the AOP framework also represents a suitable scaffold to help identifying data
gaps by analysing the weight of evidence for each KER within the deﬁned AOPs. In addition, by
suggesting and providing quantitative and measurable markers for critical biological events leading to
the development of an AO, the AOP framework may help in the revision of regulatory studies
underlining any limitation in the appropriate identiﬁcation of effects and mode of actions relevant to
complex human diseases, PD and paediatric leukaemia in the speciﬁc investigated case.
Summarising, the application of an AOP represents a transparent and weighted approach to deﬁne
and map the causal linkages between key biological processes (MIE and KEs) to an AO that represents
an apical endpoint in accepted regulatory toxicity testing. The design of an AOP, according to the
OECD guidelines, identiﬁes data gaps and provides information on the best approach to be adopted to
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investigate a deﬁned toxicity pathway (representative of a relevant pathway of complex human
diseases). This helps in identifying data gaps and in tailoring a tiered testing strategies for hazard
identiﬁcation and characterisation. When quantitative, an AOP would deﬁne a threshold able to trigger
the sequence of KEs from the MIE to the AO. Because the AOP process as such is ‘chemically agnostic’,
it provides indication of the biological plausibility of a hazard.
Based on these considerations, the contribution of the AOP concept has been evaluated by
designing a strategy based on the two AOPs relevant for PD due to their strong weight of evidence
and the richness of experimental data. In assessment of risk, the AOP framework cannot be used as a
stand-alone procedure but should inform an Integrated Approach for Testing and Assessment (IATA)
scheme, integrating the chemical speciﬁc toxicokinetic properties. This will enhance conﬁdence that
the threshold of activation linking the MIE to the AO indeed triggers the cascade and by this way
supports the regulatory process.
PPPs, Parkinson’s disease and childhood leukaemia
www.efsa.europa.eu/efsajournal 5 EFSA Journal 2017;15(3):4691
Table of contents
Abstract................................................................................................................................................. 1
Summary............................................................................................................................................... 3
1. Introduction............................................................................................................................... 8
1.1. Background and Terms of Reference as provided by EFSA............................................................. 8
1.2. Terms of Reference .................................................................................................................... 8
1.3. Interpretation of the Terms of Reference...................................................................................... 9
1.4. Additional information................................................................................................................. 10
1.4.1. Data requirements for pesticide approval in regard to neurotoxicity ............................................... 10
1.4.1.1. Triggers for neurotoxicity testing ................................................................................................. 11
1.4.1.2. Test guidelines – what do they cover ........................................................................................... 12
1.4.2. Epidemiological studies linking pesticide exposure with Parkinson’s disease and Parkinsonism .......... 17
1.4.3. Data requirements in the pesticide regulations for the exploration of carcinogenicity and haematological
endpoints ..................................................................................................................................... 19
1.4.3.1. Genotoxicity testing .................................................................................................................... 19
1.4.3.2. Long-term toxicity and carcinogenicity testing .............................................................................. 23
1.4.3.3. Haematological endpoints ........................................................................................................... 23
1.4.3.4. Previous data requirements under Directive 91/414/EEC concerning the placing of plant protection
products on the market.............................................................................................................. 27
1.4.4. Epidemiological studies linking pesticide exposure with childhood leukaemia ................................... 27
1.4.5. The Adverse Outcome Pathway (AOP) framework as a conceptual tool to support the biological
plausibility of epidemiology studies .......................................................................................... 29
2. Introduction to Parkinson’s disease, parkinsonian disorders and application of the AOP conceptual
framework ............................................................................................................................ 31
3. Plausibility of the involvement of pesticide exposure as a risk factor for Parkinson’s disease and
contribution of the AOP concept to support plausibility ........................................................... 33
3.1. Biological plausibility in support of pesticide-associated Parkinson’s disease..................................... 33
3.2. To what extent do experimental toxicity studies on mechanisms of toxicity cover mechanisms relevant
for PD, and what is the contribution of the AOP in supporting biological plausibility ............................ 35
3.2.1. Rationale of the working approach 40.......................................................................................... 35
3.2.2. Capturing of a complex disease (PD) by AOP................................................................................ 36
3.2.3. Selection of the AO .................................................................................................................... 36
3.2.4. Choice of example AOP relevant both for parkinsonian motor symptoms and for pesticides as risk
factors....................................................................................................................................... 36
3.2.5. Use of tool chemicals to determine whether their mechanism of action overlaps with AOP for PD..... 37
3.2.6. Evaluation of the AOP concerning consistency and strength of evidence ......................................... 37
3.2.7. Support of mechanistic plausibility by AOP ................................................................................... 38
3.2.8. Conclusions from AOPs on suitability of current testing methods .................................................... 38
3.3. AOPs as informative sources for appropriate identiﬁcation of data gaps and testing strategy............ 39
3.3.1. AOP as a scaffold to help identifying data gaps............................................................................. 39
3.3.2. Present data gaps in regulatory studies........................................................................................ 40
4. Introduction to childhood leukaemia ............................................................................................ 42
5. Plausibility of the involvement of pesticide exposure as a risk factor for infant and childhood
leukaemia and contribution of the AOP concept to support plausibility ................................ 43
5.1. Biological plausibility in support of pesticide-associated IFL and CHL .............................................. 43
5.2. To what extent do experimental toxicity studies on mechanisms of toxicity cover mechanisms relevant
for IFL and CHL, and what is the contribution of the AOP in supporting biological plausibility ..............
47
5.2.1. Rationale of the working approach .............................................................................................. 47
5.2.2. Capturing complex diseases (IFL and CHL) by AOP ....................................................................... 47
5.2.3. Selection of the AO .................................................................................................................... 48
5.2.4. Choice of example AOP relevant both for IFL/CHL and for pesticides as risk factors (see Appendix B) .. 48
5.2.5. Use of tool chemicals to check whether their mechanism of action overlaps with AOP for IFL and CHL . 48
5.2.6. Evaluation of the AOP concerning consistency and strength of evidence ......................................... 49
5.2.7. Support of hazard plausibility by AOP........................................................................................... 49
5.3. Data gaps and suggestion for testing strategy. Also include the AOP as informative source for
appropriate identiﬁcation of data gaps and testing strategy................................................... 50
5.3.1. AOP as a scaffold to help identifying data gaps............................................................................. 50
5.3.2. Conclusions from AOP on suitability of current testing methods and present data gaps in regulatory
studies ...................................................................................................................................... 51
5.3.3. Consideration on testing strategy ................................................................................................ 53
PPPs, Parkinson’s disease and childhood leukaemia
www.efsa.europa.eu/efsajournal 6 EFSA Journal 2017;15(3):4691
6. Application of the AOP concept to support the regulatory process; using parkinsonian motor deﬁcits
as an example ........................................................................................................................... 53
6.1. Which types of data are needed to predict risk of parkinsonian motor deﬁcits applying an AOP-
informed IATA ..................................................................................................................... 54
7. Uncertainties.............................................................................................................................. 56
8. Discussion and conclusions ......................................................................................................... 58
9. Recommendations ...................................................................................................................... 62
References............................................................................................................................................. 64
Abbreviations ......................................................................................................................................... 70
Appendix A – AOP developed for parkinsonian motor deﬁcit ...................................................................... 72
Appendix B – AOPs developed for Infant Leukaemia and Childhood Leukaemia ........................................... 274
PPPs, Parkinson’s disease and childhood leukaemia
www.efsa.europa.eu/efsajournal 7 EFSA Journal 2017;15(3):4691
1. Introduction
1.1. Background and Terms of Reference as provided by EFSA
According to Regulation (EC) No 1107/2009 on placing of plant protection products on the market,
applicants submitting dossiers for approval of active substances shall provide ‘scientiﬁc peer-reviewed
open literature [. . .] on the active substance and its relevant metabolites dealing with side-effects on
health [. . .] and published within the last ten years before the date of submission of the dossier’. This
should include epidemiological studies, as explicitly listed in Commission Regulation 283/2013 setting
out the data requirements for active substances.
In 2013, EFSA published an external scientiﬁc report carried out by the University of Ioannina Medical
School in Greece on a literature review linking exposure to pesticides and human health effects based on
a systematic review of epidemiological studies published between 2006 and 2012 (Ntzani et al., 2013,
EFSA 2013:EN-497). This report summarises the association between pesticide exposure (assessed by
different methods) and 23 major categories of human health outcomes. A statistically signiﬁcant
association was observed through ﬁxed and random effect meta-analyses between pesticide exposure
and the following health outcomes: liver cancer, breast cancer, stomach cancer, amyotrophic lateral
sclerosis, asthma, type II diabetes, childhood leukaemia (CHL) and Parkinson’s disease (PD). The results
from the meta-analysis of the two latter health outcomes were supported by similar ﬁndings in
previously and subsequent published studies (additional information Sections 1.4.2 and 1.4.4).
Despite the large volume of available research data and the large number (> 6,000) of analyses,
ﬁrm conclusions could not be drawn for the majority of the outcomes studied. This observation is in
line with previous studies on environmental epidemiology and in particular on pesticides which all
acknowledge that such epidemiological studies generally suffer from many methodological limitations
and large heterogeneities in their conduct. Also, due to the generic terms used for the pesticides
assessed in the epidemiological studies, no information could be retrieved on speciﬁc pesticides.
In addition, the involvement of pesticide exposure in relation to the aetiology of most of the health
outcomes reported by Ntzani et al. (2013) is unknown, and is likely to be inﬂuenced by environmental,
lifestyle and genetic factors, which may add to the complexity of the interpretation of both
epidemiological and experimental data. Consequently, the use of epidemiological studies and their
integration in regulatory risk assessment represents a major challenge for scientists, risk assessors and
risk managers and the impact of these studies in regulatory risk assessment is still limited.
Nevertheless, the ﬁndings observed in the Ntanzi et al., report raise the question on whether the
available experimental data and information on mechanisms of toxicity of pesticides can support these
observations and if the regulatory risk assessment carried out to authorise the placing of plant
protection products on the market covers the hazard assessment of pesticides with regard to these
diseases.
The evaluation of the methodological limitations identiﬁed in epidemiological studies included in the
Ntanzi et al., report (2013) is outside the scope of the mandate and will be addressed in a follow-up
mandate.
1.2. Terms of Reference
The PPR Panel is requested to prepare a Scientiﬁc Opinion investigating experimental toxicological
properties of plant protection products having a potential link to PD and CHL based on the ﬁndings in
the Ntanzi et al., report (2013). This opinion will:
• Review the available data in the open literature and in regulatory toxicological data of pesticide
active substances for which a potential link with a Mode of Action (MoA) relevant for the PD
and CHL is known to exist to:
– develop a prototype to assess the risk factor using the principles established for adverse
outcome pathways (OECD, 2013);
– analyse the plausible involvement of pesticide exposure as a risk factor for the
development of PD and CHL;
– evaluate if, how and to what extent the experimental toxicity studies on mechanisms of
toxicity cover effects and modes of action that are relevant to Parkinson’s disease and
childhood leukaemia and are in line with the adverse outcome pathways.
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• Make recommendations to address the remaining data gaps for assessing the link between
pesticide exposure and PD and CHL, and potential weaknesses in the current regulatory
dossiers in supporting the hazard assessment of pesticides with regard to these diseases.
1.3. Interpretation of the Terms of Reference
In the Terms of Reference, EFSA has requested a Scientiﬁc Opinion on investigating experimental
toxicological properties of plant protection products having a potential link to PD and CHL. The terms of
reference further elaborates that the European Food Safety Authority (EFSA) asked the Panel on Plant
Protection Products and their Residues (PPR Panel) should develop Adverse Outcome Pathways (AOP)’s
for these two diseases on the basis of a systematic literature review and the available toxicological data
of pesticide active substances. The PPR Panel is indeed aware that the associations found between
pesticide exposure and PD or CHL could be partly due to bias or confounding; also the potential role
of pesticides has to be put in context with other risk factors. In the meantime, the Panel wishes to
stress that a prominent goal of this opinion is exactly to explore whether the building of AOPs is able to
throw light on the biological plausibility underlying the epidemiologically observed associations. The
Panel believes that this approach would be beneﬁcial, particularly in pointing out which kind of further
studies would be needed to either support or disproof the plausibility of the epidemiological observations.
The AOP framework facilitates functional understanding of complex biological systems and the
pathways of toxicity that results in adverse outcomes (AO). The AOP has a broader scope than the WHO
International Programme of Chemical Safety (IPCS) MoA concept, which illustrates how to organise and
apply mechanistic information on chemical’s MoA to understand human relevance of animal data (Meek
et al., 2014). In this perspective, the MoA is chemical speciﬁc while the AOP is not.
The methodology provides a framework to collect and evaluate relevant chemical, biological and
toxicological information in such a way that it is useful for risk assessment (OECD, 2013). The OECD
has incorporated the IPCS framework on MoA in its guidance document on developing and assessing
AOPs (Handbook series no. 184) in order to evaluate the biological plausibility of the relationships
between the identiﬁed key events. These key events must be experimentally measurable and causally
linked to the AO, which is usually associated with the ﬁndings of experiments based on in vivo OECD
test guidelines. The AOP identiﬁed must not contradict any steps of normal biological processes since
they need to be biologically plausible.
The human relevance of the MoA framework has been applied in a number of speciﬁc case studies
on compounds with a focus on quantitative time– and dose–response relationships. Modiﬁed Bradford–
Hill’s criteria for a causal relationship in epidemiological studies are also applied to the AOP concept as
a critical foundation for overall weight of evidence (WoE) evaluation. Therefore, if data are available,
the causative link between the identiﬁed molecular initiating event (MIE), intermediate key events and
ﬁnal adverse outcome should be described in a quantitative manner, thus increasing the conﬁdence for
use in the regulatory context.
For the scope of this scientiﬁc opinion, any AOP (e.g. putative, qualitative and/or quantitative) will
be useful for hazard identiﬁcation or priority setting for further testing and development. The
Panel understands that the ToR does not encompass full risk assessment (i.e. exposure assessment) of
pesticides potentially involved in the diseases. Thus, the opinion will neither address speciﬁc exposures
to pesticides found to be associated with PD and CHL in epidemiological studies, nor consider exposure
scenarios of speciﬁc active substance and their uses as speciﬁed in dossiers submitted for the
European Union (EU) approval and the subsequent evaluation.
The ToR, instead, addresses the potential uses of the AOP concept in the regulatory risk assessment
including the deﬁnition of biological plausibility in relation to the epidemiological studies i.e. that a
plausible mechanism between a cause and an effect exists. The mandate is intended to support the
future hazard assessment of pesticides; thus, the AOP conceptual framework will describe the identiﬁed
MIE and its relationship with intermediate key events leading to a deﬁned AO using a WoE approach
based on so called ‘modiﬁed Bradford–Hill criteria’. For the empirical support, the panel will use data
obtained from experimental studies of tool chemicals to establish response–response, temporality and
incidence concordance within the AOP scheme. The mandate will also analyse to what extent the
available experimental toxicity studies cover the identiﬁed pathways of toxicity that are relevant for
the development of the two diseases. Furthermore, the potential gaps of knowledge and uncertainties in
the current pesticide data requirements and dossiers will be identiﬁed.
By making its evaluation, the Panel realised that the health outcomes from the epidemiological
studies did not distinguish between parkinsonian disorders and PD, and between CHL and infant
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leukaemia (IFL). Conversely, the Panel addressed more speciﬁc health outcome in line with the AOP
conceptual framework, i.e. parkinsonian motor deﬁcit, CHL and IFL.
In the context of this Scientiﬁc Opinion, the Panel made, where possible, a tentative quantitative
insight, by estimating the concentration at the target site able to trigger the sequence of events up to
the AO.
In conclusion, according to the ToR, the opinion will:
1) analyse the plausible involvement of pesticide exposure as a risk factor for the development of
PD, childhood and infant leukaemia on the basis of AOPs for these diseases;
2) use the AOP as guidance to evaluate, if the experimental toxicity studies on mechanisms of
toxicity cover effects and modes of action relevant to PD and childhood/infant leukaemia;
3) develop a prototype approach to assess pesticides as risk factors for complex diseases using
the principles (OECD, 2013) established for adverse outcome pathways.
1.4. Additional information
This chapter is intended to inform the reader on:
• data requirements for pesticide approval in regard to the hazards associated with neurotoxicity,
carcinogenicity and haematology as they are expected to include apical endpoints relevant for
the diseases considered in this opinion;
• a summary of the epidemiological information linking exposure to pesticides and the diseases
considered in this opinion;
• an introduction to the AOP conceptual framework.
1.4.1. Data requirements for pesticide approval in regard to neurotoxicity
Previous data requirements under Directive 91/414/EEC concerning the placing of plant protection
products on the market:
Under Directive 91/414/EEC, in order to apply for the inclusion of an active substance in Annex I, a
dossier satisfying the requirements of Annex II has to be submitted.
The toxicological and metabolism requirements, listed in point 5 of the Annex II of the Directive
should permit a decision as to whether, or not, the active substance could be included in Annex I, to
specify appropriate conditions or restrictions of use, to classify the active substance as to hazard, to
establish relevant reference values as regards human health to perform risk assessment for man and
to identify relevant ﬁrst aid measures.
In routine required toxicological studies (acute toxicity studies point 5.2, short-term toxicity studies
point 5.3, long-term toxicity and carcinogenicity studies point 5.5, and reproductive toxicity studies
point 5.6), all potentially adverse effects found should be investigated and reported including
neurotoxicity. In cases where speciﬁc effects (e.g. neurotoxic effects) are identiﬁed, additional
studies may be carried out in order to establish a no observed adverse effect level (NOAEL), to assess
the signiﬁcance of these effects and to investigate the probable MoA.
• The need for such supplementary studies on the active substance (as indicated in point 5.8.2
of Annex II) must be made on a case-by-case basis, taking into account the results of the
available toxicological and metabolism studies and the most important exposure routes.
• A speciﬁc data requirement is dedicated to delayed neurotoxicity (point 5.7). The test
submitted should conclude whether the active substance induces delayed neurotoxicity after
acute exposure. Such a test is mandatory for substances of similar or related structures to
organophosphates.
Current data requirements under REGULATION (EC) No 1107/2009 concerning the placing of plant
protection products on the market and repealing Directives 79/117/EEC and 91/414/EEC:
REGULATION (EC) No 1107/2009 came into force on 14 December 2009 and applied from 14 June
2011 replacing Directive 91/414/EEC.
Under REGULATION (EC) No 1107/2009, an active substance is approved at EU level, following
assessment against a set of agreed criteria. Those criteria not only cover both the risks arising from
the use of plant protection products which contain it as it was already the case under Directive
91/4141/EEC, but also the intrinsic properties of the active substance (i.e. an assessment of its
hazard).
PPPs, Parkinson’s disease and childhood leukaemia
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Indeed different categories of active substances are deﬁned in REGULATION (EC) No 1107/2009
(active substances candidate for substitution, low risk active substances, basic substances) based on
their hazard which impact the conditions of their approval.
Neurotoxicity among other criteria is taken into account to categorise active substances. In this
way, an active substance:
• shall not be considered of low risk or as basic substance where it has neurotoxic effects (article
22 and 23);
• shall be approved as a candidate for substitution, if there are reasons for concern linked to
developmental neurotoxic effects (article 24).
For approval of pesticides under REGULATION (EC) No 1107/2009, the data requirements are set
out in Regulation (EU) No 283/2013 (replacing Annex II of Directive 91/414/EEC).
As was already the case under Directive 91/414/EEC, potential neurotoxic effects shall be carefully
addressed and reported in routine required toxicological studies (acute toxicity studies point 5.2, short-
term toxicity studies point 5.3, long-term toxicity and carcinogenicity studies point 5.5, and
reproductive toxicity studies point 5.6).
Compared to Directive 91/414/EEC, neurotoxicity requirements have been given more importance,
the main differences are:
• In point 5.6.2 dedicated to developmental toxicity requirements, it is mentioned that
information on developmental neurotoxicity may be required when such effects are indicated
by observation in other studies or suspected based on the MoA of the active substance.
• Point 5.7 is not only restricted to delayed neurotoxicity requirements but also includes both
neurotoxicity in rodents (point 7.1) and delayed polyneuropathy studies (point 5.7.2).
Regarding neurotoxicity in rodents, inclusion of neurotoxicity investigations in routine toxicology
studies shall also be considered.
1.4.1.1. Triggers for neurotoxicity testing
The circumstances in which neurotoxicity studies should be performed are listed in Regulation (EU)
No 283/2013.
• Speciﬁc neurotoxicity studies in rodents (point 7.1) shall be performed in case of one of the
following conditions:
– there is indication of neurotoxicity in routine toxicity studies carried out with the active
substance;
– the active substance is a structurally related to known neurotoxic compound;
– the active substance has a neurotoxic mode of pesticidal action.
• Delayed neurotoxicity studies shall be performed for active substances with similar or related
structures to compounds capable of inducing delayed polyneuropathy such as
organophosphates.
• Developmental neurotoxicity study may be performed when indication of such effects have
been triggered in previous toxicity studies.
As a result, while neurotoxicity screening is part of the requirements in current guidelines of
standard toxicity studies (OECD 407, 408 and optionally in OECD 452 see Table 1), speciﬁc
neurotoxicity studies are not routinely required for all pesticide active substances.
Triggers to perform those tests are well deﬁned for acetylcholine esterase inhibitors for which
delayed neurotoxicity studies are systematically carried out and pesticides with neurotoxic mode of
pesticidal action for which at least acute neurotoxicity study in rodent has to be performed.
In other cases, speciﬁc neurotoxicity testing becomes obligatory only if neurotoxicity has been
observed during organ toxicity testing or in case of structural analogy with a known neurotoxic
compound. However, clear and consistent criteria to trigger submission of such data are still lacking
and ‘routine’ required in vivo toxicity studies may be not sensitive enough to alert on potential
neurotoxicity.
The development of a neurotoxicity testing strategy including robust and reliable in vitro assays
along with other alternative methods could be of value, as also raised as one of the main conclusions
and recommendations in the EFSA opinion on acetamiprid and imidacloprid (EFSA, 2013).
Furthermore, understanding of toxicity mechanisms is given an increasing importance in risk
PPPs, Parkinson’s disease and childhood leukaemia
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assessment and therefore alternative methods including in vitro assays could also provide useful
information on toxicity mechanisms involved.
1.4.1.2. Test guidelines – what do they cover
In the EU, pesticides neurotoxicity testing for regulatory purposes is based on in vivo animal test
methods. The Commission Communication provides the list of test methods and guidance documents
relevant to the implementation of Regulation (EU) No 283/2013.
In the table below, the test guidelines not only for neurotoxicity testing but also for organ toxicity
testing that can highlight neurotoxic effects are summarised (including principle of the assay, the
clinical effects, the functional tests and the pathology examinations performed in regard to
neurotoxicity).
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1.4.2. Epidemiological studies linking pesticide exposure with Parkinson’s
disease and Parkinsonism
The association between pesticide exposure and PD has been investigated in numerous
epidemiological studies. Priyadarshi et al. (2000) conducted the ﬁrst meta-analysis on 19 studies
published between 1989 and 1999, and found a positive and signiﬁcant association between pesticide
exposure and PD (OR: 1.94; 95% CI: 1.49–2.53), although with signiﬁcant heterogeneity among
studies. Further systematic reviews and meta-analyses conducted since then have lent support to this
observational association (Breckenridge et al., 2016; Hernandez et al., 2016a).
The EFSA external scientiﬁc report (Ntzani et al., 2013) reviewed 32 studies assessing the
association between pesticide exposure and PD published between 2006 and 2012. Most of the studies
(80%) involved occupational exposures where general pesticide use was assessed retrospectively by
means of questionnaires. Only a minor proportion of studies was prospective in design (10%) or
assessed exposure by biomonitoring techniques (particularly for the lipophilic organochlorines DDT and
HCB, which represent 10% of the studies). The EFSA external scientiﬁc report performed meta-
analyses for general pesticide use, DDT and paraquat exposures (which included 26, 5 and 9 studies,
respectively). A signiﬁcantly increased risk of PD was observed for exposure to pesticides in general,
although with high heterogeneity (OR: 1.49; 95% CI: 1.28–1.73, random effect model) and for
paraquat exposure (OR: 1.32; 95% CI: 1.09–1.60, ﬁxed effect meta-analysis), which showed moderate
heterogeneity. No signiﬁcant association was observed for DDT. These results are in accordance with
the largest studies carried out on the association between pesticide exposure and PD published from
2000 to 2013. The observed association between pesticides and PD holds true even though the latest
meta-analyses were published considerably later, and contain a large number of additional data,
relative to the earlier meta-analyses. This indicates consistency of results over time. Moreover, different
methodologies used to synthesise the available evidence resulted in the same overall result.
Tanner et al. (2011) performed a different kind of analysis in which pesticides were classiﬁed by
presumed mechanism of toxic action rather than by functional categories or chemical class. Signiﬁcant
associations were found between PD and the use of pesticides grouped as ‘inhibitors of mitochondrial
complex I’ or as ‘inducers of oxidative stress’, thus providing support in humans to ﬁndings from
experimental studies. Use of rotenone, or any of the group of complex I inhibitors, was associated
with PD (OR: 2.5 and 1.7, respectively). An interesting subanalysis, intended to provide evidence for
temporal concordance, included only studies in which exposure to rotenone was documented up to
15 years before PD diagnosis, and an association of similar magnitude was still observed. Similarly, use
of paraquat, or any of the group of oxidative stressors, was associated with PD (OR: 2.5 and 2.0,
respectively). Although this study was of considerable size, limitations were reported in terms of
variability of exposure, quality of diagnosis, reliability of pesticide exposure information, no separation
between prevalent and incident cases, no justiﬁcation for the subgroup analyses and potential bias
could have occurred during selection (Mandel et al., 2012). In addition, the possibility that the results
could be attributed to combined exposure or other agents was not considered in the analysis.
A further meta-analysis on 12 cohort studies published between 1985 and 2011 reported a
combined OR of 1.28 (95% CI: 1.03–1.59, random effects model), although with high heterogeneity
and inconsistency among studies (van Maele-Fabry et al., 2012). The 28% increased risk did not vary
substantially when omitting studies with extreme weight values, and the highest increased risks were
observed for studies with a better design.
The last meta-analysis conducted so far (Breckenridge et al., 2016) found that most of the studies
(88%) of pesticide exposure relied on self-reported pesticide use obtained either through personal
interviews (49%) or by other methods. Despite an extensive effort to correct potential statistical artefacts
(correcting for publication bias, stratifying by study characteristics, ﬁxed and random effect models, etc.),
the observed association between pesticide use and PD was statistically signiﬁcant for this meta-analysis
(OR: 1.22; 95% CI: 1.18–1.27 for ﬁxed effects model and OR: 1.56; 95% CI: 1.37–1.77 for the random
effects model). Use of herbicides or insecticides was associated with statistically signiﬁcantly increased PD
risk using the ﬁxed effects model (OR: 1.20 and 1.32, respectively). Similar results were obtained with the
random effects model. High herbicide and high insecticide use were independently and signiﬁcantly
associated with an increased risk of PD; conversely, use of fungicides failed to be signiﬁcantly associated
with PD. Regarding paraquat use, a statistically signiﬁcant association was found for PD (OR: 1.69 and
1.47 using the ﬁxed or random effects model, respectively). Moreover, a high paraquat use showed a
signiﬁcantly greater risk of PD as compared to non-use (OR: 1.75; 95% CI: 1.19–2.57, ﬁxed effects meta-
analysis). ORs for paraquat use, calculated using the ﬁxed effects model, were statistically signiﬁcant
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regardless of interview type (in-person or other), method of paraquat use ascertainment (self-reported or
other) and confounder adjustment (Breckenridge et al., 2016).
An additional factor to take into account is that the use of personal protection measures and
hygiene practices are important modiﬁers of the association between occupational pesticide exposure
and PD (Thomas et al., 2009; Hines et al., 2011; Furlong et al., 2015).
The vast majority of studies on PD are case–control in design that rely on prevalent – existing – rather
than incident – newly diagnosed – PD cases, potentially leading to recall bias. Besides, the diagnosis of PD
is often based on self-reporting, potentially resulting in outcome misclassiﬁcation and distortion of the
estimated exposure-disease association. Indeed, the number of prospective cohort studies is much
smaller. While almost all studies found a positive association between exposure to pesticides and PD, the
association was not always statistically signiﬁcant. A small number of studies found a negative
association; however, none of them reached statistical signiﬁcance (Breckenridge et al., 2016). The
consistency of the size of the effect (OR/RR) between meta-analyses combining case–control studies and
cohort studies (particularly prospective cohorts) strengthens the hypothesis that exposure to pesticides
may be an aetiological factor of PD (van Maele-Fabri et al., 2012). The overall appraisal of meta-analyses
available so far suggests that there is sufﬁcient evidence to conclude an association between pesticide
exposure (broad deﬁnition) and PD, but not enough to support a causal relationship with speciﬁc
pesticide classes or compounds. This last concept is also supported by the fact that pesticides are a broad
category of functionally diverse substances; rather, toxicity is expected to be related to speciﬁc pathways
perturbed by a causative agent.
The above observational studies on the relationship of PD and pesticides have intrinsic weaknesses,
and their design does not allow conclusions on causal relationships. Limitations include the lack of an
accurate exposure estimate (from both a qualitative and quantitative standpoint), the scarcity of
information on dose–response relationships (which is difﬁcult to achieve because of the long latency
period of PD) and a lack of temporal concordance (most studies are case–control in design). A
particular weakness is that exposure is not assessed for deﬁned chemical entities, but rather for broad
categories like ‘pesticide’ or functional ‘classes of pesticides’. Even when pesticide subgroups were
used, they often provided no useful information and the subgroups herbicides and insecticides cannot
be evaluated independently because most of the herbicide-exposed subjects were also exposed to
insecticides. This fact is illustrated by the statistically signiﬁcant correlations observed between ORs
derived from the same studies, e.g. pesticide use and insecticide use (r = 0.82), pesticide use and
paraquat use (r = 0.84), herbicide use and insecticide use (r = 0.66), and insecticide use and fungicide
use (r = 0.90) (Breckenridge et al., 2016). Another general limitation is that subjects seldom recall the
speciﬁc class of pesticides used, and when doing so, such statements cannot be validated. The studies
found in general that the risk of PD increases with longer exposure durations, but no other indications
of a dose–response relation were found. It needs to be noted that environmental, lifestyle and genetic
risk factors may exist that have not been corrected for in the epidemiological studies. For instance,
allelic variants and single nucleotide polymorphisms (SNP) in certain genes (e.g. ABCB1 transporter
(Narayan et al., 2015), nitric oxide synthase (Paul et al., 2016a) can strongly affect the association of
pesticide exposure and PD. Thus, effects of environmental chemicals may only get manifest on certain
genetic backgrounds (Logroscino, 2005; Hernandez et al., 2016b); in addition, different exposed
populations might have unknown differences in the frequency of vulnerable genotypes. This adds a
layer of uncertainty for the interpretation of the study data, in addition to the general limitations of
study size (power). Concerning the latter, it has been argued that the inconsistency of ﬁndings in
human populations regarding paraquat exposure and PD might be accounted for by the statistical
variation of results in relatively small studies (Tanner et al., 2011).
Major advances in order to reduce uncertainties in epidemiological studies will be obtained by
assessment of speciﬁc exposure and more accurate diagnostic criteria. Due to the relevance of addressing
quality in the epidemiological studies, the PPR Panel is therefore elaborating a Scientiﬁc Opinion
(Epidemiological Studies in Pesticide Risk Assessment), which will be highly complementary to the present
and will speciﬁcally address the issues, limitations and uncertainties of epidemiological studies.
More studies are needed to identify individual pesticides that might be associated with PD, in
particular with prospective cohort design and with a better characterisation of exposure at the level of
individual pesticides. While the available epidemiological studies support an association between
pesticides and PD, complementary experimental research is needed to overcome the limitations
inherent to those studies. The ultimate goal is that experimental and mechanistic data lend support
and biological plausibility to the human epidemiological data. Indeed, the concept of AOP can help in
supporting biological plausibility by means of linking a MIE to an AO which is relevant for a given
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disease. Complex and multihits diseases, like PD, will beneﬁt of this approach by identifying MIE(s)
triggering the AO, thus identifying potential risk factors. Moving from identiﬁcation of a risk factor to a
more causal link (i.e. single substance) will need integration of toxicokinetic elements able to support
risk assessment.
1.4.3. Data requirements in the pesticide regulations for the exploration of
carcinogenicity and haematological endpoints
Under REGULATION (EC) No 1107/2009, an active substance is approved at EU level, following
assessment against a set of agreed criteria.
The required toxicological data should permit to identify the hazard of an active substance, to
propose a classiﬁcation according to CLP Regulation, to set relevant reference values as regard human
health in order to perform risk assessment and to ﬁnally draw a conclusion as to whether, or not, the
active substance could be approved with potential appropriate conditions or restrictions of use.
In routine required toxicological studies, all potentially adverse effects observed should be
investigated and reported including genotoxicity, carcinogenicity and haematological endpoints.
Furthermore, in REGULATION (EC) No 1107/2009, active substances are categorised according to
their intrinsic hazard, which impact the conditions of their approval.
Genotoxicity and carcinogenicity among other criteria are taken into account to categorise active
substances. In this way, an active substance:
• shall not be approved if it is or has to be classiﬁed as mutagen category 1A or 1B, or as
carcinogen category 1A or 1B, in accordance with the CLP criteria (Article 4 and Annex II
points 3.6.2 and 3.6.3);
• shall be approved as a candidate for substitution, if it is or has to be classiﬁed as carcinogen
category 1A or 1B and has not be excluded (Article 24 and Annex II point 4);
• shall not be considered of low risk or as basic substance if it is or has to be classiﬁed as
mutagen or as carcinogen (Article 22 and Annex II point 5).
For approval of pesticides under REGULATION (EC) No 1107/2009, the data requirements are set
out in Regulation (EU) No 283/2013.2
As regard to genotoxicity (point 5.4) and carcinogenicity (point 5.5), speciﬁc dedicated studies are
routinely performed for all pesticide active substances.
As regard to haematological endpoints, they are investigated in the different repeated dose studies
required (i.e. short-term studies point 5.3, long-term studies point 5.5).
Commission Communication provides the list of test methods and guidance documents relevant to
the implementation of Regulation (EU) No 283/2013.3
1.4.3.1. Genotoxicity testing
The genotoxicity tests should address the three genotoxic endpoints, namely gene mutations,
structural and numerical chromosome aberrations. The aims of the tests battery to be performed are to:
• predict genotoxic potential of active substances;
• identify genotoxic carcinogens at an early stage;
• elucidate the mechanism of action of some carcinogens.
In order to address the genotoxicity proﬁle of pesticide substances, a stepwise approach is followed
with in vitro testing preceding in vivo testing.
First step: In vitro tests
The basic in vitro tests battery comprises two gene mutation tests (one in bacterial cells and one in
mammalian cells) and a test investigating structural and numerical chromosomal alterations.
Studies to investigate gene (point) mutation:
• bacterial reverse mutation test (OECD TG 471);
• in vitro mammalian cell gene mutation tests using the Hprt or Xprt genes (OECD TG 476);
• in vitro mammalian cell gene mutation tests using the thymidine kinase gene (OECD TG 490);
2 http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2013:093:0001:0084:EN:PDF
3 http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:52013XC0403(02)&from=EN
PPPs, Parkinson’s disease and childhood leukaemia
www.efsa.europa.eu/efsajournal 19 EFSA Journal 2017;15(3):4691
Studies to investigate chromosome aberrations:
• in vitro mammalian chromosomal aberration test (OECD TG 473);
• in vitro mammalian cell micronucleus test (OECD TG 487).
For active substances harbouring structural alerts not detected by the standard test battery, speciﬁc
tests investigating properly those alerts may be required.
Second step: In vivo tests
If all the results of the in vitro studies are clearly negative, at least one in vivo study is performed.
The appropriate test to be conducted is an in vivo micronucleus assay.
If an equivocal or a positive test result is obtained in any in vitro test, the additional testing needed
is considered on a case-by-case basis taking into account all relevant information.
In vivo tests performed should cover the genotoxic endpoint(s) identiﬁed as positive or equivocal
in vitro and investigate appropriate target organs.
Studies to investigate gene mutations:
Transgenic rodent somatic and germ cell gene mutation assays (OECD TG 488)
Studies to investigate chromosome damage:
Mammalian erythrocyte micronucleus test (OECD TG 474)
Mammalian bone marrow chromosome aberration test (OECD TG 475)
Studies to investigate primary DNA damage:
In vivo alkaline mammalian comet assay (OECD TG 489)
Unscheduled DNA synthesis (UDS) test with mammalian liver cells in vivo (OECD TG 486)
In Table 2, the test guidelines for the exploration of genotoxicity under Regulation (EU) No 283/2013
are summarised.
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1.4.3.2. Long-term toxicity and carcinogenicity testing
The aims of the long-term toxicity testing are to:
• identify adverse effects resulting from long-term exposure to the active substance;
• identify target organs, where relevant;
• establish the dose–response relationship;
• establish the NOAEL and, if necessary, other appropriate reference points.
As for carcinogenicity testing, it permits one to:
• identify carcinogenic effects resulting from long-term exposure to the active substance;
• establish the species, sex and organ speciﬁcity of tumours induced;
• establish the dose–response relationship;
• identify the maximum dose eliciting no carcinogenic effect where possible;
• determine the MoA and human relevance of any identiﬁed carcinogenic response where possible.
A long-term oral toxicity study and a long-term carcinogenicity study (2 years) in rat are to be
conducted; where possible these studies shall be combined. A second carcinogenicity study in mouse is to
be conducted, unless it can be scientiﬁcally justiﬁed that this is not necessary. In that case, a scientiﬁcally
validated alternative carcinogenicity model may be used instead of a second carcinogenicity study.
The relevant regulatory test guidelines are as follows:
Carcinogenicity studies (OECD TG 451);
Chronic toxicity studies (OECD TG 452);
Combined chronic toxicity/carcinogenicity studies (OECD TG 453).
1.4.3.3. Haematological endpoints
No speciﬁcally dedicated study is required. However, haematological endpoints among other
toxicological endpoints are systematically addressed in routine required repeated dose studies (short-
term toxicity studies, long-term toxicity and carcinogenicity studies point).
Haematological parameters are also to be investigated in the extended one-generation reproductive
toxicity study while they are not part of the investigated endpoints of the two-generation reproductive
toxicity study. Moreover, when warranted by available information, the extended one-generation study
protocol can include a cohort dedicated to detailed investigation of developmental immunotoxicity.
The haematological parameters monitored in repeated dose studies are:
• red blood cells parameters (haematocrit, haemoglobin concentration and erythrocyte count);
• total and differential leucocyte count;
• platelet count;
• blood clotting time/potential.
The relevant regulatory test guidelines are as follows:
• Short-term studies:
– repeated dose 28-day oral toxicity study in rodents (OECD TG 407);
– repeated dose 90-day oral toxicity study in rodents (OECD TG 408);
– repeated dose 90-day oral toxicity study in non-rodents (OECD TG 409).
• Long-term/carcinogenicity studies:
– carcinogenicity studies (OECD TG 451);
– chronic toxicity studies (OECD TG 452);
– combined chronic toxicity/carcinogenicity studies (OECD TG 453).
• Reproductive toxicity study:
– extended one-generation reproductive toxicity study (OECD TG 443).
In Table 3, the test guidelines for the exploration of carcinogenicity and haematological endpoints
under Regulation (EU) No 283/2013 are summarised (including the test procedure, the haematological
parameters investigated and the organs going through to histopathological examination relevant to
pick up haematopoietic disorders).
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1.4.3.4. Previous data requirements under Directive 91/414/EEC concerning the placing
of plant protection products on the market
As detailed above, in the data requirements of the previous regulation 91/414/EEC genotoxicity,
carcinogenicity and haematological endpoints are all mandatory to address.
In regard to genotoxicity testing, Salmonella Typhimurium reverse mutation test, in vitro
mammalian cytogenetic test and in vitro mammalian cell gene mutation test were the only acceptable
tests. Even when all in vitro tests were negative, one in vivo test was to be carried out (the
micronucleus test OECD 474). If indicated from the in vitro results, further in vivo testing could be
triggered. These are the chromosomal aberration test (OECD 475) or unscheduled DNA synthesis test
(OECD 486). Thus, the former data requirements were less comprehensive, in particular in regard to
in vivo mutagenicity testing and for most of the in vivo genotoxicity tests, i.e. the in vivo bone marrow
micronucleus test, proof of actual bone marrow exposure was often not shown but was only assumed.
This is currently being critically assessed in each case during the re-assessment of active substances.
In relation to carcinogenicity and haematological testing, the former data requirements were as the
current except that extended one generation study (OECD 443) was not available and not required.
1.4.4. Epidemiological studies linking pesticide exposure with childhood
leukaemia
There is increasing concern about chronic low-level pesticide exposure during pregnancy or
childhood and its inﬂuence on childhood cancers. Epidemiological studies have suggested that
maternal exposure to certain household pesticides during pregnancy may increase the risk of childhood
leukaemia; however, these studies are limited because no speciﬁc pesticides were directly associated
with the risk of leukaemia, but rather the broad term pesticide exposure was applied (Lu et al., 2015).
The EFSA external scientiﬁc report (Ntzani et al., 2013) updated the meta-analysis conducted by
Turner et al. (2010) on residential pesticide exposure during pregnancy and found an increased risk of
childhood leukaemia associated with exposure to unspeciﬁed pesticides (OR: 1.30; 95% CI: 1.06–1.56.
When exposure was restricted to insecticides, a somewhat stronger association was observed (OR:
1.69; 95% CI: 1.35–2.11). In contrast, meta-analyses on studies examining preconception exposure
failed to show statistically signiﬁcant results. Ntzani et al. (2013) also updated the meta-analysis of
Turner et al. (2010) on pesticide exposure during childhood and found a signiﬁcant increased risk of
childhood leukaemia (OR: 1.36; 95% CI: 1.19–1.55). In spite of these positive associations, the
evidence must be carefully interpreted because most studies were of small size, exposure was
assessed through non-validated self-reported questionnaires (that are prone to misclassiﬁcation) and
concern was raised on publication bias. Also, only few studies included data on leukaemia subtypes.
More recently, meta-analyses have been carried out on occupational and residential exposure to
pesticides and risk of childhood leukaemia. Maternal occupational pesticide exposure during pregnancy
and/or paternal occupational pesticide exposure around conception have indicated an increased risk of
leukaemia in the offspring. Bailey et al. (2014) pooled data from 13 case–control studies participating
in the Childhood Leukaemia International Consortium (CLIC) and found a signiﬁcant increased risk of
acute myeloid leukaemia (AML) in children born from mothers exposed to pesticides during pregnancy
(OR: 1.94; 95% CI: 1.19–3.18), which is consistent with previous meta-analyses; however, no
signiﬁcant risk was found for paternal exposure around conception (OR: 0.91; 95% CI: 0.66–1.24). In
relation to acute lymphocytic leukaemia (ALL), Bailey et al. (2014) observed a 20% increased risk with
paternal exposure around conception (OR: 1.20; 95% CI: 1.06–1.38), which appeared to be more
evident for children with T-cell ALL; however, no association was found between maternal exposure
during pregnancy and risk of ALL (OR: 1.01; 95% CI: 0.78–1.30).
In a separate study investigating residential pesticide exposure, Bailey et al. (2015) pooled data
from 12 case–control studies in the CLIC and found an increased risk of ALL associated with exposure
to any pesticide shortly before conception, during pregnancy and after birth. The three exposure
windows had essentially the same OR: 1.39 (95% CI: 1.25–1.55), 1.43 (95% CI: 1.32–1.54) and 1.36
(95% CI: 1.23–1.51), respectively. Little variation was found by time period, type of pesticide or
among other subgroups. Regarding AML, an increased risk was found for exposure to any pesticide in
the few months prior to conception (OR: 1.49; 95% CI: 1.02–2.16), and during pregnancy (OR: 1.55,
95% CI: 1.21–1.99); however, exposure after birth did not show a signiﬁcantly increased risk (OR:
1.08, 95% CI: 0.76–1.53). The relative similarity in ORs between leukaemia types, time periods and
pesticide types may suggest similar exposure patterns and effects across the time periods in ALL and
AML, exposure to multiple pesticides or recall bias.
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The meta-analysis conducted by Chen et al. (2015) found that children of residents exposed to
indoor but not outdoor insecticides had an increased risk of childhood leukaemia (OR: 1.47; 95% CI:
1.26–1.72). A signiﬁcant association was also found for herbicide exposure during childhood (OR: 1.26;
95% CI: 1.10–1.44).
Almost all the available studies addressing paediatric leukaemia included both infant leukaemia and
childhood leukaemia in the same diagnosis. Very few studies examined the risk of pesticide exposure
with IFL (< 1 year) as a separate entity. The Brazilian Collaborative Study Group of Infant Acute
Leukaemia found an increased risk of IFL in mothers exposed to domestic insecticides during
pregnancy (OR: 2.18, 95% CI: 1.53–2.13) with a rather small samples size of 91 cases (Pombo de
Oliveira et al., 2006). A further study also conducted in Brazil (Ferreira et al., 2013) found that ever
use of pesticides during pregnancy was associated with ALL (OR: 2.10; 95% CI: 1.14–3.86) and AML
(OR: 5.01; 95% CI: 1.97–12.7) in children < 1 year of age. In particular, maternal exposure to
permethrin was associated with a signiﬁcantly higher risk of leukaemia in children < 1 year of age (OR:
2.47; 95% CI: 1.17–5.25 for ALL; and OR: 7.28; 95% CI: 2.60–20.38 for AML).
Observational studies on pesticide exposure and paediatric leukaemia have important weaknesses in
establishing causal relationships. The consistency of ﬁndings across studies may be due to the
considerable overlap in the studies included in the different meta-analyses carried out. Limitations
include the lack of an accurate exposure estimate (from both a qualitative and quantitative standpoint),
lack of temporal concordance (most studies were case–control in design) and little information on dose–
response relationship. In addition, the sound epidemiological evidence available may be challenged by
endogenous or exogenous factors, such as genetic polymorphisms, diet, lifestyle and co-exposure to
other environmental agents. Hence, accounting for simultaneous exposure to multiple agents would help
to delineate true associations, but this has not been possible for most of the available evidence because
of difﬁculties in properly assessing multiple exposures. The question arises as to whether, and to what
extent, experimental and mechanistic data can lend support to the human data.
In evaluating the aetiological role of environmental factors in the pathogenesis of childhood
leukaemia, there is a need to know the evidence for an association between exposure to certain
environmental factors and the incidence of the disease assessed by epidemiological studies.
Furthermore, evidence from experimental research is also required to know the possible mechanisms
that would explain an observed or hypothesised association between the exposure to certain
environmental factors and the incidence of CHL.
In observational studies, the quality of exposure assessment is crucial, especially in deriving dose–
response relations. Moreover, the reduction in bias and the adjustment for confounding factors are
important in assessing the evidence for causality of associations. Because of the controversy regarding
the role of pesticide exposure in CHL, a WoE analysis based on Bradford–Hill criteria was performed to
evaluate the available scientiﬁc evidence linking pesticide exposure with CHL (Health Council of the
Netherlands. Childhood leukaemia and environmental factors. The Hague: Health Council of the
Netherlands, 2012; publication no. 2012/33).
Strength. The observed associations between pesticide exposure through parental occupational
exposure or residential exposure and CHL are rather weak (OR/RR < 2–3) and not always statistically
signiﬁcant. However, misclassiﬁcation of exposure, a real problem in many types of epidemiological
studies, leads to underestimation of the real risk when pesticide exposure is categorised in a
dichotomous manner, thus decreasing the strength of the association. Conversely, for measures of
exposure that are not dichotomous, the bias may result in either under or overestimation of the effect.
Consistency. Despite exposure often not being identical in most situations, almost all meta-analyses
published so far show a trend towards increased risk with minor differences. Overall, pesticide
exposure during pregnancy tends to support a positive relationship; however, many individual studies
included in the different meta-analyses are often the same ones.
Speciﬁcity. The aetiology of CHL is multifactorial, resulting from the interplay of genetic or
environmental factors. It is not possible to associate speciﬁc pesticide exposures with CHL because of
the low prevalence of this disease and the imprecise exposure assessment. On the other hand,
pesticide exposure is associated with many other diseases. While most of the epidemiological studies
evaluated are focussed on CHL and other diseases/outcomes are usually not considered, this does not
mean that other outcomes do not occur, simply studies were not designed to address them.
Temporality. When risk factors for CHL are investigated in case–control studies, exposure is usually
measured retrospectively, so temporality cannot be properly addressed as they can in prospective
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cohort studies. Besides, responder and recall bias, might inﬂuence the accurate timing of exposure.
Many epidemiological studies have assessed exposure during pregnancy or even before (prior to
conception) such that the risk factor precedes the development of the disease. Nonetheless, the time
window at which pesticides might exert its causative action (prior to conception, during early, mid or
late pregnancy, or during childhood) is not clear. However, exposures during childhood appear to be
less consistently associated with CHL than exposures during pregnancy.
Biological gradients. Exposure–response relationships can only be assessed when exposure is
measured adequately and with sufﬁcient precision. However, exposure is often assessed using
questionnaires, or at best with biomonitoring techniques on spot-samples. Accordingly, exposure
assessment (and even accumulated exposure to individual chemicals) is difﬁcult to perform and often
poorly characterised. In the case of CHL, an additional limitation is that exposure can occur at different
stages of the development (early pregnancy, late pregnancy or postnatally) and effects of chemicals at
each stage may be different. Additionally, children and their parents are exposed to mixtures of
different agents, and chemical interactions are not usually studied as well as the potential combined
effect to the same agent(s) between prenatal and postnatal stages.
Many of the epidemiological studies did not assess the risk of CHL in response to the frequency or
intensity of pesticide exposures. The only weak support for a positive exposure–response relationship
found that the risk of leukaemia increased with the frequency of pesticide use (Van Maele-Fabry et al.,
2011).
Biological plausibility. The growing experimental studies and animal models on the biology of CHL show
increased evidence for effects for chemicals, thus strengthening the biological plausibility of an
association. However, there are no experimental models on speciﬁc pesticides (and hence no dose–
response relationship) and the animals used failed to recapitulate all the features of the human disease.
Besides, for pesticides and CHL, the qualitative and quantitative evidence on the biological mechanisms
underlying the ﬁrst initiating events at molecular levels is lacking. Pesticides are biologically active
molecules that may play some role in cancer aetiology. Consequently, in the European Union, the use of
pesticides showing some evidence of carcinogenicity or genotoxicity has been restricted or banned.
Nevertheless, potential gaps in the regulatory studies, interspecies variability in target cells, and the use
of co-formulants or potential epigenetic factors cannot be ruled out.
Regarding coherence, the cause and effect interpretation should not seriously conﬂict with the
generally known facts of the natural history and biology of the CHL. However, the natural history of
this disease is far from being adequately understood, thus coherence cannot be properly assessed.
Another Bradford–Hill criterion is analogy. This means that if it is known that the effect of one type
of exposure can lead to CHL, a similar effect from another type of exposure might also. However, the
different variety of types of exposures associated to the disease (ionising radiation, electromagnetic
ﬁelds, chemicals other than pesticides) are of little help and prevent analogy from being a useful
consideration in practice.
In addition to the Bradford–Hill considerations, alternative explanations for epidemiological
associations other than causality should be considered: chance, bias (speciﬁcally exposure
misclassiﬁcation) and confounding. If these are unlikely, a causal relation is more likely.
Despite the positive associations reported in the meta-analyses on pesticide exposure and CHL, it is
not possible to identify any individual pesticide associated with CHL because of the imprecise exposure
assessment and the low prevalence of this complex disease.
1.4.5. The Adverse Outcome Pathway (AOP) framework as a conceptual tool to
support the biological plausibility of epidemiology studies
Regulatory studies, traditionally based on animal experimentation, are intended to explore any
potential hazard but they are not speciﬁcally designed to inform about speciﬁc and complex human
health outcomes. New data type and methods can be more effective in hazard identiﬁcation, but there
is a need to deﬁne which data could be used and/or be more valuable for compound speciﬁc risk
assessment and which could be informative on data gaps in the standard regulatory assessment or
add an insight for their interpretation.
The inclusion of epidemiology ﬁndings into risk assessment is an attempt to integrate human data
with toxicological data and approaches elucidating mechanisms or pathways of toxicity, rather than
relying only on the standard regulatory requirements. Furthermore, human data are compelling and
trigger important risk perception opinions that are frequently reported in the media. Many
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epidemiological studies include pesticides and their integration (why and how) or exclusion in the risk
assessment should be legitimate. In this top-down context, epidemiology ﬁndings can be used for
validation purposes; however, in the context of risk assessment, they can trigger alternative
approaches to investigate the biological plausibility, i.e. that a plausible mechanism between cause and
effect exists, overcoming their own limitations or help when human data are not corroborated by the
regulatory toxicological studies (Li et al., 2012). Thus, the complex scientiﬁc process for the
identiﬁcation of human risk has to involve both epidemiological and experimental data. Furthermore,
when epidemiological data are lacking, experimental data are relevant to inform on the biological
plausibility as part of the overall WoE.
The AOP is an organisational framework, it combines information from multiple ﬁelds of inquiry and
provides knowledge of biological pathways, highlight species differences or similarities, identiﬁes
research needs and supports regulatory decisions (Villeneuve et al., 2014a,b). In this context, the AOP
approach could help in organising all the available experimental knowledge providing a mechanistic
based assessment of biological plausibility. The PPR Panel therefore recognises the value of using all
the available information when conducting the risk assessment and is considering the AOP framework
as a systematic and transparent tool for organising, reviewing and interpreting complex information
from different sources. The AOP, being a conceptual framework to mechanistically understand apical
endpoints of regulatory relevance, the human health outcome should be included as part of the hazard
assessment and the AOP will serve as tool for hazard identiﬁcation.
The AOP framework is similar to the IPCS Mode of Action/Human Relevance framework (Meek et al.,
2003; Seed et al., 2005) with major differences being the dominant applications to which it is applied
and the inclusion of the formal incorporation of Bradford–Hill’s considerations. Because AOPs are only
covering toxicodynamic aspects, they are not intended to be chemical speciﬁc in the sense that they are
not developed to describe what a single chemical does, but rather to describe how any chemical,
sufﬁciently triggering the MIE might perturb a physiological pathway adversely. The response–response,
temporal and incidence concordance will be based on empirical data provided by tool compounds, i.e.
the chemical stressor. Consequently, describing an AOP does not require chemical-speciﬁc information
but when applying the pathway in a predictive context relevant for risk assessment, such information is
needed. Nevertheless, it requires understanding of the chemical tool-speciﬁc properties like potency or
absorption, distribution, metabolism and excretion (ADME) properties as these data will be informative
for dictating the magnitude and duration of the perturbation at the MIE.
In 2012, the OECD launched the AOP development programme followed by the publication in 2013
of the OECD Guidance Document on Developing and Assessing AOPs, addressing conventions and
terminology, information content of an AOP description, WoE evaluation and standardisation and rigour
for developing AOPs. Conventionally, an AOP consists of a single sequence of key events connecting
the MIE to an AO; the idea is to have a tool that pragmatically simpliﬁes complex biological events
(OECD, 2013, 2014).
The MIE is deﬁned as a specialised type of KE that represents the initial point of chemical
interaction on the molecular level, within an organism, that results in a perturbation that starts the
AOP. The AO is deﬁned as a specialised type of KE that is generally accepted as being of regulatory
signiﬁcance on the basis of correspondence to an established protection goal or equivalence to an
apical endpoint in an accepted regulatory guideline toxicity test.
The MIE and the AO are linked by a series of KEs deﬁning a direct relationship among them (KER)
where the KE should provide some ability to predict or infer the state of the downstream KEs and their
relationships have to be supported by biological plausibility and scientiﬁc evidence, with a quantitative
understanding in a codiﬁed assembly of WoE. The availability and robustness of experimental data will
classify the AOP developed into a given category, but the AOP will be considered as a living document
that can change in category on the basis of new available data. In moving down from a putative AOP
to a quantitative AOP it is expected to see an increase in: strength of evidence, understanding,
transparency, defensibility, quantitative precision, cost, data needs and time (Table 4).
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In this context, it is clear that an objective and complete AOP does not exist as methods and/or
new experiments can change the existing one. It is also clear that any stage of AOP development has
a potential utility as the level of development desired/required depends on its potential application.
The PPR Panel has applied the AOP approach to investigate and possibly provide an objective and
transparent mechanistic support for the biological plausibility linking a MIE to AO relevant to
Parkinson’s disease/parkinsonian disorders and childhood/infant leukaemia. Understanding the link
between a speciﬁc MIE and an AO relevant for a human disease will help in understanding the role of
speciﬁc pesticides as risk factors and will further develop compound-speciﬁc MoA (with the inclusion of
TK/ADME data) informing causality in a relationship.
These human health outcomes were selected because they are consistently observed in different
meta-analyses and represent relevant disease models for the application of the approach. While the
link between environmental factors and Parkinson’s disease/parkinsonian disorders is relatively data
rich, data supporting the link to childhood/infant leukaemia is more scarce. This allows evaluation of
the ﬂexibility of the approach and to compare evaluations of data similarity and/or data gaps between
the standard regulatory requirements and alternative studies designed to investigate toxicological
endpoints speciﬁc for the diseases.
2. Introduction to Parkinson’s disease, parkinsonian disorders and
application of the AOP conceptual framework
Parkinson’s disease is a chronic progressive neurodegenerative disorder with a higher prevalence in
the aged male population (Cereda et al., 2016). It is a chronic disease as the mean duration is
15 years from the recognition of the disease until death (Shulman et al., 2011) and is progressive as
the clinical signs and their severity are linked to the spread and progression of the pathology. Although
the clinical symptoms include slowness of movement, resting tremor, rigidity and disturbances in
balance, it is now recognised that additional non-motor symptoms can occur as a result of the
progression of the disease. Some or all of the motor symptoms can, however, be observed in different
disorders and the resulting syndrome is deﬁned as ‘parkinsonism’. When parkinsonism is the prominent
part of the disorder, these are referred to as ‘parkinsonian disorders’ and include PD (Dickinson, 2012).
The primary pathology is, however, common to all parkinsonian disorders and is represented by a
selective degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNpc), which
project mainly to the striatum, in association with the development of cytoplasmic, protein-rich
inclusions, called Lewy bodies (LB) and decreased levels of striatal dopamine. One of the main
components of LB is the aberrant oligomeric a-synuclein (a presynaptic neuronal protein) and a
parallelism exist between the presence of motor and non-motor symptoms and the ﬁnding of
a-synuclein pathology beyond the SNpc. This is the basis of the Braak paradigm (Braak et al., 2004,
2009), which proposes a staging system to describe the spread and progression of the pathology
resulting from multiple detailed post-mortem analysis in PD patients. The sequential occurrence of
alterations and the involvement of different structures of the nervous system, including the peripheral
one, is a key aspect of the disease that is relevant to understand the contribution of environmental
factors and their role in the initiation of the disease (Pan-Montojo et al., 2012).
Complex molecular landscape of PD and parkinsonian disorders
Indeed, although the molecular aetiology of the disease is unknown, it is most likely caused by a
complex interplay of genetic and environmental factors with multiple interacting pathways including
Table 4: AOP categories
Stages of AOP
development
Characteristics
Putative AOPs Hypothesised set of KEs and KERs primarily supported by biological plausibility and/or
statistical inference
Qualitative AOPs Include assembly and evaluation of the supporting weight of evidence – developed in
AOP knowledgebase in accordance with internationally harmonised OECD guidance
Quantitative AOPs Supported by quantitative relationships and/or computational models that allow
quantitative translation of key event measurements into predicted probability or
severity of adverse outcome
AOP: Adverse Outcome Pathway; KE: key event; KER: key event relationship; OECD: Organisation for Economic Co-operation and
Development.
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synaptic and mitochondrial dysfunction, impaired protein degradation, a-synuclein pathobiology and
neuroinﬂammation (Fujita et al., 2014). Some cases may have a clear genetic cause while others can
be caused by effects of toxins (e.g. MPTP) and/or a gene–environment interaction; however, although
these degenerative disorders can be inherited or idiopathic they all have as a common denominator
the loss of dopaminergic neurons projecting from the substantia nigra to the putamen (Dickinson,
2012). In this context, the role of pesticides as potential environmental risk factors for PD has long
been suspected and recurrent through multiple epidemiological meta-analyses, though the speciﬁc
causative agents and the mechanisms underlying the disease are not fully understood (Priyadarshi
et al., 2000; Franco et al., 2010; Shulman et al., 2011; Ntzani et al., 2013; Baltazar et al., 2014). For
this reason, PD and parkinsonian disorders in general is of high interest for the pesticides risk
assessment and several experimental models have been proposed (Drechsel and Patel, 2008; Cicchetti
et al., 2009; Moretto and Colosio, 2011; Baltazar et al., 2014). However, the linkage of a complex,
multihit and unique human disease with experimental toxicological studies is still representing an
important challenge for risk assessment. This is because, regulatory toxicology studies, as good as
they are for exploring any potential hazards, are not designed to understand relevant mechanisms of
toxicity and, particularly, they can be of limited sensitivity when hazards are likely consequent to long-
term, low-dose exposure to toxicants, or when multiple toxicants are interacting on the same AO
through different MIE or when the genetic background is inﬂuencing the adverse outcome. Due to the
complexity of the disease, multiple MIEs and AOPs can be developed for PD. For this reason, the PPR
Panel considered as the initial step in the construction of AOPs of interest for PD the general scientiﬁc
consensus that mitochondrial and protein dysfunctions, aggregation of toxic oligomers of a-synuclein,
oxidative stress and neuroinﬂammation are involved in the degeneration of dopaminergic neurons in
the SNpc, and that loss of these neurons is leading to parkinsonian motor symptoms. Based on the
existing knowledge supporting such a consensus, the PPR Panel built up a number of initial schemes
from which two AOPs were selected for further development. Tool chemicals were selected based on
data availability and their use as prototype chemicals in experimental models of PD.
Tool chemicals for the AOP building
In this context, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), rotenone and paraquat, are
likely to be the most widely used chemical substances to induce loss of dopaminergic neurons. In
particular, MPTP is of high interest as it was able to produce Parkinson-like motor disorders in human a
few days following exposure to an illicit substance of abuse containing this compound as a contaminant.
MPTP is able to cross the blood–brain barrier and is selectively taken up by dopaminergic neurons after
metabolic activation by MAO-B of astrocytes to MPP+. Rotenone is a highly lipophilic insecticide/piscicide
which, unlike MPTP/MPP+, lacks speciﬁcity for dopaminergic neurons but this chemical is able to
reproduce features of PD when chronically administered to rodents at doses that achieved complex I
inhibition, similar to that observed in platelets of PD patients (Betarbet et al., 2000; Cannon et al.,
2009). The susceptibility of dopaminergic neurons is likely due to their sensitivity to the toxicity induced
by rotenone rather than toxicokinetic (i.e. metabolic) characteristics. For both substances, the
neurotoxic effect is considered consequent to inhibition of complex I in the mitochondrial respiratory
transport chain leading to mitochondrial dysfunction. However, both MPTP/MPP+ and rotenone can
produce neuronal loss by a large number of processes and this was considered an important limitation in
the construction of the AOPs (Aguilar et al., 2015). However, at least for rotenone, it was demonstrated
that it causes microtubule depolymerisation at a concentration of 10 lM (Ren et al., 2005), while the
IC50 for complex I inhibition is approximately 10–20 nM (Degli Espositi, 1998). It is also worth to note
that these substances were mainly used as tools to reproduce in vivo and/or in vitro models of PD or to
study mechanisms relevant for PD rather than for hazard identiﬁcation.
Paraquat is an herbicide belonging to the chemical class of bipyridyl quaternary ammonium.
Although the general toxicity of paraquat and its target organs is well characterised, its neurotoxic
effect has been mainly explored in the last decade (Baltazar et al., 2014). The mechanism underlying
paraquat neurotoxicity is not fully elucidated, although several pathways have been proposed the
toxicity is essentially linked to its redox potential. Paraquat has complex toxicokinetics and this also
includes interaction with microglia (Baltazar et al., 2014). As toxicokinetic and metabolism
considerations are not relevant for the construction of the AOPs, in this context, paraquat will be used
as a tool chemical to deﬁne an AOP dealing with oxidative stress, mitochondrial dysfunction and
neuroinﬂammation (Baltazar et al., 2014).
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3. Plausibility of the involvement of pesticide exposure as a risk factor
for Parkinson’s disease and contribution of the AOP concept to
support plausibility
3.1. Biological plausibility in support of pesticide-associated Parkinson’s
disease
In addition to the above-mentioned epidemiological studies, laboratory experiments have provided
evidence for neurotoxic effects and biologically plausible mechanisms linking pesticides to PD.
Biologically plausible mechanisms for PD causation have been postulated for speciﬁc pesticides,
including inhibition of mitochondrial complex I by rotenone, induction of oxidative stress by paraquat,
and inhibition of aldehyde dehydrogenase by the dithiocarbamate fungicides maneb, ferbam or
mancozeb (reviewed in Breckenridge et al., 2016).
Studies with rotenone are consistent with the assumed role of respiratory chain complex I and
mitochondrial dysfunction in PD pathogenesis; data on paraquat are in line with the assumed role of
oxidative stress in the disease; the toxicity of maneb in experimental animals also involved
mitochondrial dysfunction. These experimental toxicants selected from the group of pesticides have
triggered many of the features known from PD in animal models. They have in particular been shown
to trigger dopaminergic neuronal cell death in the substantia nigra, similar to the pathology observed
in PD (Drechsel and Patel, 2008; Hatcher et al., 2008).
Despite the large body of epidemiological and experimental evidence linking pesticide exposure to
PD, the exact aetiological factors remain elusive, and pathogenic mechanism(s) triggering neuronal
loss and PD progression are not completely known. Advances concerning the plausibility of the
association have been made in the following areas:
a) Repeated and multiple chemical exposures
Pesticides currently used do not strongly bioaccumulate in the human body, whereas in the past
this was not the case. Prolonged effects may therefore arise from long exposure periods or previous
exposure to more bioaccumulating compounds. Alternatively, single exposure may cause minute,
clinically undetectable neurotoxic effects that, if accumulated over the course of decades, might lead
to triggering of disease or to the enhancement of ongoing endogenous disease progression. In this
context, it is important that PD symptoms become clinically apparent only after considerable
dopaminergic cell death has been ongoing. Most likely, it takes years of only a few individual neurons
dying per day or month, until the threshold for clinical symptoms is reached.
The majority of work identifying potential dopaminergic toxicants associated with PD comes from
studies examining mechanisms and risks arising from a single chemical. However, human environmental
exposures are much more dynamic and they likely involve numerous risk modiﬁers including multiple
chemicals or chemical mixtures. Pesticides consist of a wide range of chemical structures with diverse
mechanisms of toxicity and not necessarily all of them contribute to the development of PD. The effect of
pesticide mixtures has to be considered for risk assessment. The multihit hypothesis supporting
neurodegeneration and PD, suggests that the brain may be capable of withstanding the effects of an
individual chemical targeting dopaminergic neurons. However, when multiple chemicals target numerous
sites within the dopaminergic system, defence mechanisms may be compromised resulting in cumulative
damage and neuronal death (Hatcher et al., 2008). Furthermore, exposure to different pesticides may
initiate a number of neurotoxic mechanisms that may converge later in a chain of linked events
eventually leading to nigrostriatal dopaminergic cells death and impaired motor function. This might
explain why pesticides dissimilar in their chemical structure and unlikely affecting the same cellular
structure, trigger similar downstream events (e.g. mitochondrial dysfunction and oxidative stress).
Paraquat is a herbicide that has long been considered a potential risk factor for PD because of its
structural similarity to MPP+, the active metabolite of MPTP. While much of the focus has been put on
paraquat, other classes of pesticides are also known to impair dopaminergic neurons. Exposure to
maneb, a dithiocarbamate fungicide, has been linked to neurological impairments in agricultural
workers, and there are epidemiological data showing that neurodegeneration occurs more frequently
in environments where workers are co-exposed to paraquat and maneb (Thrash et al., 2007).
Paraquat and maneb administered individually to mice caused no neurological damage, but when
administered as a mixture, produced traits characteristic of PD (Thiruchelvam et al., 2000). A further
study on mice demonstrated enhanced sensitivity of the ageing nigrostriatal dopaminergic pathway to
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the combination of paraquat and maneb, resulting in irreversible and progressive neurotoxicity
(Thiruchelvam et al., 2003). These results were partially supported by a case–control study on 362
incident PD cases recruited between 2001 and 2007, where ambient exposures to the pesticides
paraquat, maneb and ziram were estimated. The combined exposure to these pesticides at workplaces
increased threefold the risk of PD, whereas the combined exposure to only ziram and paraquat,
excluding maneb exposure, was still associated with a 80% increase in risk (Wang et al., 2011).
A further type of chemical interaction may occur, if one chemical, given at an early time in life,
sensitises to another chemical, given at a later time point. This was observed in an experiment where
(perinatal exposure during gestation and lactation exposure (i.e. developmental) to low dieldrin levels
altered dopaminergic neurochemistry in offspring and exacerbated MPTP toxicity later in life
(Richardson et al., 2006)).
Potentially interaction of chemicals may also occur through the links of epigenetic changes (Balmer
and Leist, 2014) or of neuroinﬂammation, even in cases in which exposure periods are far apart. For
instance, the short exposure to MPTP/MPP+ in humans resulted in an injury that initiated self-
perpetuating pathological processes, and neuroinﬂammation persisted for many years (Langston et al.,
1999), making the respective brain regions vulnerable to potential second hits.
b) Genetic factors and gene–environment interactions
There is growing evidence suggesting that genetics may affect susceptibility to PD among the
subgroup of people exposed to pesticides. Exposure to pesticides (or to speciﬁc pesticides) over the
course of decades could initiate or accelerate the underlying neurodegenerative process; however,
without concurrent genetic or metabolic risk factors pesticides may not necessarily lead to the disease.
While a minority of PD cases may be primarily due to a speciﬁc genetic or environmental risk factor,
most cases are likely due to gene–environment interactions (Fujita et al., 2014). These kinds of
interactions may explain why despite the large number of people regularly exposed to pesticides not
everyone develops the disease; it may only affect those carrying a genetic vulnerability. Highly
penetrant mutations in some genes (SNCA, Parkin, DJ-1, PINK 1, LRRK2 and VPS35) produce rare,
monogenic forms of PD, while unique variants within LRRK2 and GBA show incomplete penetrance and
are strong risk factors for the disease (Hernandez et al., 2016b). On the other hand, polymorphisms of
genes encoding enzymes involved in the metabolism of pesticides or in cell damage mechanisms, in
particular PON1, PON2, NQO1, NAT2, NOS and ALDH-2 may point towards an inherent population-
speciﬁc genetic predisposition (Fong et al., 2005; Manthripragada et al., 2010; Punia et al., 2011;
Wang et al., 2011; Furlong et al., 2016; Paul et al., 2016a). However, most studies addressing gene–
environment interactions are limited by the small sample size and recall bias inherent to case–control
studies.
c) Oxidative stress
The role of oxidative stress in the aetiopathology of PD is well established (Zhou et al., 2008;
Surmeier et al., 2011; Schildknecht et al., 2013). The metabolism of DA can lead to the generation of
hydrogen peroxide (H2O2) and other reactive oxygen species (ROS). This exposes dopaminergic
neurons of the SNpc to a higher level of oxidative stress than other brain regions. There is evidence
that some pesticides would enhance these oxidative stress events. Structurally diverse pesticides can
do this, based on several different mechanisms that eventually converge on a shift of the redox
balance of the dopaminergic cell. For instance, paraquat toxicity is related to its ability to redox cycle,
accepting an electron from an appropriate donor with subsequent reduction in oxygen to produce
superoxide while also regenerating the parent compound. Moreover, paraquat may enhance oxidative
stress by activating the NADPH oxidase of microglia cells (Drechsel and Patel, 2008). A third way to
increase oxidative stress would be to activate glial cells (neuroinﬂammation), which may directly
mediated neurotoxicity or exacerbate the toxic outcomes already initiated within neurons following
exposure to toxic chemicals (Ramsey and Tansey, 2014). Moreover, part of the toxic mechanism of
dithiocarbamate fungicides (e.g. maneb) has been associated with the dopamine oxidation and
chelation of metals, leading to alterations in cellular redox status. Permanent parkinsonism has been
reported following chronic occupational exposure to maneb (Meco et al., 1994), which supports the
potential role of this fungicide in the aetiology of PD. Although dopaminergic areas of the brain
(striatum, substantia nigra and nucleus accumbens) have the highest levels of the antioxidant enzyme
paraoxonase (PON2), levels in males are two- to threefold lower than in females. These lower PON2
levels may provide weaker defences against oxidative stress in male dopaminergic neurons and may
support the higher incidence of PD in males (Furlong et al., 2016).
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d) Aldehyde dehydrogenase (ALDH) inhibition
ALDH enzymes are responsible for detoxiﬁcation of exogenous and endogenous aldehydes by
oxidising aldehydes to carboxylic acids. Aldehyde metabolites have been suggested to be involved in the
pathogenesis of PD; for instance, 4-hydroxy-nonenal (4-HNE), a common aldehyde product of lipid
peroxidation, promotes the formation of a-synuclein oligomers (Zhang et al., 2015). ALDH also
continuously detoxiﬁes 3,4-dihydroxyphenylacetaldehyde (DOPAL). This degradation product of
dopamine is generated in neurons by monoamine oxidase (MAO), and has been involved in the loss of
dopaminergic neurons in PD as a result of generating hydroxyl radicals. Under speciﬁc experimental
conditions, ALDH activity can be inhibited by pesticides such as the metal-complexed dithiocarbamates
(e.g. maneb, ziram), imidazoles (benomyl, triﬂumizole), phthalimides (captan, folpet) and organo-
chlorines (dieldrin) (Fitzmaurice et al., 2013, 2014).
e) Mitochondrial dysfunction
Inhibition of complex I of the mitochondrial electron transport chain is a biologically plausible
mechanism for the development of PD that has gained growing relevance. Damaged mitochondrial
DNA, as evidence of mitochondrial oxidative stress is, e.g. found in PD brains (Sanders et al., 2014).
Both intoxication with MPTP/MPP+ and that with rotenone directly result in inhibition of complex I and
in mitochondrial dysfunction (reviewed in Breckenridge et al., 2016). Dopaminergic neurons of the
SNpc have been shown to be uniquely sensitive because of their higher production of mitochondrial
H2O2 in response to complex I inhibition as compared to cortical neurons (Sanders et al., 2014).
Inhibition of complex I activity can lead to the generation of ROS, which then target and inhibit the
respiratory chain leading to subsequent ROS production and further mitochondrial damage. The
consequent failure in energy production may disrupt the vesicular storage of dopamine, leading to
increased free cytosolic concentrations of this auto-oxidisable neurotransmitter (Drechsel and Patel,
2008). Two other pesticides, maneb and dieldrin, have been suggested to also inhibit the respiratory
chain. For instance, exposure to maneb has been found to result in inhibition of mitochondrial complex
III. This contributes to ROS production and mitochondrial dysfunction (Zhang et al., 2003; Drechsel
and Patel, 2008). Organochloride pesticides related to dieldrin have been suggested to impair
sequestration of dopamine into neurotransmitter vesicles, and the resultant increase in cytosolic
dopamine may increase the risk of oxidative stress (Miller et al., 1999; Vergo et al., 2007).
f) Congruence of clinical features
Parkinsonism is a complex syndrome with a heterogeneous set of clinical features. For instance,
parkinsonism observed in humans due to high-dose exposure to manganese or carbon monoxide, has
clinical features that differ from those that are normally related to idiopathic PD. For instance, there is a
poor response to dopaminergic therapy. This situation is different for cases of PD associated to pesticides
(Tanner et al., 2011). Similar clinical features were found in PD cases that did or did not have exposure to
rotenone, paraquat, or groups of pesticides with similar mechanisms. This observation suggest that PD
associated with these agents is clinically typical, and this provides further plausibility for a role of pesticide
exposure in the aetiology of typical PD.
3.2. To what extent do experimental toxicity studies on mechanisms of
toxicity cover mechanisms relevant for PD, and what is the
contribution of the AOP in supporting biological plausibility
3.2.1. Rationale of the working approach
At present, different and separate sets of information exist concerning the following ﬁve domains:
pesticide exposure, toxicant MoA, experimental studies, disease pathogenesis and the occurrence of
PD. The combination of information from these domains may shed light on the questions (i) whether
the statistical correlation of pesticide exposure and occurrence of PD is mechanistically plausible,
(ii) whether there are causal links and (iii) if such links can be conﬁrmed or refuted by experimental testing.
As a starting point, data are available from regulatory toxicity studies that link pesticides to
traditional endpoints (e.g. histopathology). In addition, for some toxicants a mechanism of action is
known. The ﬁrst question relevant to the working group’s mission was to investigate, whether a
mechanism of pathogenesis could be assigned to PD in form of an AOP. The second open issue
addressed was to investigate whether experimental studies would yield information concerning the
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mechanism of action of toxicants. The third step was then to investigate whether mechanisms of
action of toxicants overlapped with mechanisms of disease pathogenesis (AOPs) relevant for PD.
Finally, the answer to these questions was used to establish plausible links between the exposure to
pesticides and the risk of developing PD.
3.2.2. Capturing of a complex disease (PD) by AOP
The AOP concept has been developed by toxicologists to describe the hazard of toxicants. The
concept has not been envisaged to cover complex human disease. This has several reasons: deﬁned
MIE may not exist for diseases; diseases may follow a multihit principle instead of linear chains of
events; diseases have multiple symptoms instead of one ﬁnal unhealthy outcome; pathogenesis of
chronic degenerative diseases is likely to be based on cyclic events; KEs of chronic disease are difﬁcult
to capture or to be modiﬁed experimentally; data on diseases and disease pathogenesis are different
in type and in the way they can be obtained than data of poisonings with toxicants; experimental data
on disease are either difﬁcult to obtain and to reproduce or they cannot be obtained at all.
Considering the above arguments, the development of ‘AOP for diseases’ will only be possible in
some favourable situations. ‘AOP relevant for a certain disease’ is a more exact deﬁnition than the
more superﬁcial but easy to remember term ‘disease AOP’. The process of AOP development is greatly
facilitated, if the disease has a variant that is known to be induced by a deﬁned toxicant; if deﬁned
molecular interventions are known to block the pathogenesis of the disease; if complete sets of data
are known on deﬁned stages of the disease; and if biomarkers or measures obtainable by non-invasive
methods describe the progression of the disease.
The most important restriction is that the AOP should not be deﬁned for the disease as such, but
for a sharply deﬁned symptom of the disease (as equivalent to an adverse outcome for toxicants). A
second important condition is that this endpoint can be reproduced in animal models, and that
chemicals exist that trigger the same endpoint in the animal models; this implies that example (tool)
chemicals are available that are likely to trigger the envisaged ‘disease AOP’. As such conditions were
fulﬁlled here, it was scientiﬁcally acceptable to work on model AOPs relevant to PD.
3.2.3. Selection of the AO
Parkinson’s disease is a human-speciﬁc clinical syndrome, usually not observed in animals. The key
clinical signs are bradykinesia, rigidity, resting tremor and postural instability. In addition, the disease
may be associated with vegetative symptoms (intestinal disturbances, disturbed sleep pattern),
cognitive decline and affective symptoms (most frequently depression). Many different AOPs may thus
be associated to the disease. This is because ﬁrst, the disease has several adverse outcomes, and
second, several AOP may converge onto each of these AO, according to the OECD deﬁnition of AOP.
For proof of concept, ‘parkinsonian motor symptoms’, i.e. what is described in patients mainly as
bradykinesia and rigour, were chosen as AO. Parkinsonian motor symptoms were deﬁned here as the
typical motor deﬁcit observed in human disease and in experimental conditions, as a result of the loss
of dopaminergic neurons of the nigrostriatal pathway. Other AO could have been chosen. For instance,
cognitive function (Paul et al., 2016b) and tremor would have been candidate endpoints. The choice of
the Panel was driven by the relative speciﬁcity of the endpoint for PD, by the possibility to associate
the AO to known and deﬁned pathologic changes, and by the transferability to animal models.
Parkinsonian motor symptoms were considered to be relatively speciﬁc, to be found universally in all
cases of PD, have a well-deﬁned underlying pathology, and to be measurable and modiﬁable (by
drugs) in experimental animals. Notably, parkinsonian motor symptoms are not 100% speciﬁc for PD,
but this is not a necessary condition for an AO.
3.2.4. Choice of example AOP relevant both for parkinsonian motor symptoms
and for pesticides as risk factors
Having chosen the AO, the next question was which types of assumed pathological sequences were
to be reﬂected by a proof-of-concept AOP. The decision was taken to consider only pathological
processes occurring during adult life. It has been hypothesised that PD may also have developmental
origins (Landrigan et al., 2005), and pesticides may have effects on early brain development, but this
potential aetiology was deliberately not considered here. For practical reasons, pathological processes
were preferred for which there was sound and ample evidence that they were triggered by chemicals
in experimental animals, and preferably also in humans. Having decided on these criteria, and on the
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AO, the literature was screened for chemicals that triggered parkinsonian motor symptoms. For this,
on the one hand, a systematic literature review commissioned by EFSA (EN-955, 2016) was consulted,
and on the other hand, expert knowledge on the state of experimental parkinsonism research was
used. On this basis, the Panel decided to develop two relevant AOP up to a quality level sufﬁcient for
submission to the OECD. These two AOPs (described in detail in Appendix A) are mainly based on data
for three chemicals (MPTP/MPP+, rotenone, paraquat) that had particularly abundant documentation
and that could be used to deﬁne the corresponding AOP.
This decision process has some important implications for the interpretation of this opinion. The
most important one is that the AOP developed here may only explain a small fraction of the supposed
interaction of pesticides and PD risk. As the initial molecular structures and biochemical pathways
disturbed by a toxicant are highly compound-speciﬁc, there is no such thing as a ‘pesticide AOP’ or a
MoA that makes the connection of pesticide exposure and PD risk plausible. This also applies to
smaller subclasses, such as herbicides, fungicides or insecticides (Breckenridge et al., 2016). The aim
of the Panel was to test whether the hazard posed by individual pesticides could be linked to the
pathogenesis of PD via AOP. If the outcome of this approach is considered promising, then a multitude
of AOPs would need to be developed to allow linking of many different pesticides to various symptoms
of PD. Some pesticides may fail to ﬁt any of these AOPs, which could be an interesting ﬁnding as such.
On the other hand, several of these AOP may share common key events, such as oxidative stress, and
this would considerably reduce the development work to the deﬁnition of partial AOP and their
connection to common KE.
3.2.5. Use of tool chemicals to determine whether their mechanism of action
overlaps with AOP for PD
The three most data rich chemicals were selected from the literature to build AOP that would describe
their hazard. MPTP/MPP+ was chosen, as there are well-documented human poisoning data, large sets of
primate data and very extensive sets of rodent data, documented by several hundred publications per
year (Daneshian et al., 2015). Rotenone was chosen because of the numerous data from rodent models,
and because its molecular target, the mitochondrial complex I is particularly well-characterised. Notably,
MPTP/MPP+ is assumed to have the same target, and also for human disease pathology there is good
evidence that this target plays a role (Schildknecht et al., 2015). Paraquat was chosen, ﬁrst as there is
good evidence for its toxicity in animal models, and second as this has been an individual compound (as
opposed to the group ‘pesticides’) that was associated to PD in epidemiological studies. In line with the
example chemicals chosen, two MIE were deﬁned: binding to mitochondrial complex I and initiation of a
redox cycling process. These were linked to the AO via two AOP.
This process was fundamentally different from biomedical and systems biology initiatives to deﬁne
disease pathogenesis. For instance, a universal PD map has been developed (Fujita et al., 2014) that
incorporates the biomedical knowledge on disease processes relevant to PD. This map takes into
account multiple genetic susceptibility factors and modulating events, and its organisation is non-linear.
Nevertheless, the two AOP chosen by the panel can be identiﬁed also on this complex map as relevant
pathways (among others) and thus are consistent with current medical knowledge on the disease
process of PD. The prototype AOPs are fully reported in the Appendix.
3.2.6. Evaluation of the AOP concerning consistency and strength of evidence
A large part of the effort to develop AOPs was used for their evaluation, and the documentation of
this process. The strength of association was judged by a WoE approach based on modiﬁed Bradford–
Hill criteria. This is fully described in Appendix A.
Based on the overall WoE, the Panel concluded that the link between the MIEs and the AOs as
proposed in the developed AOPs is strong and that the proposed KEs (including the MIEs and the AO)
can be used as a tool for exploring the hazard of a chemical to trigger parkinsonian motor deﬁcits.
One key conclusion from this is that, if a chemical triggers the MIE or an intermediate KE of such
an AOP to a sufﬁciently large extent, it is likely that it will also trigger the downstream KE, including
the AO. This would be a large conceptual advance in predicting chemical hazard in terms of increasing
the risk for chronic human disease. Another important feature also resulted from the evaluation: it is
highly important to obtain as much quantitative data as possible on the KE relationships in order to
practically apply hazard predictions based on AOP.
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3.2.7. Support of mechanistic plausibility by AOP
Based on above considerations, the Panel is supporting the use of the AOP framework to explore a
plausible mechanism linking pesticide exposure and Parkinson’s disease. The recommendation is that
pesticides affecting the AOPs developed here should be considered as potential risk factors (with
respect to the development of PD). The same would apply to other AOPs linked to PD, and that would
need to be developed in the future.
To avoid misunderstandings, it needs to be stressed that the Panel pursued the development of
AOP and the recommendations of their use speciﬁcally for the identiﬁcation of risk factors, and not for
risk assessment. This is fully in line with the standard backbone of risk assessment, i.e. to evaluate
whether there is any hazard at all, and if so, to proceed with more complex evaluation of the risk.
This exclusive focus on hazard is logical and necessary, as the AOP framework does not consider
(external or internal) exposure data or any toxicokinetic and metabolic processes. To fully rationalise
this, it needs to be recalled that an AOP is a ‘pathway’, i.e. a series of biochemical interactions and
pathological events. From this, it becomes evident that the pathway as such cannot have
pharmacokinetic parameters. These latter ones are associated with individual compounds that trigger
the pathway, and they are evidently unique for each chemical, i.e. cannot be associated to the AOP as
such. For practical risk assessment, this means that potential triggering of an AOP by a chemical
corresponds to the step of hazard evaluation. The next step within the MoA framework of risk
assessment would then be the consideration of exposure and speciﬁc ADME properties of a given
compound to come to an overall conclusion on the likelihood of a pesticide to trigger PD.
3.2.8. Conclusions from AOPs on suitability of current testing methods
The Panel is interpreting the AOP as a practical, transparent and pragmatic tool to integrate
knowledge on mechanisms of toxicity with the measurement of apical endpoints of toxicity. In the case of
‘AOPs relevant for human disease’, as developed here, the integration of different levels of information
goes one step further. The AOP integrates mechanistic knowledge on disease pathogenesis, apical
endpoints, as measured in experimental toxicity studies and clinical symptoms of the disease. This
situation allows solutions to the question, in how far the apical endpoints measured in animal studies
adequately reﬂect endpoints of disease. Already during the process of development of the small number
of AOPs of this Panel assignment, it became obvious that there are limitations of the standard regulatory
studies when dealing with hazards linked to human complex multihit diseases like PD and parkinsonian
disorders in general. The AO (parkinsonian motor deﬁcits) and the KE linked to degeneration of DA
neurons of the nigrostriatal pathway (which are common to both AOPs developed by the Panel) are
typical apical endpoints that would in theory be identiﬁable in the regulatory toxicity studies. However, a
review of the standard technology and approach used for such studies, showed that changes in these
endpoints would most likely be missed, even if large adverse effects were present (e.g. loss of 30% of all
nigral dopaminergic neurons). The identiﬁcation of neuropathology would require speciﬁc sectioning of
the respective area (which is not done in standard OECD 90-day guideline studies), and it would require
immunohistochemical approaches instead of standard H/E staining. The motor deﬁcit would also not be
identiﬁable if neuronal loss in the nigrostriatal pathway was below the threshold activating motor deﬁcits
(i.e. below 50–70% loss).
The lessons learned from the AOP suggest that even if histological sectioning of the substantia nigra
and staining for dopaminergic markers were included in a guideline study, severe adverse effects of test
chemicals may still be missed. Both AOPs indicate that the perturbation of the key events shows not only
a response–response concordance, but also that triggering of some downstream KE requires disturbance
of the upstream KE for a prolonged period of time. This has major implications for the study design. For
instance, dosing should be tailored in a way to continuously trigger the MIE for a long time. This may not
be the case, if toxicants are dosed only once or twice a week, and only three to four times altogether.
With an inappropriate dosing schedule, changes in the downstream KE or AO (i.e. the apical endpoints
of regulatory studies) may be very low, or even absent. In view of these considerations, AOPs, and the
mechanistic information derived from them should be used. Optimising the design of hazard
identiﬁcation studies according to the expected mechanisms of toxicity can then be achieved. Moreover,
AOP can be used to indicate data gaps in cases of inconsistent experimental studies, and to provide
guidance for improved study design to address data gaps, inconsistencies and uncertainties. This also
comprises suggestions on additional endpoints to be assessed, either as direct indicators of hazard or as
mechanistic support to improve data interpretation and species extrapolation.
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3.3. AOPs as informative sources for appropriate identiﬁcation of data
gaps and testing strategy
3.3.1. AOP as a scaffold to help identifying data gaps
Due to the nature of the AOP that is building KERs and thus supporting causality of events with a
WoE approach, the AOP concept is very well suited for identifying data gaps. Based on the
epidemiological data linking pesticide exposure to PD and the deﬁnition of the AO being ‘parkinsonian
motor deﬁcits’, several modes of action were identiﬁed linking an initiating event to the KE essential for
the AO. This essential KE is the death of dopaminergic neurons of the nigrostriatal pathway with
decrease in DA, which is essential for motor control. Thus, for the AOPs developed by the Panel, the
causality of substance binding to and subsequent inhibition of complex I or mitochondrial ROS
formation by redox cycling both leading to mitochondrial dysfunction, impaired proteostasis, death of
DA neurons of the nigrostriatal pathway and parkinsonian motor deﬁcits is biologically plausible and
essential.
Assessment of data gaps within an AOP is feasible by analysing the WoE for each KER within an
AOP. In the case of KER ‘Binding of inhibitor to NADH-ubiquinone oxidoreductase (complex I) leads to
its inhibition, the WoE is strong. Despite this high level certainty, there are several open questions
within this KER: (1) low doses of complex I inhibitors with only partial inhibitory function do not
compromise cellular ATP levels suggesting an alternative mechanism contributing to long-term, low-
dose nigrostriatal toxicity; (2) few data on complex I inhibitor concentration–response using human
brain cells/mitochondria thus lacking sufﬁcient quantitative human data. Also, the KER ‘A Redox Cycling
compound leads to mitochondrial ROS formation and dysfunction’ has a high WoE. This is especially
true for substances with an electron reduction potential more negative than O2, which effectively
produce superoxide. Generation of superoxide and subsequent mitochondrial dysfunction has been
well described in different taxa. The second level of KER ‘Inhibition of Complex I leads to mitochondrial
dysfunction’ also has a strong WoE as complex I inhibition causes loss in mitochondrial membrane
potential with decrease in ATP production, elevated levels of ROS, followed by reduced activities of
enzymes of the mitochondrial respiratory chain causing ultimate mitochondrial dysfunction: a process,
which is also very well studied.
Although there is the notion that other mechanisms than complex I inhibition might be responsible
for dopaminergic cell death by complex I inhibiting substances, the overall data supporting this KER is
outweighing. The KER ‘Mitochondrial dysfunction results in an impaired proteostasis’ has a strong WoE
because there is a high biological plausibility that proteasome activity is dependent on mitochondrial
function and that increased ROS formation interferes with proteasomal function. However, there is
data gap on the sequence of events triggering proteasomal dysfunction. This is the case as there is a
vicious cycle concerning a-synuclein aggregation and proteasomal dysfunction and it is not clear which
one is occurring in a ﬁrst instance. Some studies suggest that induced oxidative stress leads to
a-synuclein aggregation that triggers proteasomal dysfunction. Other studies report that initial
proteasomal dysfunction induced by ROS causes a-synuclein aggregation. Moreover, the role of
alterations in the cytoskeleton contributing to proteasomal dysfunction is not clear. For example,
tubulin colocalises with a-synuclein in Lewy bodies and tubulin function is ATP dependent.
WoE for the KER ‘Impaired proteostasis leads to degeneration of DA neurons of the nigrostriatal
pathway’ is strong. Yet, the essentiality for impaired proteostasis for nigrostriatal cell death is moderate,
e.g. acute MPTP exposure leads to speciﬁc DA cell death without the formation of Lewy bodies. This
might be due to the acute exposure scheme followed in the assay. Effects of long-term and low-dose
exposure on proteostasis would be of interest and is representing a data gap in that it is not know how
long this KE needs to be perturbated to trigger DA neuronal death. In addition, different features of
imbalanced proteostasis can trigger one another (e.g. disturbed protein degradation, pathological protein
aggregation, microtubule dysfunction); and each of them can lead to cell death. Therefore, the ‘single’
event triggering axonal degeneration or neuronal death is not known. For instance, for a-synuclein
aggregation, it is not clear whether this causes death because some vital function of neurons is lost, or
whether some protein increases, e.g. because of inhibited chaperone-mediate autophagy.
The involvement of the KER ‘neuroinﬂammation leading to nigrostriatal cell death and vice-versa’ by
interaction of a chemical with microglia/astrocyte cells as a MIE is discussed controversially. Some
compounds like paraquat might directly activate microglia/astrocyte cells by ROS production through
redox cycling by interaction with inﬂammatory cells NADPH oxidase. Moreover, neuroinﬂammation is
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debated as a modulatory KE possibly enhancing nigrostriatal toxicity of chemicals. In the two AOPs
related to PD, neuroinﬂammation was placed as a late event, paralleling degeneration of dopaminergic
cells of the nigrostriatal pathway. More exactly, the placement of neuroinﬂammation in the AOP
assumes that degeneration is an important trigger of neuroinﬂammation, and that neuroinﬂammation
contributes to degeneration. This cyclic nature of events is common to many chronic disease
processes. In the case of neuroinﬂammation, even further cycles may be involved that have not been
considered here: (i) possibly some features of neuroinﬂammation are already triggered by earlier KE
and (ii) neuroinﬂammation may further enhance early KE of the AOPs. This complex relationship of
neuroinﬂammation to other KE makes it difﬁcult to deﬁne thresholds for its activation.
Furthermore, there is a data gap in the precise understanding on how activation of
neuroinﬂammatory cells might contribute to DA toxicity and how to quantify it. There is strong WoE for
the KER ‘Degeneration of DA neurons of nigrostriatal pathway leads to parkinsonian motor symptoms’.
Impaired motor symptoms are expected to be clinically visible when striatal dopamine levels drop by
approximately 80%, corresponding to a DA neuronal loss of approximately 60%. However, in vivo
experimental studies gave inconsistent results upon compound treatment. Yet, the precise reasons for
inconsistencies in results in well-performed in vivo studies are not known, indicating a data gap.
3.3.2. Present data gaps in regulatory studies
In humans, the main neurological symptoms of PD are tremor, rigidity, bradykinesia and postural
instability, which can be accompanied by non-motor symptoms such as olfactory deﬁcits/anosmia,
sleep impairments, depression, cognitive impairment, constipation, incontinence and autonomic
dysfunctions.
Pathologically, PD is characterised by the loss of dopaminergic neurons in the SNpc and the
presence of cytoplasmic protein aggregates, Lewy bodies (LB), in remaining dopaminergic cells and a
loss of dopamine (DA) in the striatum. Although PD animal models developed for better understanding
of the disease and development of new therapeutics do not exactly reproduce the human disease,
they exhibit some of the hallmarks of PD (both motor dysfunction and pathological outcomes). With
regard to neurotoxicity requirements for pesticides regulatory assessment, the question is if the
guidelines followed may identify these speciﬁc motor dysfunction and pathological outcomes.
Motor dysfunction
Detailed clinical observations including: autonomic activity, body position, activity level, gait,
posture, reactivity to handling, placing or other environmental stimuli, the presence of clonic or tonic
movements have to be performed in all OECD toxicity guidelines.
Motor activity should be measured once in short-term repeated dose toxicity studies (OECD 407,
408 and 422) and several times in speciﬁc neurotoxicity studies (OECD 424, OECD 426 and cohort 2 of
OECD 443). The same measurements (of horizontal and/or vertical movements in a test chamber) are
implemented in both routine studies and neurotoxicity studies.
However, this is not a requirement in chronic toxicity studies unless neurotoxic effects have been
reported in the shorter studies.
In PD animal models, co-ordination and balance are evaluated by rotation, rotarod or pole tests,
and gait abnormalities by forepaw stride length test (Li et al., 2014). Those tests are not required by
any repeated dose toxicity OECD guidelines and they can be optionally incorporated in the design of
neurotoxicity studies OECD 424 and OECD 426.
Pathology outcomes
Brains should be weighed and histopathological examination performed on the brain, spinal cord
and peripheral nerves in all OECD guidelines.
Perfusion ﬁxation of brains for neuropathology evaluation is only required in both OECD 424 and 426,
while morphometric evaluation should be performed in OECD 426 but is only optional in OECD 424.
In order to detect damage on the substantia nigra, appropriate samples of the brain should be
obtained (i.e. rostral midbrain section through the anterior colliculus).
The standard three brain sections performed in repeated dose toxicity studies do not contain the
substantia nigra while in OECD 424 and 426 adequate samples from all major brain regions should be
taken (e.g. olfactory bulbs, cerebral cortex, hippocampus, basal ganglia, thalamus, hypothalamus,
midbrain (tectum, tegmentum, and cerebral peduncles), pons, medulla oblongata, cerebellum) to
ensure a thorough examination.
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Both the Society of Toxicologic Pathology (Bolon et al., 2012) and the National Toxicology Program
(Rao et al., 2011) recommend routine sampling of six to seven coronal sections of the brain in
standard general toxicity studies including a section through the midbrain, with the substantia nigra
listed as one of the speciﬁc areas of interest. However, those recommendations are not included in
current OECD 407, 408 or 452 guidelines. Furthermore, studies complying to former guidelines
constitute the dossiers of many pesticides for the renewal process, thus, the recommendations are
most likely not applied in the studies.
Furthermore, in order to capture the hallmarks of PD, speciﬁc procedures could be necessary (see
also Appendix A) as:
• detailed neuropathology assessment of the SNpc and striatum for cell death and
neuroinﬂammation (Breckenridge et al., 2013; Smeyne et al., 2016);
• detection of the total number of TH (the enzyme responsible for catalysing the conversion of
the amino acid L-tyrosine to L-3,4-dihydroxyphenylalanine (L-DOPA)) positive neurons in SNpc
and TH positivity in the striatum by immunocytochemistry. Stereological protocols for cell
counting should be applied (Tieu et al., 2003; Breckenridge et al., 2013; Smeyne et al., 2016);
• it is important that an unbiased assessment of neuronal cell loss must include carefully
conducted stereology (not simply morphometry) and pathology studies where the pathologist
is ‘blinded’ to the treatment regimen of each experimental animal assessed (Breckenridge
et al., 2013; Smeyne et al., 2016);
• neurochemistry toxicity endpoints: Dopamine (DA) and dopamine metabolites (DOPA and
homovanillic acid);
• immunostaining to detect a-synuclein (AS) aggregates.
All such procedures are not routinely carried out in a standard toxicological data package submitted
for pesticide approval.
With regard to the regulatory requirements, identifying hallmarks of PD may be challenging for
active substance for which no previous data indicating potential neurotoxic effect is available. Indeed,
only motor activity measurements performed in short-term organ toxicity studies could give rise to a
presumption. If there are no signals of neurotoxic effect in those studies, then speciﬁc neurotoxicity
studies will not be required and motor activity will not been assessed in chronic toxicity study
(although longer exposure may lead to different results). In the same way, histopathological measures
carried out in routine studies may be not speciﬁc enough to stress PD outcomes.
In case of suspected neurotoxicity (like pesticidal mode of action or structural similarity to known
neurotoxicants, neurotoxicity study (OECD 424) is required and inclusion of more specialised tests of
sensory, motor function or learning and memory, speciﬁc pathological procedures should be considered
in order to examine these possible effects (in this case PD) in greater detail.
Neuroinﬂammation
The identiﬁcation of the several different features of neuroinﬂammation during the AOP construction
process showed an important shortcoming of regulatory experimental test procedure: the lack of speciﬁc
methods to assess neuroinﬂammation. The standard neurotoxicity testing does not require
measurements of any marker of neuroinﬂammation, except for fuel additives, where testing for a
potential increase in glial ﬁbrillary acidic protein (GFAP), as marker of astrocyte reactivity, is mandatory
according to the US EPA (40 CFR 79 67). This is a deﬁciency for two reasons: (i) neuroinﬂammation is
not easily identiﬁed by standard histopathological methods (e.g. neutrophil inﬁltration as in many
peripheral tissues is rarely observed in the brain); (ii) neuroinﬂammation is obviously a good indicator of
a multitude of different damage processes., i.e. it indicates a toxic action of a compound even if other
damage parameters are only slightly affected (and thus remain undetected by standard methods). The
latter point is related to the relatively low speciﬁcity of neuroinﬂammation. Indeed, this process is not
only exclusively observed in PB, but also observed in most neurodegenerative diseases (Whitton, 2007;
Tansey and Goldberg, 2009; Niranjan, 2014; Verkhratsky et al., 2014; Sampson et al., 2016).
Neuroinﬂammation can also be triggered by several classes of toxicants (Monnet-Tschudi et al., 2007).
This relative non-speciﬁcity (i.e. the capture of many different AOPs with one apical endpoint) makes the
testing of neuroinﬂammation an interesting additional endpoint in regulatory toxicology to provide an
alert of ongoing damage that may otherwise have been missed. Nevertheless, neuroinﬂammation testing
is still a challenging issue since it requires multiple endpoints and careful consideration of the test data.
This is because neuroinﬂammation is a complex event (not a single biochemical reaction), involving
different cell types (mainly microglial cell and astrocytes), responding to diverse (sometimes yet
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unknown) inﬂammogens or signals from injured neurons (Graeber and Streit, 1990; Monnet-Tschudi
et al., 2007; Kraft and Harry, 2011; Claycomb et al., 2013). Activated glial cells release a large panel of
mediators, which can (i) have positive or negative consequences on the adjacent neurons; (ii) change
composition during the long duration of the neuroinﬂammatory process; or (iii) lead to a self-sustained
vicious circle (Carson et al., 2006; Glass et al., 2010; Aguzzi et al., 2013). Thus, neuroinﬂammation
depends strongly on the pathogenic context. The problem is that the negative/neurodegenerative
consequences of neuroinﬂammation do not only depend on the intensity of the glial reaction (quantity),
but also rather on the type of the neuroinﬂammatory process (quality). For instance, activated microglia
can be in the M1 (prodegenerative) or the M2 (protective) state (Ponomarev et al., 2007; Maresz et al.,
2008; Kigerl et al., 2009; Perego et al., 2011). Both phenotypes can be observed concomitantly (von
Tobel et al., 2014) and the features of neuroinﬂammation can change over time, e.g. with a
neurodegenerative phenotype appearing late, after cessation of exposure, as observed after repeated
treatments with the herbicide paraquat (Sandstrom von Tobel et al., 2014). Therefore, it is not possible
to deﬁne a threshold that should be reached to trigger the next key event, but the phenotype, the
production and the composition of the inﬂammatory mediators, such as pro-inﬂammatory cytokines,
reactive oxygen (ROS) or nitrogen species (RNS) (Dong and Benveniste, 2001; Brown and Bal-Price,
2003) should rather be considered in order to predict the consequences of the neuroinﬂammatory
process. In addition, as inhibition of one or two features of neuroinﬂammation leads only to partial
protection of dopaminergic neurons and terminals following rotenone, MPTP/MPP+, or paraquat
exposure (for references, see table of quantitative relationships in KER neuroinﬂammation to
neurodegeneration of nigrostriatal pathway), it is a combination of several factors and not a single one
that trigger the neurodegenerative process. Therefore, neuroinﬂammation cannot be sufﬁciently
characterised by measurement of a single parameter. All these considerations make it, for the time
being, a challenge to include neuroinﬂammation in the standard regulatory studies. However, the future
mechanistically driven hazard identiﬁcation approaches implies also the development of in vitro testing
and several test systems for neuroinﬂammation have been developed, based on cocultures of neurons
and glial cells in 2D and 3D, using human or rodent cells as a starting point (Monnet-Tschudi et al., 2007;
Alepee et al., 2014; Sandstrom von Tobel et al., 2014; Efremova et al., 2015, 2016).
4. Introduction to Childhood Leukaemia
Paediatric leukaemia is a common childhood cancer (representing 30% of all cancers in children
under the age of 15) with an incidence peak between 3 and 5 years of age. The disease is
phenotypically and genetically heterogeneous, targeting B-cell, T cell or myeloid progenitors and can
be additionally stratiﬁed according to the differentiation stage at which the haematopoietic stem and
progenitor cells (HSPC) are blocked. The HSPC being the target cell, fetal haematopoiesis and in utero
exposure are key elements that have to be considered for the assessment of the relationship between
pesticide exposure and the disease. Fetal haematopoiesis starts in the aorta gonad-mesonephros
region and yolk-sac (ref) and colonises the fetal liver and eventually, just before birth, the bone
marrow (Wang et al., 2011). The fetal liver haematopoiesis is therefore representing the sensitive
target as it is entailing a massive active proliferation of progenitor cells, rendering the HSPC
susceptible to oncogenic transformation following DNA damage during pregnancy (Emerenciano et al.,
2007). Although the aetiology of the acute leukaemia is not deﬁned, in utero exposure to
environmental factors represents a relevant aetiological suspect; nevertheless, the paucity of
mechanistic data is still representing a major obstacle to understand which toxicological pathways are
involved. This is also corroborated by the likely multifactorial origin of the disease with the risk derived
from environmental exposure and inﬂuenced by genetic susceptibility (Hernandez and Menendez,
2016). In addition, recent mechanistic data has supported previous epidemiological data on the role of
late infections in clonal evolution of ALL. Whether environmental (i.e. pesticides) cues are affecting
infection development during childhood remains unknown (Greaves, 2006).
Of note, almost all the available epidemiological evidences are not making a distinction between
infant and childhood leukaemia which are two distinct aetiological and pathological entities and this is
complicating the interpretation of the epidemiological outcome where the terms paediatric or childhood
leukaemia is frequently generalised. Although chromosomal translocation is likely representing the
common initiating oncogenic event for both disease, IFL shows a unique biological feature which is
the common association with the rearrangements of the MLL gene, a master gene that regulates the
normal progression of the human haematopoietic development and differentiation (Ernst et al., 2002).
It has to be recognised, however, that there are ALLs with normal karyotypes, i.e. no translocation
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detected. It is obvious that the MIE in these cases is more obscure. Although the MLL (and analogous
gene) rearrangement is representing (one of) the key events for the initiation of the disease in the
HSPC (or an earlier mesenchymal cell), it is likely that it is sufﬁcient only for the development of the
overt IFL and additional factors would contribute to the aberrant proliferation of the initiated cells in
CHL. These might depend on alternative (epi)genetic cooperating lesions at a critical developmental
window. In addition, and relevant for this Scientiﬁc Opinion, epidemiological and genetic studies
suggest that MLL rearrangement may result from in utero exposure to DNA topoisomerase-II poisons,
including but not limited to the chemotherapeutic agent etoposide (Emerenciano et al., 2007; Sanjuan-
Pla et al., 2015). A chain of pathogenetic events linking the in utero exposure to Topo-II poisons to IFL
is fully reported in Appendix B and is representing the attempt made by the Panel to build up a
qualitative AOP to mechanistically support the biological plausibility that exposure to pesticides could
be linked to the development of IFL.
In utero exposure to environmental risk factors is also relevant for the development of CHL.
However, for the CHL, although the initiation event still involves a structural or numerical chromosomal
alteration, the development of the leukaemia requires the activation of cell proliferation. The longer
latency period for the CHL (when compared to the IFL) clearly indicates that the initiating event is not
enough for the conversion of a preleukaemic clone into cancer, strongly suggesting that a second, very
likely postnatal, hit is necessary. Dysfunction of the immune system and delayed infections have been
frequently linked to CHL by means of mechanistic considerations like a dysregulated immune response
consequent to a low repertoire of infections during the early development of the immune system and
an aberrant congenital response to infections (Greaves, 2006). In its attempt to build an AOP speciﬁc
for the CHL, the Panel found insufﬁcient evidence to identify a mechanistically plausible MIE and no
chemicals were identiﬁed to empirically support the toxicity pathway. Nevertheless, considering the
relevance of the debate linking pesticide exposure and potential development of CHL, the
Panel developed a hypothetical AOP which is fully reported in Appendix.
5. Plausibility of the involvement of pesticide exposure as a risk factor
for infant and childhood leukaemia and contribution of the AOP
concept to support plausibility
5.1. Biological plausibility in support of pesticide-associated IFL and CHL
In contrast to the epidemiological studies mentioned above, there is scarce experimental and
mechanistic evidence supporting an association between exposure (at any stage of development) to
pesticides (or any other chemical excluding benzene and related compounds) and paediatric
leukaemia. While for CHL, there is no tool chemical capable of inducing the disease under
experimental conditions, for IFL there is enough evidence for the anticancer drug etoposide. Despite
the distinct natural history and pathogenesis of infant and childhood leukaemia, both entities share a
chromosomal translocation as the major initiating oncogenic event.
Most of the studies available in the open literature pertaining to pesticides do not directly link
pesticide exposure to development of CHL. Nevertheless, they do provide some evidence of the
genotoxic or cancer-promoting capacities of some pesticides based on cellular studies, suggesting the
potential of these compounds to trigger leukaemogenesis. An in vitro study showed that a human
leukaemic (K562) cell line exposed to 1 lg/mL isofenphos for 72 h exhibited an enhanced proliferation
and poor cellular differentiation (Boros and Williams, 2001). In addition, human peripheral
lymphocytes exposed to 0.1–10 lg/mL isofenphos for 1 h exhibited dose-dependent damage to
chromosomal DNA (using the comet assay) as well as disruption of the cholinergic nuclear signalling
pathway, which collectively could lead to genomic instability and leukaemogenesis (Williams et al.,
2004). On the other hand, human K562 cells exposed to 0.1 lM of diazinon resulted in
hypermethylation of several genes involved in cell cycle arrest such as cyclin-dependent kinase
inhibitors (CDKN1A and CDKN1C) as well as tumour suppressor genes such as p53 and PTEN (Zhang
et al., 2012). Furthermore, human mammary carcinoma MCF-7 cells exposed to low concentrations of
diazinon http://www.who.int/foodsafety/areas_work/chemical-risks/jmpr/en/) or fenitrothion (0.001–10 nM)
for 24 h exhibited a higher degree of micronucleus formation (Ukpebor et al., 2011).
Lu et al. (2015) found that human fetal liver HSPCs exposed to chlorpyrifos for 24 h resulted in MLL
re-arrangements and double-strand DNA breaks in a dose- and time-dependent manner. This study
suggested that chlorpyrifos might act as a topoisomerase II (TOP2) poison similar to benzoquinone
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(a benzene metabolite), etoposide and bioﬂavonoids, thus belonging to chemicals capable of
interacting with TOP2, the MIE target in the AOP IFL. However, given some limitations of the study,
ﬁrm conclusions can for the time being not be drawn based on this one study.
Pesticides other than OPs have been demonstrated in in vitro studies to show genotoxic properties,
which could be linked to the MIE of the AOP CHL and IFL. For instance, human neuroblastoma SH-SY5Y
cells and human T-cell leukaemia Jurkat cells exposed to methyl-pyrazole insecticides (tebufenpyrad,
bixafen, fenpyroximate or tolfenpyrad) for 1 h showed increased induction of c-H2AX (a marker of
double strand DNA breaks) attributed to the generation of oxidative stress as a result of impairment of
the mitochondrial electron transport chain (Graillot et al., 2012). Furthermore, exposure of the CEM x
174 cell line, a hybrid of human T and B cells, to 50 lM heptachlor, chlordane or toxaphene for 24–36 h
showed decreased protein levels of the tumour suppressors p53 and Rb (Rought et al., 1998, 1999).
Low concentrations of heptachlor (5–10 lM) suppressed doxorubicin-induced caspase-3 activity and
subsequent activation of apoptosis in this cell line (Rought et al., 2000). Human peripheral lymphocytes
exposed to 20 lg/mL of a commercial formulation of the fungicide dinocap for 24 h exhibited increased
chromosomal aberrations, formation of sister chromatid exchanges and decreased mitotic index (Celik
et al., 2005). In vitro studies with the chloroalkylthiocarboximide fungicides captan and captafol at a
concentration of 1 lM have shown to decrease the activity of murine TOP2 by 50% and 20%,
respectively (Rahden-Staron, 2002). Similarly, thiram (a dithiocarbamate fungicide) inhibits TOP at
10 lM (Rahden-Staron et al., 1993). However, the in vivo genotoxic potential of these fungicides (i.e.
genetic deletions and/or mutations) occurred only at very high doses in Drosophila (10–100 mM)
(Rahden-Staron, 2002).
In assessing the above studies coming from the open literature, ﬁndings from regulatory studies
should also be taken into account. Tebufenpyrad, bixafen, fenpyroximate, captan, chlorpyrifos and
thiram are approved in the EU, and none of them are classiﬁed for genotoxicity, thus the mandatory
regulatory studies did not show genotoxic potential. Captan is classiﬁed for carcinogenicity (duodenal
tumours in mice). For the rest of the pesticides not approved in the EU, none of them are currently
classiﬁed as being genotoxic, while two are classiﬁed being carcinogenic; namely chlordane and
captafol. Thus, although a thorough assessment of the genotoxic potential of the mentioned pesticides
have not been undertaken, the Panel ﬁnds that the few in vitro studies available from the open
literature so far to support the epidemiological evidence for the association between childhood
leukaemia and exposure (in utero and/or after birth) to some classes of pesticides is limited. Also,
there is limited evidence from in vivo studies. However, it remains uncertain whether this association
arises from a causal or non-causal relationship and biological studies to provide evidence for a
potential mechanism have been inconclusive. Almost all in vitro studies used immortalised cell lines or
primary human lymphocytes from adults and 3-week-old mice, which are not appropriate cell models
for studying CHL. The only one study using fetal liver HSPCs can be considered as the best cell model
for this purpose.
This clearly indicate how complex is to deﬁne and weight biological plausibility when both
regulatory studies and experimental studies from the open literature are contradicting.
The mechanisms underlying the association between pesticides and CHL are currently poorly
understood and more studies are needed to better understand this association. There is agreement in
the scientiﬁc community that a well deﬁned key event involved in paediatric leukaemogenesis is the
induction of chromosomal rearrangements. The hypothetical mechanistic linkage between some
pesticides and this genetic damage may be accounted for by TOP2 poisoning (for IFL) or generation of
oxidative stress leading directly or indirectly to DNA damage.
a) TOP2 poisoning (inhibition)
TOP2 has critical functions in both DNA replication and transcription processes. Under physiological
circumstances, the active site tyrosine in TOP2 serves as a nucleophile to initiate the ﬁrst
transesteriﬁcation reaction to form a covalent adduct with the backbone phosphate in DNA, thus
generating a transient break. The second transesteriﬁcation reseals the DNA break and regenerates
the free tyrosine (Chen et al., 2013). In contrast, exposure to TOP2 poisons can lead to the
stabilisation of the transient DNA/Top2 cleavage complex resulting in an increased frequency of DNA
double-strand breaks and error-prone non-homologous end-joining (NHEJ) repair. For this reason,
these chemicals are called TOP2 poisons to distinguish them from catalytic inhibitors of the enzyme.
Cells harbouring accumulated breaks in DNA are not able to enter into the mitotic phase of the cell
cycle, thus undergoing cell death.
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Some anticancer drugs (i.e. etoposide, doxorubicin), environmental chemicals (i.e. benzene, some
pesticides) and natural substances (i.e. bioﬂavonoids) are TOP2 poisons with DNA cleavage activity
(Pendleton et al., 2014). Among the TOP2-poison chemicals, only etoposide has strong evidence for
causing acute leukaemia in human via the general process of the AOP described herein. For the other
Top2 poisons, including bioﬂavonoids, the evidence is weaker.
Etoposide is a semisynthetic derivative of podophyllotoxin that exhibits cytotoxicity by inhibiting
DNA synthesis as described above. However, if cells manage to bypass cell death, the accumulation of
DNA double-strand breaks (DSB)s can lead to chromosomal translocations and further generation of
fusion gene products (particularly MLL rearrangement). Evidence supporting the causal relationship
between etoposide-induced TOP2 inhibition and the MLL rearrangement is strong regarding treatment-
related acute leukaemia (Cowell and Austin, 2012; Pendleton et al., 2014). Between 2% and 12% of
patients that receive epipodophyllotoxin develop secondary AML, with the mean latency period from
drug administration to the onset of secondary leukaemia being about 2 years. The risk of secondary
AML appears to be dependent on both treatment schedule and dose. Typically, epipodophyllotoxin-
induced AML occurs after multiple doses administered in brief intravenous infusions with cumulative
doses ranging from 5,200 to 19,200 mg/m2 (Ezoe, 2012). Dose–response relationships between
etoposide and treatment-related leukaemia are difﬁcult to unravel, but risk of leukaemia seems to
increase with larger total exposure to etoposide. There is no doubt that the fusion genes are caused
by etoposide treatment because MLL rearrangements have not been detected in bone marrow samples
banked before the start of the treatment of the ﬁrst malignancy (Pendleton et al., 2014).
Chemical-induced DNA breakpoints are associated with predicted Top2 cleavage sites (i.e. MLL),
supporting an essential role for TOP2-mediated breakage. The high frequency of Top2 recognition sites
in speciﬁc DNA regions and the high expression of this enzyme in human CD34+ HSPCs represent
favourable conditions for breakage following exposure to Top2 poisons. Because CD34+ HSPCs appear
to be more sensitive to DNA damage than committed progenitor cells, exposure to low levels of different
chemicals may induce DNA breakage at certain sites in HSPCs, increasing the risk of chromosomal
rearrangements (Bueno et al., 2009; Montecucco et al., 2015; Thys et al., 2015; Hernandez and
Menendez, 2016).
Studies on identical twins and neonatal blood samples strongly implicate an in utero occurrence of the
key events (Sanjuan-Pla et al., 2015). Furthermore, a study in pregnant mice demonstrated that in utero
exposure of the fetus to etoposide causes the MLL chromosomal translocation analogously as in humans
but with different gene fusion partners (Nanya et al., 2015). Indirect evidence from human
prehaematopoietic/mesenchymal stem cells and fetal liver HSPCs strengthens the biological plausibility.
Experimental evidence in these cell lines has demonstrated that etoposide causes DSBs in MLL and
partner genes, which leads to the formation of fusion genes and their products (Sanjuan-Pla et al., 2015).
Nanya et al. (2015) have shown that in utero exposure to etoposide induces MLL translocations in
ATM-knockout mice, which are defective in the DNA damage response, but not in wild-type mice.
Moreover, fetal liver HSPCs were more susceptible to etoposide than maternal bone marrow
mononuclear cells, pointing out the life stage-related susceptibility in regard to Top2 inhibition also in
the mouse. However, in utero exposure to etoposide failed to induce leukaemogenesis (Nanya et al.,
2015). However etoposide can induce a large number of MLL rearrangements, most of them occur
within non-coding regions, without eliciting direct oncogenic consequences. The appropriate oncogenic
event needs to occur in a target cell within a relatively small and spatially restricted cell population
during the appropriate and epigenetically plastic developmental window. Thus, it is a very rare event
and difﬁcult to support empirically.
Li et al. (2014) developed a cell model based on the hypothesis that cells are capable of clearing
low-level DNA damage with existing repair capacity. When the number of DSBs exceeds a certain
value, ATM and p53 become fully activated through reversible mechanism, leading to elevated repair
capacity. The dose–response relationships for activation of p53 and the formation of micronuclei in the
target cell model indicate that critical concentrations of etoposide are in the range of 0.01–0.1 lM (Li
et al., 2014). This range is in agreement with the increased levels of DSBs observed in human fetal
liver CD34+ cells at a concentration of 0.14 lM of etoposide; however, MLL translocations were
detectable at higher concentrations (Moneypenny et al., 2006; Bueno et al., 2009).
Despite the limited number of studies investigating the role of chemicals in the pathogenesis of
paediatric leukaemia, the consistent observation of the inhibition of Top2 activity suggests that this
might be a key mechanism induced by chemicals with leukaemogenic potential. Apart from this, there
are also other common mechanisms observed among the studies involving chemicals, such as
oxidative stress.
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b) Oxidative stress
Oxidative stress has been implicated in haematotoxicity induced by benzene and pesticides (Choi
et al., 2016).
Under some circumstances, oxidative lesions can lead to DNA DSB formation in HSPCs.
Environmental exposures to numerous chemicals, including many pesticides, have been shown in vivo
and in vitro to generate ROS that can ultimately induce DNA oxidative damage, leading to single-
strand breaks (SSBs) and DSB formation in the DNA (Sedelnikova et al., 2010). For example, OP
insecticides (chlorpyrifos, methyl-parathion, malathion), methyl-carbamates (methomyl) and the
herbicide paraquat all cause oxidative DNA damage followed by DNA SSBs and DSBs (Muniz et al.,
2008; Guanggang et al., 2013; Ojha and Srivastava, 2014; Esperanza et al., 2015). There is also
evidence of pesticide-induced oxidative stress and DNA damage in agricultural workers (Muniz et al.,
2008). Additionally, oxidative species may interact with biological molecules to disrupt normal DNA
synthesis and repair, and so inhibition/inactivation of antioxidant proteins or DNA repair enzymes may
also be an underlying molecular mechanism (Kryston et al., 2011).
ROS are not known to directly cause DSBs; however, DSBs could be generated if two SSBs oppose
each other on complementary strands or could occur as secondary lesions at the replication fork or
during an intermediate step in a repair process (Li et al., 2013). DNA DSBs are the most harmful initial
event in molecular and cell carcinogenesis. Unrepaired DSBs may result in structural chromosomal
abnormalities, whole or partial chromosome loss and genetic recombination, but can also lead to the
breakdown of DNA replication, causing apoptosis to prevent a possible mutation being passed or
during replication (Ap Rhys and Bohr, 1996).
Speciﬁc oncogene activation in different tumour models has been linked to DNA DSBs and the
activation of DNA-damage checkpoints. Efﬁcient DSB repair is crucial for the maintenance of genomic
integrity. In response to DNA damage, phosphatidylinositol-3 kinase-related kinases ATM (ataxia
telangiectasia mutated) and ATR (ATM- and Rad3-related) are initially activated and subsequently
phosphorylate a variety of proteins that regulate the DNA-damage response. DNA DSBs observed in
some studies with chlorpyrifos and atrazine may be due to the ability of these compounds to generate
highly reactive molecules/radicals (Huang et al., 2015; Lu et al., 2015). Aldicarb has caused a dose-
dependent DNA damage, with single-strand breaks being produced by low concentrations during short
time, which could be repaired, whereas high concentration led to DSBs which were difﬁcult to repair
(Li et al., 2003). Tetrachlorohydroquinone, the major toxic metabolite of pentachlorophenol, can
induce DNA lesions as this metabolite contributes to the release of free radicals which have been
linked to tumour promotion (Chen et al., 2015).
When the ROS are elevated beyond physiological levels, oxidative stress can cause HSPC
dysfunction. These cells are extremely sensitive to oxidative stressors, such as anticancer agents,
radiation, and the extensive accumulation of ROS. NADPH oxidase has been proposed for ionising
radiation-induced persistent and prolonged intracellular ROS generation in human CD34+ HSPCs, such
that the resulting oxidative stress is associated with inhibition of the clonogenic potential of these cells
(Yamaguchi and Kashiwakura, 2013).
ROS-induced DSBs in human fetal liver CD34+ HSPCs following maternal exposure to chemicals
trigger recombination/repair pathways by NHEJ. The majority of damaged HSPCs may either
successfully repair the DNA DSBs or fail to do so and undergo apoptotic cell death. If the DNA DSBs
within particular breakpoint cluster regions (bcr) are not correctly repaired, chromosomal
translocations or deletions may occur, although this possibility is very unlikely and would only happen
in a small fraction of cells. For fusion genes to be leukaemogenic, DSBs must occur simultaneously in
two chromosomes and must also involve the coding region of the genes to generate an exon-exon in-
frame functional chimeric gene product. Importantly, this has to occur in a HSPC that has managed to
bypass cell death and displays a sustainable lifespan and clonal potential to propagate the chimeric
gene product (Hernandez and Menendez, 2016).
In the case of infant leukaemia, and based on the very short latency of the disease, it is not
completely clear whether the fusion gene generated from chromosomal translocations requires
additional cooperating oncogenic hits for leukaemogenesis. Recurrent activating mutations of genes
associated with cellular proliferation, such as components of the RAS signalling pathway, are important
for tumour maintenance rather than initiation in human HSPCs (Prieto et al., 2016). The transformation
mediated by the aberrant proteins encoded by fusion genes might depend on alternative (epi)genetic
cooperating lesions at a critical developmentally earlier window of stem cell vulnerability to develop
overt leukaemia (Sanjuan-Pla et al., 2015).
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For CHL, chromosomal translocations resulting in aberrant chimeric proteins alter the normal
transcriptional program of HSPCs and block normal B-cell and/or myeloid differentiation. In contrast to
MLL-associated infant leukaemia, chromosomal translocations linked to childhood leukaemia (i.e. TEL-
AML1) are not sufﬁcient to cause the disease by themselves. As TEL-AML1 fusion gene is observed in
cord blood from about 1% of normal newborns, a signiﬁcant proportion of the population carries self-
limiting preleukaemic clones, the majority of which do not result in disease. The longer latency and
that only a fraction of children carrying the translocation develop the disease unequivocally indicates
that the initiating chromosomal translocation per se is unlikely to convert a preleukaemic clone into an
overt disease, consequently secondary cooperating (epi)genetic events are needed. In this regard,
developmental dysfunction of the immune system followed by an aberrant immune response upon
delayed infections has been linked to the development of CHL (Greaves, 2002; Pui et al., 2008; Teitell
and Pandolﬁ, 2009; Wiemels, 2012).
5.2. To what extent do experimental toxicity studies on mechanisms of
toxicity cover mechanisms relevant for IFL and CHL, and what is
the contribution of the AOP in supporting biological plausibility
5.2.1. Rationale of the working approach
At present, the scientiﬁc evidence available sheds light on the following topics: pesticide exposure,
toxicant MoA (e.g. etoposide), experimental studies, disease biology and the occurrence of paediatric
leukaemia (including both infant and childhood leukaemia). The combined information allows
understanding better whether the statistical association of pesticide exposure with the development of
paediatric leukaemia is mechanistically plausible; whether causal links are indicated; and if such links
can be conﬁrmed or refuted by experimental testing.
As a starting point, there is sound epidemiological evidence in support of the association between
pesticide exposure (either occupational or environmental/residential, either pre- or postnatal) and
paediatric leukaemia. However, positive data from regulatory toxicity studies linking pesticides to
traditional endpoints (e.g. genotoxicity) are lacking. In addition, for some chemicals, a mechanism of
action is known (e.g. etoposide), but this is not the case for pesticides for which the evidence is weak.
The ﬁrst question to be addressed was to evaluate whether a pathogenic mechanism could be
assigned to paediatric leukaemia in form of an AOP. This could only be achieved for IFL but not for
CHL because of the lack of clearly delineated molecular initiating events. The second issue raised was
to ascertain whether experimental studies provide information concerning the mechanism of toxic
action of chemicals. The next step was to investigate whether toxicity pathways of chemicals
overlapped with the mechanisms supporting the disease pathogenesis (AOPs) relevant for infant and
childhood leukaemia. Finally, the answer to these questions was used (see Section 8.4) to establish
plausible links between exposure to pesticides and the risk of developing paediatric leukaemia.
5.2.2. Capturing complex diseases (IFL and CHL) by AOP
A major obstacle in developing AOP of events leading to AO in paediatric leukaemia stems from the
complex nature of this disease. The MIE and the adverse outcome highly depend on the subtypes of
the disease (e.g. infant or childhood leukaemia, lymphoblastic or myeloid leukaemia).
Furthermore, the most important restriction is that the AOP should not be deﬁned for the disease as
such, but for a sharply deﬁned feature of the disease (as equivalent to an endpoint or adverse outcome
for toxicants). A second important condition is that this endpoint can be reproduced in animal models,
and that there exist chemicals that trigger the endpoint in the animal models. This implies that example
chemicals are available that are likely to trigger the envisaged ‘disease AOP’. As such conditions were
partially fulﬁlled herein (only for IFL), it was scientiﬁcally acceptable to work on model AOPs relevant to
IFL but only an hypothetical AOP could have been developed for CHL. Although the apical outcome is
the same for those clinical conditions, the natural history of the disease is different for IFL and CHL and
the MIE has been identiﬁed only for IFL. This can be considered as a developmental disease with all the
relevant pathogenic steps occurring in utero and with an exceptionally short latency. In contrast,
childhood leukaemia ﬁts better to the two-hit model conﬁrmed in the natural history of several cancers
and hypothesised for leukaemogenesis. The initiating event would occur in utero and the promoting
event would occur postnatally. Besides, whereas a single event is enough for IFL (as exempliﬁed by MLL
rearrangement), a similar event is not enough to trigger childhood leukaemia.
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5.2.3. Selection of the AO
Leukaemia is a group of cancers that presents with the proliferation of immature, clonal, myeloid or
lymphoid precursors leading to progressive marrow failure and ultimately death. Clinical symptoms and
signs of paediatric leukaemia usually reﬂect bone marrow inﬁltration by leukaemic blasts and/or
extramedullary disease. The major clinical signs consist of neutropaenia, thrombocytopenia and
anaemia, with these signs being responsible for symptoms such as increased susceptibility to infections
(with fever), bruising, bleeding, pallor and fatigue. Accordingly, many different AOPs might be
associated with the disease because of the several adverse outcomes of the disease, as well as
pathway may converge into the same AO or share the same KE. Despite this, leukaemia has been
identiﬁed in several animals and animals’ models have been developed to study the disease, the
disease as such is not an apical endpoint in the regulatory toxicity studies and a mechanistic
understanding of apical hazard suggestive of the AO is needed.
For proof of concept, symptoms and signs of overt paediatric leukaemia were chosen as AO. However,
human leukaemia features have not been fully recapitulated in experimental animal models and the
major candidate endpoints consist of chromosomal translocations that show similarities with those found
in humans (sometimes paediatric patient-derived leukaemia xenografts with MLL or TEL/AML1
translocations). The wide range of genetic and epigenetic changes needed for the expansion of
preleukaemic clones prevents from delineating a sharp deﬁnition of paediatric leukaemia, either IFL or
CHL.
5.2.4. Choice of example AOP relevant both for IFL/CHL and for pesticides as
risk factors (see Appendix B)
Once the AO had been deﬁned, the next question was to describe the sequence of pathogenic
events that could be incorporated into a proof-of-concept AOP. For practical reasons, etoposide (a non-
pesticide chemical; a chemotherapeutic drag currently used for the treatment of cancer at various
sites) was chosen as a tool example for IFL leukaemia because of the sound and consistent evidence
in humans and experimental animals pointing out the pathophysiological processes triggered by this
chemical. However, no chemical has been identiﬁed so far with the capability of triggering the
toxicological pathway leading to childhood leukaemia. Notwithstanding this limitation for building an
AOP, the systematic literature review commissioned by EFSA (Ntzani et al., 2013) concluded that there
was sound epidemiological evidence linking pesticide exposure at diverse developmental stages and
paediatric leukaemia. Moreover, expert knowledge on the state of experimental paediatric leukaemia
research was used. On this basis, the Panel decided to develop two relevant AOPs one of them based
on data for etoposide and the second AOP was a putative one because of the lack of empirical data at
clinical, cellular, mechanistic or regulatory level that support any particular chemical with the onset of
childhood leukaemia. However, there is abundant data that could be used to deﬁne the rest of the
corresponding AOP.
This decision process has some important implications for the interpretation of this scientiﬁc
opinion. The most important one is that the AOPs developed herein fail to support strongly how the
different pesticides can lead to any of the different types of paediatric leukaemia. Besides, as the initial
molecular targets and biochemical pathways disturbed by a toxicant are highly chemical-speciﬁc, a
‘pesticide AOP’ cannot be deﬁned. Likewise, there is no a plausible MoA that relates exposure to any
individual pesticide (or pesticide classes) with paediatric leukaemia. Therefore, the PPR Panel decided
to test whether the hazard posed by pesticides could be linked to the pathogenesis of paediatric
leukaemia via AOPs. However, a single AOP may not capture all events that contribute to the relevant
adverse outcome, instead sets of AOPs sharing at least one common event may capture more
realistically potential toxic effects. If this approach is considered useful, then a multitude of AOPs could
be developed for the many different pesticides currently used for improving our knowledge on their
mechanism of toxic action. It can be anticipated that not all pesticides will ﬁt any of these AOPs and
also that several of these AOPs may share common KEs, or may converge into common intermediate
key events, which would allow the deﬁnition of partial AOPs and their connection to a common KE.
5.2.5. Use of tool chemicals to check whether their mechanism of action
overlaps with AOP for IFL and CHL
Etoposide was selected from the biomedical literature as the most promising tool chemical to build
an AOP that would describe its hazard. The rationale is that well-documented human and experimental
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data, both in vivo and in vitro, support the involvement of etoposide in the development of leukaemia.
Its molecular target, TOP2, is particularly well-characterised. Also, for infant leukaemia biology, there is
good evidence that this target plays a key role (Pendleton et al., 2014). In contrast, no tool chemical
has been identiﬁed in the open literature for CHL. Since data are lacking to delineate the MIE for this
disease, efforts were made to ﬁll a conceptual gap by presenting a hypothetical framework that
provides sufﬁcient biological plausibility based on an analogy approach derived from toxic mechanism
following exposure to ionising radiation. Accordingly, the example chemical chosen for IFL allowed to
deﬁne a MIE (TOP2 inhibition/poisoning), whereas the lack of MIE for CHL restricted the exercise to
develop a putative AOP linked to the AO. The approach followed takes into account multiple genetic
susceptibility factors and modulating events such that it falls within ‘system toxicology’. By analogy to
systems biology, this approach is intended to decode the toxicological blueprint of an active substance
that interact with biological targets that function as a network in cells, tissues or organisms (Sturla
et al., 2014).
The two AOPs chosen by the PPR Panel can be ﬁtted on this complex scenario as relevant
pathways and are consistent with current medical knowledge on the disease biology of paediatric
leukaemia. The prototype AOPs are fully reported in Appendix B.
5.2.6. Evaluation of the AOP concerning consistency and strength of evidence
Data generated from experimental models collectively contribute to the WoE supporting the
proposed AOP. A large part of the effort to develop AOPs was used for their evaluation, and the
documentation of this process. The strength of association was judged by a WoE approach based on
modiﬁed Bradford–Hill criteria. This is fully described in Appendix B.
Based on the overall WoE, the PPR Panel concluded that the link between the MIE and the AO as
proposed in the developed AOPs for IFL is strong and that the proposed key events (together with the
MIE and the AO) can be used as a tool for exploring the IFL-triggering hazard of a chemical. Once an
AOP has been established, the MIE can be used to develop screening assays for compounds that
might affect the AOP and networks of interacting AOPs (Knudsen et al., 2015). However, this
framework is not valid for CHL because of the lack of a clearly deﬁned MIE as aforementioned. This
limitation is partially overcome by a set of hypothetical mechanisms that can provide a plausible
biological basis for the epidemiological evidence gathered on the association between pesticides
exposure and CHL.
One key conclusion that can be drawn from this approach is that any chemical triggering the MIE,
or an intermediate key event of the proposed AOP, to a sufﬁciently quantitative extent, may also be
expected to trigger the downstream key events and eventually the AO under certain qualiﬁed and
speciﬁed conditions. This represents an important conceptual advance in predicting chemical hazards
in terms of increasing the risk for human disease. Another important conclusion is the need of
obtaining and using quantitative data as much as possible on the key event relationships for a practical
application of hazard predictions based on AOPs.
5.2.7. Support of hazard plausibility by AOP
Based on the above considerations, the Panel is supporting the use of the AOP framework to
explore the biological plausibility of the epidemiological association between pesticide exposure and
paediatric leukaemia. The recommendation is that pesticides affecting the AOPs proposed in this
opinion should be considered as potentially hazardous with respect to the development of paediatric
leukaemia. The same would apply to other AOPs linked to this disease that could be developed in the
future.
It is stressed again that the PPR Panel recommended the use of AOP speciﬁcally for hazard
identiﬁcation, and not for the assessment of risk. According to the risk assessment process, once any
hazard has been identiﬁed, there is a need to proceed with a more complex evaluation of the risk. The
AOP framework is exclusively focused on hazard and considers neither exposure data nor toxicokinetic
(including metabolism) processes. The series of biochemical reactions and pathological events of an
AOP by deﬁnition cannot have pharmacokinetic parameters. Doses of chemicals are taken into account
for deﬁning a threshold above which individual compounds may trigger the pathway, and they are
evidently unique for each chemical but are not associated with the AOP as such.
Nevertheless, certain features of paediatric leukaemia should be considered for the hazard
plausibility. The scientiﬁc evidence undoubtedly indicates that exposure to chemicals takes place
in utero (prenatal) and even prior to conception. This assumption implies the need to account for
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toxicokinetic factors as chemicals will need to go across the placenta to reach fetal targets. In addition,
many compounds are not only active by themselves but also need to be bioactivated by maternal (and
to a lower extent fetal) biotransformation processes as occurs with etoposide for IFL or with benzene
for adult myeloid leukaemia. The active chemical, either the parent compound or a metabolite, needs
to reach the proper target in the embryo/fetus at a proper time window of development and at a
concentration high enough to trigger the initiating events deﬁned in the AOP. However, these
considerations are not directly related to the chain of pathogenic events involved in the AOP as these
are meaningful only for hazard plausibility. Another feature of paediatric leukaemia is related to
toxicodynamic factors since differences in susceptibility regarding ontogeny processes may be relevant.
For instance, IFL is considered a ‘developmental disease’ showing different features and pathogenesis
than CHL, as more immature haematopoietic precursors are involved. The physiological role and
susceptibility of these precursors to chemicals may vary depending on the embryonic/fetal stage of
development.
5.3. Data gaps and suggestion for testing strategy. Also include the AOP
as informative source for appropriate identiﬁcation of data gaps
and testing strategy
5.3.1. AOP as a scaffold to help identifying data gaps
Since the AOP concept shows causality of events under a weight of evidence approach, it is very
well suited for identifying data gaps. Based on the epidemiological data linking pesticide exposure to
paediatric leukaemia, and the AO being deﬁned as ‘overt leukaemia’, several modes of action were
identiﬁed linking an initiating event to the key event essential for the AO. This essential KE is the
chromosomal translocations within HSPCs, which are cells essential for haematopoiesis. Thus, for the
AOPs developed, the causality of substance binding to and subsequent inhibition of Top2, non-repaired
DNA DSBs or leading to chromosomal translocations, differentiation block of HSPCs, clonal expansion
of preleukaemic clones and overt paediatric leukaemia is biologically plausible and essential. However,
the main challenge of developing AOPs for leukaemia is the complex nature of the disease. For
example, a tumour suppressor gene could be mutated or transcriptionally inactivated while in another
instance an oncogene could be activated to trigger leukaemogenesis. Different genetic aberrations are
associated with different subtypes of leukaemia. In addition, although leukaemia is a cancer with a low
mutation rate, paediatric (childhood and infant) leukaemia are the second cancer with the least
somatic mutations of all cancers sequenced so far (Bardini et al., 2010, 2011; Dobbins et al., 2013;
Andersson et al., 2015). This stable genome makes difﬁcult to unravel the aetiology and pathogenesis
of paediatric cancer and there are no many genetic tags to be traced back for associating exposure to
speciﬁc compounds and then validate the pathway.
Assessment of data gaps within an AOP is feasible by analysing the weight of evidence for each
KER within an AOP. For IFL, the KER ‘In utero exposure to DNA Top2 poisons leading to MLL
chromosomal translocation’ has a strong WoE, although there are still some open questions. For
instance, the appropriate target cell model that recapitulates the production of DSB as a result of Top2
‘poisoning’ has not been identiﬁed so far. Approximately 80% of IFL cases have the MLL
rearrangement, but the remaining 20% carry other chromosomal aberrations leading to different
fusion genes that eventually result in the same leukaemia phenotype. In utero etoposide-treatment in
a murine model, failed to induce leukaemogenesis because the appropriate chromosomal
rearrangement is a rare event that needs to occur in a target cell within a relatively small and spatially
restricted cell population during the appropriate, epigenetically plastic, developmental window.
Moreover, although the risk of IFL seems to increase with larger total exposure to etoposide, dose–
response relationships between etoposide and treatment-related leukaemia are difﬁcult to unravel. In
contrast, for CHL, there is no evidence at the molecular level as to how some chemicals interact with
biological targets to elicit DNA damage. This is not a straightforward question as genetic damage in
HSPCs may be properly repaired in most cases, but if not cells undergo apoptosis. The exact nature of
how and when this damage is not repaired has not yet been clariﬁed as many factors are involved,
thus contributing to a stochastic process with the ﬁnal occurrence of the disease being very unlikely.
The genetic damage (i.e. chromosomal translocations) has to occur in a particularly vulnerable genetic
locus, within the proper cell, and in a speciﬁc time window; however, details of this entire process and
how it happens are not clear.
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The second level of KER for IFL ‘In utero MLL chromosomal translocation leading to infant leukaemia’
also has a high weight of evidence as the potential of both differentiation blockage and clonal expansion
are inherent properties of the MLL-rearranged fusion product. Thus, WoE indicates that IFL originates
from one ‘big-hit’ occurring during a critical developmental window of stem cell vulnerability. However,
although the MLL rearrangement is essential to develop leukaemia, it alone may not be sufﬁcient and
further (epi)genetic factors would contribute to convey a proliferative advantage to preleukaemic clones
to develop overt leukaemia. On the other hand, the MLL-AF4 knock-in mice developed leukaemia only
after a prolonged latency, thus not recapitulating an important feature of IFL.
For CHL, the KE ‘In utero chromosomal translocations leading to differentiation arrest of HSPCs’ has
a high WoE as this process has been very well studied, although the identity of leukaemia-initiating
mutations that result in preleukaemic clones is still an important open question. The block of
differentiation of HSPCs confers self-renewal properties to these cells and provides proliferative
advantage to lymphoid progenitors. However, chromosomal translocations are insufﬁcient by
themselves to cause overt disease. Additional postnatal events are needed for the development of full-
blown disease, but they are not yet sufﬁciently well understood. Experimental models should be
developed in cell lines and in mice to accurately recapitulate human leukaemogenesis. Additionally,
oncogenes and chromosomal translocations should be studied in the appropriate cellular context,
which consist of primary human haematopoietic cells. If the initiating oncogenic alteration is not
occurring in the right cell, mouse models would be unlikely to recapitulate the human disease and
would constitute an inaccurate model of human leukaemia.
The KE ‘Differentiation arrest of HSPCs leading to clonal expansion of leukaemogenic cells’ has a
sound WoE as murine models with human precursor cells harbouring the TEL-AML1 fusion gene need the
acquisition of additional genetic abnormalities to result in overt leukaemia. However, the reproducibility
and accuracy of these models have yet to be validated for humans, providing a data gap. Functional
studies are needed to unveil the key mechanisms driving the evolution of these progenitors/stem cells
into the appropriate type of leukaemia. Besides, individual patients harbour multiple genetic subclones
of leukaemia-initiating cells, with a complex clonal architecture which limits to build a consistent AOP.
Owing to the technical challenge of distinguishing and isolating distinct cancer subclones, many aspects
of clonal evolution are poorly understood. For instance, it remains to be demonstrated to what extent
epigenetic diversity contributes to subclonal heterogeneity in acute leukaemia.
There is scarce scientiﬁc evidence for the KER ‘clonal expansion of leukaemogenic cells leading to
overt childhood leukaemia’ since there are data gaps in the precise understanding on how leukaemic
clones grow and expand. However, the biological plausibility of this KER is large as the pathobiology of
the disease together with its evolutionary genetic landscape clearly indicates a causal linkage between
the expansion of leukaemic clones within either the myeloid or lymphoid lineage and the onset of
clinical phenotype of the disease.
5.3.2. Conclusions from AOP on suitability of current testing methods and
present data gaps in regulatory studies
According to Regulation 1107/2009 on placing of plant protection products on the market,
carcinogenicity and haematological endpoints must be evaluated for hazard identiﬁcation and
characterisation of active substances in order to decide on their approval. In addition, Regulation 283/2013
setting out the data requirements for active substances indicates that genotoxicity and carcinogenicity
studies are always required and that haematological endpoints will be addressed and reported in general
toxicity studies (repeated doses – short-term and long-term – and reproductive toxicity studies).
Haematological endpoints addressed in these studies include red blood cell parameters, total and
differential leucocyte count, platelet count and blood clotting time among others. In addition,
haematopoietic organs are investigated in repeated dose and carcinogenicity studies, so that substances
inducing leukaemia in rodents are expected to be identiﬁed in the basic data set.
The adequate evaluation of the genotoxic potential of a chemical is consistently addressed in
regulatory dossiers by the assessment of different endpoints, i.e. induction of gene mutations,
structural and numerical chromosomal alterations. These endpoints can only be covered by the use of
diverse test systems as no individual test can simultaneously provide information on all of them. The
bacterial reverse mutation assay covers gene mutations and the in vitro micronucleus test allows for
the identiﬁcation of both structural and numerical chromosome aberrations. If all these endpoints are
clearly negative, the substance can be reasonably regarded as devoid of any genotoxic potential.
Conversely, in the case of inconclusive, contradictory or equivocal results from this basic battery of
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tests, further in vitro testing must resolve the situation. In the case of positive results, further tests
in vitro are appropriate either to optimise any subsequent in vivo testing or to provide additional useful
mechanistic information. In vivo tests (mammalian erythrocyte micronucleus or transgenic rodent gene
mutation assays) should relate to the genotoxic endpoint(s) identiﬁed as positive in vitro and to
appropriate target organs or tissues (EFSA Scientiﬁc Committee, 2011). According to this testing
strategy, a substance inducing leukaemia by a genotoxic mode of action is supposed to be captured by
the genotoxicity tests battery.
However, the cell lines or primary cell cultures routinely used for regulatory in vitro genotoxicity
testing may not be representative of HSPCs. The cell systems used in the different tests consist of
adult cells and it is a widely recognised assumption that exposure of these cell systems at high
dosages (until cytotoxicity occurs) would stress the cells to the extent that genotoxic properties would
be found if the chemical was actually genotoxic. However, very early HSPCs have been considered
particularly sensitive to genotoxicity because inter alia of the unfolded nature of their DNA, immature
repair systems, high division rate, high TOP2 expression and activity levels.
Concerning assessment of carcinogenicity and haematological end-points, the design of regulatory
studies does not include a prenatal exposure. While a speciﬁc window of exposure is explored in the
two-generation reproduction toxicity studies, haematological measurements and histopathology of
haematopoietic organs are not performed.
The only regulatory test guideline where haematology and histopathology of haematopoietic organs
are investigated in animals exposed in utero to the testing chemicals is the extended one-generation
reproduction toxicity study. However, only 10 male and 10 female rats per group are examined for
those parameters in order to assess the potential impact of the substance on the immune system.
Nonetheless, this regulatory study is not intended to explore any carcinogenic event, which would
require 50 animals/sex per group. Since this guideline has been adopted recently (2011), this kind of
study has been submitted in very few cases compared to the two-generation reproduction toxicity
study.
For adult leukaemogenesis induced by external factors, the following four main patterns were
outlined by the US-EPA (Eastmond, 1997):
a) the primary type of lymphohaematopoietic cancer induced by chemicals and ionising radiation
in humans is myeloid leukaemia;
b) potent human leukaemia-inducing agents produce signiﬁcant myelotoxicity and structural
chromosomal aberrations in humans and animal models;
c) administration of human leukaemia-inducing agents to mice results in more lymphohaematopoietic
tumours that, unlike to happen in humans, are primarily lymphoid in origin;
d) the rat is considerably less responsive than the mouse to the induction of lymphohaematopoietic
neoplasia following administration of human leukaemogenic agents.
Chemical- and radiation-induced lymphohaematopoietic tumours are complex processes involving
multiple genes, chromosomal alterations and altered differentiation. In addition, other factors such as
metabolic capabilities, DNA repair and genetic susceptibilities may inﬂuence cancer incidence. Given
the complexity and multiplicity of steps, animal models are unlikely to reproduce precisely all the
critical stages involved in development of chemical-induced leukaemias or lymphomas in humans
(Eastmond, 1997).
Other limitations of rodent models for assessing the risk of leukaemias are represented by the
different classiﬁcation schemes of haematopoietic neoplasms used for rodents and humans. In mouse,
histopathological distinction between malignant and non-malignant myeloproliferations is also hard to
establish. Likewise, distinction between lymphoma and leukaemias is often difﬁcult, particularly in
mouse, which can lead to misclassiﬁcations. Rats are relatively resistant to chemically induced
leukaemogenesis; however, Fischer 344 rats, which are commonly used in carcinogenesis studies,
exhibit a high incidence of spontaneous large granular lymphocyte leukaemia (LGLL). In contrast,
spontaneous leukaemias are rare in other rat strains. The background incidence of LGLL in F344 rats
has increased over time reaching more than 50% in males (Irons, 1991). Therefore, the usefulness of
this strain for haematopoietic neoplasms exploration is questionable. Despite signiﬁcant interspecies
differences, rodents are valuable models for immunotoxic and myelotoxic effects, including
leukaemogenesis. Furthermore, chronic animal bioassays using mouse models have been shown to be
effective in identifying human (adult) leukaemia-inducing agents (Eastmond, 1997).
Paediatric leukaemias represent a diverse group of diseases with distinct biological features
compared with adult leukaemias. B-cell acute lymphoblastic leukaemia, the most frequent leukaemia
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found in children, is characterised by an uncontrolled expansion of immature B cell (pre-B phenotype).
However, in the particular case of infant B-cell acute lymphoblastic leukaemia, a very early
haematopoietic precursor (pro-B phenotype) is involved. These progenitor cells are initiated in utero,
usually as a result of structural or numerical chromosomal aberrations and/or gene mutations. A wide
range of acquired chromosomal translocations have been associated with early stages of acute
leukaemias pathogenesis, with MLL gene being frequently involved. Special techniques not routinely
performed, such as ﬂuorescence in situ hybridisation (FISH), can be combined to classic genotoxicity
protocols in order to identify speciﬁc translocations with dedicated probes. This would gain additional
mechanistic information.
In summary, assuming that the critical events of paediatric leukaemia consist of in utero induction of
chromosome aberrations followed in cases of CHL by an aberrant postnatal immune response to
common infections, it is evident that the current animal tests/models do not cover these critical events.
5.3.3. Consideration on testing strategy
The above considerations point out that the current testing paradigm is not designed to detect
those leukaemogenic agents that act only during early life stages (prenatal and early postnatal). There
appear to be different sensitivities between cells for in vitro genotoxicity testing (notably HSPCs are
considered more sensitive to genotoxic damage than other cells) and some in vivo tests (i.e. the
chromosomal aberration test and the micronucleus test) have shown a poor sensitivity, likely because
of the low exposure of haematopoietic cells in vivo. Besides, the carcinogenicity study design does not
cover the relevant window of exposure and the model does not include a second hit that has been
captured in experimental models (i.e. aberrant immune response to delayed infections). The only test
guideline that covers this developmental period of susceptibility is the extended one generation test, in
which haematology parameters and histopathology of haematopoietic organs are assessed on animals
exposed in utero and during the juvenile period. However, this guideline has a low power to detect the
leukaemogenic potential of a chemical because of the low number of animals examined. Besides, since
this is a recent testing protocol there is scarce data on chemical substances already on the market.
The EFSA Scientiﬁc Committee recommended a stepwise approach for the generation and evaluation
of data on genotoxic potential. This approach consist of: (a) a basic battery of in vitro tests; (b)
consideration of whether speciﬁc features of the test substance might require substitution of some of
the recommended in vitro tests by other in vitro or in vivo tests in the basic battery; (c) in the event of
positive results from the basic battery, review of all the available relevant data on the test substance;
and (d) where necessary, conduct of an appropriate in vivo study (or studies) to assess whether the
genotoxic potential observed in vitro is expressed in vivo (EFSA Scientiﬁc Committee, 2011).
For a practical testing approach to leukaemogenesis potential of chemicals, in vitro genotoxicity
should be tested in the relevant cells, particularly HSPCs, and technologies should be applied to detect
structural or numerical chromosomal abnormalities (i.e. FISH). Besides this, evidence of target cell
exposure is necessary for in vivo tests. In relation to whether or not the carcinogenicity studies (or the
combined chronic toxicity/carcinogenicity studies) are appropriate to capture the carcinogenic potential
of chemical exposures during developmental phases, consensus among the scientiﬁc (and regulatory)
community is needed to reach sound and feasible recommendations as to how to proceed. It seems
reasonable that improved models for in vitro testing should be used as a screening tool and that
optimised carcinogenicity studies should be triggered when sufﬁcient positive evidence has been
obtained from lower tier tests. AOP can be used to design a testing strategy.
6. Application of the AOP concept to support the regulatory process;
using parkinsonian motor deﬁcits as an example
AOPs are not chemical speciﬁc and do not include ADME data of the chemical. Therefore, the
Panel decided to evaluate the effective application of the AOP concept to the regulatory process by
designing an exemplary strategy based on the two AOPs relevant for PD. The choice of the Panel was
mainly motivated by the completeness of these two AOPs. In this process, the Panel is proposing to
use the AOPs to build up an IATA strategy to evaluate whether the exposure to a pesticide (e.g.
triggering mitochondrial dysfunction) causes dopaminergic neurodegeneration and ultimately
parkinsonian motor deﬁcits.
The AOP-based KE testing cannot be used as a stand-alone approach but needs integration of
ADME data and embedding into an IATA framework. This will give the conﬁdence that the threshold of
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KEs activation will indeed trigger the full cascade of events and that a dose, temporal and response
concordance is maintained.
In designing a test battery for parkinsonian motor deﬁcits in the context of IATA, the following
considerations should be taken into account:
• duration of exposure, e.g. how long proteostasis needs to be impaired for inducing DA
neuronal death;
• in vitro concentrations relevant to hazard assessment;
• metabolic capacity of the test system;
• assays permitting evaluation of KERs and modulatory factors or measuring recognised
biomarkers reﬂecting KERs activation;
• predictive capacity of the assays, e.g. taking into account a role of glial cells, species
differences, etc.
6.1. Which types of data are needed to predict risk of parkinsonian
motor deﬁcits applying an AOP-informed IATA
Elaboration on the IATA proposal is not formally part of this mandate; however, for understanding the
value of an AOP-based testing strategy and placing the AOP in a larger context for any potential
application in risk assessment, the Panel considered an introduction to the AOP-based IATA as necessary.
For the proposed AOP-informed IATA ‘Assessment of nigrostriatal toxicity’, the Panel adapted the general
IATA concept from the AOP-informed IATAs for skin irritation and corrosion (NV/JM/MONO(2014)19). Ten
modules were identiﬁed for assessing if a compound poses a hazard for inducing Parkinsonian motor
deﬁcits in humans (Table 5).
The ﬁrst step consists in collecting all available data (including regulatory toxicology studies) and
human epidemiological information (Modules 1 & 2) followed by integration of toxicokinetic information
(information on ADME, Module 3; Table 1, Figure 1). Moreover, information on physicochemical
properties, e.g. compound’s redox potential, are gathered (Module 5). Here, the focus lies on the
Table 5: Parts and Modules of the proposed IATA for assessment of nigrostriatal toxicity (adapted
from NV/JM/MONO(2014)19)
Part Module Data
Part 1
(Existing information, physicochemical
properties and non-testing methods)
1
2
3
• Existing information – Existing human
epidemiological data
• Existing guideline studies including nervous system
evaluation (OECD TG 424, 452 and 453)
• In vitro neurotoxicity data
– Other in vivo and in vitro data with the focus
on dopaminergic neurons
4
5
• ADME data
• Physicochemical properties e.g. on redox potential
6 • Non-testing methods
– for substances: (Q)SAR, read-across, grouping
and prediction systems;
– for mixtures: bridging principles and theory of
additivity
Part 2 (WoE analysis) 7 • Phases and elements of WoE approaches
Part 3
(Additional testing, if required)
8
9
10
• Additional in vitro AOP KE-based testing
• Additional in vivo testing
• Additional data on ADME
OECD: Organisation for Economic Co-operation and Development; ADME: absorption, distribution, metabolism and excretion;
(Q) SAR: quantitative structure–activity relationship; WoE: weight of evidence; AOP: Adverse Outcome Pathways; KE: key event.
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compounds’ abilities to (a) be taken up by dopamine transporter or other transporters, (b) generate
ROS, or (c) interfere with complexes of the mitochondrial respiratory chain. Apply (Q)SAR and read
across where possible (module 6). All these data should be evaluated by a WoE approach (module 7).
The WoE approach should be structured and possibly quantitative, and should inform on data gaps for
decision making. At this stage, decision should be taken if new data are needed. However, it is beyond
the scope of this opinion to detail on WoE analysis in general, but guidance on transparent WoE
analysis is being developed by EFSA.
Part 3; if new data are required, an AOP-informed IATA will be used to set-up the most appropriate
testing approach (modules 8–10 and Figure 1). After data generation, the WoE has to be re-evaluated
and decision taken on hazard assessment.
The Panel recommends that the following points are considered for an AOP informed IATA for
‘Parkinsonian motor deﬁcits’.
• should be based on human cells when necessary;
• testing for neurotoxicity performed only on neuronal monoculture might not be sufﬁcient
because glial cells could be modiﬁers of the toxicity; either by promoting toxicity through,
Figure 1: Schematic representation of proposal for IATA process
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e.g. pro-inﬂammatory stimuli or by buffering toxicity through e.g. activation of the cellular
antioxidative defence (Henn et al., 2009; Efremova et al., 2015, 2016);
• dopaminergic neurons should be the preferred neuronal subtype for testing;
• in cases where cell–cell contacts affect cellular responses a 3D format may be considered
(Alepee et al., ALTERNATIVES TO ANIMAL EXPERIMENTATION (ALTERNATIVES TO ANIMAL
EXPERIMENTATION (ALTEX) 2014; Yamada & Cuckierman Cell, 2007);
• cells used for testing should be without ethical concern and of high availability. The human
induced pluripotent stem cells (hiPSC) are envisioned to solve the ethical issues and limitation
of material when working with cells of human origin. They can be differentiated into
(dopaminergic) neurons and astroglia functioning also in vivo when transplanted into rodent
brains (Wernig et al., 2008; Palm et al., 2015);
• the result of the tests must be in line with the temporal and concentration concordance as
described in the AOP;
• apply quality control and good cell culture practice (GCCP) principles to ensure reproducibility
of the results.
Initially, the testing strategy should consider all KEs followed by selection of the most predictive
assays.
According to the proposed AOPs, the following endpoints could be considered for testing: (1)
oxidative stress, (2) mitochondrial dysfunction, (3) proteasomal dysfunction, (4) a-synuclein
accumulation and (5) dopaminergic cell death (Figure 2). Moreover, the testing strategy should include
considerations on the temporality of events as described in the AOPs, by selecting the appropriate
timing for endpoint measurements which has to reﬂect the time concordance. For example, oxidative
stress as KE1 should occur before disturbance of proteasomal function as KE3.
The Panel also recommends that in the context of these AOPs, length of treatment/exposure should
allow for triggering the KEdown (Betarbet et al., 2000; Fornai et al., 2003). The Panel does not expect this
battery consisting of, for example, ﬁve assays (Figure 2) measuring the endpoints mentioned above, to
be the ﬁnal testing strategy, but recommends a statistical analysis of data with a test set of compounds
for selecting a minimum amount of tests that would predict the adverse outcome with the highest
predictivity value. The Panel is also recommending that a tiered approach should be considered.
The structure provided by the 10 modules described above (Table 1) allow for composing an IATA.
Ideally, this IATA should make the maximum use of existing data, being resource efﬁcient and
minimising or eliminating the requirement for animal experiments.
7. Uncertainties
A number of uncertainties were identiﬁed by the Panel for each AOP developed; such uncertainties
are reported in detail in the Appendices. The Panel has, however identiﬁed general uncertainties
concerning human epidemiological studies, experimental evidences and AOP development
methodologies.
• Epidemiological studies
Figure 2: Proposed KERs-based testing strategy established on the AOPs for ‘Parkinsonian Motor
Deﬁcits’. Assay 1: measurement of oxidative stress; Assay 2: assessment of mitochondrial
function; Assay 3: determination of proteasomal function as a measure of proteostasis; Assay
4: identiﬁcation of a-synuclein accumulation; and Assay 5: assessment of dopaminergic cell
death
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Human diseases from epidemiological studies and meta-analyses have been used in this Scientiﬁc
Opinion to deﬁne the adverse outcome (AO) and this is considered an uncertainty per se due to the
known intrinsic limitations of the epidemiological studies.
Deﬁnition of the human health outcome, when this is a complex, multifactorial human disease was
considered by the Panel as an uncertainty. This issue is exempliﬁed by epidemiological studies showing
an association with ‘childhood leukaemia’ (i.e. the diagnosis of leukaemia in infants and children),
whereas the AOP development led to the identiﬁcation of two distinct diseases, i.e. IFL and CHL. The
current epidemiological data do elucidate whether the association with pesticide exposure concerns
infant and/or childhood leukaemia. This problem leads to signiﬁcant data heterogeneity in the
epidemiological studies.
Exposure estimates was considered by the Panel as a major limitation and uncertainty of the
epidemiological studies. Indeed, this uncertainty includes two components: (a) the generic deﬁnition of
the substances of concern which in most cases refers to large usage groups of diverse pesticides (e.g.
‘insecticides’) and only in some cases refers to pesticide structural groups (‘organophosphates’, ‘chloro-S-
triazines’). This generic deﬁnition of exposure cannot identify the individual substances contributing to
the risk; (b) lack of detailed quantitative information concerning internal exposure. For chronic diseases,
such as PD, it is difﬁcult to integrate biomonitoring (biomarkers of exposure) and epidemiology (health
outcomes) information, leading the investigators to use methodologies with low accuracy, e.g. pesticide
usage. Furthermore, in a realistic ﬁeld scenario, humans are exposed to several substances and
coformulants contained in actual pesticide products, representing an additional source of uncertainties. It
should be also noted that epidemiological studies are referring to formulated products while experimental
studies are conducted with the active substance and this should be considered as an uncertainty.
The design of epidemiological studies and the heterogeneity of the target populations may
introduce a considerable heterogeneity among studies that apparently investigate the same outcomes
weakening the reliability of meta-analyses and this was considered by the Panel as an uncertainty.
An uncertainty directly relevant to AOP development is the limitation of knowledge about the
aetiology of multifactorial human diseases, involving the presence of different phenotypes, genetic
factors and environmental factors, other than pesticides. This limitation affects the characterisation of
KEs as well as the estimation of the effects of modulating factors on the KERs.
A second opinion will further elaborate on general uncertainties of epidemiological studies (Q. . .. . .).
• Animal studies
Regulatory toxicity studies have shown intrinsic limitations leading to uncertainties (Paparella et al.,
2013). These are also relevant in relation to this scientiﬁc opinion as regulatory toxicity studies may
not include endpoints that model or predict the relevant adverse outcomes deriving from the
mechanistic understanding of human health outcomes. The Panel also recognises lack of (human)
disease-speciﬁc animal models as an uncertainty. This lack is due to the problem that the adverse
outcome is complex and multifactorial and poorly understood. In particular, the Panel notes the
deﬁciency in predictive in vivo models for both IFL and CHL.
• AOP development
Some uncertainties in the process of AOP development were identiﬁed by the Panel.
• Most of the empirical support for the on MIEs and KEs is currently derived from in vitro assays
using ad-hoc non-standardised models, whereas MIE and KEs can be accurately identiﬁed,
their full description and characterisation may be affected by such factors as the available
models in the literature (e.g. life stage of primary cell cultures) or the use of tool chemicals at
very high concentrations.
• In general, there are uncertainties in correlating in vitro to in vivo concentration. However, the
AOP conceptual framework, should be regarded as a tool for building evidence of response–
response and temporal concordance.
• Correlation between the duration of the exposure in vitro and in vivo is also considered an
uncertainty. Similarly, methods of administering the chemical stressors in experimental
conditions are an uncertainty when considering the presumed routes and duration of exposure
in humans. Nevertheless, at a minimum, the AOP model can provide proof of concept that
environmental chemicals can cause the AOs.
• An AOP illustrated by a single chemical stressor or on a limited number of chemical stressors
(for empirical supports) is recognised as an uncertainty.
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• The extent of which the study(ies) supporting the empirical evidences has/have been
reproduced is recognised as an uncertainty.
• The Panel recognise that the AOPs proposed for the parkinsonism motor symptoms are very
speciﬁc and do not cover all the complexity of PD. In particular, the pathology evaluation
reﬂected in these AOPs is only detailed for the SNpc and different brain areas can be involved
in PD-related pathology.
• Lack of criteria for data selection (assembling evidence) might account for differences in the
strength of an AOP. In addition, there is uncertainty about the consistent way to include the
role of modulating factors into AOP development, particularly when dealing with AOs derived
from complex human diseases.
• Finally, there is uncertainty whether the developed AOPs are the only ones linking PD, IFL and
CHL to pesticide toxicological MoAs.
8. Discussion and Conclusions
Human health risk assessment for pesticides is mostly based on experimental toxicity studies
performed in laboratory animals by oral dosing. These studies are conducted at relatively high doses
with the highest dose expected to be the maximum tolerated dose for the experimental animal species
and strain to be tested and for the predeﬁned study design. The outcome of these pivotal studies is
extrapolated to humans, to other exposure routes and to relatively low environmental doses. With
some exceptions, human data are only available through the epidemiological studies which are
required to be incorporated into the risk assessment according to Regulation No 1107/2009 when
available, and as indicated in Regulation 283/2013 setting out data requirements for active substances.
It is then essential for the evaluation of epidemiological data to weigh, integrate and make use of all
the available information coming from multiple experimental studies. This complex task becomes more
difﬁcult when epidemiological data deals with multifactorial, multihit, chronic diseases, for which
toxicological models or disease-speciﬁc animal models are limited. This Scientiﬁc Opinion exploring
method and principles to guide and investigate the use of experimental data and available knowledge;
it aims to develop a mechanistically driven approach that aims to evaluate the evidence of cause–
effect relationship i.e. biological plausibility and coherence.
In the context of the current opinion, the outcome from an epidemiological observation is biological
plausible if a mechanistic link between cause and effect exists and can be demonstrated using a
coherent framework linking a MIE (cause) to an AO (effect) through a sequence of KEs at tissue,
cellular and population level. This is done in the AOP conceptual framework by assembling and
weighing the evidence using modiﬁed Bradford–Hill criteria. These criteria focus on the biological
plausibility of the KERs (i.e. biology of the pathway), essentiality of the KEs within the AOP (i.e.
necessity of the KEs) and empirical support of the KERs (i.e. quantitative associations among KEs
tested through application of stressors/tool compounds) in a ranking order of importance. The
empirical support should provide evidence for the response–response, incidence and temporal
concordance of the KE relationships. Consequently, in the context of the AOP framework, any chemical
triggering the MIE with a sufﬁcient intensity and time has the potential to lead to the AO. Therefore, an
AOP supporting biological plausibility (i.e. the plausibility that a chemical triggering a MIE can lead to a
speciﬁc AO) will represent relevant information for the inclusion of human data from epidemiological
studies in the process of hazard identiﬁcation. As described in the mandate, the Panel selected PD and
CHL as human health outcomes based on the associations observed for these diseases and exposure to
pesticides which are consistently reported in multiple meta-analyses (Ntzani et al., 2013).
In this attempt to integrate epidemiological studies on pesticide exposure and human diseases by
developing AOPs to assess the biological plausibility of the associations, the Panel recognised a number
of limitations. The premise of the mandate, i.e. that pesticide exposure is associated with PD and CHL, in
itself may constitute uncertainty to the epidemiological conclusions. Other uncertainties arise especially
from the lack of detailed quantitative information regarding exposure and data heterogeneity.
In regard to the link between pesticide exposure and PD, since the Ntzani report (Ntanzi et al.,
2012) the association has been further consolidated in a systematic review by Hernandez et al.
(2016a), Hernandez et al. (2016b). In this work, the authors could conﬁrm that PD is signiﬁcantly
associated with pesticide exposure; however, they could not conclusively identify a single pesticide, or
a speciﬁc pesticide group, associated with a signiﬁcant risk of PD other than paraquat. Regarding the
epidemiological evidence of pesticide exposure and the risk of CHL since the Ntanzi report (Ntzani
et al., 2012), the association has been investigated by additional meta-analyses. Again the association
PPPs, Parkinson’s disease and childhood leukaemia
www.efsa.europa.eu/efsajournal 58 EFSA Journal 2017;15(3):4691
between prenatal exposure (via occupational exposure of the parents was observed both for ALL and
AML, but recognising the considerable uncertainty in regard to the assessment of pesticide exposure.
Again, besides an association with ‘generic insecticides’ the data did not allow to conclude about a
single pesticide, or a speciﬁc pesticide group, associated with a signiﬁcant risk of CHL.
To summarise, assuming that the observed outcomes are not due to other confounders, to date
they cannot be linked to a speciﬁc pesticide active substance, but only to the exposure to pesticides.
However, exposure is rarely to a pesticide active substance alone, but to pesticide formulations and/or
multiple active substances. In reality, a plethora of coformulants that are largely uncharacterised in
regard to toxicological effects (other than acute toxicity by different routes, irritation and sensitisation)
should be considered. The recent assessment and discussion of the epidemiological ﬁndings between
exposure to glyphosate and different cancer outcomes (RAR glyphosate 2015, Addendum 2015) also
highlighted the major uncertainties in associating exposure to a certain pesticide active substance with
an adverse outcome. Uncertainty from the lack of quantitative exposure estimates was compounded
by the simultaneous co-exposure to other coformulants. Another critical issue, that was also relevant
for the conclusion of the EU assessment in regard to the carcinogenic potential of glyphosate, is the
strength of the biological plausibility of the epidemiological observations.
Why an AOP?
The terms of reference of this mandate included exploration of the use of the AOP framework for
supporting both a mechanistic-derived hazard identiﬁcation and biological plausibility of epidemiological
associations, in order to incorporate the human health adverse outcome as part of the hazard
identiﬁcation process. The AOP framework was thus selected as a ﬂexible and transparent tool for the
review, organisation and interpretation of complex information coming from different sources. In this
perspective, the AOP was intended to overcome one of the major limitations of many epidemiological
studies, i.e. lack of understanding of biological plausibility and this aspect has been investigated in this
opinion.
The Panel, in proposing the AOP framework as an integral part of this mandate also considered
several relevant aspects namely: exploring how to improve toxicity testing in regard to effects involved
in complex and multifactorial diseases such as PD and CHL; integration of in vitro predictive tools into
testing in order to shift towards a more ‘toxicity pathways’ -based framework; highlight species
differences or similarities; identify data gaps, research needs and requirements for development of
toxicological assays and IATA. All these aspects have to be dealt with in order to support regulatory
decision in a scientiﬁcally robust framework.
To support his mandate, the Panel committed a systematic review speciﬁcally tailored to serve as a
basis for deﬁning and mapping the causal linkages between an MIE and a ﬁnal AO and possibly
identify all relevant publications related to the mechanisms and chemicals involved in the pathogenesis
of PD and CHL. In case of PD, this turned out to be a considerable number, making it a challenge to
select the relevant publications but at the same time avoid ‘cherry-picking’. The Panel noted that the
use of the systematic review framework also showed some limitations. Using the outcome of the
systematic literature review in building an AOP, it was evident that relevant information was sometimes
not captured despite the very large number of publications retrieved by the search. The most likely
reason was explored and identiﬁed as the use of a structured search protocol with strict inclusion and
exclusion criteria. Although it was recognised that an extensive literature search would have been
more appropriate, the relevant scientiﬁc expertise present in the working group in the ﬁeld of
neurodegenerative diseases and childhood leukaemia with knowledge of the relevant available
literature, overcame this potential limitation. As part of the process the working group of the
Panel also met with authors of relevant publications to gain methodological details which were
considered important in the context of the AOP framework.
Indeed, an AOP need not necessarily be based on a systematic literature review. The quality
assessment of the literature is ﬁltered and guaranteed by the strength of the structured weight of
evidence analysis proposed in the AOP framework; this includes the evaluation of the empirical support
to assess the reproducibility, time and response concordance for the selected chemical tools.
It was noted that the regulatory acceptance of an AOP where the majority of the components, e.g.
the empirical data supporting a KER, is not supported by reproduced data would be very limited. Such
an AOP could, however, serve the purpose of identifying where more data should be generated.
An additional consideration for the regulatory use of AOPs is variability. Variability (due to intrinsic
factors such as genetic polymorphisms, species, age, gender, as well as ‘environmental’ factors such as
diet, lifestyles, etc.) is likely to be a considerable contributing factor for some KEs. To some extent this
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is already considered and discussed in building an AOP, but it is recognised that modulating factors
should be given more space in the AOP development. However, the role of modulating factors is a
general issue in toxicology (e.g. the use of uncertainty factors), to understand how modulating factors
can impact on a threshold is a speciﬁc challenge for AOP development. Indeed, by properly accounting
for modulating factors, AOP might provide a scientiﬁc background to build up speciﬁc uncertainty
factors.
The Panel also observed that the studies included in the empirical support can be quite
heterogeneous in terms of design and route of exposure, and this can be interpreted as a source of
inconsistencies. However, some elements of the study design are important for hazard characterisation
and ultimately for risk assessment. For example the intraperitoneal route of administration is usually
not considered a relevant exposure route for pesticide risk assessment since this route would be most
unlikely for humans. The current toxicological studies conducted in laboratory animals are designed for
hazard identiﬁcation and then for hazard characterisation, in order to determine a suitable point of
departure (NOAEL or benchmark dose). Accordingly, in the context and scope of this Scientiﬁc Opinion,
the Panel intended the development of AOPs for the purpose of solely hazard identiﬁcation to support
biological plausibility based on mechanistic knowledge. If hazard identiﬁcation was based on a route of
administration not relevant for risk assessment, the Panel still considered this to be acceptable and in
line with the principle for developing AOPs. However, for a quantitative AOP with the purpose of being
used for hazard characterisation, this would need different considerations, again depending on
problem formulation. If, for example, the scope is to deﬁne a threshold able to trigger the sequence of
KEs from the MIE to the AO, the route of administration of the tool compound used will still not be
relevant; instead, the concentration(s) at the target(s) able to activate the MIE and KE(s) will
be relevant, independently of the route of administration. Toxicokinetic and metabolism information will
be indeed very important when dealing with compound speciﬁc hazard characterisation by applying the
MOA and/or IATA framework; this information will tell the risk assessor if the concentration of
the speciﬁc compound at the target MIE will be relevant or not for its activation. In any case, the
concentrations used in the empirical support with the tool chemicals should always be assessed to
deﬁne the strength of the response–response concordance. In addition, as well as for the animal
studies, effects detected at excessive doses – close to the maximal tolerated dose/cytotoxicity – would
always require a careful assessment of the biological relevance of the observed ﬁnding.
As detailed in this opinion, the core studies of the regulatory dossiers do not necessarily capture
the potential hazard of pesticides in regard to PD and CHL. This is not unexpected when considering
the complexity of these diseases and the fact that regulatory toxicology studies are intended and
designed to explore multiple hazards and should be considered as stand-alone experiment, i.e. one
species, one strain, one NOAEL for the endpoints explored in the context of the study design. For the
purpose of analysing the plausible mechanisms linking pesticides to human health outcomes, AOPs can
serve as an important tool, particularly when the regulatory animal toxicological studies are negative
but the evaluation of the apical endpoint (or relevant biomarkers) was considered inadequate based on
the AOP.
The scientiﬁc and regulatory relevance of AOP at the different levels of maturity (whether putative,
qualitative or quantitative) would depend on it being ﬁt-for-purpose in a given context; the problem
formulation will therefore drive the building of an AOP, with the expectation that the AOP reﬂects the
current knowledge and the WoE evaluation is transparent and complete.
A putative AOP is intended as a set of hypothesised KEs and KERs primarily supported by biological
plausibility. The Panel considered that for the problem formulation, as expressed in the terms of
reference, a putative AOP can be useful in order to give indications about the strength of the
relationship between the AO (intended as a human health outcome) and pesticides affecting the
pathway. In addition, by detecting and/or identifying data gaps and/or research needs, putative AOPs
could serve to inform IATA or give guidance for further works.
The Panel considered that qualitative AOPs (intended as an AOP including the assembly and
evaluation of the supporting weight of evidence following the OECD guidance for AOP development)
should be the starting and standard approach in the process of integration of the epidemiological
studies into risk assessment by supporting (or identifying the lack of support for) that a plausible
mechanistic link exists between pesticides affecting the pathway and the AO, intended as the human
health outcome. This should be based on the agreement of the current understanding of the AO and
the strength of the weight of evidence will deﬁne the boundaries of its scientiﬁc validity. In developing
qualitative AOPs, the Panel realised that these can be also used as screening tools.
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Quantitative AOPs (intended as supported by quantitative relationship that allow quantitative
translation of KE measurement into predicted probability or severity of AO) can cover any need,
including a complete hazard assessment of a chemical, by identifying regulatory relevant point of
departures for reference values; the quantitative AOP can also support the inclusion of chemical
speciﬁc factors like internal exposure and metabolism. Fully quantitative AOP’s are very data
demanding; thus, it is envisaged that they would be a second step in a regulatory prioritisation
process. However, the Panel recognised that moving from qualitative to quantitative AOPs, would
potentially represent an important step forward to a more effective use of pathway-based data to
support risk assessment and build up a predictive network.
The Panel considered that the use of properly developed AOPs is important to guide on future
tailored and tiered testing strategies for hazard identiﬁcation and characterisation, and consequently, a
proposal for an AOP-based IATA framework for identifying the risk of PD was made. The most
sensitive, robust, reliable test for a KE can be proposed to be further validated and, if needed,
ultimately might become a part of the OECD testing programme for chemicals. This is considered a
very important element of integrating non-animal data for regulatory use (NRC, 2008). The
Panel further concluded that the AOP framework is a powerful tool to support the most appropriate
design for in vitro and in vivo studies, and increase the sensitivity of methods and experimental
designs for capturing and possibly characterising a given hazard. As an AOP is expected to reﬂect the
current knowledge, this would imply that a large number of studies and methods will be included in
the description and empirical support for KE and KER. In this perspective, the quality of the studies
and scientiﬁc validation of the methods are relevant for regulatory purposes; in the meantime, the
Panel considered that decisions on how to make the best use of the available information should
depend on the problem formulation. For the scope of this Scientiﬁc Opinion, i.e. to explore the AOP
framework as a tool for supporting biological plausibility in relation to epidemiological studies, it is
essential that the description of the WoE would be complete and transparent; merging in the WoE of
the biological plausibility, essentiality and strength of empirical support in a ranking order of relevance
for each KE and KER will foster the decision made. If AOPs are intended to inform IATA or deﬁne the
optimal study design for hazard identiﬁcation/characterisation, elements of scientiﬁc validation and
study quality should be taken into consideration.
The Panel identiﬁes AOPs as a critical element to facilitate the move towards a mechanism-based
risk assessment instead of the current testing paradigm relying heavily on apical effects observed in
animal studies (as recommended by EFSA, as well as by ECHA and OECD). Shifting the risk
assessment paradigm and mechanistic understanding would reduce limitations of the animal data in
predicting human health effects for the single pesticide, and also support the current efforts on
carrying out cumulative risk assessment of pesticide exposure. Regarding the grouping of pesticides
for cumulative risk assessment and in particular the reﬁning of groups, the Panel concluded in 2013
that the current read-out from animal studies (apical endpoints) were not tailored for this purpose and
recommended that a better mechanistic understanding of toxicity should be achieved, and in particular
recommended development of AOPs (EFSA, 2013 – SO on dissimilar MoA). In this perspective, AOP
networks represent the functional unit of prediction of the AO as AOPs are not triggered in isolation
but they rather interact. Indeed, KEs and KERs are shared by multiple AOPs. Rather than looking at
hazards or MIEs in isolation, developing AOPs in a modular approach gradually describes the
complexity of potential interactions at cell, tissue, organ, system and organism levels, thus meeting
the concept of systems biology. The Panel recommends that the use of AOP’s should be explored for
the purpose of reﬁning cumulative assessment groups; considering this speciﬁc mandate, this opinion
underlines how biological plausibility can support the link between pesticide and complex human
health outcomes (e.g. parkinsonian disorders) by evidencing how multiple MIEs can lead to the same
AO. The Panel also appreciated that interactions between AOPs can be easily made visible if AOPs are
downloaded in the AOP-Wiki.
In regard to the future process of AOP development, the collaborative AOP-Wiki of the AOP
knowledge base (https://aopkb.org) serves as a useful platform and the upload of AOPs into the AOP-
Wiki is encouraged by the Panel. The use of the AOP-Wiki would provide multiple beneﬁts in terms of
easy approach to AOPs network, transparency and accurate peer-review will be ensured by the formal
review process of the proposed AOPs. This effort is still under development and with the experience of
this mandate future work and improvements may be suggested. Common KEs should be shared only if
approved following peer-review processes. Overall, to increase the future regulatory acceptance of
AOPs and the key events based testing, more emphasis should be put on the transparent data
selection for building AOPs; accordingly, weight of evidence analysis should be conducted and built into
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the AOP-Wiki. Collier et al. (2016) have recently suggested a framework which also includes
quantitative considerations, especially on the strength of linkages between key events: such
considerations would include criteria for soundness, applicability and utility, clarity and completeness,
uncertainty and variability and last evaluation and review.
The Panel concluded that:
• The AOP framework is a useful tool for risk assessment to explore if an AO is biologically
plausible or not; by means of mechanistically describing apical endpoints, the AOP contributes
to the hazard identiﬁcation and characterisation steps in risk assessment. As the AOP
framework is chemically agnostic, it will consolidate the chemical speciﬁc risk assessment with
the aid of, and within, the MOA and/or IATA framework.
• The prototype AOPs developed by the Panel support the view that pesticides affecting the
proposed MIEs and the pathways are risk factors for the development of the diseases, i.e. PD
and IFL. This conclusion is based on a weight of evidence assessment appropriately
characterised by deﬁning questions on biological plausibility and empirical support for the KER
and on the essentiality of the KEs. In addition, inconsistencies and uncertainties were identiﬁed
and reported for each of the developed AOP.
• The Panel recognised that the systematic literature review and meta-analysis indicated that the
plausible involvement of pesticide exposure as a risk factor for the development of PD and IFL
could by linked to further AOPs development in addition to the ones developed by the Panel.
This limitation in the current Scientiﬁc Opinion does not weaken the overall conclusion about
the plausible involvement of pesticides in the pathogenesis of PD and IFL.
• The Panel concluded that the AOP developed for CHL does not yield deﬁnitive evidence of
biological plausibility. However, circumstantial evidence indicates that a hypothetical biological
plausibility could exist but cannot be formulated with the current available information. These
circumstantial evidences are mainly derived by the epidemiological observation that the disease
is prevalent following in utero exposure to pesticides and that exploration of tumour related
endpoints following in utero exposure has limitations in the standard design of regulatory
studies. In addition, the Panel recognise that an animal model recapitulating the disease is not
available and this is also weakening the assessment.
• The AOP framework was considered by the Panel as an appropriate tool to understand if
chemical hazards related to the relevant human diseases (PD, infant and childhood leukaemia)
can be explored and detected in the standard regulatory studies. Although apical endpoints in
the regulatory studies, i.e. histological evaluation of the nigrostriatal pathway and neurological
examination (for Parkinson diseases), blood analysis, genotoxicity testing, immunological
parameters in reproductive studies and carcinogenicity assays (for infant and childhood
leukaemia’s), can potentially inform KEs or AOs, the mechanistic understanding of the apical
endpoints indicate that the regulatory toxicological studies have limitations because of the
study design or because of the sensitivity of the test system. Tailored studies or more sensitive
tools should be considered to prove that a chemical has negligible hazard if it is affecting the
pathway.
9. Recommendations
• Overall, the Panel recommends the AOP conceptual framework to assess the biological
plausibility, or lack of biological plausibility, of the association between pesticide exposure and
human health effects reported in epidemiological studies by means of including the observed
effect in the AO and consequently in the hazard identiﬁcation process.
• The AOPs should stimulate regulators to ask for the application of additional testing based on
the mechanistic understanding of the MIEs and KEs. Therefore, the Panel recommends that
the AOP should be used as a mechanistic tool to support biological plausibility and mechanistic
understanding of apical hazards when toxicity studies are considered insufﬁcient, inconclusive
or inadequate, but the substance is known to affect the pathway.
• The AOPs should stimulate additional research work in order to provide a more robust
quantitative evaluation of the threshold effects for the different KEs, using the same tool
compounds used for their development. Quantitative evaluation should foster the regulatory
use of the AOP and should include, where possible, a concentration response analysis by
means of identiﬁcation of a non-effect threshold and a minimum threshold effect able to
PPPs, Parkinson’s disease and childhood leukaemia
www.efsa.europa.eu/efsajournal 62 EFSA Journal 2017;15(3):4691
trigger the pathway. A biologically relevant battery of assays preferably based on human cells,
able to recapitulate the key events of the AOP and predictive of the concentration of the
chemical leading to the AO should be developed.
• The systematic literature review indicated that the plausible involvement of pesticide exposure
as a risk factor for the development of PD and infant/childhood leukaemia could by linked to
additional AOPs other than the ones developed by the Panel. The Panel recognises this
limitation of the current Scientiﬁc Opinion and recommends that additional AOPs should be
developed with the intent of using the AOP to support the biological plausibility of additional
MIEs and pathways but also to develop an AOP network to be used as a functional unit for the
prediction of the diseases.
• The Panel recommends that the AOP network should be considered as a tool for the
reﬁnement of the Cumulative Assessment Groups to be used in cumulative risk assessment of
pesticides.
• The Panel recommends that for compounds affecting the AOPs developed for parkinsonian
motor symptoms, the evaluation of the nigrostriatal pathway should be performed by means of
application of proper stereology protocols and detailed neuropathology assessment with
inclusion of special stain procedure in addition to H/E to examine whether there is evidence for
neuronal cell loss, cell damage and any neuroinﬂammatory response. It is important that an
unbiased assessment of neuronal cell loss must include carefully conducted stereology and
pathology studies where the pathologist is ‘blinded’ to the treatment regimen of each
experimental animal assessed. Furthermore, relevant neurochemistry toxicity endpoints should
also be examined. The Panel also recommends that biomarkers, e.g. a-synuclein could be
considered to help in the study design, i.e. dose selection and length of the treatment, when
compounds are known to affect the pathway but the regulatory endpoints are negative.
• In addition, the Panel recommends investigation and evaluation of the use of mixed neurons/
glial cocultures in the development of in vitro batteries for neurotoxicity screening.
• The Panel proposes neuroinﬂammation as a key event for the two AOPs developed for the AO
‘parkinsonian motor symptoms’. The Panel does not, however, recommend the use of
neuroinﬂammatory biomarkers for the time being. Although the Panel is supporting their utility
and validity from the scientiﬁc point of view, they are still too challenging and complex for
regulatory uses. However, this does not include the use of immunomarkers for cell
phenotyping.
• The Panel recognises the limitations of the standard regulatory studies as evidenced by the
AOP developed in this Scientiﬁc Opinion and recommends that an AOP-informed IATA should
be developed to support the testing strategy. The Panel also recommends that an AOP-
informed IATA framework should be developed for the IFL and the CHL and that the testing
strategy should be based on non-animal testing as a ﬁrst approach for new data generation.
• The Panel recommends that the standard OECD guidance on histological evaluation of the
brain in the 90-day toxicity study (OECD TG 408) and in general in the toxicity studies
performed in vivo, should be revised in order to include a more in depth evaluation of brain
structures involved in Parkinson disease i.e. the nigrostriatal pathway.
• The Panel recommends that genotoxicity assays should consider the sensitive detection of
TOP2 poisons. In particular, the Panel recommends to the investigation of the differential
sensitivity (also in regard to single vs repeat exposure) of embryonic cell systems such as liver
HSPCs compared to established systems (e.g. CHO, V79, peripheral blood lymphocytes), in
regard to clastogenicity (including TOP2 poisons); this could be achieved effectively by means
of a multicentre collaborative study.
• The Panel recognises that the use of a non-validated cell system needs more scientiﬁc work in
order to provide robust data on speciﬁcity and sensitivity for an appropriate use in risk
assessment.
• The Panel recommends that the epidemiological studies and meta-analysis should make a
distinction between infant and childhood leukaemia which are aetiologically and pathologically
different entities.
• The Panel recommends that tailored and tiered testing strategies should be developed and the
assays should be anchored to the KEs identiﬁed in the AOPs. Accordingly, the test system
should be selected to model the human biology of KEs.
• In order to facilitate the regulatory relevance, the AOPs developed for this mandate should be
submitted to the AOP-Wiki and undergo the rigorous peer-review by the OECD.
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• Based on the experience gained in developing AOPs, the Panel recommends that the
transparency and WoE in building AOP’s should be strengthened in the future. An agreed
approach during the process of AOP preparation (assembling evidence) for the evaluation of data
quality of individual studies and for aggregating lines of evidence, possibly in a more quantitative
and structured way, is recommended. The framework suggested by Collier et al. (2016) could
serve this purpose. Also, the Panel notes that for the future development of AOPs and AOP-
network of the AOP-Wiki, that careful updates of KER of common KE must be implemented.
• The Panel recommends applying in vitro methods as a ﬁrst approach for gaining mechanistic
information to support the biological plausibility linking exposure to pesticide to human health
outcomes.
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ToR Term of Reference
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Appendix A – AOP developed for parkinsonian motor deﬁcit
AOP1: Inhibition of the mitochondrial complex I of nigrostriatal neurons
leads to parkinsonian motor deﬁcits
Abstract
This AOP describes the linkage between inhibition of complex I (CI) of the mitochondrial respiratory
chain and motor deﬁcit as in parkinsonian disorders. Binding of an inhibitor to complex I has been
deﬁned as the molecular initiating event (MIE) that triggers mitochondrial dysfunction, impaired
proteostasis, which then cause degeneration of dopaminergic (DA) neurons of the nigrostriatal
pathway. Neuroinﬂammation is triggered early in the neurodegenerative process and exacerbates it
signiﬁcantly. These causatively linked cellular key events result in motor deﬁcit symptoms, typical for
parkinsonian disorders, including Parkinson’s disease (PD), described in this AOP as an Adverse
Outcome (AO). Since the release of dopamine in the striatum by DA neurons of the substantia nigra
pars compacta (SNpc) is essential for motor control, the key events refer to these two brain structures.
The weight-of-evidence supporting the relationship between the described key events is based mainly
on effects observed after an exposure to the chemicals rotenone and 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP), i.e. two well-known inhibitors of complex I.
Data from experiments with these two chemicals reveal a signiﬁcant response–response
concordance between the MIE and AO and within KEs. Also, essentiality of the described KEs for this
AOP is strong since there is evidence from knock out animal models, engineered cells or replacement
therapies that blocking, preventing or attenuating an upstream KE is mitigating the AO. Similarly, there
is proved experimental support for the KERs as multiple studies performed with modulating factors
that attenuate (particularly with antioxidants) or augment (e.g. overexpression of viral-mutated
a-synuclein) a KEup show that such interference leads to an increase or attenuation/prevention of
KEdown or the AO.
Information from in vitro and in vivo experiments is complemented by human studies in brain
tissues from individuals with sporadic Parkinson’s disease (Keeney et al., 2006) to support the
pathways of toxicity proposed in this AOP.
This AOP is reported in line with the OECD Guidance Document for developing and assessing AOPs
[ENV/JM/MONO(2013)6] and with the supplemented user’s handbook.
Figure A.1: AOP scheme
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A.1. Molecular Initiating Event (MIE): Binding of an inhibitor to NADH
ubiquinone oxidoreductase (complex I)
A.1.1. How this Key Event works
Electron transport through the mitochondrial respiratory chain (oxidative phosphorylation) is
mediated by ﬁve multimeric complexes (I–V) that are embedded in the mitochondrial inner membrane
(Figure A.1). NADH-ubiquinone oxidoreductase is the Complex I (CI) of the electron transport chain
(ETC). It is a large assembly of proteins that spans the inner mitochondrial membrane. In mammals, it
is composed of about 45-47 protein subunits (45 in humans) of which 7 are encoded by the
mitochondrial ge nome (i.e. ND1, ND2, ND3, ND4, ND4L, ND5 and ND6) and the remaining ones by
the nuclear ge nome (Greenamyre, 2001). CI oxidises NADH elevating the NAD+/NADH ratio by
transferring electrons via a ﬂavin mononucleotide (FMN) cofactor and several iron-sulfur centres to
ubiquinone (Friedrich et al., 1994) (Figure A.2).
Figure A.2: The electron transport chain in the mitochondrion. CI (NADH-coenzyme Q reductase or
NADH dehydrogenase) accepts electrons from NADH and serves as the link between
glycolysis, the citric acid cycle, fatty acid oxidation and the electron transport chain.
Complex II also known as succinate-coenzyme Q reductase or succinate dehydrogenase,
includes succinate dehydrogenase and serves as a direct link between the citric acid cycle
and the electron transport chain. The coenzyme Q reductase or Complex III transfers the
electrons from CoQH2 to reduce cytochrome c, which is the substrate for Complex IV
(cytochrome c reductase). Complex IV transfers the electrons from cytochrome c to
reduce molecular oxygen into water. Finally, this gradient is used by the ATP synthase
complex (Complex V) to make ATP via oxidative phosphorylation. mtDNA: mitochondrial
DNA; nDNA: nuclear DNA
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Binding of an inhibitor to CI inhibits the NADH-ubiquinone oxidoreductase activity, i.e. blocks the
electron transfer. Recent studies suggest that a wide variety of CI inhibitors share a common binding
domain at or close to the ubiquinone reduction site (Ino et al., 2003). Furthermore, the structural
factors required for inhibitory actions have been characterised on the basis of structure–activity
relationships (Miyoshi, 1998, Hideto, 1998).
Based on molecular docking simulations, in silico models mimicking the binding of chemicals to the
pocket of NADH ubiquinone oxidoreductase have been created according to the crystal structure of
mitochondrial CI. To investigate the ability of chemicals to bind to the active pocket, around 100 individual
docking simulations have been performed. These conﬁrmed the possible site of interaction between the
chemical and the pocket of CI. In particular, Miao YJ and co-workers recently investigated the IC50 values
of 24 chemicals (annonaceous acetogenins) for inhibition of mitochondrial CI (Miao et al., 2014).
Based on their binding sites, CI inhibitors are classiﬁed as follows (Degli Esposti, 1998) (Figure A.3):
i) type A inhibitors are antagonists of fully oxidised ubiquinone binding;
ii) type B inhibitors displace the partially reduced ubisemiquinone intermediate;
iii) type C inhibitors are antagonists of the fully reduced ubiquinol product.
The afﬁnity of the different types of CI inhibitors to their diverse CI binding sites is described in the
paragraph Evidence for Chemical Initiation of this Molecular Initiating Event (see below) in the context
of a speciﬁc type of inhibitor.
A.1.2. How it is measured or detected
Two different types of approaches have been used. The ﬁrst is to measure binding as such, and the
corresponding assays are described below; the second is to infer binding indirectly from assays that
quantify e.g. CI activity and to assume that the activity can only be altered upon binding.
The second type of approach is dealt with in the chapter entitled KE1: Inhibition of NADH
ubiquinone oxidoreductase (complex I). However, it has to be noted here that indirect assays can lead
to wrong conclusions. For instance, some compounds may trigger oxidative stress without actually
binding to CI. Such compounds, by triggering the generation of reactive oxygen species (ROS), may
damage CI protein components, thus causing a reduction of CI activity.
A.1.3. Measurement of binding by quantitative autoradiography
To assess binding of an inhibitor at the rotenone binding site of CI in tissues (e.g. in the substantia
nigra or in the striatum), the standard approach is to quantify the displacement of a radioactively
labelled ligand of this binding site by the toxicant under evaluation. Most commonly, binding of
[3H]-labelled dihydrorotenone (DHR) is measured and compared in control tissue and treated tissue.
Figure A.3: Schematic representation of CI and proposed inhibition binding sites by inhibitors of class
A, B and C. Nicotinamide adenine dinucleotide (NADH, reduced and NAD, oxidised), ﬂavin
mononucleotide (FMN) and ubiquinone (Q) (Haefeli et al., 2012, ﬁg. 46, CC-BY-ND)
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Binding of this rotenone-derivative is detected by autoradiography. Unselective binding is determined
by measurement of [3H]-DHR binding in the presence of an excess of unlabelled rotenone. Since a
rotenone-derivative is used for the assay, only CI inhibitors that bind to the rotenone-binding site in CI
are detected. This was observed, for e.g. meperdine, amobarbital or MPP+. This method allows a
spatial resolution of CI expression and the mapping of the binding of a competitive inhibitor on CI.
The method can be used for (a) in vitro measurements and for (b) ex vivo measurements:
a) In vitro measurements. Tissues are embedded in a matrix for cutting by a cryostat. The tissue
slices are then mounted onto slides. For the binding experiment, they are incubated with the test
compound in the presence of labelled [3H]-DHR. Then the tissue slices are washed and prepared
for autoradiographic detection (Greenamyre et al., 1992; Higgins and Greenamyre, 1996).
b) Ex vivo measurements. As rotenone can pass the blood brain barrier, the in vitro method was
further extended for in vivo labelling of CI in the brains of living animals, and detection of
binding after preparation of the tissue from such animals. Animals are exposed to test
compounds and [3H]-DHR is applied intraventricularly for 2–6 h before the brain is dissected
and arranged for the preparation of tissue slices (Talpade et al., 2000). In untreated animals,
this method allows a precise spatial resolution of the expression pattern of CI. In animals with
impaired CI activity, either as a result of CI deﬁciencies, or upon treatment with CI inhibitors,
the assay allows an assessment of the degree of CI inhibition.
A.1.4. Complex I Enzyme Activity (Colorimetric)
The analysis of mitochondrial OXPHOS CI enzyme activity can be performed using human, rat,
mouse and bovine cell and tissue extracts (abcam: http://www.abcam.com/complex-i-enzyme-activity-
microplate-assay-kit-colorimetric-ab109721). Capture antibodies speciﬁc for CI subunits are precoated
in the microplate wells. Samples are added to the microplate wells which have been precoated with a
speciﬁc capture antibody. After the target has been immobilised in the well, CI activity is determined
by following the oxidation of NADH to NAD+ and the simultaneous reduction of a dye which leads to
increased absorbance at OD=450 nm. By analysing the enzyme’s activity in an isolated context, outside
of the cell and free from any other variables, an accurate measurement of the enzyme’s functional
state can be evaluated.
A.1.5. Evidence supporting taxonomic applicability (tissue type, taxa,
life stage, sex)
CI has a highly conserved subunit composition across species, from lower organisms to mammals
(Cardol, 2011). Fourteen subunits are considered to be the minimal structural requirement for
physiological functionality of the enzyme. These units are well conserved among bacterial
(Escherichia coli), human (Homo sapiens) and bovine (Bos taurus) (Vogel et al., 2007b; Ferguson,
1994). However, the complete structure of CI is reported to contain between 40 to 46 subunits and
the number of subunits differs, depending on the species (Gabaldon, 2005; Choi et al., 2008). In
vertebrates CI consists of at least 46 subunits (Hassinen, 2007), particularly, in humans 45 subunits
have been described (Vogel et al., 2007b). Moreover, enzymatic and immunochemical evidence
indicate a high degree of similarity between mammalian and fungal counterparts (Lummen, 1998).
Mammalian CI structure and activity have been characterised in detail (Vogel et al., 2007a,b), referring
to different human organs including the brain. There is also a substantial amount of studies describing
CI in human muscles, brain, liver, as well as bovine heart (Janssen et al., 2006; Mimaki et al., 2012)
(Okun et al., 1999).
A.1.6. Evidence for Chemical Initiation of this Molecular Initiating Event
(MIE)
The most studied examples of chemicals that inhibit CI are: rotenone and 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) (Sava et al., 2007; Desplats et al., 2012; Lin et al., 2012). Both,
rotenone (pesticide) and MPP+ (the active metabolite of MPTP) are well known to reproduce the
anatomical, neurochemical, behavioural and neuropathological features of PD-like syndrome (Betarbet
et al., 2000; Greenamyre et al., 2001). Indeed, overwhelming evidence has accumulated in the
existing literature suggesting such a link, and therefore these two inhibitors of CI will be discussed in
the context of all the KEs identiﬁed in this AOP.
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A.1.6.1. Rotenone afﬁnity to complex I binding sites
Rotenone, a colourless, odourless, crystalline ketonic chemical compound (a ﬂavonoid) naturally
occuring in the seeds and stems of several plants, such as the jicama vine plant, and the roots of
several members of Fabaceae, is a classical, high afﬁnity and irreversible inhibitor of CI and is typically
used to deﬁne the speciﬁc activity of this enzymatic complex. Rotenone is extremely lipophilic, it
crosses biological membrane easily and can get into the brain very rapidly. Dose-dependent relative
afﬁnities of rotenone to the inhibitory site of CI is shown in Figure A.4B (for more details, see
Grivennikova et al., 1997).
Most of the studies suggest that hydrophobic inhibitors like rotenone or Piericidin A most likely
disrupt the electron transfer between the terminal Fe-S cluster N2 and ubiquinone (Figure A.4A).
Rotenone structure
A.1.6.2. MPTP afﬁnity to complex I binding sites
MPTP is not directly binding to CI and it is therefore non-toxic to DA neurons. MPTP exerts its
toxicity after it is metabolised by mono-amino-oxidase, type B (MAO B) in astrocytes to 1-methyl-4-
phenylpyridinium (MPP+). This metabolite binds to CI, and is toxic. MPP+ is a good substrate for
dopamine transporters (DAT), expressed selectively by DA neurons (Greenamyre et al., 2001). Due to
both a positive charge and an amphoteric character, MPP+ speciﬁcally accumulates in mitochondria,
where despite a lower afﬁnity to the binding site of CI than rotenone, it reaches high enough intra-
mitochondrial concentrations to inhibit CI activity (Ramsay et al., 1991). The binding afﬁnity of MPP+ is
low (mM range), and it can be totally reversed by washing out. However, prolonged treatment results
Fig. Rotenone structure (left); 
schematic diagram of CI 
A
B
Figure A.4: (A) NADH ubiquinone oxidoreductase, illustrating molecular mode of action and binding
site of Rotenone (and Rotenone-like compounds) IMS: inter-membrane space (based on
Lummen, 1998). (B) Dose-dependent relative afﬁnities of rotenone to the inhibitory site
of CI (for more details, see Grivennikova et al., 1997. Reprinted from Grivennikova et al.,
1997, Fig. 1, copyright (1997) with permission from Elsevier)
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in a severe, progressive and irreversible inhibition of CI, most likely by indirect mechanisms involving
oxidative damage (Cleeter et al., 1992). Competitive binding experiments with rotenone and MPP+
suggest that the two compounds bind to the same site of the CI (Ramasay et al., 1991).
A.1.6.3. General characteristics of other complex I inhibitors
Besides rotenone, there is a variety of CI inhibitors, both naturally occurring, such as Piericidin A
(from Streptomyces mobaraensis), acetogenins (from various Annonaceae species), as well as their
derivatives, and synthetically manufactured compounds, like pyridaben and various piperazin
derivatives (Ichimaru et al., 2008). They have been used to probe the catalytic activity of CI especially
in order to clarify its ubiquinone binding site and indeed, most of these compounds inhibit the electron
transfer step from the Fe-S clusters to ubiquinone (Friedrich et al., 1994).
Therefore, classiﬁcation of CI inhibitors is based on their types of action. Type A inhibitors, like
piericidin A, 2-decyl-4-quinazolinyl amine (DQA), annonin VI and rolliniastatin-1 and -2, are considered
to be antagonists of the ubiquinone substrate. For piericidin A, it has been shown that it inhibits
NADH:Q2 activity in a partially competitive manner. Contrary to type A, type B inhibitors, like the
commonly used rotenone, have hydrogen-bonding acceptors only in the cyclic head of the molecule
and are non-competitive towards ubiquinone, but are believed to displace the semiquinone
intermediate during the catalysis (Figure 2). Finally, inhibitors classiﬁed as type C, like stigmatellin and
capsaicin, form a third group of hydrophobic CI inhibitors that are believed to act as antagonists of
reduced ubiquinone (Friedrich et al., 1994; Degli Esposti, 1998; Haefeli 2012) (Figure 2).
Competition studies with representatives of all three different types of inhibitors revealed that type
A and B, and type B and C, but not type A and C, compete with each other for binding. This led to a
suggestion that all CI inhibitors acting at the ubiquinone binding pocket share a common binding
domain with partially overlapping sites (Okun et al., 1999).
Some inhibitors bind to the outside of the ubiquinone reduction site and do not ﬁt the preceding
classiﬁcation. Examples of such compounds are ADP-ribose, which competes for substrate binding at
the NADH site (Zharova and Vinogradov, 1997), and diphenyleneiodonium (DPI) that covalently binds
to reduced ﬂavin mononucleotide (FMN) in the hydrophilic part of the enzyme, blocking the electron
transfer to the Fe-S clusters (Majander et al., 1994).
There are also new, commercially available insecticides/acaricides with potential to inhibit
mitochondrial respiration, such as benzimidazole, bullatacin, 6-chlorobenzothiadiazole, cyhalothrin,
fenazaquin, fenpyroximate, Hoe 110779, pyridaben, pyrimidifen, Sandoz 547A, tebufenpyrad and
thiangazole (Greenamyre et al., 2001). It is clear that they are capable of inhibiting the mammalian CI
by binding to and blocking ubiquinone-dependent NADH oxidation with high efﬁcacy (Lummen, 1998).
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A.2. KE1: Inhibition of NADH ubiquinone oxidoreductase (complex I)
A.2.1. How this Key Event works
Under physiological conditions complex I (CI) couples the oxidation of NADH to NAD+ by reducing
ﬂavin mononucleotide (FMN) to FMNH2. FMNH2 is then oxidised through a semiquinone intermediate.
Each electron moves from the FMNH2 to Fe-S clusters, and from the Fe-S clusters to ubiquinone (Q).
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Transfer of the ﬁrst electron results in the formation of the free-radical (semiquinone) form of Q, and
transfer of the second electron reduces the semiquinone form to the ubiquinol form (CoQH2). Altogether,
four protons are translocated from the mitochondrial matrix to the inter-membrane space for each
molecule of NADH oxidised at CI. This leads to the establishment of the electrochemical potential
difference (proton-motive force) that may be used to produce ATP (Garrett and Grisham, 2010).
Binding of an inhibitor attenuates or completely blocks the activity of CI, i.e. the oxidation of NADH is
impaired and protons are not moved. This causes two major consequences: ﬁrst, electrons are
channelled towards oxygen instead Q. This impairs normal oxygen reduction into water at complex IV
and leads to the formation of the ROS superoxide at other sites of the respiratory chain. Superoxide may
cause damage of proteins, lipid and DNA of the cell, or damage components of the mitochondria after
transformation into e.g. hydrogen peroxide. These processes result in mitochondrial dysfunction (Voet
and Voet, 2008). The second consequence is the increase of the NADH/NAD+ ratio in mitochondria. This
affects the function of key dehydrogenase enzymes in the citric acid cycle and can lead to its block,
resulting in an inhibition of mitochondrial ATP production and mitochondrial respiration.
The functional consequences of CI inhibition have been titrated in a time- and dose-dependent
manner (Barrientos and Moraes, 1999), with mitochondrial dysfunction measured by a range of
different assays (Barrientos and Moraes, 1999; Greenamyre et al., 2001). These included quantiﬁcation
of ROS derived from mitochondria, and of cellular respiration (see KE2: Mitochondrial dysfunction).
A.2.2. How it is measured or detected
As CI has an enzymatic function as such, but also contributes to the overall function of oxidative
phosphorylation, there are two fundamental approaches to assess CI inhibition. The ﬁrst approach
measures the enzymatic activity of the complex itself; the second one assesses the overall activity of
oxidative phosphorylation of entire mitochondria, and indirectly infers from this a potential dysfunction
of CI.
A.2.3. Direct detection of complex I activity
This type of assay is always performed in homogenates of cells or tissues, and requires at least a
partial puriﬁcation of mitochondria or respiratory chain components. In order to focus on CI activity,
the activities of complex III (e.g. antimycin A) and complex IV (e.g. cyanide) need to be blocked by
pharmacological inhibitors in these setups.
A.2.3.1. Forward Electron Transfer
Submitochondrial particles or intact isolated mitochondria are incubated with NADH as electron
donor and with an electron acceptor to measure the ﬂow of electrons from NADH, through CI to the
acceptor. As readout, either the consumption of NADH, or the reduction of the electron acceptor is
followed photometrically or ﬂuorometrically (Lenaz et al., 2004; Kirby et al., 2007; Long et al., 2009;
Spinazzi et al., 2012). The physiological electron acceptor of CI is Coenzyme Q10 (CoQ10). Due to its
hydrophobicity, it is not suitable for use in an experimental in vitro setup. Short-chain analogs of
CoQ10, such as CoQ1 or decylubiquinone (DB) with a 10 carbon-atom linear saturated side chain are
hence applied as alternatives. With these non-physiological electron acceptors, it is important to
consider that the activity of CI can easily be underestimated. As water-soluble electron acceptors,
either ferricyanide or 2,6-dichlorophenolidophenol (DCIP) are used. However the reduction of such
compounds is not strictly coupled to the transduction of energy. To identify the portion of rotenone-
inhibitable CI activity, all samples investigated are assayed in parallel following treatment with
rotenone. In contrast to the autoradiography assays, direct CI activity detection allows the
identiﬁcation also of CI inhibitors that bind to sites of CI different from the rotenone binding site.
A.2.3.2. Reverse Electron Transfer
An alternative setup for the direct measurement of CI activity with minimal interference by the
activities of complex III and complex IV make use of the observation of a general reversibility of
oxidative phosphorylation and electron ﬂow across the mitochondrial respiratory chain (Ernster et al.,
1967). With this method, electrons enter the respiratory chain via complex II. Based on the reverse
ﬂux, this method allows the complete circumvention of complexes III and IV. As electron donor,
succinate is applied, together with NAD+ as electron acceptor. Formation of NADH from NAD+ can be
determined photometrically. The succinate-linked NAD+ reduction can be performed either with intact
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isolated mitochondria or with submitochondrial particles. For the direct assessment of CI activity,
submitochondrial particles are used. For assays with intact mitochondria, the succinate-linked reduction
of NAD+ is performed in the presence of ATP as energy source. Potassium cyanide (KCN) is added for
inhibition of forward electron transport towards complex IV.
A.2.3.3. Complex I activity dipstick assay
To assess CI activity and its inhibition in cell or tissue homogenates without interference by other
components of the respiratory chain, CI-selective antibodies attached to a matrix (e.g. multiwell plates)
are used (Willis et al., 2009). Homogenised tissue can directly be added for capturing of CI, the unbound
supernatant is washed away and leaves a complex of the antibody and mitochondrial CI. For activity
determination, NADH as electron donor and nitroblue tetrazolium (NBT) as acceptor are added. Reduced
NBT forms a coloured precipitate, its signal intensity is proportional to the amount of CI bound to the
antibody. CI inhibitors can directly be added for an assessment of their inhibitory potential. This method,
when applied in e.g. 96-well or 384-well plates, allows screening of large sets of potential CI inhibitors
without any interference by other elements of the mitochondrial respiratory chain.
A.2.4. Indirect measurements of complex I activity
Such assays mostly require/allow the use of live cells.
A.2.4.1. Oxygen consumption
Electrons, fed into the mitochondrial respiratory chain either by CI or complex II, ultimately reduce
molecular oxygen to water at complex IV. In a closed system, this consumption of oxygen leads to a
drop of the overall O2 concentration, and this can serve as parameter for mitochondrial respiratory
activity. Measurements are traditionally done with a Clark electrode, or with more sophisticated optical
methods. At the cathode of a Clark electrode, oxygen is electrolytically reduced, which initiates a
current in the electrode, causing a potential difference that is ultimately recorded. Clark electrodes
however have the disadvantage that oxygen is consumed. Furthermore, interferences with nitrogen
oxides, ozone, or chlorine are observed (Stetter et al., 2008). To circumvent these limitations, optical
sensors have been developed that have the advantage that no oxygen is consumed, combined with a
high accuracy and reversibility. Optical oxygen sensors work according to the principle of dynamic
ﬂuorescence quenching. The response of the respective ﬂuorescence dye is proportional to the amount
of oxygen in the sample investigated (Wang and Wolfbeis, 2014). In a model of isolated mitochondria
in the absence of complex II substrates, oxygen consumption can serve as surrogate readout for the
assessment of the degree of CI inhibition. It is however essential to realise that also complex III and
complex IV activities are involved and their inhibition also results in a decline in O2 consumption. In
addition to that, CI inhibitors can lead to a one-electron reduction of molecular oxygen at the site of CI
to yield superoxide. The amount of superoxide formed hence contributes to the consumption of
oxygen, but this must not be interpreted as oxygen consumption as a result of controlled and coupled
electron ﬂux through the complexes of the mitochondrial respiratory chain. A modern convenient
method to measure oxygen consumption is provided by the Seahorse technology of extracellular ﬂux
(XF) analysis, in which cells are kept in a very small volume, so that changes of oxygen levels can be
detected very sensitively by an oxygen sensor. To allow manipulation of the mitochondria in cells, the
cell membrane can be permeabilised with saponin (SAP), digitonin (DIG) or recombinant perfringolysin
O (rPFO) (XF-plasma membrane permeabiliser (PMP) reagent), to allow addition of speciﬁc substrates
to measure activity of different respiratory chain complexes, including CI (Salabei et al., 2014).
A.2.4.2. Intracellular ATP levels
Intracellular ATP levels originate both from mitochondria and from glycolysis. If glycolytic ATP
production is impaired or inhibited, the cellular production of ATP is a measure of mitochondrial
function. If it is assumed that the ATP consumption remains constant, then the steady state ATP levels
can serve as indirect readout for mitochondrial activity, and the latter depends on the functioning of
CI. Inhibitors of CI reduce cellular ATP levels, but it has to be remembered that intracellular ATP levels
are also affected by inhibitors of other parts of the respiratory chain, of the citric acid cycle or of the
transport of energy substrates. For a proper interpretation of assay results, it has to be ascertained in
each particular test system, that ATP production from other sources is excluded and that the cellular
ATP consumption remains constant. ATP levels can be easily measured from lysates of in vitro cell
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cultures or from tissues by a luminometric luciferase/luciferin assay. The amount of light emitted is
proportional to the amount of ATP in the sample (Nguyen et al., 1988; Leist, 1997).
A.2.4.3. Other approaches
As mitochondrial activity is coupled to many cellular functions, there is a multitude of other indirect
assays that are sensitive to inhibitors of CI. Some of these tests may indeed be very sensitive, while
they have a low speciﬁcity. Thus, their application requires usually a good control of the experimental
system and care with the interpretation of the data. One exemplary approach is the measurement of
NADH/NAD+ ratios in mitochondria by imaging methods. This provides resolution on the level of
individual mitochondria within a living cell (van Vliet et al., 2014)
A.2.5. Evidence Supporting Taxonomic Applicability
The CI is well-conserved across species from lower organisms to mammals. The central subunits of
CI harbouring the bioenergetic core functions are conserved from bacteria to humans. CI from bacteria
and from mitochondria of Yarrowia lipolytica, a yeast genetic model for the study of eukaryotic CI
(Kerscher et al., 2002) was analysed by x-ray crystallography (Hofhaus et al., 1991; Baradaran et al.,
2013; Zickermann et al., 2015). The CI of the mitochondria of eukaryotes and in the plasma membranes
of purple photosynthetic bacteria are closely related to respiratory bacteria and the close homology of
sequences, function, and prosthetic groups shows a common ancestry (Friedrich et al., 1995).
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A.3. KE2: Mitochondrial dysfunction (ENV/JM/WRPR(2016)34; 2016)
A.3.1. How this Key Event works
Mitochondria play a pivotal role in cell survival and cell death because they are regulators of both
energy metabolism and apoptotic/necrotic pathways (Fiskum, 2000; Wieloch, 2001; Friberg and
Wieloch, 2002). The production of ATP via oxidative phosphorylation is a vital mitochondrial function
(Kann and Kovacs, 2007; Nunnari and Suomalainen, 2012). The ATP is continuously required for
signalling processes (e.g. Ca2+ signalling), maintenance of ionic gradients across membranes, and
biosynthetic processes (e.g. protein synthesis, haem synthesis or lipid and phospholipid metabolism)
(Green, 1998; Hajnoczky et al., 2006; McBride et al., 2006; Kang and Pervaiz, 2012). Inhibition of
mitochondrial respiration contributes to various cellular stress responses, such as deregulation of
cellular Ca2+ homoeostasis (Graier et al., 2007) and ROS production (Nunnari and Suomalainen, 2012;
reviewed in Mei et al., 2013).
It is well established in the existing literature that mitochondrial dysfunction may result in: (a) an
increased ROS production and a decreased ATP level, (b) the loss of mitochondrial protein import and
protein biosynthesis, (c) the reduced activities of enzymes of the mitochondrial respiratory chain and
the Krebs cycle, (d) the loss of the mitochondrial membrane potential, (e) the loss of mitochondrial
motility, causing a failure to re-localise to the sites with increased energy demands, (f) the destruction
of the mitochondrial network, (g) increased mitochondrial Ca2+ uptake, causing Ca2+ overload
(reviewed in Lin and Beal, 2006; Graier et al., 2007), (h) the rupture of the mitochondrial inner and
outer membranes, leading to the release of mitochondrial pro-death factors, including cytochrome c
(Cyt. c), apoptosis-inducing factor, or endonuclease G (Martin, 2011; Braun, 2012; Correia et al., 2012;
Cozzolino et al., 2013), which eventually leads to apoptotic, necrotic or autophagic cell death (Wang
and Qin, 2010). Due to their structural and functional complexity, mitochondria present multiple
targets for various compounds.
A.3.2. How it is measured or detected
Mitochondrial dysfunction can be detected using isolated mitochondria, intact cells or cells in culture
as well as in vivo studies. Such assessments can be performed with a large range of methods (revised
by Brand and Nicholls, 2011) for which some important examples are given. All approaches to assess
mitochondrial dysfunction fall into two main categories: the ﬁrst approach assesses the consequences
of a loss-of-function, i.e. impaired functioning of the respiratory chain and processes linked to it. Some
assays to assess this have been described for KE1, with the limitation that they are not speciﬁc for CI.
In the context of overall mitochondrial dysfunction, the same assays provide useful information, when
performed under slightly different assay conditions (e.g. without addition of complex III and IV
inhibitors). The second approach assesses a ‘non-desirable gain-of-function’, i.e. processes that are
usually only present to a very small degree in healthy cells, and that are triggered in a cell upon
mitochondria failure.
A.3.2.1. Mitochondrial dysfunction assays assessing a loss-of function
A.3.2.1.1. Cellular oxygen consumption
See KE1 for details regarding oxygen consumption assays. The oxygen consumption parameter can
be combined with other endpoints to derive more speciﬁc information on the efﬁcacy of mitochondrial
function. One approach measures the ADP-to-O ratio (the number of ADP molecules phosphorylated
per oxygen atom reduced (Hinkle, 1995 and Hafner et al., 1990). The related Phosphate/Oxygen (P/O)
ratio is calculated from the amount of ADP added, divided by the amount of O consumed while
phosphorylating the added ADP (Ciapaite et al., 2005).
PPPs, Parkinson’s disease and childhood leukaemia
www.efsa.europa.eu/efsajournal 82 EFSA Journal 2017;15(3):4691
A.3.2.1.2. Mitochondrial membrane potential (Dwm)
The mitochondrial membrane potential (Dwm) is the electric potential difference across the inner
mitochondrial membrane. It requires a functioning respiratory chain in the absence of mechanisms
that dissipate the proton gradient without coupling it to ATP production. The classical, and still most
quantitative method uses a tetraphenylphosphonium ion (TPP+)-sensitive electrode on suspensions of
isolated mitochondria.
The Dwm can also be measured in live cells by ﬂuorimetric methods. These are based on dyes
which accumulate in mitochondria because of Dwm. Frequently used are tetramethylrhodamine ethyl
ester (TMRE), tetramethylrhodamine methyl ester (TMRM) (Petronilli et al., 1999) or 5,50,6,60-
tetrachloro-1,10,3,30-tetraethylbenzimidazole carbocyanide iodide (JC-1). In particular, mitochondria
with intact membrane potential concentrate JC-1, so that it forms red ﬂuorescent aggregates, whereas
de-energised mitochondria cannot concentrate JC-1 and the dilute dye ﬂuoresces green (Barrientos
et al., 1999). Assays using TMRE or TMRM measure only at one wavelength (red ﬂuorescence), and
depending on the assay setup, de-energised mitochondria become either less ﬂuorescent (loss of the
dye) or more ﬂuorescent (attenuated dye quenching).
A.3.2.1.3. Enzymatic activity of the electron transport system (ETS)
Determination of ETS activity can be determined following Owens and King’s assay (1975). The
technique is based on a cell-free homogenate that is incubated with NADH to saturate the mitochondrial
ETS and an artiﬁcial electron acceptor [l-(4-iodophenyl)-3-(4-nitrophenyl)-5-phenyltetrazolium chloride
(INT)] to register the electron transmission rate. The oxygen consumption rate is calculated from the
molar production rate of INT-formazan which is determined spectrophotometrically (Cammen et al.,
1990).
A.3.2.1.4. ATP content
For the evaluation of ATP levels, various commercially available ATP assay kits are offered (e.g.
Sigma, http://www.abcam.com/atp-assay-kit-colorimetricfluorometric-ab83355.html), based on luciferin
and luciferase activity. For isolated mitochondria various methods are available to continuously
measure ATP with electrodes (Llaudet et al., 2005), with luminometric methods, or for obtaining more
information on different nucleotide phosphate pools (e.g. Ciapaite et al., 2005).
A.3.2.2. Mitochondrial dysfunction assays assessing a gain-of function
A.3.2.2.1. Mitochondrial permeability transition pore (PTP) opening
The opening of the PTP leads to the permeabilisation of mitochondrial membranes (Lemasters
et al., 2009; Fiskum, 2000), so that different compounds and cellular constituents can change
intracellular localisation. This can be measured by assessment of the translocation of cytochrome c,
adenylate kinase or the apoptosis-inducing factor (AIF) from mitochondria to the cytosol or nucleus.
The translocation can be assessed biochemically in cell fractions, by imaging approaches in ﬁxed cells
or tissues, or by life-cell imaging of GFP fusion proteins (Single et al., 1998; Modjtahedi et al., 2006).
An alternative approach is to measure the accessibility of cobalt to the mitochondrial matrix in a
calcein ﬂuorescence quenching assay in live permeabilised cells (Petronilli et al., 1999).
A.3.2.2.2. mtDNA damage as a biomarker of mitochondrial dysfunction
Various quantitative polymerase chain reaction (QPCR)-based assays have been developed to detect
changes of DNA structure and sequence in the mitochondrial genome (mtDNA). mtDNA damage can be
detected in blood after low-level rotenone exposure, and the damage persists even after CI activity has
returned to normal. With a more sustained rotenone exposure, mtDNA damage can be also detected in
skeletal muscle. These data support the idea that mtDNA damage in peripheral tissues in the rotenone
model may provide a biomarker of past or ongoing mitochondrial toxin exposure (Sanders et al., 2014).
A.3.2.3. Generation of ROS and resultant oxidative stress
A.3.2.3.1. General approach
Electrons from the mitochondrial ETS may be transferred ‘erroneously’ to molecular oxygen to form
superoxide anions. This type of side reaction can be strongly enhanced upon mitochondrial damage.
As superoxide may form hydrogen peroxide, hydroxyl radicals or other ROS, a large number of direct
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ROS assays and assays assessing the effects of ROS (i.e. indirect ROS assays) are available. Direct
assays are based on the chemical modiﬁcation of ﬂuorescent or luminescent reporters by ROS species.
Indirect assays assess cellular metabolites, the concentration of which is changed in the presence of
ROS (e.g. glutathione, malonaldehyde, isoprostanes, etc.). In living animals, the effects of oxidative
stress can be detected by analysis of speciﬁc biomarkers in the blood or urine.
A.3.2.3.2. Measurement of the cellular glutathione (GSH) status
GSH is regenerated from its oxidised form (GSSH) by the action of a NADPH-dependent reductase
(GSSH + NADPH + H+ ? 2 GSH + NADP+). The ratio of GSH/GSSG is therefore a good indicator for the
cellular NADP+/NADPH ratio (i.e. the redox potential). GSH and GSSH levels can be determined by HPLC,
capillary electrophoresis, biochemically with DTNB (Ellman’s reagent, 5,5’-dithio-bis-[2-nitrobenzoic acid])
or by mean of luminescence-based assays (for example, GSH-GloTM Glutathione Assay, https://www.
promega.co.uk/resources/protocols/technical-bulletins/101/gsh-glo-glutathione-assay-protocol/). As
excess GSSG is rapidly exported from most cells to maintain a constant GSH/GSSG ratio, a reduction of
total glutathione levels is often considered a good surrogate measure for oxidative stress.
A.3.2.3.3. Quantiﬁcation of lipid peroxidation
Measurement of lipid peroxidation has historically relied on the detection of thiobarbituric acid
(TBA)-reactive compounds, such as malondialdehyde generated from the decomposition of cellular
membrane lipid under oxidative stress (Pryor et al., 1976). This method is quite sensitive, but not
highly speciﬁc. A number of commercial assay kits are available for this assay using absorbance or
ﬂuorescence detection technologies. The formation of F2-like prostanoid derivatives of arachidonic
acid, termed F2-isoprostanes (IsoPs) has been shown to be more speciﬁc for lipid peroxidation. A
number of commercial ELISA kits have been developed for IsoPs, but interfering agents in samples
requires partial puriﬁcation before analysis. Alternatively, gas chromatography–mass spectrometry
(GC-MS) may be used as a robust, speciﬁc and sensitive method.
A.3.2.3.4. Detection of superoxide (O2
) production
Generation of superoxide by inhibition of CI and the methods for its detection are described by
Grivennikova and Vinogradov (2006). A range of different methods is also described by BioTek (http://
www.biotek.com/resources/articles/reactive-oxygen-species.html). The reduction of ferricytochrome c
to ferrocytochrome c may be used to assess the rate of superoxide formation (McCord and Fidovich,
1968). Like in other superoxide assays, speciﬁcity can only be obtained by measurements in the
absence and presence of superoxide dismutase. Chemiluminescent reactions have been used for their
increased sensitivity. The most widely used chemiluminescent substrate is lucigenin. Coelenterazine has
also been used as a chemiluminescent substrate. Hydrocyanine dyes are ﬂuorogenic sensors for
superoxide and hydroxyl radical, and they become membrane impermeable after oxidation (trapping at
the site of formation). The best characterised of these probes are Hydro-Cy3 and Hydro-Cy5.
Generation of superoxide in mitochondria can be visualised using ﬂuorescence microscopy with
MitoSOXTM Red reagent (Life Technologies). MitoSOXTM Red reagent is a cationic derivative of
dihydroethidium that permeates live cells and accumulates in mitochondria.
A.3.2.3.5. Detection of hydrogen peroxide (H2O2) production
There are a number of ﬂuorogenic substrates, which serve as hydrogen donors that have been
used in conjunction with horseradish peroxidase (HRP) enzyme to produce intensely ﬂuorescent
products in the presence of hydrogen peroxide (Ruch et al., 1983; Zhou et al., 1997). The more
commonly used substrates include diacetyldichloro-ﬂuorescein, homovanillic acid, and Amplex Red
(https://www.thermofisher.com/order/catalog/product/A22188). In these assays, increasing amounts of
H2O2 leads to increasing amounts of ﬂuorescent product (Tarpley et al., 2004).
A.3.3. Evidence Supporting Taxonomic Applicability
Mitochondrial dysfunction is a universal event occurring in cells of any species (Farooqui and Farooqui,
2012). Many invertebrate species (e.g. Drosophila melanogaster and Caenorhabditis elegans) are
considered as potential models to study mitochondrial functionality. New data on marine invertebrates,
such as molluscs and crustaceans and non-Drosophila species, are emerging (Martinez-Cruz et al., 2012).
Mitochondrial dysfunction can be measured in animal models used for toxicity testing (Waerzeggers et al.,
2010; Winklhofer and Haass, 2010) as well as in humans (Winklhofer and Haass, 2010).
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A.4. KE3: Impaired proteostasis
A.4.1. How this key Event works
The concept of proteostasis refers to the homoeostasis of proteins in space and time, i.e. the
correct balance between protein synthesis, modiﬁcation, transport and degradation. Disturbance of
proteostasis results in pathological changes either by loss of function events (lack of a pivotal protein/
protein function) or by a gain of undesired functions (aggregation of a protein leading to the formation
of inclusions and new structures in cells and disturbing turnover of many unrelated proteins).
Proteostasis regulation is the main defence mechanism against toxic proteins, whose accumulation
could greatly compromise normal cellular function and viability. Therefore, the chaperone and
degradation systems assuring the removal of misfolded and aggregated proteins, as well as damaged,
dysfunctional cellular organelles (e.g. defective mitochondria) play a key role in cellular homoeostasis
(Lee et al., 2012).
The two major degradation systems are the ubiquitin–proteasome system (UPS) and the
autophagy–lysosome pathway (ALP) (Korolchuk et al., 2010; Kroemer et al., 2010; Ravikumar et al.,
2010). The UPS works through the attachment of multiple ubiquitin molecules to a protein substrate,
followed by the subsequent degradation of the tagged polyubiquitinated protein by the proteasome
(Ciechanover, 1998; Ciechanover and Brundin, 2003). A compromised function of the UPS leads to the
accumulation of ubiquitylated proteins, such as a-synuclein (Ii et al., 1997; Spillantini et al., 1997;
Sulzer and Zecca 2000). The accumulation of polyubiquitinated proteins, as a consequence of a
dysfunctional proteasome activity, is observed in some pathologies, and experimental inhibition of the
proteasome has been shown to trigger parkinsonian neurodegeneration (Hardy et al., 2001; McNaught
and Jenner 2001).
ALP involves the engulfment of cytoplasmic materials into autophagosomes, which are degraded by
lysosomal enzymes after fusion of autophagosomes with lysosomes (Kuma et al., 2004) or direct
import of proteins into lysosomes (Cuervo, 2004; Mizushima et al., 2008). Autophagy also plays an
essential role for the removal of damaged organelles, such as mitochondria. Both, excessive autophagy
or reduced autophagic ﬂux can compromise cell survival (Rothermel and Hill, 2007), and several
genetic forms of PD are linked to the autophagy-related genes Pink1, Parkin or Uchl1.
Autophagy enables cell survival during mitochondrial stress by clearing the damaged organelles
(Lee et al., 2012).
One of the main aggregated proteins found to accumulate in nigrostriatal cells during Parkinson’s
disease is a-synuclein. Aggregation of a-synuclein can obstruct normal cellular transport, leading to
impaired intracellular trafﬁcking and/or trapping of cellular organelles in inappropriate locations, this
resulting in synaptic and cell dysfunctions (Cookson, 2005; Bartels et al., 2011; Bellucci et al., 2012;
Games et al., 2013; Hunn et al., 2015).
Importantly, accumulation of a-synuclein affects mitochondrial trafﬁcking. The polarity and correct
function of different types of cells depend on an efﬁcient transport of mitochondria to areas of high
energy consumption (Sheng, 2014). Therefore, the correct distribution of mitochondria to various parts
of a cell is essential to preserve cell function (Zhu et al., 2012; Schwarz, 2013).
A.4.2. How it is measured or detected
A.4.2.1. Evaluation of UPS function
A.4.2.1.1. General turnover assays
Quantitative evaluation can be based on the detection of increased ubiquitin or ubiquinated
proteins, as well as proteasomal subunits, either by immunocyto/histochemistry or by western blotting
(Rideout et al., 2001; Ortega and Lucas, 2014). UPS activity can be continuously monitored by
quantitating (by mean of ﬂow cytometry or microscopy) the level of e.g. EGFP-degron fusion proteins
that are selectively degraded by the proteasome (Bence et al., 2001).
A.4.2.1.2. Proteasome activity assay
Various ﬂuorogenic substrates (e.g. Suc-Leu-Leu-Val-Tyr-AMC for the chymotrypsin-like activity) can
be used for the determination of proteasomal activity in in vivo or in vitro applications. These
substrates may be applied to tissue or cell homogenates, but speciﬁc measurements require partial
puriﬁcation of the proteasome (Kisselev and Goldberg, 2005).
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A.4.2.1.3. Detection of a-synuclein (AS) aggregates
The most common methods to detect AS aggregates use immunostaining for AS (in cells or in
tissues). In cell culture, AS may also be epitope-tagged or coupled to GFP to allow an indirect
detection. The detection of small, not microscopically visible AS aggregates is indicative of protease-
resistance. Tissue slices may be exposed to proteases before immunostaining for AS. Alternatively,
small or large aggregates may be biochemically enriched by differential centrifugation and proteolytic
treatment, and then analysed, e.g. by western blot, mass spectrometry or ELISA-like
immunoquantiﬁcation.
A.4.2.2. Evaluation of ALP function
A.4.2.2.1. Quantiﬁcation of lysosomes or autophagosomes
Disturbances of ALP often result in counter-regulations that can be visualised by staining of lysosomes
or parts of the autophagy system. Several weakly basic dyes can be used to stain acidic organelles
(lysosomes) in live cells. For example, the dye LysoTracker Red stains lysosomes and can be used to
monitor autophagy (Klionsky et al., 2007, 2008). The autoﬂuorescent drug monodansylcadaverine (MDC)
has also been used as autophago-lysosome marker (Munafo and Colombo, 2002). A convenient way to
stain lysosomes in tissue or ﬁxed cells is the use of antibodies against the Lysosomal-Associated
Membrane Protein 1 (LAMP-1) (Rajapakshe et al., 2015) or against cathepsins (Foghsgaard et al., 2001).
For qualitative or semiquantitative estimates of lysosomes and related organelles, transmission
electron microscopy has been frequently used (Barth et al., 2010).
A.4.2.2.2. Monitoring of autophagy-related molecules
The amount and the localisation of autophagy-related proteins can change during disturbance of
the ALP. Especially in cell culture, but also in transgenic mice, various techniques have been used to
monitor autophagy by mean of ﬂuorescence-tags or other substrates, e.g. ATG, autophagy-related
protein or autophagy substrates, to monitor their fate in cells and thus provide information on
disturbed ALP, or the overexpression of GFP–LC3, in which GFP (green ﬂuorescent protein) is
expressed as a fusion protein at the amino terminus of LC3 (microtubule-associated protein 1A/1B-light
chain 3), which is the a mammalian homologue of Saccharomyces cerevisiae ATG8 (Kadowaki and
Karim, 2009).
A.4.2.2.3. Monitoring autophagic ﬂux
The lysosomal degradation of the autophagic cargo constitutes the autophagic ﬂux, which can be
measured by assessing the rate of turnover of long-lived proteins that are normally turned over by
autophagy (Bauvy et al., 2009) This is performed by labelling intracellular proteins with either [14C]-
leucine or [14C]-valine, followed by a long culture period in standard medium. The release of
radioactive leucine or valine into the culture medium corresponds to the protein degradation rate in
cells, and it may be measured by liquid scintillation counting.
A.4.2.2.4. Monitoring the conversion of LC3-I to LC3-II
The progression of autophagy (autophagic ﬂux) can be studied by the conversion of LC3-I into LC3-
II (i.e. a post-translational modiﬁcation speciﬁc for autophagy) by mean of Western blot analysis. The
amount of LC3-II correlates with the number of autophagosomes. Conversion of LC3 can be used to
examine autophagic activity in the presence or absence of lysosomal activity (Klionsky et al., 2007,
2008). The technology can also be used in vivo, e.g. by the use of transgenic mice that overexpress
GFP–LC3 (Kuma et al., 2004).
A.4.2.2.5. Evaluation of intracellular transport of mitochondria and other organelles
A range of technologies has been used to visualise mitochondrial dynamics in live cells (Jakobs,
2006; Grafstein and Forman, 1980). They usually employ a combination of mitochondrial labelling with
ﬂuorescent dyes (e.g. DiOC6 (3,30-dihexyloxacarbocyanine iodide), JC-1 (5,50,6,60-tetrachloro-1,10,3,30-
tetraethylbenzimida-zolylcarbo-cyanine iodide), MitoTracker, MitoFluor probes, etc.), followed by video-
or confocal microscopy for live cell imaging (Pool et al., 2006; Schwarz, 2013). Most frequently,
mitochondrial mobility is observed along neurites, and measurable endpoints may be mitochondrial
speed and direction with regard to the cell soma (Schildknecht et al., 2013). Additionally, also
mitochondrial fusion and ﬁssion have been monitored by such methods (Exner et al., 2012). The
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transport of other organelles along neurites may be monitored using similar methods, and the
microtubule structures that serve as transport scaffold may be co-stained.
A.4.3. Evidence supporting taxonomic applicability
The ubiquitin proteasome system is highly conserved in eukaryotes, from yeast to human. Ubiquitin
is a small (8.5 kDa) regulatory protein that has been found in almost all tissues of eukaryotic
organisms. For instance, drosophila has been used as PD model to study the role of ubiquitin in a-
synuclein induced-toxicity (Lee et al., 2009). Human and yeast ubiquitin share 96% sequence identity.
Neither ubiquitin nor the ubiquitination machinery is known to exist in prokaryotes.
Autophagy is ubiquitous in eukaryotic cells and is the major mechanism involved in the clearance of
oxidatively or otherwise damaged/worn-out macromolecules and organelles (Esteves et al., 2011). Due
to the high degree of conservation, most of the knowledge on autophagy proteins in vertebrates is
derived from studies in yeast (Klionsky et al., 2007).
Autophagy is seen in all eukaryotic systems, including fungi, plants, slime mould, nematodes, fruit
ﬂies and insects, rodents (i.e. laboratory mice and rats), and humans. It is a fundamental and
phylogenetically conserved self-degradation process that is characterised by the formation of double-
layered vesicles (autophagosomes) around intracellular cargo for delivery to lysosomes and proteolytic
degradation.
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A.5. KE4: Degeneration of dopaminergic neurons of the nigrostriatal
pathway
A.5.1. How this Key Event works
Degeneration of dopaminergic neurons (DA neurons) within the Substantia Nigra pars compacta
(SNpc), i.e. the nigrostriatal pathway, paralleled by the formation of cytoplasmic ﬁbrillar inclusions
called Lewy bodies (LB), is regarded as a key event in Parkinson’s disease (PD) and is in a quantitative
manner directly linked to the occurrence of clinical signs indicative of PD, i.e. impaired motor
behaviour (Dauer et al., 2003; Jellinger et al., 2009; Shulman et al., 2011; Dickinson, 2012). The
severity of the clinical signs correlates with the degree of nigral cell loss, and the reduced level of
dopamine in the striatum. It is estimated that at the onset of clinical signs, 60% of SNpc neurons are
lost, corresponding to an 80% depletion of striatal dopamine (Jellinger et al., 2009).
PD is clinically and pathologically deﬁned as a progressive disorder: There is a temporally progress,
according to a speciﬁc pattern, from the brain stem to the nigrostriatal areas and to cortical locations
PPPs, Parkinson’s disease and childhood leukaemia
www.efsa.europa.eu/efsajournal 90 EFSA Journal 2017;15(3):4691
(Braak et al., 2004, 2009) and there is a temporal increase in the occurrence of Lewy bodies, of
dopamine depletion in the striatum and of loss of DA neurons in the SNpc (Shulman et al., 2012).
Indeed, in patients dying with PD there is a more evident loss of dopamine in striatum compared to
SNpc, indicating that striatal dopaminergic nerve terminals are the primary target of the degenerative
process in the nigrostriatal pathway and that neuronal loss in SNpc would result as a ﬁnal outcome
(Bernhaimer et al., 1973; Hornykiewicz et al., 1966; Dauer et al., 2003; Pavese et al., 2009). Post-
mortem studies in PD patients and experimental models are also suggesting that progression from
striatal terminal to loss of DA neurons occurs through a ‘dying back’ axonopathy pathology and that
axonal dysfunction may be an important hallmark in PD (Raff et al., 2002, Orimo et al., 2005, O’Malley
2010, Kim-Han et al., 2011).
In human brain, the classical Lewy body (LB) is characterised at light microscopy by eosinophilic,
spherical, intracytoplasmic inclusion and it stains for a-synuclein and ubiqutin proteins which form the
ultrastructural ﬁbrillar core of LB visible at transmission electron microscopy. On autopsy, from
individuals affected by PD, accumulation of aggregates positive for a-synuclein protein are also
observed within neuronal processes, called Lewy neurites, as well as by neurons showing a more
diffuse or granular perinuclear pattern (Dickson, 2012). Because dopaminergic cells are rich in melanin,
their loss is detectable by depigmentation of the midbrain at gross pathology examination (Shulman
et al., 2010; Dickson 2012). However, it should be noted that, although LB are recognised as
characteristic of PD, they are not found in a minority of clinically deﬁned PD cases (Dauer, 2003) and
they can also be observed in other diseases (Dickson, 2012).
The biological function of the nigrostriatal pathway depends on the intactness of its anatomical
structure. Preservation of the striatum terminals and of neuronal cell bodies of DA neurons in the SNpc is
a prerequisite for the maintenance of the physiological function (Fujita et al., 2014). The nigrostriatal
system is anatomically located in the basal ganglia circuit which comprises the motor system structures
caudate nucleus, putamen, globus pallidum and substantia nigra. The caudate nucleus and the putamen
are collectively called striatum (David Robinson in: Neurobiology, Springer edition, 1997). The system
plays a unique integrative role in the control of movement as part of a system called the ‘basal ganglia
motor loop’. This anatomical loop includes structures in the thalamus, motor and somatosensory cortex
and wide regions of surrounding cortex. Neurons of the SN produce dopamine (DA) and project to the
striatum. They give dopaminergic excitatory (D1 receptors) and inhibitory (D2 receptors) inputs to striatal
interneurons (GABAergic). These control thalamic output to the motor cortex. Degeneration within the
SNpc leads to a decreased thalamic activation of the motor cortex (Shulman et al., 2011).
The dopaminergic cells localised in the SNpc synthesise the transmitter substance dopamine (DA) and
make extensive contacts within the caudate and putamen (the striatum). These DA neurons have a
complex morphology and high energy demand. They are provided with very long and dense
arborisations projecting into the striatum where DA is released. This unique morphological characteristics
demand a high level of energy to maintain the activity at the synaptic level, to compensate for the risk of
depolarisation of the unmyelinated ﬁbres and to support a long distance axonal transport. This puts a
tremendous burden on mitochondrial functions (Pissadaki et al., 2013). SNpc neurons are provided with
speciﬁc calcium channels, the L-type Cav 1.3 which are intended to regulate the autonomous ﬁring as
‘pacemaker’. The high demand of calcium buffering arising from this is handled by the endoplasmic
reticulum (ER) and by the mitochondria. This is a function speciﬁc for SNpc DA neurons, as the
dopaminergic neurons belonging to the ventral tegmental area (VTA) are using Na+ channels as a
pacemaker. Additional peculiarities of the neurons of the nigrostriatal pathway are the high number of
synapses and the higher probability of these neurons to accumulate misfolded proteins, including a-
synuclein. Furthermore, the nigrostriatal metabolic pathway of DA is known to induce oxidative and
nitrative stress (Asanuma et al., 2003, Cantuti-Castelvetri et al., 2003, Pissadaki et al., 2013; Fujita et al.,
2014) making DA neurons particularly sensitive to oxidative stress (Lotharius and Brundin, 2002). DA
neurons in SNpc also have a relatively low mitochondria mass which may contribute to the vulnerability
of these neurons (Liang et al., 2007). In addition, increased levels of iron have been observed in SN of
PD patients (Gotz et al., 2004) and the high content of iron in dopamine neurons has been reported to
trigger oxidative/nitrosative stress and subsequent neurodegeneration (Benshachar et al., 1991; Ayton
and Lei 2014). As a consequence, these neurons are particularly sensitive to various stressors that can
contribute to their preferential loss (Fujita et al., 2014).
PPPs, Parkinson’s disease and childhood leukaemia
www.efsa.europa.eu/efsajournal 91 EFSA Journal 2017;15(3):4691
A.5.2. How it is measured or detected
The presence of DA cells in the SNpc and DA terminals in the striatum can be visualised using
different phenotypic histological markers. Changes can be captured by measurement of markers
speciﬁc for dopaminergic neurons such as tyrosine hydroxylase (TH), dopamine transporter (DAT) and
vesicular monoamine transporter type 2 (VMAT2). Degenerating and/or degenerated neurons can be
detected by the silver stains and the Fluoro-Jade stains.
The silver degeneration stain is considered as the best method to trace degeneration of axons. By
this matter, products from disintegrated cells are visualised (Betarbet et al., 2000; Switzer, 2000).
Evaluation of neuronal degenerative changes in the SNpc and in the striatum is complex and should be
performed by a detailed neuropathological evaluation complemented by unbias stereological count of
neurons and by the evaluation of neurochemistry endpoints of toxicity, i.e. DA, DOPAC and HVA.
Neuropathology and stereological counts should be done using a ‘blind’ protocol for all the samples
from treated animals (Beckenridge et al., 2013; Smeyne et al., 2016)
• Fluoro Jade stain is a ﬂuorochrome derived from ﬂuorescein used in neuroscience disciplines to
label degenerating neurons. It is an alternative technique to traditional methods for labelling
degenerating neurons such as silver degeneration staining. Fluoro-Jade may be preferred to
other degeneration stains due to the simplicity of staining procedures, which are a common
drawback of conventional stains. However, the mechanism by which Fluoro-Jade labels
degenerating neurons is unknown (Schmued et al., 1997; Betarbet et al., 2000).
• Detection of TH, the enzyme responsible for catalysing the conversion of the amino acid
L-tyrosine to L-3,4-dihydroxyphenylalanine (L-DOPA), a precursor for dopamine. Detection of
TH can be done either by immunocytochemistry (at the protein level) followed by cell counting
(quantitative evaluation) or by western blot followed by densitometry analysis (Lee 1987;
Fetissov 1999; Betarbet et al., 2000).
• Counting of cells, immunostained for TH, or counting of nuclei by e.g. with Nissel’s, DAPI
(Kapuscinski, 1995) or Hoechst stain (Latt et al., 1976) should be done following standard
morphometric protocols. However, inclusion of stereological cell counts to assess
neurodegeneration represents the most sensitive method to conﬁrm quantitatively this speciﬁc
morphological change (Brooks, 1992; Thiruchelvam, 2000a,b; Dauer, 2008; Baquet, 2009;
Tapias et al., 2013; Smyne, 2016).
• Quantiﬁcation of dopaminergic neurons in SNpc: the average number of DA neurons in adult
mouse SN is approximately 8.000 to 14.000, depending on strain (Zaborszky and Vadasz,
2001). Their distribution is not homogeneous with difference in density between the caudal
and rostral part of the SN. The gold standard for counting neurons is then to use an unbiased
stereological protocol for cell counting with an optical dissector system (Tieu et al., 2003). This
requires a computerised stereology software. The count should include TH+ neurons as well
the total count of neurons using a non-speciﬁc cell stain (e.g. Nisell’s, Fox3).
• Quantiﬁcation of dopaminergic terminals in the striatum: the density of dopaminergic terminals
is not homogeneous in the striatum, increasing from the rostral to the caudal part and
representative regions of the striatum should be assessed. This can be done by digitalisation of
the ﬁbres and quantiﬁcation by optical density or quantiﬁcation of the ﬁbre density identiﬁed
by TH+ immunoreactivity (Tieu et al., 2003; Fernagut et al., 2007). Alternatively, striatal tissue
can be isolated for immunoblotting of TH or DAT.
• DA transporters (DAT) and vesicular monoamine transporter type 2 (VMAT2) can be visualised
and quantiﬁed using immunocytochemistry (single cell levels) or western blot followed by
densitometry analysis, to quantify the changes in their expression (Ciliax et al., 1995; Fornai
et al., 2003; Hirata et al., 2007; Tong et al., 2011).
• DA, DOPAC (DA metabolite) and HVA (homovanillic acid), formed from dopamine that escapes
conversion to noradrenaline in noradrenergic neurons throughout the body as well as from
dopamine synthesised in dopaminergic neurons that are mainly in brain(Kopin et al., 1988))
content in the striatum can be quantiﬁed through several methodologies such as capillary
electrophoresis, spectroﬂuorimetry and high performance liquid chromatography (HPLC). The
commonly used detectors for chromatography include MS, UV, optical ﬁbre detector,
electrochemical detector and ﬂuorescence detector (Magnusson et al., 1980; Fornai et al.,
2005; Zhao et al., 2011).
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• Identiﬁcation of LB in standard histological sections stained with haematoxylin and eosin, they
are characterised by the presence of pale eosinophilic vacuoles (Pappolla, 1988; Dale, 1992;
Betarbet, 2000,2006).
• Immunostaining for a-synuclein and ubiquitin to identify and quantify Lewy bodies presence. In
vivo, a-synuclein and ubiqutin can be evaluated in the ﬁxed tissue and quantiﬁed for
ﬂuorescence intensity (Kuzuhara, 1988; Tiller-Borcich, 1988; Galloway, 1992; Forno, 1996;
Betarbet, 2000,2006; Kuusisto, 2003).
• Imaging techniques: 18-ﬂuorodopa positron emission tomography (PET) quantiﬁcation of
various dopamine presynaptic markers (e.g. dopamine transporter DAT, vesicular monoamine
transporter type 2 VMAT2) identiﬁed by single photon emission tomography (SPECT). They
permit to visualise the loss of nigrostriatal DA neurons in patients (Shapira, 2013).
A.5.3. Evidence Supporting Taxonomic Applicability
Parkinson’s disease (PD) is a progressive age-related human neurodegenerative disease with a
multi-factorial pathogenesis implicating various genetic and environmental factors and is more
prevalent in males (Fujita et al., 2014). However, the anatomy and function of the nigrostriatal
pathway is conserved across mammalian species (Barron et al., 2010). Pathological changes, similar to
the one described in PD, have been reproduced with chemicals such as rotenone and MPTP. These
chemicals have been tested successfully in primates and mice. The mouse C57BL/6 strain is the most
frequently used strain in the reported experiments. A difference in vulnerability was observed,
particularly for rats, depending on the strain and route of administration. The Lewis strain gives more
consistency in terms of sensitivity when compared to the Sprague–Dawley. A genetic-based
susceptibility has been also described for mice following paraquat treatment, underlying the relevance
of the genetic component in Parkinsonism syndromes with the C57BL/6J strain resulting the more
susceptible (Yin et al., 2011; Jiao et al., 2014). In addition to rodents, the pesticide rotenone has been
also studied in C. elegans, Drosophila, zebraﬁsh and Lymnaea stagnalis (Johnson et al., 2015).
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A.6. KE5: Neuroinﬂammation (ENV/JM/WRPR(2016)34; 2016)
A.6.1. How this KE works
Neuroinﬂammation or brain inﬂammation differs from peripheral inﬂammation in that the vascular
response and the role of peripheral bone marrow-derived cells are less conspicuous. The most-easily
detectable feature of neuroinﬂammation is the activation of microglial cells and astrocytes. It is
evidenced by changes in shape, increased expression of certain antigens, and accumulation and
proliferation of these glial cells in affected regions (Graeber and Streit, 1990; Aschner, 1998; Streit
et al., 1999; Monnet-Tschudi et al., 2007; Kraft and Harry, 2011; Claycomb et al., 2013). Upon
stimulation by cytokines or inﬂammogens (e.g. from pathogens or from damaged neurons), both glial
cell types activate inﬂammatory signalling pathways, which result in increased expression and/or
release of inﬂammatory mediators such as cytokines, eicosanoids and metalloproteinases (Dong and
Benveniste, 2001), as well as in the production of reactive oxygen (ROS) and nitrogen species (RNS)
(Brown and Bal-Price, 2003). Different types of activation states are possible for microglia and
astrocytes, resulting in different responses concerning pro-inﬂammatory/anti-inﬂammatory signalling
and other cellular functions (such as phagocytosis) (Streit et al., 1999; Nakajima and Kohsaka, 2004).
Therefore, neuroinﬂammation can have both neuroprotective/neuroreparative and neurodegenerative
consequences (Carson et al., 2006; Monnet-Tschudi et al., 2007; Glass et al., 2010; Aguzzi et al., 2013).
Under normal physiological conditions, microglial cells scan the nervous system for neural integrity
(Nimmerjahn et al., 2005) and for invading pathogens (Kreutzberg, 1995, 1996; Aloisi, 2001; Rivest,
2009). They are the ﬁrst type of cell activated (ﬁrst line of defence), and can subsequently lead to
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astrocyte activation (Falsig, 2008). Two distinct states of microglial activation have been described
(Gordon, 2003; Ponomarev et al., 2005; Maresz et al., 2008; Mosser and Edwards, 2008; Kigerl et al.,
2009; Perego et al., 2011): The M1 state is classically triggered by interferon-gamma and/or other pro-
inﬂammatory cytokines, and this state is characterised by increased expression of integrin alpha M
(Itgam) and CD86, as well as the release of pro-inﬂammatory cytokines (TNF-alpha, IL-1beta, IL-6), and it
is mostly associated with neurodegeneration. The M2 state is triggered by IL-4 and IL-13 (Ponomarev
et al., 2007; Maresz et al., 2008; Perego et al., 2011) and induces the expression of mannose receptor 1
(MRC1), arginase 1 (Arg 1) and Ym1/2; it is involved in repair processes. The activation of astrocytes by
microglia-derived cytokines or TLR agonists resembles the microglial M1 state (Falsig, 2006).
A.6.2. How it is measured or detected
Neuroinﬂammation, i.e. the activation of glial cells can be measured by quantiﬁcation of cellular
markers (most commonly), or of released mediators (less common). As multiple activation states exist
for the two main cell types involved, it is necessary to measure several markers of neuroinﬂammation:
• Microglial activation can be detected based on the increased numbers of labelled microglia per
volume element of brain tissue (due to increase of binding sites, proliferation, and immigration
of cells). A speciﬁc microglial marker, used across different species, is CD11b. Alternatively,
various speciﬁc carbohydrate structures can be stained by lectins (e.g. IB4). Beyond that,
various well-established antibodies are available to detect microglia in mouse tissue (F4/80),
phagocytic microglia in rat tissue (ED1) or more generally microglia across species (Iba1).
Transgenic mice are available with ﬂuorescent proteins under the control of the CD11b
promoter to easily quantify microglia without need for speciﬁc stains.
• The most frequently used astrocyte marker is GFAP (99% of all studies) (Eng et al., 2000). This
protein is highly speciﬁc for astrocytes in the brain, and good clinically validated antibodies are
available for immunocytochemical detection. In neuroinﬂammatory brain regions, the stain
becomes more prominent, due to an upregulation of the protein, a shape change/proliferation of
the cells, or better accessibility of the antibody. Various histological quantiﬁcation approaches can
be used. Occasionally, alternative astrocytic markers, such as vimentin of the S100beta protein
have been used for staining of astrocytes (Struzynska et al., 2007).
• All immunocytochemical methods can also be applied to cell culture models.
• In patients, microglial accumulation can be monitored by PET imaging, using [11C]-PK 11195
as microglial marker (Banati et al., 2002).
• Activation of glial cells can be assessed in tissue or cell culture models also by quantiﬁcation of sets
of activation markers. This can for instance be done by PCR quantiﬁcation of inﬂammatory factors,
of by measurement of the respective mediators, e.g. by ELISA-related immunoquantiﬁcation. Such
markers include:
• Pro- and anti-inﬂammatory cytokine expression (IL-1b; TNF-a, Il-6, IL-4); or expression of
immunostimmulatory proteins (e.g. MHC-II)
• Itgam, CD86 expression as markers of M1 microglial phenotype
• Arg1, MRC1, as markers of M2 microglial phenotype
• (for description of techniques, see Falsig, 2004; Lund, 2006; Kuegler, 2010; Monnet-Tschudi
et al., 2011; Sandstrom von Tobel et al., 2014; von Tobel et al., 2014).
A.6.3. Evidence supporting taxonomic applicability
Neuroinﬂammation is observed in human, monkey, rat, mouse, and zebraﬁsh, in association with
neurodegeneration or following toxicant exposure. Some references (non-exhaustive list) are given
below for illustration:
In human: Vennetti et al., 2006 in monkey (Macaca fascicularis): Charleston et al., 1994, 1996 in
rat: Little et al., 2012; Zurich et al., 2002; Eskes et al., 2002 in mouse: Liu et al., 2012 in zebraﬁsh: Xu
et al., 2014.
6.4. Regulatory examples using the KE
Measurement of glial ﬁbrillary acidic protein (GFAP), whose increase is a marker of astrocyte
reactivity, is required by the US EPA for fuel additives (40 CFR 79.67), but is optional for other toxicant
evaluation.
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A.7. Adverse Outcome: parkinsonian motor deﬁcits
A.7.1. How this key events works
A large number of neurological disorders are characterised by a clinical syndrome with motor
symptoms of bradykinesia, tremor, rigidity and postural instability. As these clinical features are
common to multiple disorders, the clinical syndrome is referred as ‘parkinsonism’ and when
parkinsonism is representing the prevalent part of the syndrome, these are referred as ‘parkinsonian
disorders’. Parkinson’s disease (PD) is one of parkinsonian disorders and can have an idiopathic,
genetic or toxic (i.e. MPTP-induced parkinsonism) cause (Dickson, 2012). The pyramidal motor system
comprises bundles of neurons originating in the motor centres of the cerebral cortex to terminate in
the brainstem or in the spinal cord where they are responsible for voluntary control of motor functions
(Brooks, 1971). The extrapyramidal system, which is in the centre of AO, is the part of the motor
system primarily involved in the control and regulation of involuntary motor control, and in ﬁne tuning
(Barnes, 1983). Especially the initiation and maintenance of complex movement patterns or of
neuronal regulatory pathways involved in postural control of the body are regulated by the nigrostriatal
system that is affected in parkinsonian states. The CNS input is modulated by extrapyramidal circuits
before the execution of complex motor movements. The modulated information from the basal ganglia
is looped back through the thalamus to the cortex, from where ﬁnal motor signals are sent via the
pyramidal system; i.e. the basal ganglia system is not involved in the control of motor neurons and
striatal muscles, but it modulates the signals from the cortex to these systems. Thus, an impaired
input of dopamine into the striatum leads to an impairment of this modulation loop, and a disturbance
of basal ganglia feedback to the thalamus and cortex. This ultimately manifests in key parkinsonian
symptoms such as tremor, rigidity, or bradykinesia (Bernheimer, 1973). These conditions can be
generated experimentally by dopamine depletion with reserpine (Carlsson), by inhibition of dopamine
receptors, by mechanical or chemical ablation of nigrostriatal dopamine neurons (cut of the median
forebrain bundle or injection of the toxicant 6-OH-dopamine) or the application of toxicants that
leading to a relatively selective death of dopaminergic neurons in the substantia nigra (e.g. MPTP) and
therefore a reduction of dopamine in the striatum (Kolata, 1983).
The basal ganglia loop include the ventral striatum, the neostriatum composed of the putamen and
the caudate nucleus, the globus pallidus pars externa (GPe), the globus pallidus pars interna (GPi), the
subthalamic nucleus (STN), the substantia nigra pars reticulata (SNpr) and the substantia nigra pars
compacta (SNpc) (Obeso, 2008). The main input sites into basal ganglia are the striatum and the STN
where cortical (glutamatergic) innervations terminate in a topographically organised manner that
largely reﬂects the organisation in the cortex (Fallon, 1978; Takada, 1998). Both the GPi and the SNpr
represent the main output nuclei projecting into the thalamus (Alexander, 1990; Parent, 1999). The
connection between input and output nuclei is functionally organised into a ‘direct’ and an ‘indirect’
pathway (Silverdale et al., 2003). These two pathways in parallel regulate the activity of the basal
ganglia output neurons of the GPi and STN and are modulated by dopamine in the striatum. The
dopaminergic terminals in the striatum originate from dopaminergic projections from the SNpc. Striatal
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dopamine modulates the activity of inhibitory GABAergic medium spiny neurons that make up 90% of
all neurons in the striatum (Smith, 1994). Medium spiny neurons that preferentially express the D1
dopamine receptor are involved in the direct pathway and directly project into the two main output
nuclei (GPi and SNpr). Activation of the D1 medium spiny neuronal direct pathway results in a
reduction of the inhibitory basal ganglia output (GPi and SNpr) leading to a disinhibition of thalamic
target neurons (Bolam, 2000). These events ultimately lead to an elevated activity in the respective
cortical neurons, i.e. D1 signalling in the striatum leads to an increase in motor activity.
Medium spiny neurons predominantly expressing the D2 dopamine receptor mostly project to the
GPe (Gerfen, 1990). Activation of D2 expressing neurons leads to an inhibition of their activity. D2
neurons of the indirect pathway connect the striatum with GPi/SNpr via synaptic connections in the
GPe and the STN. Activating neurons originating in the STN project into the GPi/SNpr are
glutamatergic. From the STN, activating glutamatergic neuronal projections into the GPi/SNpr lead to a
basal, low activation. Activation of the indirect pathway by striatal dopamine from the substantia nigra
hence leads to a low basal inhibitory GABAergic output into thalamic structures, and thus allows a
strong motor cortex activation of the thalamus.
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Parkinson’s disease is characterised by a decline in striatal dopamine input from the substantia nigra
pars compacta (Smith, 1994). Under normal conditions, ganglial output via GPi/SNpr nuclei causes a
moderate inhibitory inﬂuence on cortical and brainstem motor neurons. A reduction in striatal
dopamine leads to an underactivation of D1 receptor-expressing medium spiny neurons of the direct
pathway. This insufﬁcient activation of the inhibitory GABAergic medium spiny neurons results in a
reduction of its normal inhibitory inﬂuence on GPi and SNpr output nuclei. As a consequence,
dopamine depletion leads to the overactivation of the inhibitory GABAergic GPi/SNpr output via the
direct pathway (Mitchell, 1989).
In the indirect pathway, the reduced activation of D2 receptors expressing neurons leads to an
overactivation of inhibitory output nuclei projecting into the GPe. The resulting inhibitory output of the
GPe is hence reduced, thus leading to a declined inhibition of the STN. Overactivation of the
Figure A.5: Functional anatomy of basal ganglia. (A) Normal conditions. Striatal (STR) dopamine
mainly originates from projections originating in the substantia nigra pars compacta (SNc).
The STR is mainly composed of inhibitory GABAergic medium spiny neurons (MSN). MSN
involved in the direct pathway directly project to the globus pallidus pars interna (GPi) and
the sunstantia nigra pars reticulata (SNpr) leading to a basal inhibition of these output
nuclei. MSN involved in the indirect pathway send inhibitory projections to the globus
pallidus pars externa (GPe). Their activity is dampened by dopamine binding to D2 receptor
expressing MSN in the striatum. (B) Lack of striatal dopamine. Under conditions of a lack of
striatal dopamine, inhibitory GABAergic neurons, originating in the striatum, receive less
activation, resulting in a declined inhibition of GPi and SNpr inhibitory output. In the
indirect pathway, the lack of dopamine causes a lack of its inhibitory inﬂuence on inhibitory
GABAergic projections into the GPe. This accelerated inhibition of the GPe results in a
decline in its inhibitory output into the STN. According to Silverdale et al., 2003, the decline
in STN inhibition allows its overactivation, resulting in an excessive activation of stimulatory
glutamatergic projections into the GPi and SNpr
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stimulatory glutamatergic projections originating in the STN leads to the hyperactivation of the output
GPi/SNpr nuclei. As a consequence of striatal dopamine depletion, the direct pathway becomes
underactivated and the indirect pathway becomes overactivated. This leads to an overactivation of the
basal ganglia output nuclei. Due to their inhibitory inﬂuence on thalamocortical motor centres, the
resulting reduced cortical activation leads to the prominent impairment of motor functions in
parkinsonian states (Silverdale et al., 2003).
The model of direct and indirect pathways linking striatal dopamine content with the basal ganglia
output nuclei has been criticised in recent years as it ignores the inﬂuence of extrastriatal dopamine
(Smith 2000), or the fact that some medium spiny neurons express dopamine receptors of both the D1
and of the D2 type (Surmeier, 1996). Principal validity of the model and the central role of striatal
dopamine was e.g. demonstrated by L-DOPA-mediated supplementation of striatal dopamine content in
unprimed PD patients that causes a partial reduction in the overactivation of GPi/SNpr output (Heimer,
2006; Yuan, 2010). As an alternative way for symptomatic treatment of parkinsonian conditions, deep
brain stimulation of either the STN or the GPi was shown to relieve from parkinsonian motor features
(Mazzone, 2003; Odekerken, 2013).
A.7.2. How is it measured or detected
For the analysis of striatal dopamine content and its correlation with motor control, both
biochemical analysis methods on the cellular and tissue level as well as behavioural tests are required.
Available test models are mice and rats on the one hand and non-human primates and humans on the
other. Motor impairment features associated with parkinsonian states in man serve as reference
standard. Monkey models have the advantage to largely reﬂect complex motor impairment patterns
observed in humans which are rather difﬁcult to assess in rodents. Rodent models in contrast are cost-
efﬁcient and allow both biochemical analysis that require major invasive methods as well as basic
behavioural tests. Due to the limitations in the assessment of moderate motor impairment in rodents
and the well-established correlation between striatal dopamine content and impaired motor output,
analysis of striatal dopamine is often applied as surrogate readout for the assessment of motor
deﬁcits.
A.7.2.1. Detection of striatal dopamine (total or extracellular)
The standard method used in the majority of experimental work is the determination of total
contents of dopamine and its two degradation metabolites HVA and DOPAC. For this purpose, the
striatum is quickly removed from experimental animals, homogenised in a suitable acidic buffer, and
the dopamine (metabolites) determined by HPLC with electrochemical detector or by HPLC-MS.
For live in vivo detection of extracellular dopamine levels, a microdialysis probe is inserted into the
striatum. Microdialysis can be performed in anesthetised animals or freely moving animals; basal
dopamine levels or stimulated levels (amphetamine, KCl) can be recorded. Dopamine and its
metabolites are detected in the dialysate either by HPLC or by HPLC–mass spectrometry analysis
(Saraswat, 1981; Cui, 2009; Gonzalez, 2011).
A.7.2.2. Detection of dopamine neuron terminals in the striatum
As alternative to the detection of striatal dopamine that is to a large extent limited to live detection
setups due to its instability in tissues, the number of remaining dopamine neurons in the substantia
nigra pars compacta was suggested as alternative readout (Burns, 1983). It allows the analysis of
ex vivo samples without the limitations associated with the instability and reactivity of extravesicular
dopamine. Although the number of surviving dopamine neurons in the SNpc in PD or in complex-I
inhibitor challenged test animals is a valuable parameter on its own, it was discovered that the number
of DA neurons in the SNpc not necessarily correlates with the amount of dopamine released in the
striatum. Tyrosine hydroxylase (TH) was regularly stained as marker for DA neurons, however it was
observed that TH expression was very variable following MPTP intoxication in the absence of cell death
and therefore has only limited suitability for the assessment of DA neuronal numbers (Aznavour, 2012).
Second, many DA neurites and terminals displayed damage or degradation in the absence of death of
the corresponding neuronal cell (Ling, 2015). Hence, even in the presence of viable DA neurons in the
SNpc, their corresponding terminals could no longer be able to release dopamine into the striatum.
Staining of DA neuronal terminals in the striatum is therefore used as a more reliable indirect marker
for striatal dopamine content. For the analysis of nigrostriatal terminals, the dopamine transporter
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(DAT) is visualised either by antibody-mediated staining in tissue slices or by the application of
radioactively labelled DAT ligands that allow their application both in vivo and in ex vivo samples
(Morris, 1996).
A.7.2.3. Behavioural tests: Rodent models
Rotation: the rotation model of Ungerstedt et al. (1970) is based on the unilateral lesion of the
nigrostriatal dopamine neuron system either in rodents or in non-human primates. The lesion can be
produced either surgically, or by stereotaxic infusion of e.g. 6-OHDA into the nigrostriatal system of
one hemisphere, or by infusion of MPTP through one carotid (single sided). After the lesion, animals
are left to recover, then the dopamine system is stimulated by injection of amphetamine. The
asymmetry of remaining dopamine neurons (only on one side) triggers spontaneous asymmetric motor
behaviour, i.e. rotations of the animals. Each full turn of an animal is recorded, the respective numbers
of left- and right turns are plotted versus time, respectively. In the standard rotation model, monkeys
become hypokinetic in the limbs on the contralateral side of the brain hemisphere treated. Rats
preferentially rotate towards the side of the lesion upon treatment with drugs that trigger activation of
the remaining dopamine neurons.
Rotarod: assessment of motor coordination. The animals are placed on a rotating rod that is
subjected to linear acceleration. The latency to fall from the rod is detected (Jones 1968).
Hang test: Detection of neuromuscular strength. Mice are placed on a horizontal grid. When the
animals grabbed the grid with their fore- and hindpaws, the grid is inverted with the animal hanging
upside down. In a typical setup, mice are required to remain on the grid for at least 30 s (Tillerson 2002).
Forepaw Stride length during walking: Ink is applied to the forepaws and the mice walk across a
blank sheet of paper. Training of the animals to walk across the white paper in a straight line without
stopping is performed before the respective treatment. The distance between single steps on each
side are measured (Klapdor, 1997).
Grid test: Mice hang upside down for 30 s on the grid that is also used for the Hang test and are
recorded on video for closer analysis. With this method, the average forepaw distance is measured by
assessing the distance covered, divided by the number of successful forepaw steps. In the course of
the analysis, the number of unsuccessful forepaw steps are detected and displayed as percentage of
the total number of steps performed (Crawley, 1999).
Akinesia: the animal is placed on a ﬂat surface and the latency until it has moved all of its four
limbs is assessed.
Open ﬁeld test: Infrared beams detect the animals activity for the determination of parameters
such as the time spent locomoting, the distance travelled, or the number of rearings.
Pole test: the animal is placed on a gauze-taped pole with the head upwards below the top of the
pole. Two parameters are detected: 1) time until animals turn by 180°; 2) time until the animals reach
the ﬂoor.
A.7.2.4. Non-invasive imaging of DA neuron terminals
Positron emission tomography (PET): Based on its appropriate half life time of ca. 2 h for
clinical investigations, ﬂuorine-18 labelled L-[18F]-ﬂuorodopa is routinely used in trace amounts for
intravenous administration. Striatal uptake of L-[18F]-ﬂuorodopa is followed by applying positron
emission tomography (PET) (Leenders, 1986).
Single photon emission computed tomography (SPECT): monitoring of dopamine transporter (DAT).
Iodine-123-b-CIT is used as a sensitive ligand for dopamine and serotonin transporters and was
applied in monkeys and humans (Winogrodzka, 2003).
A.7.2.5. Human neurological tests
A recent systematic review and evaluation of currently used rating scales for the assessment of
motor impairment and disability in PD patients identiﬁed the (1) Columbia University rating scale, (2)
the Northwestern University Disability Scale and (3) the Uniﬁed Parkinson’s Disease rating scale as the
most evaluated and reliable scales available (Ramaker, 2002). All scales evaluate several parameters,
some of which are not motor related. Thus, only subscales are useful for readout of motor symptoms
(e.g. 13 of the 42 UPDRS parameters). Of these, not all are equally dependent on nigrostriatal
dopamine. Examination needs to be done by a trained neurologist.
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A.7.2.6. Regulatory examples using this Adverse Outcome
Neurotoxic effects shall be carefully addressed and reported in routine required regulatory
toxicological studies (acute toxicity studies, short-term toxicity studies, long term toxicity and
carcinogenicity studies and reproductive toxicity studies). Regarding neurotoxicity in rodents, inclusion
of neurotoxicity investigations in routine toxicology studies shall also be considered. For pesticide
active substances the circumstances in which neurotoxicity studies should be performed are listed in
Regulation (EU) No 283/2013:
Speciﬁc neurotoxicity studies in rodents shall be performed in case the following conditions:
• there is indication of neurotoxicity in routine toxicity studies carried out with the active
substance;
• the active substance is a structurally related to known neurotoxic compound;
• the active substance has a neurotoxic mode of pesticidal action.
As a result, speciﬁc neurotoxicity studies are not routinely required for all pesticide active substances.
Speciﬁc neurotoxicity testing becomes obligatory only if neurotoxicity has been observed during
histopathological evaluation or in case of structural analogy with a known neurotoxic compound. Motor
activity should be measured once in short-term repeated dose toxicity studies (OECD 407, 408 and 422)
and several times in speciﬁc neurotoxicity studies (OECD 424, OECD 426 and cohort 2 of OECD 443).
However, this is not a requirement in chronic toxicity studies unless neurotoxic effects have been reported
in the shorter studies. The same test (measures horizontal and/or vertical movements in a test chamber)
is implemented in both routine studies and neurotoxicity studies. Coordination and balance are evaluated
by rotation or rotarod or pole tests, and gait abnormalities by forepaw stride length test. Those tests are
not required by any repeated dose toxicity OECD guidelines and they can be optionally incorporated in
the design of neurotoxicity studies OECD 424 and OECD 426.
Although motor deﬁcits is the AO in this AOP, degeneration of DA neurons, is also considered an
adverse effect in the regulatory framework, even in the absence of clear clinical symptoms or motor
deﬁcits. Morphological assessment of brain structures is a standard requirement in the regulatory
toxicological studies supporting the risk assessment of chemical substances and it is a regulatory
expectation that the anatomical structures belonging to the nigrostriatal pathway would be included
and evaluated as part of the standard evaluation of the brain. Treatment related neuronal
degeneration, when occurring as a consequence of the treatment, is generally dose-dependent in
incidence and severity. However, if not accompanied by clinical signs or behavioural changes indicative
of central nervous system pathology, minimal loss of DA neurons would likely remain undetected in the
standard histological evaluation, due to the presence of non DA neurons or as a consequence of the
subjectivity of non-quantiﬁable analysis, unless speciﬁc markers are used. As multiple forms of
perturbation can affect the neurons, some changes are potentially still reversible (e.g. loss of TH or
DA) and irreversibility should be conﬁrmed as part of the assessment. It is then important to apply a
sensitive and appropriate method (Switzer, 2000) and evaluation of the phenotypic markers in the
striatum and in the SNpc should be always performed as a minimum standard (Minnema et al., 2014)
when investigating perturbation of the nigrostriatal pathway. It should additionally considered that rat
is likely to be a poor model to capture this kind of hazard, as demonstrated by the poor sensitivity of
rat to MPTP or related compounds and this should be taken into account for the design and
interpretation of the studies.
Dissimilarities of chemical-induced animal models to human disease are also important and should
be carefully weighted when considering the duration and schedule of the study/treatment. Differently
from the human disease, with the MPTP animal model, the damage occurs rapidly, is hardly
progressive, is little age-dependent and formation of Lewy bodies is sometime not occurring (Efremova
et al., 2015, 2016). Therefore, for different animals models, the standard 90 days toxicity study could
not match with the chronic and progressive characteristics of the human disease and compensatory
changes inﬂuencing DA metabolism and turnover and protein catabolism can occur during the
treatment period with an impact on the time of onset of the lesion (Ossowska et al., 2005).
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KEY EVENTS RELATIONSHIPS (KERs)
1st KER: Binding of inhibitor to NADH-ubiquinone oxidoreductase (complex
I) leads to its inhibition
A.1.1. How does this Key Event Relationship work
It is well documented that binding of an inhibitor to CI inhibits its activity (see MIE). Naturally
occurring and synthetic CI inhibitors have been shown to inhibit the catalytic activity of CI, leading to
partial or total inhibition of its activity in a dose response manner (Degli Esposti and Ghelli, 1994;
Barrientos and Moraes, 1999; Betarbet et al., 2000; Ichimaru et al., 2008). Indeed, binding of
inhibitors stops the electron ﬂow from CI to ubiquinone. Therefore, the Fe-S clusters of CI become
highly reduced and no further electrons can be transferred from NADH to CI. This leads to the
inhibition of the NADH oxidoreductase function, i.e. CI inhibition.
A.1.2. Weight of Evidence for the KER
The weight of evidence supporting the relationship between binding of an inhibitor to NADH-
ubiquinone oxidoreducatse and its inhibition is strong.
A.1.2.1. Biological Plausibility
There is an extensive understanding of the functional relationship between binding of an inhibitor
to NADH-ubiquinone oxidoreductase (CI) and its inhibition. As the ﬁrst entry complex of mitochondrial
respiratory chain, CI oxidises NADH and transfers electrons via a ﬂavin mononucleotide cofactor and
several Fe-S complexes to ubiquinone. The electron ﬂow is coupled to the translocation of protons
from the matrix to the intermembrane space. This helps to establish the electrochemical gradient that
is used to fuel ATP synthesis (Greenamyre et al., 2001). If an inhibitor binds to CI, the electron
transfer is blocked. This compromises ATP synthesis and maintenance of Dwm, leading to
mitochondrial dysfunction. As CI exerts a higher control over oxidative phosphorylation in synaptic
mitochondria than in non-synaptic mitochondria in the brain (Davey and Clark, 1996), speciﬁc
functional defects observed in PD may be explained.
It is well documented that CI inhibition is one of the main sites at which electron leakage to oxygen
occurs. This results in a production of ROS, such as superoxide (Efremov and Sazanow, 2011) and
hydrogen peroxide, which are main contributors to oxidative stress (Greenamyre et al., 2001).
A.1.2.2. Empirical support for linkage
A variety of studies show a signiﬁcant correlation between binding of an inhibitor to CI and its
inhibition, usually measured by the decreased mitochondrial respiration. Different classes of CI
inhibitors, such as rotenone, MPP+, piericidin A, acetogenins, pyridaben, and various piperazin
derivatives (Ichimaru et al., 2008) have been shown to bind to the ubiquitin site of CI, leading to a
partial or total inhibition of oxidoreductase activity in a dose response manner (Grivennikova et al.,
1997; Barrientos and Moraes, 1999; Betarbet et al., 2000).
The reduction of CI activity is well documented in a variety of studies using isolated mitochondria
or cells, as well as in in vivo experiments and in human post mortem PD brains. Usually it is measured
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by assays described in 2nd Key Event Relationship (KER): Inhibition of complex I leads to
mitochondrial dysfunction.
It has been shown that binding of rotenone to CI (e.g. Betarbet et al., 2000, Greenamyre et al.,
2001) or MPP+ (e.g. Langston, 1996; Krug et al., 2014) can reproduce the anatomical, neurochemical,
behavioural and neuropathological features of PD. Therefore, the empirical support for this KER will be
mainly based on the experiments performed after exposure to rotenone or MPP+.
• The binding of rotenone to CI resulted in time- and dose-dependent inhibition of CI activity
measured in submitochondrial particles. The kinetics of the active CI inhibition was determined
after exposure to rotenone at 20, 30 and 40 nM at different times of exposure (30 s, 1 min or
2 min) (Grivennikova et al., 1997). This study suggests that two rotenone binding sites exist in
CI: one affecting NADH oxidation by ubiquinone and the other one operating in ubiquinol-
NAD+ reductase action.
• Partial inhibition of CI produces a mild, late-onset mitochondrial damage. The threshold effect
seen in brain mitochondria (25–50% decrease in activity) may not directly impact ATP levels or
Dwm but could have long-term deleterious effects triggered by oxidative stress, as it has been
shown that an electron leak upstream of the rotenone binding site in CI leads to ROS
production (Greenamyre et al., 2001).
• Exposure of rats to rotenone (2 days, 2 mg/kg) produced free brain rotenone concentration of
20–30 nM and resulted in 73% inhibition of speciﬁc binding to CI of [3H] dihydrorotenone
(Betarbet et al., 2000). However, oximetry analysis indicated that in brain mitochondria (but
not liver mitochondria) this rotenone concentration (30 nM maximum) was insufﬁcient to
inhibit glutamate (CI substrate)-supported respiration (Betarbet et al., 2000) suggesting that
this rotenone concentration did not alter mitochondrial oxygen consumption in isolated brain
mitochondria.
• Rotenone has been reported to be a speciﬁc and potent mitochondrial CI inhibitor with IC50
values from 0.1 to 100 nM depending on the system and methods used (Chinopoulos and Vizi,
2001; Lambert and Brand, 2004; Beretta et al., 2006; Ichimaru et al., 2008).
• Mesencephalic cultures prepared from C57BL/6 mice and treated with 5, or 10 nM rotenone for
24 h inhibited CI activity by 11% or 33%, respectively (Choi et al., 2008).
• The inhibition of CI was studied in the human osteosarcoma-derived cell line (143B) after the
exposure to rotenone or using a genetic model (40% loss of CI activity in human
xenomitochondrial cybrids (HXC) lines). Different degrees of CI inhibition were quantitatively
correlated with levels of decreased cellular respiration (Barrientos and Moraes, 1999). Only
when CI was inhibited by 35–40% (< 5 nM rotenone), cell respiration decreased linearly until
30% of the normal rate. Increasing concentrations of rotenone produced further but slower
decrease in CI activity and cell respiration (Figure 1). Cells with the complete rotenone-induced
CI inhibition still maintain a cell respiration rate of approximately 20% because of an electron
ﬂow through complex II. At high concentrations (ﬁve- to sixfold higher than the concentration
necessary for 100% CI inhibition), rotenone showed a secondary, toxic effect at the level of
microtubule assembly (Barrientos and Moraes, 1999).
• Bovine submitochondrial particles were used to test rotenone afﬁnity binding at 20 nM. This
concentration of rotenone reduced the NADH oxidation rate by approximately 50% (Okun
et al., 1999)
• MPP+ (an active metabolite of MPTP) is an inhibitor of CI (Sayre et al., 1986; Nicklas et al.,
1987; Mizuno et al., 1989). Inhibition of the mitochondrial CI by MPP+ suppresses aerobic
glycolysis and ATP production (Book chapter in Cheville, 1994).
• MPP+ binds loosely to CI and causes reversible inhibition of its activity: approximately 40%
inhibition was observed at 10 mM concentration within 15 min of incubation. However, prolonged
incubation (> 15 min) produces up to 78% of irreversible inhibition of CI (Cleeter et al., 1992).
Human studies
There are many studies that show impaired catalytic activity of CI in multiple PD post-mortem brain
tissues. For example (Parker and Swerdlow, 1998), ﬁve PD brains were used to measure activities of
complexes I, III, IV, and of complexes I/III together (NADH: cytochrome c reductase). These
measurements were performed in puriﬁed frontal cortex mitochondria and revealed a signiﬁcant loss of
CI activity in these PD samples as compared to controls.
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Human data indicate that impairment of CI activity may contribute to the pathogenic processes of
PD (e.g. Schapira et al., 1989; Greenamyre et al., 2001; Shults, 2004).
A.1.3. Uncertainties or inconsistencies
• It is not clear the number of subunits constituting CI in mammals, as according to the existing
literature different numbers are cited (between 41 and 46) (Hassinen, 2007; Vogel et al.,
2007a). The majority of data claims that mammalian CI is composed of 46 (Greenamyre et al.,
2001; Hassinen, 2007) or 45 subunits (Vogel et al., 2007). It is not sure whether there may
exist tissue-speciﬁc subunits of CI isoforms (Fearnley et al., 2001). It is unclear, which subunit
(s) bind rotenone or other inhibitors of CI.
• Additionally, it is not clear whether CI has other uncharacterised functions, taking into
consideration its size and complexity (43–46 subunits vs. 11 subunits of complex III or 13
subunits of complex IV) (Greenamyre et al., 2001).
• There is no strict linear relationship between inhibitor binding and reduced mitochondrial
function. Low doses of rotenone that inhibit CI activity partially do not alter mitochondrial
oxygen consumption. Therefore, bioenergetic defects cannot account alone for rotenone-
induced neurodegeneration. Instead, under such conditions, rotenone neurotoxicity may result
from oxidative stress (Betarbet et al., 2000). Few studies used human brain cells/human brain
mitochondria. Therefore, full quantitative data for humans are not available.
A.1.4. Quantitative understanding
The kinetics of binding and CI inhibition by rotenone has been quantitatively evaluated in a dose-
dependent manner using the submitochondrial particles (Grivennikova et al., 1997) The consequences
of CI inhibition were quantitatively measured by a variety of assays that are used to study
mitochondrial dysfunction (see Key Event Relationship (KER): Inhibition of Complex I leads to
mitochondrial dysfunction). There are also many in vitro and in vivo studies combining the
quantiﬁcation of CI inhibition and DA cell death (e.g. Betarbet et al., 2000; Choi et al., 2008; see KER
Mitochondrial dysfunction induces degeneration of nigrostriatal pathway).
The binding of different classes of inhibitors (e.g. pesticides, drugs and other toxins) to CI has been
determined quantitatively and I50, and KI values are available. Potency relative to that of rotenone has
been determined under the same conditions in beef mitochondria or submitochondrial particles using
the ratio of the KI values, when they were available (Degli Esposti, 1998; Okun et al., 1999). Rotenone
I50 value is deﬁned as 20 nM (Okun et al., 1999).
Example of a quantitative evaluation of concentration-dependent CI inhibition by rotenone (from
Barrientos and Moraes, 1999, Figure A.6).
Time- and concentration-relationship of NADH oxidase inhibition by rotenone (Figure A.7 from
Grivennikova et al., 1997).
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Figure A.6: Effect of CI (NADH decylubiquinone reductase) inhibition on endogenous cell respiration.
Cells were treated with different concentrations of rotenone for 4 h before measuring cell
respiration in whole cells and CI activity in isolated mitochondria. Complete CI inhibition
was achieved with 100 nM rotenone. The cell respiration was inhibited also in a dose-
dependent manner but showed different inhibition kinetics and a saturation threshold. For
comparison, the genetically altered cell line HXC had an approximately 40% CI reduced
activity and an approximately 80% residual cell respiration. HXC, human xenomitochondrial
cybrids (This research was originally published in the Journal of Biological Chemistry,
Barrientos and Moraes, 1999, copyright the American Society for Biochemistry and
Molecular Biology)
Figure A.7: Panel A and B: Time- and concentration-relationship of NADH oxidase inhibition by
rotenone. The numbers on the curves indicate the ﬁnal concentrations of rotenone (0, 20,
30, 40, 1,000 nM). In Panel B: vo, zero-order rate of NADH oxidation in the absence of
rotenone; vt, the `instant’ values of the rates approximated within 10 s time intervals.
Panel C: The dependence of ﬁrst-order inhibition rate constant on the concentration of
rotenone (for further description see Grivennikova et al., 1997. Reprinted from Grivennikova
et al., 1997, copyright (1997) with permission from Elsevier)
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A.1.5. Evidence Supporting Taxonomic Applicability
The CI is well-conserved across species from lower organism to mammals. The central subunits of
CI harbouring the bioenergetic core functions are conserved from bacteria to humans. CI from bacteria
and from mitochondria of Yarrowia lipolytica, a yeast genetic model for the study of eukaryotic CI
(Kerscher et al., 2002) was analysed by x-ray crystallography (Zickermann et al., 2015).
However, the afﬁnity of various chemicals to cause partial or total inhibition of CI activity across
species is not well studied (except for rotenone).
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2nd KER: Inhibition of Complex I lead to mitochondrial dysfunction
A.2.1. How does this Key Event Relationship work
Inhibited CI is unable to pass off its electron to ubiquinone and it cannot translocate protons across
the mitochondrial inner membrane. This creates a back-up of NADH within the mitochondrial matrix
(Brown and Borutaite, 2004). This leads to an arrest of the citric acid cycle and a failure to build a
proton gradient (mitochondrial membrane potential, Dwm) across the inner membrane. This results in
impaired ATP production. In addition, the direct transfer of electrons from CI to oxygen is increased.
This leads to oxidative stress as ROS (e.g. superoxide, hydrogen peroxide) are produced, which can
damage DNA, proteins, lipids and other cell components and function (Sanders et al., 2014).
A.2.2. Weight of Evidence
The weight of evidence supporting the relationship between inhibition of CI and mitochondrial
dysfunction is strong. The mechanisms behind this KER are partially understood and well documented
based on in vitro as well as in vivo experiments (e.g. Sanders et al., 2014), complemented by data
from human post-mortem PD brain evaluations (Parker et al., 1989; Schapira et al., 1989; Sherer
et al., 2003).
A.2.2.1. Biological Plausibility
The biological plausibility that inhibition of CI activity triggers mitochondrial dysfunction is strong. It
is well understood, how the inhibition of CI can lead to mitochondrial dysfunction as measured by: a)
decreased oxygen consumption, b) decrease or loss of ATP production, c) decrease of Dwm, d) the loss
of mitochondrial protein import and protein biosynthesis, e) reduced activities of enzymes of the
mitochondrial respiratory chain and the Krebs cycle, f) elevated levels of ROS, g) the loss of
mitochondrial motility, causing a failure of mitochondria to re-localise to sites of increased energy
demands (such as synapses), h) destruction of the mitochondrial network, i) increased mitochondrial
uptake of Ca2+ causing mitochondrial Ca2+ overload (Graier et al., 2007) and opening of mitochondrial
PTP, (j) rupture of the mitochondrial inner and outer membranes, leading to release of mitochondrial
pro-death factors, including cytochrome c, AIF and endonuclease G (Braun, 2012; Martin, 2011; Correia
et al., 2012; Cozzolino et al., 2013). These pathological mechanisms are extremely well studied.
A.2.2.2. Empirical support for linkage
Many studies show that the pathophysiological consequences of a partial or total CI inhibition are
linked to mitochondrial dysfunction. In many of these experiments the cellular damage caused by
mitochondrial dysfunction is reduced (or entirely prevented) by treatment with antioxidants.
Different degrees of CI inhibition by rotenone have been studied in the human osteosarcoma-
derived cell line (143B). A quantitative correlation between increasing inhibition of CI and mitochondrial
dysfunction (as shown by inhibition of mitochondrial respiration, reduced ATP production, increased
ROS release and lipid peroxidation, as well as decreased Dwm) was established (Figure 1 and Table 1
based on Barrientos and Moraes, 1999).
Based on the existing literature it is suggested that rotenone exerts toxicity via oxidative stress,
rather than via decrease of ATP synthesis (bioenergetics effects).
A few examples illustrating mitochondrial damage and oxidative stress in animal model of PD and
human cells induced by:
Rotenone
• Rotenone administered subcutaneously for 5 weeks (2.5 mg/kg/d) caused a selective increase
(by ~ 2 fold) in oxidative damage in the striatum, as compared to the hippocampus and cortex,
accompanied by massive degeneration of DA neurons (~ 80% decrease) in the substantia nigra.
Rotenone reduced intracellular ATP levels in the striatum (by > 40%), increases malondialdehyde
(MDA, indicative of lipid peroxidation, by ~ 60%), reduced GSH levels (by ~ 20%), thioredoxin
(by ~ 70%), and manganese superoxide dismutase (SOD, by ~ 15%) (all parameters signiﬁcantly
changed in the striatum). Antioxidant polydatin (Piceid) treatment signiﬁcantly prevented the
rotenone-induced changes by restoring the above parameters to control levels, conﬁrming that
rotenone-induced mitochondrial dysfunction resulted in oxidative stress (Chen et al., 2015).
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• Rotenone was administered 2.5 mg/kg body weight to male Wistar rats for 4 weeks in the
presence or absence of ferulic acid (FA, at the dose of 50 mg/kg) that has antioxidant and
anti-inﬂammatory properties. Rotenone administration caused DA neuronal cell death (~ 50%),
signiﬁcant reduction in endogenous antioxidants, such as superoxide dismutase (~ 75%),
catalase (~ 40%), and glutathione (~ 50%), and induced lipid peroxidation evidenced by
increased MDA formation (~ 2 folds). Treatment with FA rescued DA neurons in substantia
nigra pars compacta area and nerve terminals in the striatum, as well as restored antioxidant
enzymes, prevented depletion of glutathione, and inhibited lipid peroxidation induced by
rotenone (Ojha et al., 2015).
• Many studies have shown that mitochondrial aldehyde dehydrogenase 2 (ALDH2) functions as
a cellular protector against oxidative stress by detoxiﬁcation of cytotoxic aldehydes. Dopamine
is metabolised by monoamine oxidase to yield 3,4-dihydroxyphenylacetaldehyde (DOPAL) then
converts to a less toxic acid product by ALDH. The highly toxic and reactive DOPAL has been
hypothesised to contribute to the selective neurodegeneration of DA neurons. In this study,
rotenone (100 nM, 24 h) in both SH-SY5Y cells and primary cultured substantia nigra (SN) DA
neurons, was shown to reduce DA cell viability (~ 40%), reduce Dwm (~ 40%, as shown by
TMRM), induce mitochondrial ROS production (~ 30%, as shown by increase of MitoSox Red),
and increased cytosolic protein levels of proteins related to the mitochondrial apoptotic
pathway (i.e. Bax, cytochrome c, active caspase-9 and active caspase-3) (~ 2 folds for all
proteins).
• The neuroprotective mechanism of ALDH2 was observed as overexpression of wild-type ALDH2
gene (but not the enzymatically deﬁcient mutant ALDH2*2 (E504K)) reduced rotenone-induced
DA neuronal cell death, prevented rotenone-induced reduction in TMRM signal (95.7  1.6%
vs 67  3.5%), and prevented rotenone-induced increase in MitoSox Red intensity
(103.1  1% vs 133.4  0.8%). Additionally, pretreatment of cells with Alda-1 (activator of
ALDH2) (1–10 lM, for 24 h) prevented rotenone-induced loss of Dwm and ROS production in a
dose-dependent manner. These results were conﬁrmed by in vivo studies. Rotenone (50 mg/kg
per day, oral administration for 14 days) or MPTP (40 mg/kg per day, i.p. for 14 days) both
administered to C57BL/6 mice caused signiﬁcant SN TH+ DA neuronal cell apoptosis (~ 50%).
Alda-1 attenuated rotenone-induced apoptosis by decreasing ROS accumulation, reversing
Dwm depolarisation, and inhibiting the activation of proteins related to mitochondrial apoptotic
pathway. The present study demonstrates that rotenone or MPP+ induces DA neurotoxicity
through oxidative stress. Moreover, Alda-1 is effective in ameliorating mitochondrial dysfunction
by inhibiting rotenone- or MPP+-induced mitochondria-mediated oxidative stress that leads to
apoptosis (Chiu et al., 2015).
• Rotenone-induced mitochondrial dysfunction was observed in human neuroblastoma cells
exposed to 5 nM rotenone for 1–4 weeks. After 3–4 weeks of treatment, rotenone-treated cells
showed evidence of oxidative stress, including loss of GSH (by 5%) and increased oxidative
DNA (qualitative, measured by using antibodies to 8-oxo-dG) and protein damage (223  29%
of control, as shown by the large increase in protein carbonyls in the insoluble fraction)
(Sherer et al., 2002). This chronic rotenone treatment markedly sensitised cells to further
oxidative challenge since in response to H2O2 cytochrome c release from mitochondria and
caspase-3 activation occurred earlier and to a greater extent in rotenone-treated cells vs Ctr
(1.44  0.02% vs 0.38  0.07% apoptosis/h). This study indicates that chronic, low-level CI
inhibition by rotenone induces progressive oxidative damage, and caspase-dependent neuronal
cell death (Sherer et al., 2002).
• By using antioxidant, kaempferol (6 lM, 1 h prior addition of rotenone) and rotenone (50 nM,
max up to 24 h) on SH-SY5Y cells, kaempferol was found to counteract rotenone-induced ROS
production (especially superoxide: with kaempferol, ethidium ﬂuorescence decreased below the
control (Ctr) levels), rotenone-induced mitochondrial oxidative dysfunction (protein carbonyls
values: 2.5 in Ctr, 6.2 with rotenone, 2.7 with kaempferol + rotenone), rotenone-induced
oxygen respiration (values of nmol of atomic oxygen/minute per mg protein: 5.89 Ctr, 0.45
with rotenone, 2.47 with kaempferol + rotenone), rotenone-induced Dѱm decrease (~ 70%
cells of with rotenone only vs ~ 30% with kaempferol + rotenone) (Filomeni et al., 2012).
• To model the systemic mitochondrial impairment, rats were exposed to rotenone. A single
rotenone dose (10 nM, for 24 h) induced mtDNA damage in midbrain neurons (> 0.4 lesions/
10 kb vs 0 lesions/10 kb in vehicle), but not in cortical neurons; similar results were obtained
in vitro in cultured neurons. Importantly, these results indicate that mtDNA damage is
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detectable prior to any signs of neuronal degeneration and is produced selectively in midbrain
neurons. The selective vulnerability of midbrain neurons to mtDNA damage was not due to
differential effects of rotenone on CI since rotenone suppressed respiration equally (~ 60%) in
midbrain and cortical neurons compared to vehicle. However, in response to CI inhibition,
midbrain neurons produced more mitochondrial H2O2 (5 min of rotenone increased MitoPY1
ﬂuorescence of ~ 10% in midbrain mitochondria vs vehicle, and progressively for the duration
of measurement), than cortical neurons. The selective mtDNA damage in midbrain could serve
as a molecular marker of vulnerable nigral neurons in PD. Oxidative damage to cell
macromolecules in human PD and the rotenone model have been recently reviewed (Sanders
et al., 2014).
• Adult male Sprague–Dawley rats were intranigrally infused with rotenone (6 lg in 1 ll) alone
or in the presence of L-deprenyl (0.1, 1, 5 and 10 mg/kg; i.p.) at 12 h intervals for 4 days.
Rotenone alone (100 lM, 30 min) increased the levels of hydroxyl radials in the mitochondrial
P2 fraction 2,3-DHBA (122.90  5.4 pmol/mg protein) and 2,5-DHBA (146.21  6.3 pmol/mg
protein). L-deprenyl (100 nM–1 mM) dose-dependently attenuated rotenone-induced OH
generation in the mitochondrial P2 fraction. L-deprenyl-induced attenuation in the rotenone-
mediated 2,3-DHBA generation was from 17  1.1% to 67  4.3%, respectively, for 100 nM–
1 mM of the MAO-B inhibitor. Also, rotenone caused about 51  3.3% reduction in GSH levels
in the cell body region, SN and 34  1.1% decrease in the nerve terminal region, NCP
(nucleus caudatus putamen). L-deprenyl alone did not cause any signiﬁcant difference in the
GSH content in either region. L-deprenyl treatment dose-dependently attenuated the rotenone-
induced GSH depletion in SN from 51  3.1% to 44  2.1%, 32  1.7% and 9  1.0%,
respectively, for doses of 1, 5 and 10 mg/kg. Additionally, SOD activity was assayed in
rotenone-lesioned animals, which were treated with l-deprenyl at different doses (1–10 mg/kg).
SN exhibited two- and threefold activity of Cu/Zn-SOD (i.e. cytosolic SOD fraction) and Mn-SOD
(i.e. particulate SOD fraction), respectively, compared to the nerve terminal region, NCP.
L-deprenyl (5 and 10 mg/kg) in rotenone-lesioned animals caused a signiﬁcant increase in the
cytosolic Cu/Zn SOD activity in SN of both the sides. Intranigral infusion of rotenone alone caused
a signiﬁcant increase in the enzyme activity in SN of the side of infusion as compared to the
non-infused side (~ 20%). L-deprenyl (5 and 10 mg/kg) further increased catalase activity in
both ipsilateral SN and striatum, as compared to the contralateral side of infusion. Finally,
rotenone caused a 74% reduction in the striatal TH staining intensity, which was partially
recovered by L-deprenyl. These results showed that oxidative stress is one of the major causative
factors underlying DA neurodegeneration induced by rotenone and they support the view that
L-deprenyl is a potent free radical scavenger and an antioxidant (Saravanan et al., 2006). Similar
results were obtained after exposure to MPP+ (Wu et al., 1994).
• Antioxidant (piperaceae; PLL) with some anti-inﬂammatory activities demonstrated in preclinical
studies protective effects in PD animal models. Rats treated with rotenone and PLL-derived
alkaloids showed decreased ROS, stabilised Dwm, and the opening of the mitochondrial
PTP – which is triggered by ROS production – was inhibited. In addition, rotenone-induced
apoptosis was abrogated in the presence of these alkaloids (Wang et al., 2015b).
• In SK-N-MC human neuroblastoma cells, rotenone (10 nM – 1 lM, 48 h) caused dose-dependent
ATP depletion (~ 35% reduction by 100 nM rotenone vs Ctr), oxidative damage (100%
increase of carbonyls levels upon 100 nM rotenone), and death (100 nM rotenone after 48 h
caused 1.1 AU (arbitrary units) increase of cell death vs untreated – 0.00 AU -). a-Tocopherol
pretreatment (62.5 or 125 lM 24 h before rotenone (10 nm)) attenuated rotenone toxicity
(Sherer et al., 2003).
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) or MPP+ (1-methyl-4-phenyl-
pyridinium ion)
• MPTP converted into MPP+ inhibits mitochondrial CI activity, resulting in excessive intracellular
ROS production followed by further mitochondrial dysfunction leading to mitochondrial-
dependent apoptosis. Lutein, a carotenoid of xanthophyll family (antioxidant) reversed MPTP-
induced mitochondrial dysfunction, oxidative stress, apoptotic cell death and motor
abnormalities. These results revealed that antioxidant protected DA neurons and diminished
mitochondrial dysfunction and apoptotic death (Nataraj et al., 2015).
PPPs, Parkinson’s disease and childhood leukaemia
www.efsa.europa.eu/efsajournal 113 EFSA Journal 2017;15(3):4691
• Antioxidant (salidroside; Sal) pretreatment protected DA neurons against MPTP/MPP+-induced
toxicity in a dose-dependent manner by: (1) reducing the production of ROS, (2) regulating
the ratio of Bcl-2/Bax, (3) decreasing cytochrome-c and Smac release, and inhibiting caspase-
3, caspase-6, and caspase-9 activation, which are known to trigger apoptosis following
mitochondrial dysfunction. Sal acted as an effective neuroprotective agent through modulation
of the ROS-induced mitochondrial dysfunction in vitro and in vivo (Wang et al., 2015a).
• In an in vitro study, MPP+ (1 mM, 24 h) was found to elicit production of ROS (by 2 fold vs
Ctr) and reduce by 50% SOD (by about 50%) and catalase (by about 65%) activity in
SH-SY5Y human neuroblastoma cells. Pretreatment with the antioxidant astaxanthin (AST;
50 lM, 24 h) inhibited MPP+-induced production of ROS and attenuated both SOD and
catalase activity decrease. Furthermore, MPP+ (1 mM, 48 h) increased caspase-3 activity to
243% of the Ctr and also increased cleaved caspase-3 in the cells (qualitative). Addition of
50 lM AST attenuated MPP+-induced caspase-3 activation (57% suppression). MPP induced
also a 70% reduction of Dwm and cytochrome c release (qualitative), while AST prevented
both these effects. The protective effects of AST on MPP+-induced mitochondrial dysfunction
was due to its antioxidative properties and antiapoptotic activity via induction of expression of
SOD and catalase (as shown above) and regulating the expression of Bcl-2 and Bax (Bax/Bcl-2
ratio increased to 1.6-fold vs Ctr upon treatment with MPP+, while AST prevented the MPP+-
induced increase of the Bax/Bcl-2 ratio). These results were conﬁrmed by in vivo studies
(Lee et al., 2011).
• DA neurons in primary mesencephalic cultures treated with MPP+ (100 lM, for 48 h)
underwent reduction of cell viability (~ 55% MTT reduction), LDH release (~ 90%), about 60%
reduction of TH+ cells, disruption of Dwm (~ 45% decline) and ROS production (~ 60%
increase), upregulation of Nox2 (~ 45%) and Nox4 (~ 60%), while promoting a decrease of
both SOD (~ 45%) and GSH activity (~ 85%). Additionally, MPP-induced apoptosis via
mitochondrial dysfunction, as shown by induction of cytochrome c (~ 55%), cleaved-caspase-3
(~ 75%), upregulation of Bax expression (~ 55%), and downregulation of Bcl2 (~ 60%).
Liuwei dihuang (LWDH), a widely used traditional Chinese medicine (TCM), has antioxidant
characteristics. LWDH-WH, derivative of LWDH (0.01–10 lg/ml, added 1 h prior to MPP+
addition) reduced oxidative damage via increasing antioxidant defence (SOD, GSH), decreasing
ROS production, and downregulating NADPH oxidases (Nox2 and Nox4). LWDH-WH also
inhibited neuronal apoptosis by increasing antiapoptotic protein Bcl-2 expression, and
downregulating apoptotic signalling (Bax, cytochrome c, cleaved-caspase-3) in MPP+-treated
neurons. All these protective effects were induced in a dose-dependent manner (Tseng et al.,
2014).
• PC12 cells treated with MPP+ (500 lM, for 24 h) underwent reduction of viability (~ 55% MTT
reduction), oxidative stress (~ 160% increase in ROS production) and downregulation of haem
oxygenase-1 expression (~ 2-fold). Pretreatment with edaravone, a novel free radical
scavenger, (25, 50, 75, 100 lM, for 1 h prior MPP+ treatment) protected PC12 cells against
MPP+-cytotoxicity via inhibiting oxidative stress and upregulating haem oxygenase-1
expression in a dose-dependent manner (Cheng et al., 2014).
• The protective effects of antioxidant, apigenin (AP), naturally occurring plant ﬂavonoids were
observed on the MPP+–induced cytotoxicity in cultured rat adrenal phaeochromocytoma cells
(PC12 cells). The PC12 cells were pretreated with various concentrations of the test compound
for 4 h, followed by the challenge with 1,000 lM MPP+ for 48 h. Pretreatment with AP (3–6–
12 lM) before MPP+ signiﬁcantly reduced the level of intracellular ROS and elevated Dwm in
the MPP+–treated PC12 cells. In addition, AP markedly suppressed the increased rate of
apoptosis and the reduced Bcl–2/Bax ratio induced by MPP+ in the PC12 cells. The ﬁndings
demonstrated that AP exerts neuroprotective effects against MPP+–induced neurotoxicity in
PC12 cells, at least in part, through the inhibition of oxidative damage and the suppression of
apoptosis through the mitochondrial pathway (Liu et al., 2015).
• Brain mitochondria isolated from ventral midbrain of mitochondrial matrix protein cyclophilin D
(CYPD) knockout mice were signiﬁcantly less sensitive to acute MPP+ (20 lM)-induced effects.
CYPD ablation attenuated in vitro Ca2+ -induced mitochondrial dysfunction and ROS
generation upon Ca2+ loading, both in the absence and in the presence of MPP+, compared
to wild-type mice. CYPD ablation conferred a protection to mitochondrial functions upon in vivo
treatment with MPTP.
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• Ventral midbrain mitochondria (that constitutes < 5% of SNpc DA neurons) isolated from
brains of wild type (wt) mice acutely treated with MPTP (single MPTP 20 mg/kg injection,
analysis done after 4 h), as compared with saline-treated mice, showed a reduction of CI (by
53%), a reduced rate of phosphorylating respiration (by 38%), a reduced respiratory control
index (by 37%), and a decreased ADP/O ratio (by 18%).
• Ventral midbrain mitochondria isolated from brains of CYPD knockout mice acutely treated with
MPTP, as compared with MPTP-treated wt mice, exhibited higher activity of CI (~ 80%, vs 53%
wt), higher rate of phosphorylating respiration (~ 82%, vs 62% wt), a better respiratory
control index (~ 79%, vs 63% wt), and a higher ADP/O ratio (~ 90% vs 82% wt) (Thomas
et al., 2012).
• CYP plays as a regulatory component of a calcium-dependent permeability transition pores
(PTP), and the data suggest that PTP is involved in MPP+-induced mitochondrial damage.
Under oxidative stress, the prolonged opening of the PTP results in calcium overload and with
time mitochondrial dysfunction as they get de-energised, depolarised, triggering apoptotic or
necrotic cell death (Bernardi, 1999).
There are many other studies showing that MPP+ induces NADH-dependent SOD formation and
enhances NADH-dependent lipid peroxidation in submitochondrial particles, conﬁrming that oxidative
stress is induced by MPP+ (e.g. Ramsay and Singer, 1992; Takeshige, 1994).
Based on the human post mortem studies of PD brains it is well established that oxidative stress
and mitochondrial dysfunction accompany the pathophysiology of PD (e.g. Hartman et al., 2004; Zhu
and Chu, 2010; Dias et al., 2013; Fujita et al., 2014).
Examples of human data conﬁrming the presence oxidative stress and mitochondrial
dysfunction in PD post mortem brains:
• A signiﬁcant decrease in CI activity has been identiﬁed in a large study of post-mortem PD
brains, speciﬁcally in substantia nigra compared with age matched controls. In idiopathic PD all
10 patients studied had signiﬁcant reductions of CI activity (Parker et al., 1989). It is
hypothesise that the CI dysfunction may have an aetiological role in the pathogenesis of PD
(Schapira et al., 1989; Greenamyre et al., 2001; Sherer et al., 2003).
• The structure and function of mitochondrial respiratory-chain enzyme proteins were studied
post-mortem in the substantia nigra of nine patients with PD and nine matched controls. Total
protein and mitochondrial mass were similar in the two groups. CI and NADH cytochrome c
reductase activities were signiﬁcantly reduced, whereas succinate cytochrome c reductase
activity was normal. These results indicated a speciﬁc defect of CI activity in the substantia
nigra of patients with PD (Schapira et al., 1990).
• Post mortem human studies show that CI deﬁciency in PD is anatomically speciﬁc for the
substantia nigra, and they are not present in another neurodegenerative disorder involving the
substantia nigra. These results suggest that CI deﬁciency may be the underlying cause of DA
cell death in PD (Schapira et al., 1990; Schapira, 1994).
• The mitochondrial respiratory chain function was studied in various brain regions as well as in
skeletal muscle and in blood platelets from patients with idiopathic PD and from matched
controls. The evidence suggests that the CI deﬁciency in PD is limited to the brain and that
this defect is speciﬁc for the substantia nigra (Mann et al., 1992).
• Immunoblotting studies on mitochondria prepared from the striata of patients who died of PD
were performed using speciﬁc antisera against Complexes I, III and IV. In four out of ﬁve
patients with PD, the 30, 25 and 24 kDa subunits of CI were moderately to markedly
decreased. No clear difference was noted in immunoblotting studies on subunits of Complexes
III and IV between the control and PD. The authors claim that deﬁciencies in CI subunits seem
to be one of the most important clues to elucidate pathogenesis of PD (Mizuno et al., 1989).
• Redox markers have been found unchanged in PD patient-derived vs Ctr-derived ﬁbroblasts at
baseline. Basal mitochondrial respiration and glycolytic capacity resulted similar at baseline
between PD and Ctr ﬁbroblasts, while rotenone-sensitive respiration (analysed by using 0.5 lM
rotenone) resulted lower in PD ﬁbroblasts vs Ctr (174.74  48.71 vs 264.68  114.84)
(Ambrosi et al., 2014).
• Augmented oxidative metabolism has been detected in PD brains by magnetic resonance
studies, in conjunction with energy unbalance. Decreased glucose consumption (22% mean
reduction), likely reﬂecting a decrease in neuronal activity, has been reported in the
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nigrostriatal system of PD patients (Piert et al., 1996). These symptoms were hypothesised to
be indicative of mitochondrial dysfunction as early markers, present in the brain of patients
with PD even in the absence of overt clinical manifestations (Rango et al., 2006). In particular,
by using high temporal and spatial resolution 31P magnetic resonance spectroscopy (31P MRS)
technique authors studied mitochondrial function by observing high-energy phosphates (HEPs)
and intracellular pH in the visual cortex of 20 PD patients and 20 normal subjects at rest,
during, and after visual activation. In normal subjects, HEPs remained unchanged during
activation, but rose signiﬁcantly (by 16%) during recovery, and pH increased during visual
activation with a slow return to rest values. In PD patients, HEPs were within the normal range
at rest and did not change during activation, but fell signiﬁcantly (by 36%) in the recovery
period; pH did not reveal a homogeneous pattern with a wide spread of values. Energy
unbalance under increased oxidative metabolism requirements, that is, the post-activation
phase, discloses a mitochondrial dysfunction that is present in the brain of patients with PD
even in the absence of overt clinical manifestations (Rango et al., 2006).
There are many other studies providing evidence that oxidative stress and mitochondrial
dysfunction play an important role in PD pathophysiology (see indirect KER Mitochondrial dysfunction
induced DA neuronal cell death of nigrostriatal pathway).
A.2.3. Uncertainties or inconsistencies
• Some studies suggest that rotenone may have effects other than CI inhibition, and it has been
claimed that rotenone induces microtubule disruption, rather than ETC CI inhibition (Ren et al.,
2005; Feng, 2006).
• Some studies suggested that there was no evidence for signiﬁcant change in mitochondrial CI
function in PD patients’ brains (Jenner et al., 1992).
• It is still unclear whether the site of superoxide production in CI inhibited mitochondria is CI
itself or not (Singer and Ramsay, 1994).
A.2.4. Quantitative Understanding of the Linkage
Based on the available data, the threshold effect seen in brain mitochondria indicates that modest
CI inhibition (~ 25–50% decrease in activity) may not directly impact ATP levels or Dwm. Indeed, low
levels of CI inhibition produces an oxidative stress without any signiﬁcant changes in mitochondrial
respiration (Betarbet et al., 2000; Greenamyre et al., 2001) or causes not signiﬁcant changes in ATP
levels (Sherer et al., 2003).
In particular, in rotenone-infused animals (2.0 mg/kg per day for 2 days), [3H] dihydrorotenone
binding to CI in brain was reduced by about 73%. Based on this degree of binding inhibition, the
rotenone concentration in brain was estimated to be between 20 and 30 nM. Complexes II and IV
were unchanged by rotenone infusion (Betarbet et al., 2000).
However, such defects have long-term deleterious effects. It is well documented that that there is a
site of electron leak upstream of the rotenone binding site in CI (i.e. on the ‘NADH side’ of the
complex) (Hensley et al., 1998) leading to the superoxide (O2
) and followed up by H2O2 production
by CI (Greenamyre et al., 2001). The relative role of each ETC complex in forming superoxide differs
by tissue; however CI is a major source of O2
 in the brain (Halliwell, 2007).
Thus, a low inhibition of CI activity that is insufﬁcient to affect cell respiration may lead to
mitochondrial damage and chronic upregulation of ROS production. Therefore, it is suggested that
rotenone that binds to CI with an afﬁnity of 10–20 nM induces toxicity not by bioenergetics effects but
rather via accumulative oxidative stress. Sustained oxidative stress leads to decrease levels of reduced
glutathione; activation of superoxide dismutase (SOD) (scavenger of O2
), catalase and indeed,
treatments with antioxidants reduce the oxidative stress-induced damage. Such data are abounded in the
existing literature based both on in vivo and in vitro studies and a few examples are described.
A.2.5. Empirical support for linkage
The selective CI defects (other complexes were unaffected) (Schapira et al., 1990a) and
induced mitochondrial damage followed by oxidative stress is also described in PD patients brains
as documented by: (a) reduced glutathione levels (Jenner et al., 1992); (b) increased content of
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8-oxo-deoxyguanine, a marker of oxidatively damaged nucleic acids (Mecocci et al., 1993; Alam et al.,
1997); (c) increased level of malondialdehyde (marker of lipid peroxidation) (Navarro et al., 2009); (d)
increased cholesterol lipid hydroperoxide (Dexter et al., 1994); (e) increased protein oxidation
measured, e.g. by elevated levels of methionine sulfoxide formation or protein carbonyl content (Alam
et al., 1997). These studies in human brain present a semiquantitataive evaluation of the oxidative
stress, as there is no data showing KER between the various degrees of CI inhibition and mitochondrial
damage (ROS production) and the parameters described above. However, these studies clearly
conﬁrmed that oxidative stress in PD patient brain is increased as shown by the measured biomarkers
(Sanders and Greenamyre, 2013).
In in vitro and in in vivo animal studies there are some data showing the quantitative relationship
between the oxidative stress produced by inhibition of CI and mitochondrial damage measured by the
same assays, as described in human studies, and a few examples of such experiments are discussed
below.
The quantitative evaluation of the causative relationship between the CI inhibition (KEup) induced
by rotenone (4 h exposure) and mitochondrial dysfunction (KEdown) measured in human-chimpanzee
isolated mitochondria (xenomitochondrial cybrids; HXC) by a decreased cell respiration and Dwm,
increased ROS production and lipid peroxidation showed linear, time- and concentration-dependent
effects (below Figure A.8 from Barrientos and Moraes, 1999).
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The endogenous respiration was inhibited in a dose-dependent manner but showed different
inhibition kinetics. Only when CI was inhibited by 35–40% (< 5 nM rotenone), cell respiration started
decreasing (a threshold for inhibition for cell respiration triggered by rotenone). Between 40 and 60%
of CI inhibition (5–10 nM), cell respiration decreased linearly until 30% of the normal rate. Increasing
Figure A.8: A dose- and time-dependent effect of CI inhibition by rotenone on (A) reactive oxygen
species production (ROS), (B) Lipid peroxidation and (C) mitochondrial membrane
potential (Dwm) studied in the human osteosarcoma-derived cell line (143B) or using a
genetic model (40% CI inhibited in HXC lines) (This research was originally published in
the Journal of Biological Chemistry, Barrientos and Moraes, 1999, ﬁg. 5, copyright the
American Society for Biochemistry and Molecular Biology)
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concentrations of rotenone produced further but slower decrease in CI activity and cell respiration.
100% CI inhibition was achieved with 100 nM rotenone but the cells still maintained a cell respiration
rate (through complex II), approximately 20% and the rate of ROS production increased by a
maximum of 20–25% (4 h treatment). ROS production was saturated at 100 nM rotenone but an
initial effect was observed already at 1–5 nM (Barrientos and Moraes, 1999). Inhibition of CI activity
triggered decrease of cell respiration by different concentrations of rotenone and resulted in
mitochondrial damage measured not only by ROS production, but also by lipid peroxidation and
decreased Dwm. Inhibition of CI by 25, 50, 75 and 100% decreased cell respiration by 5, 20, 53, 81%,
increased ROS production by 48, 81, 157, 216%, increased lipid peroxidation by 8, 27, 45, 55% and
decreased Dwm by 6, 13, 20, and 37% respectively (approximately).
Similar studies were also performed using different types of neuronal cells.
Hoglinger and colleagues, by using DA neurones derived from the rat (embryonic day 15.5) ventral
mesencephalon, showed that CI inhibition by rotenone at 30 nM, (or MPP+ 3 lM) for 24 h decreased
ATP levels (by > 80%) within the ﬁrst 6 h, and neuronal cell death within 24 h. When residual ATP
levels remained above 20%, there was no or little neuronal loss, suggesting that 20% of normal ATP
level was the minimum compatible with neuronal survival. Rotenone (and MPP+) increased ROS
(≥40% over control levels) already at low concentrations that were subtoxic or only moderately toxic
(i.e. 10–30 nM for rotenone, 10–30 lM for MPP+) (Figure A.9) (Hoglinger et al., 2003).
Shamoto-Nagai and colleagues showed that 25 or 50 nM rotenone decreased ATP levels over time.
In particular, the intracellular ATP level was reduced to 18.0% and 19.6% of control after 44 h of
treatment with 25 and 50 nM of rotenone, respectively, and thereafter the decreased level was
sustained (Figure A.10, left) (Shamoto-Nagai et al., 2003). Also, The production of ROS-RNS increased
6 h after the rotenone treatment, and the increase was about 1.5-fold of the basal value. With
treatment with the higher (50 nM) concentration of rotenone, DCF production level was restored to
the basal level after 48 h, whereas, at the lower concentration (25 nM), DCF production increased
again at 48 h and then declined to the basal value after 90 h (Figure A.10, right) (Shamoto-Nagai
et al., 2003, copyright John Wiley and Sons).
Figure A.9: ATP levels, ROS production and neuronal surviving cells in mesencephalic cultures treated
with CI inhibitors (rotenone and MPP+) (from Hoglinger et al., 2003, ﬁg. 4a,b, copyright
John Wiley and Sons)
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Human neuroblastoma cell line (SK-N-MC) exposed to 5 nM rotenone chronically, for 4 weeks
caused reduction in GSH by 44%, GSSG by 40%. These effects were not observed after 2 weeks of
exposure. Total cellular GSH levels were reduced after 4 weeks of exposure by 50% (Sherer et al.,
2002). Similarly, in the same study, 1–2 weeks of treatment did not alter protein carbonyl levels
(oxidative protein damage) but exposure for 3–4 weeks caused a large increase in carbonyls in the
insoluble fraction by approximately 223% of control. Systemic in vivo rotenone infusion (up to
5 weeks, 3.0 mg/kg per day) modestly elevated soluble protein carbonyls in the rat cortex by
approximately 19%, in the striatum by 27% and the largest elevation occurred in the DA neurons of
midbrain, around 41% (no effect in cerebellum or hippocampus) (Sherer et al., 2003).
The prolonged treatment with rotenone (3–4 weeks, not 1–2 weeks) caused also a marked
increase in 8-oxo-dG immune-reactivity (i.e. oxidative DNA damage) and redistribution of cytochrome c
(Sherer et al., 2002).
The same group showed that exposure of SK-N-MC cells for 6–8 h to low concentrations of
rotenone (100 pM, 1 nM, 10 nM and 100 nM) produced a concentration-dependent decrease in ATP
levels by 0, 2.5, 10, and 32.2% respectively (Sherer et al., 2003).
The oxidative stress (mitochondrial damage) induced by rotenone exposure was conﬁrmed in
ex-vivo studies using brain sections at the level of the substantia nigra that were treated with 50 nM
rotenone over 1 week. A signiﬁcant increase of protein carbonyls (indicative of oxidative damage to
proteins; biomarkers of oxidative stress) was observed (~ 25%) when compared to the untreated
slices. Exposure to 100 M tocopherol, antioxidant (vitamin E) signiﬁcantly protected the neurons from
the oxidative damage induced by 50 nM rotenone over 1 week (~ 25%), as shown by lower protein
carbonyl levels (~ 3%), with very similar effects observed with 20 nM rotenone over 2 weeks (Testa
et al., 2005).
The same assays for mitochondrial dysfunction evaluation after exposure to rotenone, MPTP or
other chemicals were used through a range of different studies (Betarbet et al., 2000; Sherer et al.,
2003) and the role of CI inhibition in PD is discussed in many published reviews (Schapira et al.,
1990a,b; Greenamyre et al., 2001; Sanders and Greenamyre, 2013).
Conclusions: It is well documented in human PD brain studies as well as in vivo and in vitro
existing data that CI inhibition induces mitochondrial dysfunction as shown by measuring the
decreased cellular respiration and induced oxidative damage to protein, lipids and nucleic acids, as well
as compromised function of antioxidant defence mechanisms (e.g. decreased levels of reduced
glutathione). As discussed above, oxidative damage is largely reversed by antioxidants treatments.
These data are largely semi quantitative only, as the full dose- and time response curves are available.
They indicate that low levels of CI inhibition for long periods of time (4–5 weeks) mostly increase ROS
production, having negative effects on DA neurons in SNpc, which seem to be affected more than
Figure A.10: Effect of rotenone on ATP level (left) and on ROS and RNS production (right) in SH-
SY5Y cells. SH-SY5Y cells were treated with 25 nM (circles) or 50 nM (triangles) of
rotenone. *Indicates signiﬁcant difference from control (p < 0.05) (from Shamoto-Nagai
et al., 2003, ﬁgs. 2, 3)
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other neuronal cell types in other brain structures (reviews e.g. by Schapira et al., 1990a,b;
Greenamyre et al., 2001; Sanders and Greenamyre, 2013).
A.2.6. Evidence Supporting Taxonomic Applicability
Mitochondrial CI in eukaryotes has highly conserved subunit composition based on protein
databases (Cardol, 2011).
The characterisation of induced mitochondrial dysfunction phenotypes in zebraﬁsh was studied in
the presence of CI and CII inhibitors (Pinho et al., 2013).
Exposure of Caenorhabditis elegans (C. elegans) to rotenone, reduced bioluminescence (an assay
for mitochondrial dysfunction) after both relatively short (2 h) and longer exposures (24 h) to a range
of concentrations. A sharp decline in bioluminescence (maximal inhibition) relative to controls occurred
at the lowest rotenone concentration of 2.5 lM. This decline in bioluminescence was consistent with
reduced cellular ATP (Lagido et al., 2015).
The results obtained from C. elegans exposed to rotenone suggested that chronic exposure to low
concentration (2 or 4 lM) caused mitochondrial damage through persistent suppression of
mitochondrial biogenesis and mitochondrial gene expression leading to mitochondrial dysfunction that
contributed to DA neuron degeneration (Zhou et al., 2013).
Drosophila melanogaster has been proven suitable to study signalling pathways implicated in the
regulation of mitochondrial function and integrity, such as the PINK1/parkin pathway (controlling
mitochondrial integrity and maintenance), DJ-1 and Omi/HtrA2 genes (associated with the regulation
of mitochondrial functionality). Notably, PINK1, PARKIN, and DJ-1 genes are associated with recessive
forms of PD (Guo, 2012). Drosophila ﬂies lacking DJ-1 result to be viable, but show an increased
sensitivity to oxidative stress induced upon rotenone or Paraquat (an herbicide inducer of CI-
dependent ROS) feeding (Menzies et al., 2005; Meulener et al., 2005, 2006). Moreover, it has been
reported in Drosophila that inhibition of CI by mean of sublethal chronic exposure to rotenone
(< 750 lM) via the feeding medium caused a selective loss of DA neurons in all of the brain regions
and locomotor impairments, while L-dopa (3,4-dihydroxy-L-phenylalanine) rescued the behavioural
deﬁcits (but not neuronal death) (Coulom and Birman, 2004).
MPTP causes Parkinsonism in primates including humans. However, rodents (rats) are much less
susceptible to MPTP+ but are fully susceptible to MPP+ (due to the differences in toxicokinetics). In all
species, CI inhibition leads to mitochondrial dysfunction. Mitochondrial dysfunction is an universal
event occurring in cells of any species (Farooqui and Farooqui, 2012).
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3rd KER: Mitochondrial dysfunction results in an impaired proteostasis
A.3.1. How this Key Event Relationship work
In any cell type, including neurons, the protein homoeostasis (proteostasis) plays a key role in
cellular functions. There are two major systems involved in the removal of damaged cellular structures
(e.g. defective mitochondria) and misfolded or damaged proteins, the ubiquitin–proteasome system
(UPS) and the autophagy–lysosome pathway (ALP). These processes are highly energy demanding and
highly susceptible to oxidative stress. Upon mitochondrial dysfunction UPS and ALP functions are
compromised resulting in increased protein aggregation and impaired intracellular protein/organelles
transport (e.g. Sherer et al., 2002; Esteves et al., 2011; Fujita et al., 2014; Song and Cortopassi,
2015; Zaltieri et al., 2015).
A.3.2. Weight of Evidence
The weight of evidence supporting the relationship between mitochondrial dysfunction and
impaired proteostasis, including the impaired function of UPS and ALP that results in decreased protein
degradation and increase protein aggregation is strong.
A.3.2.1. Biological Plausibility
The biological relationship between Mitochondrial dysfunction and Impaired proteostasis
(unbalanced protein homoeostasis) that involves dysregulation of proteins degradation (misfolded or
damaged) as well as removal of cell organelles is partly understood. Under physiological conditions,
mechanisms by which proteostasis is ensured include regulated protein translation, chaperone assisted
protein folding and functional protein degradation pathways. Under oxidative stress, the proteostasis
function becomes burdened with proteins modiﬁed by ROS (Powers et al., 2009; Zaltieri et al., 2015).
These changed proteins can lead to further misfolding and aggregation of proteins (especially in non-
dividing cells, like neurons). Particularly in DA cells, oxidative stress from dopamine metabolism and
dopamine auto-oxidation may selectively increase their vulnerability to CI inhibitors (such as rotenone)
and cause additional deregulation of protein degradation (Lotharius and Brundin, 2002; Esteves et al.,
2011). As most oxidised proteins get degraded by UPS and ALP (McNaught and Jenner, 2001),
mitochondrial dysfunction and subsequent deregulation of proteostasis play a pivotal role in the
pathogenesis of PD (Sherer et al., 2002; Fornai et al., 2005; Pan et al., 2008; Dagda et al., 2013).
It is also well documented that increased oxidative stress changes the protein degradation
machinery and leads to a reduction of proteasome activity (Lin and Beal, 2006; Schapira, 2006).
A.3.2.2. Empirical support for linkage
Based on the existing in vitro and in vivo data it is suggested that mitochondrial dysfunction impairs
protein homoeostasis through oxidative and nitrosative stress resulting in protein aggregation,
disruption of microtubule assembly and damaged intracellular transport of proteins and cell organelles.
Mitochondrial dysfunction by rotenone or MPP+ reduces UPS activity
• Mitochondrial dysfunction induced by systemic and chronic CI inhibition by rotenone, results in
a selective inhibition of proteasomal function in the midbrain (not in cortical or striatal
homogenates) of rats that had lost the TH-positive terminals in the striatum. Initially,
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proteasomal activity showed an acute increase prior to a decrease by 16–31%, during chronic
rotenone exposure (3.0 mg/kg per day, through osmotic pump during 5 weeks). In the same
animals a signiﬁcant and selective increase in ubiquitinated proteins (~ 25%) was observed in
the ventral midbrain of lesioned rats, indicating an increase in the proteins levels that have
been marked for degradation by UPS. These results were conﬁrmed immunocytochemically,
pointing out that ubiquitin levels were elevated selectively in DA neurons present in SNpc
(Betarbet et al., 2006).
• Nigral neurons in chronically rotenone-treated rats (up to 5 weeks, infusion of rotenone at
2.5 mg/kg per day) accumulate ﬁbrillar cytoplasmic inclusions that contain ubiquitin and
a-synuclein (the main protein of Lewy bodies observed in PD) (qualitative data, obtained by
immunoelectron microscopy) (Betarbet et al., 2000).
• Inhibition of proteasomal function was also observed in in vitro systems using SK-N-MC human
neuroblastoma. Exposure to 5 nM rotenone, for up to 4 weeks caused 60% increase in the
levels of ubiquinated proteins, suggesting that chronic exposure to rotenone increased the
level of misfolded or oxidised proteins targeted for degradation by UPS (Betarbet et al., 2006).
• To determine whether rotenone-induced proteasomal inhibition was due to CI inhibition or
direct effects of rotenone on the UPS, proteasomal activity was determined in SKN-MC cells
expressing the rotenone-insensitive single-subunit NADH dehydrogenase of Saccharomyces
cerevisiae (NDI1), which acts as a ‘replacement’ for the entire CI in mammalian cells (Seo
et al., 2000, 2002; Bai et al., 2001). The obtained results conﬁrmed that rotenone-induced
proteasomal dysfunction is due to CI inhibition and not to direct effects of rotenone on
proteasomal function (Betarbet et al., 2006). In the same study the decreased proteasomal
activity and an accumulation of ubiquitinated proteins was completely prevented by continuous
treatment with a-tocopherol (62.5 lM added 1 week prior to and continuously thereafter along
with 5 nM rotenone) (qualitative data), conﬁrming that oxidative damage played a major role
in rotenone-induced proteasomal dysfunction rather than bioenergetic defects. Indeed,
chronic, low levels of rotenone exposure did not changed signiﬁcantly ATP levels
(111.5  1.5% of control), but produced ROS (data not shown in this study). Similar results
were published by Shamoto-Nagai’s group (Shamoto-Nagai et al., 2003).
• Rotenone signiﬁcantly lowered UPS activity in a concentration dependent manner in HEK
(human embryonic kidney cells) and SK-N-MC human neuroblatoma cells even after 24 h
exposure to doses as low as 10 nM. It caused a reduction in the 20S proteasome activity (by
5–25%) and of the 20S proteasome subunit (by 20–60%) (as shown by increase of GFP-U
ﬂuorescence) (Chou et al., 2010). Similar results were obtained using other pesticides that
inhibit CI, including pyridaben and fenazaquin (Wang et al., 2006). This effect was mediated
by oxidative stress as antioxidants, such as butylated-hydroxy toluene (BHT), and catalase
attenuated rotenone-induced UPS inhibition. Additionally, nitric oxide (NO) and peroxynitrite
contributed to this effect as well, since neuronal nitric oxide synthase (nNOS) inhibitor
(LNMMA) attenuated rotenone-induced proteasome inhibition by 20% (Chou et al., 2010)
indicating that both oxidative and nitrative stress can directly inhibit the proteasome activity
through increased degradation of proteasome subunits. The same mechanisms of proteasome
inhibition were suggested by many other studies (e.g. Szweda et al., 2002; Shamoto-Nagai
et al., 2003; Osna et al., 2004).
• CI inhibition-induced proteasomal dysfunction has been reported in ventral mesencephalic
cultures following acute rotenone or MPP+ exposure (Hoglinger et al., 2003). In DA neurones
derived from rat (embryonic day 15.5) ventral mesencephalon, it has been shown that
proteasome inhibition (by 100 nm epoxomicin) exacerbated the neurotoxicity of CI inhibitors
(by mean of rotenone 30 nM, or MPP+ 3 lM, for 24 h). All three proteasomal peptidase
activities (i.e. chymotrypsin (CT)-like, trypsin (T)-like, and peptidylglutamyl-peptide hydrolase
(PGPH) activity) signiﬁcantly decreased in cultures upon 6 h treatment with 30 nM rotenone
(by 50 + -60%) or 30 lM MPP+ (by 25–30%) (Hoglinger et al., 2003).
• CI inhibition-induced proteasomal dysfunction has been reported in human SH-SY5Y
neuroblastoma cells following acute rotenone exposure (Shamoto-Nagai et al., 2003). After
96 h of incubation with 25 or 50 nM rotenone, the activity was reduced respectively to 28.7%
and 21.9% of control, and adding ATP did not increase the activity. After 120 h, the activity was
virtually undetectable (with or without added ATP). On the contrary, the levels of the proteins
composing proteasome did not change with rotenone treatment (Shamoto-Nagai et al., 2003).
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• The ability of rotenone to cause proteasome inhibition via disruption of microtubules (MT)
assembly has been also documented. In human embryonic kidney (HEK) and neuroblastoma SK-
N-MC cells rotenone (10–100–100 nM, 24 h) was found to inhibit 26S UPS activity (by 25%, at
10 nM) (Chou et al., 2010). Rotenone was found to interfere with MT assembly at concentrations
as low as 10 nM, providing evidence that there could be additional mechanisms implicated in the
rotenone induced UPS inhibition, possibly mediated by nitric oxide (NO). In the same study,
nocodazole, a MT disrupter (positive control), strongly inhibited the UPS activity (e.g. 10 lM
nocodazole caused ~ 80% decrease of 26S UPS activity) (Chou et al., 2010).
• Oxidative stress triggered by the MPP+ inhibited CI (1 mM, for 2–6–24 h) led to a decrease in
proteolytic activity, as shown in NT2 human teratocarcinoma cells containing mitochondrial
DNA (q+) and NT2 cells depleted of mtDNA (q0) (Domingues et al., 2008). In particular, MPP+
(1 mM, 2 h) elevated ubiquitinylated protein content (by ~ 3 fold compared to untreated Ctr),
and after 24 h induced a signiﬁcant decrease of chymotrypsin-like activity (by ~ 30%) and
peptidyl-glutamyl peptide hydrolytic-like activity (by ~ 75%) compared to untreated cells
(Domingues et al., 2008).
• Mice following continuous MPTP infusion (1–5–30 mg/kg daily) exhibited inhibition of the UPS
(respectively by 40–50–60%) and increased inclusions of ubiquitin and a-synuclein in the
neurons in the substantia nigra (Fornai et al., 2005).
• A mouse model of mitochondrial CI deﬁciency (Ndufs4/ mice) showed an impaired 20S
proteasomal activity (by ~ 50%), leading to increased ubiquitin protein levels (by ~ 40%) in
the substantia nigra (not in cortex and hippocampus), increased of ubiquitin+/TH+ neurons
(by ~ 2 fold, compared to WT mice), and increased ubiquitinated neuroﬁlaments in the
midbrain (values of 1.2–2.8 vs 1.0 in WT) (Song and Cortopassi, 2015).
Human studies
• PD patients appear to have an impaired UPS. The presence of aggregated, poly-ubiquitinated
proteins in Lewy Bodies indicates that proteolytic dysfunction and proteotoxicity are critical
steps in the pathogenic cascade of PD (Betarbet et al., 2005). In this regard, impairment of
proteasomal activity and reduced expression of proteasomal subunits have been reported
selectively in substantia nigra of sporadic PD post-mortem brains (McNaught and Jenner, 2001;
McNaught et al., 2003). In particular, in PD, there was a 40.2% reduction in the amount of
a-subunits in the SNc. On the opposite a-subunits levels were increased by 9.2% in the
cerebral cortex and by 29.1% in the striatum in PD compared to Ctr (McNaught et al., 2003).
Chymotrypsin-like, trypsin-like, and peptidyl glutamyl-peptide hydrolytic (PGPH) 20/26S
proteasomal activities were signiﬁcantly decreased in the substantia nigra (by 43.9%, 45.9%,
and 44.6% respectively) (not in the cortex or striatum) in PD patients. At the same time, in PD
there was a marked increase in the levels of PA700 subunits (the 19S regulatory complex of
the 26S proteasome) in the frontal cortex and/or the striatum compared to controls, while in
the SNpc PA700 subunits resulted decreased up 33%, whereas levels of nigral PA28 were
almost undetectable in both normal and PD subjects (McNaught et al., 2003).
• Steady-state levels of soluble AF-6 (modulates parkin ubiquitin-ligase activity) have been found
signiﬁcantly lower in the caudate/putamen (~ 66% lower) as well as in the SN of PD patients
(~ 66% lower). AF-6 was also detected in ~ 25% of mature Lewy bodies and in occasional
Lewy neurites in the substantia nigra of the four PD brains analysed, and may contribute to
the disruption of mitochondrial homoeostasis (Haskin et al., 2013).
• HDAC6 has recently been identiﬁed by immunocytochemistry as a constituent in Lewy bodies
of PD and dementia with LBs (DLB), as well as in glial cytoplasmic inclusions in multiple system
atrophy (MSA) (Kawaguchi et al., 2003; Miki et al., 2011; Chiba et al., 2012). HDAC6 is
considered a sensor of proteasomal inhibition and a cellular stress surveillance factor. Upon
proteasomal inhibition, HDAC6 is relocated and recruited to polyubiquitin-positive aggresomes.
HDAC6 inhibition elicits tubulin acetylation and restores microtubule (MT)-dependent transport
mechanisms in neurons (Richter-Landsberg and Leyk, 2013).
• Basal activity of 20S proteasome was signiﬁcantly reduced (by ~ 33%) in PD as compared to
control ﬁbroblasts. Higher accumulation of ubiquitinated proteins (by ~ 2 fold), representative
of impaired 26S proteasome function, were found in PD as compared to Ctr cells at baseline.
In the presence of rotenone (20 and 500 lM, 6 h) PD-derived ﬁbroblasts showed a higher
induction of 20S proteasome activity (~ 15% higher) as compared to Ctr ﬁbroblasts, with no
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signiﬁcant changes in autophagy (except from increased LC3-II accumulation in both groups
after exposure to 500 lM rotenone) (Ambrosi et al., 2014).
Mitochondrial dysfunction by rotenone or MPP+ deregulates ALP activity
• Exposure to rotenone (10 lM, 24 h) induced neurotoxicity in human neuronal SH-SY5Y cells
(number of dead cells was 8 folds higher than Ctr group) and pretreatment with rapamycin
(3 lM, 48 h) (strong inducers of autophagy) robustly protected against rotenone-mediated
toxicity (number of dead cells was 3 folds higher than Ctr group) and this was due to the
induction of autophagy. Indeed, suppression of autophagy (by silencing of Atg5) blocked the
neuroprotection of rapamycin (Pan et al., 2009).
• Similar results were produced using kaempferol (6 lM, 1 h prior addition of rotenone) and
rotenone (50 nM, max up to 24 h) on SH-SY5Y cells. Kaempferol was found to counteract
rotenone-induced effects (see KER2) and these protective effects were related to induction of
autophagy (6 h kaempferol induced LC3-II formation, as shown by Western blot) (Filomeni
et al., 2012).
• Treatment of SH-SY5Y cells with high doses of rotenone (500 nM, 48 h) induced Atg5–Atg12
dependent autophagy, which leads to lysosomal dysfunction, increased p62 levels, and an
aberrant accumulation of a-synuclein (Pan et al., 2009; Dadakhujaev et al., 2010). In
particular, in a-synuclein expressing SH-SY5Y cells Atg5–Atg12 were increased by addition of
rotenone and rapamycin (100 nM, 48 h). Co-treatment with rotenone and autophagy inhibitors
(e.g. 3-MA, baﬁlomycin or wortmannin) similarly diminished the level of Atg5–Atg12 in
a-synuclein expressing cells (western blot analyses) (Dadakhujaev et al., 2010).
• A few studies have suggested that rotenone can act as an inducer of autophagic ﬂux. For
instance, treating human embryonic kidney cells (HEK 293) and U87 glioma cells with rotenone
(50 lM, for 0–72 h) caused cell death (in HEK 293 cells, rotenone induced 30% cell death,
after 72 h; in U87 cells, 40%) by upregulating autophagy and mitophagy (as shown by
increase of cells with AVOs (indicative of autophagosomes and autolysosomes, analysed by
ﬂow cytometry): by ~ 14% in HEK 293 cells, and by ~ 20% in U87 cells, as compared to
untreated cells, 0%), a process that is supposed to be triggered by mitochondrial superoxide
(Chen et al., 2007).
• Increased autophagic ﬂux has been observed in SH-SY5Y cells and primary cortical neurons
treated respectively with 1 lM and 250 nM of rotenone. Rotenone elicited increases in autophagy
(~ 2 folds vs Ctr) and mitophagy (i.e. as shown by the percentage of GFP-LC3 puncta colocalising
with mitochondria (~ 4 folds vs Ctr), indicating a preferential increase in ‘mitophagosomes’
relative to total autophagosomes. Additionally, rotenone induced a decrease in p62 (SQSMT1),
levels (~ 40% decrease with 250 nM), consistent with increased autophagic ﬂux. This effect was
reversed by co-treating cells with baﬁlomycin A2, a speciﬁc inhibitor of vacuolar-type H(+)-
ATPase, or by RNAi (knockdown of ATG7 and ATG8/LC3). The mechanism by which LC3
recognises damaged mitochondria in rotenone-treated neurons involves, among others, the
externalisation of cardiolipin and recruitment of LC3 at the mitochondria initiating rotenone
induced-mitophagy and lysosomal-mediated degradation of mitochondria (Chu et al., 2013).
• In the study by Wu et al. (2015) chronically rotenone-treated rats (male Lewis rats received
rotenone 1 mg/kg subcutaneously twice a day for 8 weeks) had a robust loss of TH+ neurons in
striatum (~ 50%) and in SNpc (~ 30%). However, in the remaining DA neurons of SNpc,
cytoplasmic inclusions containing a-synuclein were observed (~ 7% of a-synuclein+/TH+ cells vs
~ 2% in Ctr), probably due to rotenone-induced decreased degradation of the autophagosomes
(upregulation of LC3-II by ~ 30%, Beclin 1 by ~ 10%, and p62 by ~ 150%, after 24 h rotenone)
indicating decreased ALP function. Compared with the control group, the nigral DA neurons of
the rotenone-treated group exhibited an increased diffuse distribution of LAMP2 (~ 15% vs
~ 25% Ctr) and cathepsin D (~ 22% vs ~ 60% Ctr) instead of punctuate pattern, indicating
impaired lysosome integrity and a redistribution of cathepsin D from lysosomes to the cytosol.
In parallel in vitro studies by the same group showed that PC12 cells exposed to rotenone
(500 nM for 24 h) underwent increased protein levels (but not mRNA levels) of a-synuclein
(~ 4.5 folds vs Ctr), indicating an impairment of protein degradation. In TEM pictures, the
majority of neurons displayed mitochondrial swelling, crista fragmentation, and accumulation
of double membrane structures containing damaged mitochondria, which were stalled
autophagosomes (Wu et al., 2015).
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• Similar results, showing impaired autophagic ﬂux resulting in a-synuclein accumulation and the
rupture of lysosomes in neuronal cell lines exposed to rotenone have been described in many
other studies (e.g. Mader et al., 2012; Sarkar et al., 2014).
• Rotenone produced bidirectional effects on macroautophagy (decrease or increase). This may
be attributed to differences in the dosage, the duration, and cell type which can produce
variable levels of ROS and mitochondrial damage (Chen et al., 2007; Pan et al., 2009;
Dadakhujaev et al., 2010; Filomeni et al., 2012; Mader et al., 2012).
• MPP+ (2.5 mM, 24–48 h) increased autophagy (~ 14 folds increase vs Ctr, of LC3-II) and
mitochondrial loss in SH-SY5Y cells (a DA neuronal cell line widely used as a cell culture model
of PD) by increased MAP kinase signalling (MEK inhibition by UO126 reversed by both
autophagy and mitochondrial loss elicited by MPP+) (Zhu et al., 2007).
• Another study from the same group showed that longer MPP+ treatment (250 lM, 2 weeks)
induced formation of enlarged, coarse GFP-LC3 puncta, in a time- and dose-dependent manner
(~ 1.8% of cells presenting coarse GFP-LC3 puncta, vs ~ 0.2% in Ctr, at 14 days with 250 lM
rotenone) (Zhu et al., 2012).
• An in vitro study on MN9D cells (a fusion of embryonic ventral mesencephalic and
neuroblastoma cells, used as a model of DA neurons) showed that MPP+ (50 lM, for 24 h)
blocked autophagic ﬂux, as evidenced by increased steady-state levels of p62 (qualitative data,
Western blot), increased of authophagic vacuoles numbers (~ 3 folds vs Ctr) along with
lysosomal depletion and dysfunction presumably due to leakage of lysosomes, impaired
lysosomal biogenesis, and increased proteasomal-mediated degradation of proteins (as shown
by time-dependent increase of ubiquitinated proteins, by IC) (Lim et al., 2011).
• In another study human neuroblastoma BE-M17 cells were treated with MPP+ (0.25–2.5 mM,
24 h); Lamp1 protein levels were decreased in a dose-dependent manner in MPP+-treated
cells (by ~ 40% at 2.5 mM), without concomitant decreases in mRNA expression levels. Also,
LC3-II increased in a dose-dependent manner with MPP+ treatment (~ 3000% increase at 2.5
mM vs Ctr), indicating lysosome depletion and autophagosome accumulation upon MPP+
treatment. These data were conﬁrmed in vivo: lysosomal depletion and accumulation of
autophagosomes (as shown by ~ 600% increase of LC3-II, and ~ 40% decrease of Lamp1,
after 1 day of MPTP injection compared to saline) occurred also in MPTP-intoxicated mice
(30 mg/kg per day, for ﬁve consecutive days) (Dehay et al., 2010).
• Other in vivo data support a negative role of MPTP on autophagic ﬂux. Mice were i.p. injected
with 2 mg/ml MPTP (30 mg/kg) for 7 days. Suppression of autophagic ﬂux induced by MPTP
(~ 20% reduction vs Ctr) was detrimental to neuronal survival (as shown by ~ 60% decrease
of TH+ neurons). Treating mice with the autophagy inducer rapamycin after 7 days of MPTP
treatment (daily i.p. injections of 2 mg/mL MPTP (30 mg/kg) for 7 days, followed by 0.1 ml of
20 lg/ml rapamycin by i.v. for an additional 7 days), signiﬁcantly increased the number of
surviving dopamine neurons (~ 60% TH+ neurons vs ~ 30% with MPTP alone, as compared to
Ctr 100%) and the levels of TH protein (~ 75% vs ~ 60% with MPTP alone, as compared to
Ctr 100%) and decreased the levels of a-synuclein aggregates (~ 210% of a-synuclein protein
level, vs ~ 300% with MPTP alone, as compared to Ctr 100%) (Liu et al., 2013).
• Treating mice with the autophagy inducer rapamycin after 7 days of MPTP treatment (daily i.p.
injections of 2 mg/ml MPTP (30 mg/kg) for 7 days, followed by 0.1 mL of 20 lg/mL rapamycin
by i.v. for an additional 7 days), signiﬁcantly increased the number of surviving dopamine
neurons (~ 75% of TH protein level vs ~ 60% with MPTP alone) and decreases the levels of
a-synuclein aggregates (~ 210% of a-synuclein protein level, vs ~ 300% with MPTP alone)
(Liu et al., 2013).
MPP+ induced dysregulation of macroautophagy in neurons is discussed in recently published
reviews (e.g. Cherra et al., 2010; Jiang et al., 2010).
The potential other mechanisms by which rotenone or MPTP induce mitochondrial dysfunction are
furEsteves et al., 2011; ther discussed in recent publications (e.g. Esteves et al., 2011; Dagda et al., 2013).
Human studies
• In PD patient postmortem cortical tissues, levels of oligomeric a-synuclein in SNpc (~ 1000%
vs Ctr samples) and expression of LC3-II levels (~ 130% vs Ctr samples) were upregulated (Yu
et al., 2009) (for further info, see the review from Vekrellis et al., 2011).
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• The pathological observations in PD autopsy brains showed that LC3-II levels were elevated in
the SNpc and amygdala of PD brain samples, suggesting an increase in macroautophagy (but
they did not reach statistical signiﬁcance). LC3 colocalised with a-synuclein in most LBs and
Lewy neurites in PD SNpc as well as in small punctate a-synuclein immunoreactive inclusions
(IC images) (Alvarez-Erviti et al., 2010).
• Analogously, another study reported that brain homogenates derived from the temporal cortex
of dementia with LB (DLB) patients vs non-demented controls were characterised by higher
levels of both mTor (~ 130% vs Ctr) and p-mTor (~ 10 folds higher than Ctr), and levels of
Atg7 (molecular initiator of autophagy) were moderately reduced in DLB cases compared to
Ctr (~ 40% lower than Ctr). Consistent with the studies in human brains, levels of both mTor
and p-mTor were increased in the membrane fractions from brains of a-synuclein tg mice
compared to non tg controls (respectively, by ~ 250% and ~ 200% vs Ctr), and levels of Atg7
were reduced in a-synuclein tg brains compared to non tg controls (~ 75% less than Ctr)
(Crews et al., 2010).
• Another study showed that post-mortem brain samples derived from PD patients, compared to
age-matched controls, presented signiﬁcant reductions of LAMP1, CatD, HSP73, and 20S
proteasome (calculated by optic density (OD) measures) (Chu et al., 2009).
Group LAMP1 OD CatD OD HSP73 OD 20S proteasome OD
Age-matched control 2069.10  329.52 1809.35  533.47 2604.92  494.56 1660.84  229.87
PD 1261.54  107.77 1094.64  378.10 1799.27  376.19 1172.65  273.28
These data globally indicate that the functions of both the UPS and ALP systems seem
compromised in PD patients.
• HDAC6, which plays a central role in autophagy by controlling the fusion process of
autophagosomes with lysosomes, has recently been identiﬁed as a constituent in Lewy bodies
of PD and glial cytoplasmic inclusions of multiple system atrophy (Richter-Landsberg and Leyk,
2013).
Impaired UPS and ALP function leads to a-synuclein aggregation
a-synuclein is one of the most abundant neuronal proteins (Vekrellis et al., 2011). Several PD-related
mutations and environmental toxicants cause autophagy dysfunction and lead to the accumulation
of misfolded proteins in DA neurons, including a-synuclein. Both monomeric and aggregated forms of
a-synuclein can be degraded by macroautophagy, whereas only wild-type a-synuclein (not Ala30Pro,
Ala53Thr and Glu46Lys mutant forms) is degraded by the process of chaperone-mediated autophagy
(CMA) (Vekrellis et al., 2011).
• Rotenone-induced a-synuclein aggregation has the ability to inhibit proteasome activity due to
its propensity to assemble into ﬁlaments (as reviewed in Zaltieri et al., 2015). In particular,
expression of a-synuclein was found to inhibit proteasome activity in SH-SY5Y cells. Increased
levels of GFP-CL1 band were observed in cells coexpressing GFP-CL1 and a-synuclein (~ 9000
arbitrary units (au) vs ~ 500 au in DMSO-Ctr), indicating that proteasome activity is inhibited
effectively by expression of a-synuclein (Nonaka and Hasegawa, 2009).
• By using stable PC12 cell lines expressing wild-type (WT) or A53T mutant human a-synuclein it
has been shown that cells expressing mutant a-synuclein showed: (1) disruption of the
ubiquitin-dependent proteolytic system, manifested by small cytoplasmic ubiquitinated
aggregates and by an increase in polyubiquitinated proteins (qualitative data); (2) marked
accumulation of autophagic-vesicular structures (qualitative data); (3) reduction of lysosomal
hydrolysis and chymotrypsin-like proteasomal function (by ~ 30%, compared to WT) (Stefanis
et al., 2001).
• Rotenone- (or MPP+)-induced inhibition of CI results in calcium (Ca2+) release from
mitochondria. Calcium rise and oxidative stress cooperatively can promote a-synuclein
aggregation (Nath et al., 2011; Follett et al., 2013; Goodwin et al., 2013).
• For instance, to investigate the inﬂuence of raised Ca2+ in response to plasma membrane
depolarisation on the aggregation of a-synuclein, HEK293T and SH-SY5Y neuroblastoma cells
have been used and depolarised by addition of KCl to the cell culture medium. After KCl
treatment (50 mM) increase of cellular Ca2+ was observed (~ 90% increase 20 min after KCl
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treatment), leading to the formation of frequent perinuclear a-synuclein focal aggregates at
26–74 h post-treatment (qualitative IC images). By adding TMO (a selective T-type Ca2+
channel blocker) no a-synuclein aggregates were detected (Follett et al., 2013).
• Similarly, increased intracellular free Ca2+ (obtained by treating cells with either calcium
ionophore or thapsigargin) induced the formation of a-synuclein aggregates in a-synuclein-
GFP-transfected 1321N1 glioma cells (~ 65% increase compared to Ctr-untreated cells) (Nath
et al., 2011).
• On the other hand, a-synuclein can control mitochondrial calcium homoeostasis by enhancing
endoplasmic reticulum-mitochondria interactions. Silencing of endogenous a-synuclein (siRNA-
a-syn) in HeLa cells was found to impair mitochondrial Ca2+ transients (~ 35% decrease
compared to Ctr-scrambled siRNA) and morphology (Calı et al., 2012). Also, a-synuclein
oligomerisation exacerbates calcium dysregulation by increasing mitochondria permeability
transition (Danzer et al., 2007). Therefore, it is possible that mitochondrial dysfunction-induced
calcium rise precede the onset of a-synuclein accumulation leading to UPS inhibition (Chou
et al., 2010).
• It has been demonstrated that rotenone increased the intracellular calcium levels, triggering
aggregation and phosphorylation of a-synuclein in a calcium-dependent manner. The
aggregation of a-synuclein in PC12 cells following rotenone exposure was observed in a dose
and time-dependent manner (1, 10 and 100 nM for 48 h, 3 days, 1 and 3 weeks) (~ 4 fold
increase of a-syn with 100 nM rotenone for 48 h, vs Ctr; and also, ~ 2.5 fold increase of a-syn
with 1 nM rotenone for 1 week, vs Ctr) as evaluated via a variety of methods, including
western blotting, immunoﬂuorescence and electron microscopy. The observed attenuation of
autophagy and a-synuclein aggregation was reversed by scavenging calcium (by using the
calcium chelator BAPTA at 10 lM). Aggregated a-synuclein is typically degraded by autophagy,
but rotenone impaired this process (Yuan et al., 2015).
• Under physiological conditions, a-synuclein is degraded by both the proteasome and autophagy.
Mutant a-synuclein inhibits ALP functioning by tightly binding to the receptor on the lysosomal
membrane for autophagy pathway control (e.g. Betarbet et al., 2000; Pan et al., 2009).
• The strongest evidence supporting that mitochondrial dysfunction precedes the onset of
a-synuclein pathology derives from studies on rotenone and MPTP in which repetitive exposure
of rodents and monkeys to these chemicals via oral, intraperitoneal, intragastric, or nasal
administration resulted in the pathological accumulation of a-synuclein in central as well as
peripheral neurons (Mandel et al., 2004; Cannon et al., 2009; Drolet et al., 2009; Pan-Montojo
et al., 2012, 2010; Trist~ao et al., 2014). For example, male Lewis rats were injected with
rotenone (2.0 mg/kg, i.p.) and sacriﬁced at 0, 4, 8, 16, or 32 h after injection and showed
a-synuclein and poly-ubiquitin accumulation and aggregation (as shown by IHC data)
(Cannon et al., 2009).
• Drolet and colleagues injected rats with rotenone (2.0 mg/kg, 1.0 ml/kg, i.p. 5 injections/week
for 6 weeks) and found formic acid-resistant a-synuclein aggregates in the small intestine
myenteric plexus, particularly 6-months after the last rotenone injection (3.5 median, vs 2.0 in
Ctr) (Drolet et al., 2009).
• Mandel et al., injected male C57BL mice with MPTP (24 mg/kg per day, i.p. for 5 days) and
found a-synuclein aggregates (IHC data), which were decreased by using the radical
scavengers apomorphine (injected s.c. at 10 mg/kg per day) or epigallocatechin-3-gallate
(EGCG, given alone orally, 2 mg/kg per day) for 10 days) or a combination of both (Mandel
et al., 2004).
• Inhibition of the mitochondria respiratory chain induces oxidative stress that in turn leads to
lipid peroxidation of cellular and vesicular membranes at synaptic sites, resulting in dysfunction
of neurotransmitter release. These effects facilitate a-synuclein conformational changes, such
as accumulation, and aggregation. It has been demonstrated that synaptic dysfunction (caused
by mitochondrial dysfunction) triggered the accumulation of a-synuclein (Nakata et al., 2012).
• Also, alterations of mitochondrial ﬁssion or dynamics can reduce synaptic mitochondrial load
and impair neuronal function by hindering the proper energy demand to ensure synaptic
function. Mitochondrial behaviours, especially those regulated by neuronal activity and synapse
location, determine their distribution in the axon (Obashi and Okabe, 2013). These
observations support the idea that mitochondrial dysfunction can affect synaptic environment
and consequently result in a-synuclein accumulation at synapses (Zaltieri et al., 2015).
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• It was found that continuous administration of MPTP produced formation of nigral inclusions
immunoreactive for ubiquitin and a-synuclein (Fornai et al., 2005). Mice were implanted with
osmotic pump to deliver MPTP-HCl. Delayed and prolonged inhibition of striatal proteasome
activity (i.e. 40–50-60% inhibition of UPS) occurred after continuous MPTP administration
(respectively, 1–5–30 mg/kg MPTP daily) for the indicated time periods (Figure A.8) (Fornai et al.,
2005). Continuous MPTP infusions caused also a long-lasting activation of glucose uptake.
Additionally, in mice lacking a-synuclein, the MPTP-induced inhibition of the UPS system and the
production of inclusion bodies were reduced (e.g. Ctr mice showed ~ 40% inhibition of post-
glutamyl peptidase (PGPH) activity, vs ~ 13% inhibition observed in a-synuclein KO mice)
(Figure A.9), suggesting that a-synuclein could play an important role in UPS inhibition induced
by MPP+ (Fornai et al., 2005). These data suggest that continuous, low-level exposure of mice to
MPTP causes a Parkinson-like syndrome in a a-synuclein-dependent manner (Fornai et al., 2005).
• These results are supported by other studies showing that a-synuclein/ mice are resistant to
MPTP toxicity (Dauer et al., 2002; Drolet et al., 2004). MPTP exposure (0.5, 5, 50 lM, 48 h)
increases in a dose-dependent manner the a-synuclein protein level in mesencephalic neurons
in culture (e.g. ~ 70% increase at 5 lM vs Ctr) (Duka et al., 2006).
• Increased expression of a-synuclein predisposes DA neuronal cells to proteasomal dysfunction
(~ 50% decrease compared to Ctr-vector cells) (Sun et al., 2005).
• Accumulation/overexpression of a-synuclein, both wild type and mutant, potentiates inhibition
of proteasomal activity. Cells expressing mutant a-synuclein showed a reduction of lysosomal
hydrolysis and chymotrypsin-like UPS function (by ~ 30%, compared to WT) (Stefanis et al.,
2001).
• Proteasomal inhibition (by mean of lactacystin, a proteasome inhibitor, used at different
concentrations for 24 h) contributes to the accumulation of a-synuclein as it has been
described by immunostaining in PC12 cells (Rideout et al., 2001) and in primary mesencephalic
neurons (McNaught et al., 2002).
• a-Synuclein levels were selectively increased in the ventral midbrain (VMB) region of rotenone-
infused rats with or without lesion (~ 110% increase vs Ctr) (Figure A.3) (Betarbet et al., 2006).
Rotenone was administered up to 5 weeks, at 2.5 mg/kg per day. Additionally, 4 weeks of in vitro
rotenone exposure (5 nM, on SK-N-MC human neuroblastoma cells) increased a-Synuclein levels
by 24%, while lactacystin (9 lM, overnight) did not induce any detectable changes in a-synuclein
levels. a-Tocopherol attenuated the rotenone-induced increase in a-synuclein (comparable to Ctr)
(Figure A.10). Furthermore, levels of ubiquitinated proteins detected in solubilised protein
fractions from SK-N-MC cells resulted increased (by 60%) with rotenone treatment (5 nM), and
even more (by 484%) with rotenone combined with lactacystin (Figure A.11) (Betarbet et al.,
2006).
• CI inhibition-induced proteasomal dysfunction has been reported in human SH-SY5Y
neuroblastoma cells following acute rotenone exposure (Shamoto-Nagai et al., 2003). The
proteasome activity decreased in the cells treated with rotenone (25 or 50 nM) in a time- and
dose-dependent way. ATP addition restored the reduction of proteasome activity in the cells
treated with 25 nM rotenone for 72 h. However, after 96 h of incubation with 25 or 50 nM
rotenone, the activity was reduced respectively to 28.7% and 21.9% of control, and adding
ATP did not increase the activity. After 120 h, the activity was virtually undetectable (with or
without added ATP) (Figure A.6). On the contrary, the levels of the proteins composing
proteasome did not change with rotenone treatment (Shamoto-Nagai et al., 2003).
Cytoskeletal damage further enhances disturbed proteostasis
• a-Synuclein can trigger hyperphosphorylation of Tau. Treatment of primary mesencephalic
neurons acutely (48 h) or subchronic treatment of wild-type (WT) mice with MPP+/MPTP results
in selective dose-dependent hyperphosphorylation of Tau at Ser396/404 (p-Tau). The presence of
a-synuclein was absolutely mandatory to observe MPP+/MPTP-induced increases in p-Tau levels,
since no alterations in p-Tau were seen in transfected cells not expressing a-synuclein or in
a-synuclein/ mice. MPP+/MPTP also induced a signiﬁcant accumulation of a-synuclein in both
mesencephalic neurons and in WT mice striatum. Subchronic MPTP exposure increased
phosphorylated-Tau in striatum of WT (but not a-syn/ mice) causing microtubule (MT)
cytoskeleton instability that affects cellular microtubule transport (including axonal transport)
(Duka et al., 2006; Qureshi and Paudel, 2009). For instance, MPTP was found to elicit an increase
of phosphorylated Tau at Ser262 by 2.8-, 4.5-, 4.6-, and 4.0-fold higher in 1, 5, 25, and 50 lM
PPPs, Parkinson’s disease and childhood leukaemia
www.efsa.europa.eu/efsajournal 131 EFSA Journal 2017;15(3):4691
MPTP-treated cells than the basal level observed in Ctr/vehicle-treated cells, respectively.
Additionally, MPTP caused a dose-dependent increase in the intracellular a-synuclein level in M17
human neuroblastoma cells (~ 3.5 fold increase in cells treated with 25 lM MPTP vs Ctr) (Qureshi
and Paudel, 2009). These results were conﬁrmed by other studies (e.g. Dauer et al., 2002; Drolet
et al., 2004).
• a-Synuclein accumulation followed by MT depolymerisation induces disruption in axonal
transport, which leads to an accumulation of damaged organelles, aggregated/misfolded
proteins and impaired vesicular release. Dopamine is leaking from the vesicles to the cytosol
promoting an increase in oxidative stress, potentiated by dopamine oxidation (Feng, 2006; Kim
et al., 2007). When microtubule network is disrupted, the amount of free tubulin increases,
triggering a-synuclein ﬁbrillisation (Payton et al., 2001).
• Axonal transport might be impaired by misfolded a-synuclein through perturbation of
microtubule assembly (Lee et al., 2002; Chen et al., 2007; Esposito et al., 2007), especially
together with MAPT protein (Giasson et al., 2003; Qureshi and Paudel, 2011). It induces not
only microtubule disruption but also impairs microtubule-dependent trafﬁcking (Lee et al.,
2006). MT-dependent transport is important for maintaining the Golgi structure, and thus,
depolymerisation of the MT leads to a speciﬁc pattern of Golgi fragmentation (Cole et al.,
1996). When the MT network was disrupted by nocodazole treatment (5 lg/mL) or a-synuclein
was overexpressed, this normally compact organelle was fragmented and dispersed (IC
images) as shown in COS-7 cells (Lee et al., 2006). Similarly, overexpression of a-synuclein in
differentiated SH-SY5Y cells caused Golgi fragmentation (e.g. ~ 190% increased fragmented
Golgi at 12 m.o.i. (multiplicity of infection) of a-synuclein vs Ctr) (Lee et al., 2006).
• It was found that a-synuclein mutants associated with PD exhibit reduced transport in neurons,
as shown in rat primary neuronal cortical cultures transfected with wild-type (WT), A53T or A30P
a-synuclein. For instance, the rate of transport (expressed in lm/h) was reduced of ~ 55% and
~ 60% after 3–4 h for A30P and A53T respectively (vs Ctr-WT) (Saha et al., 2004).
• Damaged cytoskeletal proteins disrupt also mitochondrial trafﬁcking. Mitochondria use
cytoskeletal proteins as tracks for their directional movement (Nogales, 2000). The cytoskeletal
system regulates not only mitochondrial movement but also their morphology and function.
Therefore, damage to microtubules perturbs transport of mitochondria through axons,
increasing their retrograde movement. These changes in mitochondria dynamics lead to a
decrease of mitochondria numbers in axons and mitochondria accumulation in cell bodies
(Miller and Sheetz, 2004; De vos et al., 2007). Depletion of mitochondria quantity and function
in axons occurs in neurodegenerative disorders (Brownlees et al., 2002; Stamer et al., 2002).
• Since mitochondria are ATP suppliers and microtubules need ATP to accomplish their function,
mitochondrial dysfunction has a profound effect on axonal transport and function (De Vos
et al., 2008).
• Mitochondrial dysfunction may damage mitochondrial trafﬁcking through calcium dysregulation.
Cytosolic Ca2+ is one of the best-studied regulators of mitochondrial movement. Elevation of
cytosolic Ca2+ stops both the anterograde and retrograde trafﬁcking of mitochondria in
neurons and in many cell lines (Chang et al., 2006; Szabadkai et al., 2006). In H9c2 cells
simultaneous measurements of free Ca2+ levels and mitochondrial dynamics showed that 50%
reductions in mitochondrial movement occurred at concentrations of approximately 400 nM
Ca2+, and a complete arrest in the low micromolar range (Yi et al., 2004; Saotome et al.,
2008). These are indirect proofs suggesting that inhibition of CI, followed by mitochondrial
dysfunction, could damage mitochondrial trafﬁcking. Also, chronic exposure to rotenone
(50 nM at different times of exposure) was reported to reduce mitochondrial movement in
differentiated SH-SY5Y cells (e.g. ~ 30% reduction of mitochondrial movement (lm/s) after
8 days of rotenone treatment vs Ctr) (Borland et al., 2008).
A.3.3. Uncertainties or inconsistencies
• The exact molecular link from mitochondrial dysfunction to disturbed proteostasis is not
known. It is not clear which is the oxidative modiﬁcation that drives the process.
• The sequence of events taking place after inhibition of CI is not entirely clear (Zaltieri et al.,
2015). Some studies suggest that induced oxidative stress leads to a-synuclein aggregation
that triggers proteosomal dysfunction (Betarbet et al., 2006). Such order of events is
suggested to take place in vivo (McNaught and Jenner, 2001). However, in other studies
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opposite sequence of events is proposed suggesting that ﬁrst proteosomal dysfunction take
place that leads to a-synuclein aggregation.
• A vicious circle is observed here as a-synuclein aggregation potentiates proteosomal
dysfunction and v/v. In this vicious cycle it is difﬁcult to establish exact quantitative relationship
of these two events.
• Whether a-synuclein is a substrate for proteasome remains controversial since both positive
and negative data have been reported (Paxinou et al., 2001). Furthermore, polyubiquitination
of a-synuclein, a prerequisite for 26S proteasomal degradation has yet to be reported (Stefanis
et al., 2001). It is also not clear whether polyubiquitination of a-synuclein is necessary for its
degradation. However, a-synuclein gets targeted by the UPS in the SHSY5Y neuroblastoma cell
line. Phosphorylated a-synuclein gets targeted to mono- or di-ubiquitination in synucleinopathy
brains (Hasegawa et al., 2002), but it is not clear if this modiﬁcation can play any role in
proteasomal degradation since monoubiquitination of proteins serves mainly as a signal for
endocytosis or membrane trafﬁcking.
• On the contrary to the increased a-synuclein levels observed in the midbrain, decreased
a-synuclein levels were found in the cerebellums of PD patients when compared to controls,
suggesting an imbalance of a-synuclein levels in different parts of the brain (Westerlund et al.,
2008).
• Although mitochondrial alterations have been reported in PD patients (Ikawa et al., 2011) and
disease models, it is not clear whether they represent a primary pathogenic mechanism. In
particular, the critical interplay between mitochondrial dysfunction and oxidative stress, which
has been widely reported in PD (Dias et al., 2013) and could constitute either a cause or a
consequence of mitochondrial damage, hampers an effective comprehension of the above-
mentioned studies. Oxidative stress can constitute a bridge connecting mitochondrial
dysfunction to the induction of a-synuclein misfolding, aggregation, and accumulation, but
otherwise it may be also triggered by these latter events that in turn could induce
mitochondrial alterations (Zhu and Chu, 2010; Dias et al., 2013).
• It is still unclear whether the involvement of a-synuclein in chronic MPTP toxicity reﬂects a
physiological function for a-synuclein that has been activated in the wrong context, or whether
a-synuclein produces an accidental pathogenicity that contributes to MPTP toxicity but is
unrelated to the normal function of a-synuclein (Fornai et al., 2005).
• The inconsistent effects of MPP+ on autophagy (up or down regulation) are reported. It may
be attributed to differences observed between immortalised cell lines and primary neurons,
different timing or dose. While dysregulation of autophagy is always described, the direction is
not clear. Further studies are required to clarify this issue.
• MPTP administration does not induce Lewy body formation (in contrast to rotenone)
characteristic of PD, even after repeated injections (Dauer et al., 2002; Drolet et al., 2004).
• There is also controversy over whether the increase in autophagic markers is protective or, on
the contrary, causative of neuronal death.
• MPP+ may have effects apart from CI inhibition, e.g. on microtubules but it is still unclear
whether this is a primary effect. Indeed, MPP+ binds to microtubules in PC12 cells and inhibits
their polymerisation and stability (Cappelletti et al., 1999, 2001).
• It is not clear whether microtubules disruption may be associated with a-synuclein aggregation
since tubulin was shown to co-localise with a-synuclein in Lewy bodies. Furthermore, tubulin
folding is dependent on ATP and GTP hydrolysis, and mitochondrial dysfunction with subsequent
energy failure could trigger microtubules disruption. Cytoskeletal microtubule (MT) injury is likely
to be responsible for altered rearrangement and movement of cell organelles, being a common
feature of several neurodegenerative diseases including PD (Mattson et al., 1999; Wade, 2009).
• It is not clear whether rotenone could cause microtubules depolymerisation in vivo and in vitro
(Brinkley et al., 1974) by binding to the colchicine site on tubulin heterodimers (Marshall et al.,
1978). Ren and Feng (2007) found that microtubule depolymerisation induced by rotenone
caused vesicle accumulation in the soma and kills neurons.
A.3.4. Quantitative evaluation of KERs
As described in the studies above (Empirical support for linkage) a quantitative or semiquantitative
relationship has been established between rotenone-induced mitochondrial dysfunction and the
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impairment of UPS/ALP function. Below some representative studies are reported as examples for how
such quantitative evaluations can be performed.
• Human neuroblastoma SK-N-MC or human embryonic kidney (HEK) cells were exposed to
rotenone at 100 nM for 24 or 48 h (for further details, see Chou et al., 2010).
Examples of quantitative evaluation of this KER
Figure A.11: Dose- and time-dependent striatal proteasome activity after MPTP continuously infused
up to 28 days measured by relative chymotrypsin-like, trypsin-like, and peptidyl-
glutamyl-peptide hydrolysing (PGPH) proteasome activities in mice. Delayed and
prolonged inhibition of proteasome activity after continuous MPTP administration (1, 5
or 30 mg/kg MPTP daily) for the indicated time periods. Asterisks indicate statistically
signiﬁcant differences (p < 0.05) from baseline proteasome activity (single asterisk) or
from both baseline proteasome activity and activity after lower MPTP doses (1 and
5 mg/kg, daily, double asterisk; n = 5 mice) (Fornai et al., 2005, ﬁg. 2B, copyright The
National Academy of Sciences)
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Figure A.12: Effect of a a-synuclein deletion on MPTP toxicity. Proteasome activity in control and
a-synuclein KO mice continuously infused for 28 days with MPTP (30 mg/kg of body
weight daily, striatum concentration approximately 13 lM). Proteasome activities in the
substantia nigra are depicted as per cent of control (means  SEMs) as a function of time
after beginning of the infusions (ﬁve mice per group). Asterisks indicate statistically
signiﬁcantly different values (p < 0.05) from controls (Fornai et al., 2005, ﬁg. 5c,
copyright The National Academy of Sciences)
Figure A.13: a-Synuclein levels were selectively increased in the ventral midbrain (VMB) region of
rotenone-infused rats with or without lesion. a-Synuclein levels, as determined from
Western blot analysis, from rotenone-treated rats were expressed as a percentage of values
from control vehicle-infused rats. Results are mean  SEM (n = 3 control, 6 rotenone with
lesion, 3 rotenone with no lesion) *p < 0.05 vs. vehicle-infused rats (Reprinted from
Betarbet et al., 2006, ﬁg. 3A, copyright (2006) with permission from Elsevier)
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Figure A.14: Bar graph showing the effects of rotenone and lactacystin on a-synuclein levels after
4 weeks of rotenone exposure (5 nM) in vitro, on SK-N-MC human neuroblastoma cells.
Rotenone alone increased a-synuclein levels, but lactacystin alone did not. a-Tocopherol
attenuated the rotenone-induced increase in a-synuclein. Results are mean  SEM
(n = 4). *p < 0.05 vs. solvent-treated cells. CC, control cells; RC, rotenone-treated cells;
C-Lac or CL, lactacystin-treated cells; R-lac or RL, rotenone and lactacystin-treated cells;
R-AT, rotenone and a-tocopherol-treated cells (Reprinted from Betarbet et al., 2006, ﬁg.
5B, copyright (2006) with permission from Elsevier)
Figure A.15: Levels of ubiquitinated proteins were estimated in solubilised protein fractions from
SK-N-MC cells collected at the end of each week of rotenone treatment (5 nM), using
gel electrophoresis and immunoblotting. Quantitative analysis demonstrated signiﬁcant
increases in ubiquitinated protein levels 4 weeks after rotenone treatment and after
proteasomal inhibition with lactacystin. Band intensities were expressed as % of control.
Results represent mean  SEM. *p < 0.05 compared to control (Reprinted from
Betarbet et al., 2006, ﬁg. 8C, copyright (2006) with permission from Elsevier)
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Figure A.16: Effects of rotenone on the activity of proteasome. Proteasome activity in the cytoplasmic
fraction of cells treatedwith 25 nM (A) or 50 nM (B) rotenonewasmeasured ﬂuorometrically
in the absence (open triangles and circles) or presence (solid triangles and circles) of
exogenously added ATP (2 mM) (Reprinted from Shamoto-Nagai et al., 2003, ﬁg. 6,
copyright (2003) JohnWiley and Sons)
Table A.2: Quantitative evaluation of the KER
KE (upstream)
Mitochondrial
dysfunction
(rotenone, nM)
KE3 (downstream)
Impaired proteostasis
UPS inhibition
(% approx.) measured by:
Comments References
26S UPS activity + catalase (antioxidant) HEK cells exposed
for 24 h
Chou et al. (2010)
10 24 Not done
100 48 Increased UPS activity by 40%
1000 60 Not done
20S proteasome activity SK-N-MC human
neuronal cell line
(exposed for 24 h)
Chou et al. (2010)
1 8
50 4
100 18
500 22
1000 24
20S proteasome immune-reactivity decrease
10 22
100 48
100 70
MPTP administration Chymotrypsin-like UPS activities (at day 2)
1 mg/kg daily 20 Mice continuously
infused with MPTP
for 28 days
Fornai et al. (2005)
5 mg/kg daily 30
30 mg/kg daily 40
Trypsin-like UPS activities (at day 2)
1 mg/kg daily 30
5 mg/kg daily 40
30 mg/kg daily 60
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The studies presented in the above Table showed that rotenone caused a reduction in UPS activity
(measured by 26S and 20S proteasome activity) in a dose-dependent manner. Further studies showed
that rotenone increases proteasome subunit degradation, but does not alter synthesis (Western blot
and RT-PCR studies, reviewed in Chou et al., 2010). Dose- and time-dependent striatal proteasome
activity is also shown after MPTP continuously infused up to 28 days measured by relative
chymotrypsin-like, trypsin-like, and peptidyl-glutamyl-peptide hydrolysing (PGPH) proteasome activities
in mice (Fornai et al., 2005).
• PD patient-derived ﬁbroblasts (vs Ctr ﬁbroblasts) showed reduction of UPS function (by
~ 33%) and higher accumulation of ubiquitinated proteins (by ~ 2 fold) in PD as compared to
control ﬁbroblasts at baseline. Treatment with rotenone (20, 500 lM, 6 h) caused a higher
induction of 20S proteasome activity in PD ﬁbroblasts vs Ctr. An increase of LC3-II
accumulation (indicative of autophagic vesicle accumulation) in both groups (PD and Ctr) after
exposure to 500 lM rotenone was observed (Ambrosi et al., 2014).
• Human neuroblastoma cells (SK-N-MC) after short treatment with rotenone (1 week) elevated
soluble a-synuclein protein (41  16% increase) levels without changing mRNA levels,
suggesting impairment of a-synuclein degradation via UPS. Chronic rotenone exposure
(4 weeks) increased levels of insoluble a-synuclein (29  9% increase) and ubiquitin
(87  14% increase) (Sherer et al., 2012).
• SHSY-5Y cells treated with rotenone (500 nM, 24 h) showed a ~ 2 fold increase in DCF
ﬂuorescence compared to untreated cells (indicative of intracellular ROS). Additionally,
rotenone elevated cytosolic calcium (about 35–40% increase vs Ctr), ER-stress (about 45%
increase vs Ctr), impaired UPS function (~ 3-fold increase of insoluble protein aggregate vs
Ctr). Inhibition of Rac1 (Rho-like GTPase) mitigated the oxidative/nitrosative stress, prevented
calcium-dependent ER-stress, and partially rescued UPS function (Pal et al., 2014).
• Human neuronal SH-SY5Y cells treated with rotenone (10 lM, for 24 h showed accumulation
of high molecular weight ubiquitinated bands (by immunoblotting qualitative assay), and
increase of both mitochondrial- (~ 5 fold increase vs Ctr) and cytosolic- cytochrome c fractions
(~ 1.2-fold increase vs Ctr). Rapamycin pretreatment (3 lM, for 48 h prior addition of
rotenone) diminished rotenone-induced effects, as shown by enhanced degradation of
ubiquitinated proteins, and reduced levels of cytosolic cytochrome c. Also, rapamycin promoted
mitophagy (as shown by lysosome and mitochondria co-localisation within the cells) (Pan et al.,
2009).
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4th KER: Impaired proteostasis leads to degeneration of DA neurons of the
nigrostriatal pathway
A.4.1. How this key event relationship works
One of the critical functions in the long-lived cells such as neurons is the clearing system for the
removal of the unfolded proteins. This function is provided by two major systems, the ubiquitin
proteosome system (UPS) and the autophagy-lysosome pathway (ALP) (Tai, 2008; Korolchuck VI et al.,
2010; Ravikumar et al., 2010). Impaired proteostasis with formation of misfolded a-synuclein aggregates
deregulates microtubule assembly and stability with reduction in axonal transport and impairment of
mitochondrial trafﬁcking and energy supply (Chen et al., 2007; Esposito et al., 2007, Borland et al., 2008;
Weihofen et al., 2009; O’Malley, 2010; Fujita et al., 2014). Pathological consequences of these
deregulated process include interference with the function of synapses, formation of toxic aggregates of
proteins, impaired energy metabolism and turnover of mitochondria and chronic endoplasmic reticulum
stress; all eventually leading to degeneration of DA neurons in the nigrostriatal pathway (Dauer et al.,
2003; Raff et al., 2005; Orimo et al., 2008; Fujita et al., 2010; Shulman et al., 2011; Schwarz, 2015).
A.4.2. Weight of evidence
The weight of evidence for the relationship between impaired proteostasis and degeneration of
dopaminergic neurons of the nigrostriatal pathway is strong. The biological plausibility is based on the
knowledge of the physiological cellular process governing the cleaning processes of degraded proteins
and organelles and on the observations done in genetic and idiopathic forms of Parkinson’s disease.
Dose and time concordance support a strong response–response relationships which is also supported
by the very well known chronic and progressive behaviour of the Parkinson’s disease. Although
essentiality has been demonstrated in multiple models and lines of evidence, including knockout
animals, a single molecular chain of events cannot be established; therefore essentiality for this KEs
relationship was considered moderate.
A.4.2.1. Biological plausibility
The fact that impaired proteostasis can induce degeneration of DA neurons of the nigrostriatal
pathway is well known and based on the understanding of the physiological cellular processes involved
in removing degraded/misfolded proteins as they are critical for normal mitochondria and axonal
transport. Accumulation of misfolded and/or aggregated a-synuclein and the presence of abnormal
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mitochondria is a consequence of deregulation of this clearing process, and the Lewy bodies, a
pathological hallmark of sporadic PD, stain speciﬁcally for proteins associated with UPS (Gai et al.,
2000; McNaught et al., 2002; Fornai et al., 2003). Impaired proteostasis has been described in
humans affected by sporadic PD (McNaught et al., 2001, 2003), and changes induced by excess
cellular levels of degraded proteins in nigral dopaminergic neurons cause a progressive decline in
lysosome function, i.e. ALP system, contributing to neurodegeneration (Decressac, 2013). In this
context, the ALP system is likely working in a complementary way, with the UPS being the major
cleaning system in the soma and the ALP playing a role at presynaptic sites (Friedman et al., 2012).
Pathological observations from patients affected by PD and from animal models show an increased
number of autophagic vacuoles or autophagic markers (Alvarez-Erviti et al., 2010; Crews et al., 2010).
Additional observations support the role of impaired proteostasis in nigrostriatal toxicity such as:
several genetic variants of sporadic PD are due to susceptible genes able to participate in or modify
proteostasis (Leroy et al., 1998; Shimura et al., 2000; Fornai et al., 2003; Shulman et al., 2011) and
striatal microinfusion of proteasome inhibitors induce selective nigrostriatal toxicity with loss of DA and
DA metabolites (DA, DOPAC and HVA) in the striatum, retrograde loss of nigral DA cell and
intracytoplasmic inclusions positive for protein of the UPS (Fornai et al., 2003).
Transgenic overexpression of mutant or wild-type forms of a-synuclein in mice causes
neuropathological changes including dystrophic neurites and a-synuclein positive LB-inclusion (Masiliah
et al., 2000; Dauer et al., 2003). However, they fail to reproduce speciﬁc cell death in the nigrostriatal
pathway. In contrast, injection of human a-synuclein expressing viral vectors into the SN of adult rats
causes a selective death of dopaminergic neurons and formation of LB inclusions (Kirik et al., 2002; Lo
Bianco et al., 2002; Dauer et al., 2003). These effects were observed with adeno-associated virus-
mediated expression of A30P a-synuclein and with lentiviral-mediated expression of a-synuclein in rats,
mice and non-human primates (Klein, 2002; Lo Bianco, 2002, 2004; Kirk, 2003; Lauwers, 2003;
Shulman, 2010).
Impaired proteostasis and formation of proteins aggregates also affect the axonal transport and
mitochondrial trafﬁcking. a-synuclein mutants accumulate in the neuronal soma when overexpressed,
reducing the axonal transport (Saha, et al., 2004; Kim-Han, 2011); in addition, overexpressed vesicle-
associated a-synuclein binds to the microtubules with a detrimental role on axonal transport (Yang
et al., 2010; Kim-Han 2011). Postmortem studies on PD patients are indicative of axonal damage. It
appears that axonal changes precede neuronal loss, supporting the idea that axonal impairments are
early events in neurodegenerative disorders (Orimo, 2005, 2008; Raff, 2002; Braak et al., 2004). These
changes, and observation from animals models using the chemical stressor MPTP (Serra et al., 2002;
Meissner et al., 2003; Hasbani et al., 2006) are supporting the notion that DA neurons of the
nigrostriatal pathway degenerate through a ‘dying back’ axonopathy (Raff et al., 2002). It was
demonstrated that axonal degeneration follows an active process distinct from cell body loss in a
Wallerian degeneration slow (WldS) mutant mouse transgenic model. In this model, axonal
degeneration in a variety of disorders is inhibited. In WldS mice, acute treatment with MPTP (20 mg/kg
i.p. for 7 days) resulted in attenuated nigrostriatal axon degeneration and attenuated DA loss, but cell
bodies were not rescued (Hasbani et al., 2006). Indeed, multiple evidences from genetic and
experimental models (particularly using MPTP as a stressor) support an early and critical role of axonal
impairment with early occurrence of Lewy neurites preceding Lewy bodies formation and cell death
(O’Malley, 2010).
In addition, a strong link between mitochondrial dysfunction and PD came from the discovery that
mutations in PINK1, a-synuclein, LRRK2, parkin and DJ-1, all linked with genetic causes of PD, can
affect mitochondrial function (O’Malley, 2010; Rappold et al., 2014). Deregulation of mitochondrial
dynamics (ﬁssion, fusion and movement of mitochondria) can affect neuronal activity and viability and
imbalance of mitochondrial dynamics have been reported in experimental models of PD with mutated
a-synuclein (Tieu, 2014) or chronic model of primary neuronal cells treated with low concentrations
(0.1–1 nM) of rotenone (Arnold et al., 2011). Progression of neuronal changes with formation of Lewy
neurites and reduction of mitochondrial movement leading to cell death has been also observed
in-vitro in a chronic cell-based model (SH-SY5Y neuroblastoma cell line) treated with low concentration
of Rotenone (50 nM for 21 days). In this assay, reduction in mitochondrial movement was associated
with a progressive damage, ﬁrst including formation of Lewy neurites, followed by cell death (Borland
et al., 2008).
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A.4.2.2. Empirical support for linkage
Degeneration of DA neurons of the nigrostriatal pathway, similar to the one observed in PD, have
been reproduced in human and experimental animal models following exposure to MPTP (Langston,
1983; Forno, 1993; Irwin, 1993; Rose, 1993; Ovadia, 1995; Kitamura, 2000; Serra, 2002; Dauer, 2003;
Meissner, 2003 and Porras et al., 2012) and in animals following administration of rotenone through
multiple routes of exposure (Betabret, 2000, 2006; Schmidt, 2002; Sherer, 2003; Fleming, 2004,
Saravanan, 2005; Inden, 2007; Pan-Montojo, 2010; Johnson, 2015). This indicates that both chemicals
can be used as a tool compound for experimental investigations on PD and to explore the key event
relationship between impaired proteostasis and degeneration of DA neurons of nigrostriatal pathway.
Also, similar to PD, susceptibility to MPTP increases with age in both non-human primates and mice
(Irwin et al., 1993; Rose et al., 1993, Ovadia et al., 1995).
Neurotoxic external doses of both rotenone and MPTP are well characterised and reported;
however, the corresponding brain concentration is much less frequently quoted. In order to understand
the brain concentration for both compounds, data were retrieved from Betarbet et al. (2000 and 2006)
for rotenone and from Fornai et al. (2005) and Thomas et al. (2012) for MPTP. In all cases, the
compounds were administered by infusion and, at least for MPTP, the brain concentrations were taken
after chronic infusion and are expected to be at the steady state. For MPTP only, brain concentration
was expressed as ng/mg protein (Fornai et al., 2005) or as ng/mg weight tissue (Thomas et al., 2012).
To do the ﬁnal estimate we assumed a density for protein as 1.4 (Quillin and Matthews, 2000) and a
protein content in the brain of about 10% (Schwartz et al., 2012). Density for brain tissue was
assumed to be 1. The ﬁnal concentration was 12 lM (Fornai et al., 2005) and 47 lM (Thomas et al.,
2012).
It should be noted that the upstream key event includes multiple pathological events, eventually
leading to the downstream key event. As it is difﬁcult to assess real time changes for a series of
complex and dynamic events in a single experiment, most of the empirical supporting evidences are
performed by exploring single factors (e.g. impairment of ALP or UPS or axonal transports) and their
role in the degeneration of DA neurons.
MPTP/MPP+
• Inhibition of the UPS was observed following continuous infusion of MPTP at 1, 5 and 30 mg/kg
per day for 28 days in mice. A dose related decrease in the enzyme activity of the UPS was
observed and this effect was associated with a dose-related decrease of TH positive terminals
(densitometry analysis) in the dorsal and ventral striatum. This effect was accompanied by a
dose-related cell loss in the SN (counting of TH positive cells) at 5 and 30 mg/kg per day. At
30 mg/kg per day the authors reported cytoplasmic inclusions positively staining for ubiquitin
and a-synuclein in neurons of the SN (and locus coeruleus). In the same experiment, acute
administration of MPTP (single injection of 30 mg/kg/ or 4 separate injections of 20 mg/kg)
induced a transient inhibition of the UPS activity, neuronal loss but no intracytoplasmatic
inclusions, indicating that a continuous infusion is necessary to induce permanent inhibition
and pathological changes similar to the one observed in PD (Fornai et al., 2005).
• In mice lacking a-synuclein, continuous infusion of up to 30 mg/kg per day for 28 days of
MPTP neuronal cell death and behavioural symptoms were almost alleviated (Dauer et al.,
2002, Fornai et al., 2005).
• Administration of MPTP to mice (30 mg/kg per day i.p. for 5 days) produced autophagosome
(AP) accumulation (increase in LC3II) and dopaminergic cell death which was preceded by a
decrease in the amount of lysosomes in DA neurons. MPTP also induced mitochondrial-derived
ROS and permeabilisation of the lysosomal membrane. This resulted in a decrease in Lamp 1
lysosome structural protein and accumulation of undegraded AP and release of lysosomal
enzymes into the cytosol. The effect observed in-vivo was quantitatively conﬁrmed in-vitro
(human neuroblastoma cell line BEM17(M17EV)). MPP+ was tested in-vitro at the
concentrations of 0.25–2.5 lM and induced a concentration-related decrease in Lamp1,
increase in LC3II, increase in cell death and decrease in lysotracker. In the same in-vitro
system, MPP+ also induced lysosome membrane permeabilisation. In the same experiment,
induction of lysosome biogenesis by the autophagy-enhancer compound rapamycin attenuated
the dopaminergic neurodegeneration, both in vitro and in vivo, by restoring lysosomal levels
(Dehay et al., 2010).
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• In an in-vitro microchamber that allowed speciﬁc exposure of neuritis of murine mesencephalic
neurons, treatment with 1–5 lM of MPP+ induced impairment of mitochondrial transport,
neurite degeneration (degeneration of proximal dendrites) and autophagy, before cell death
(Kim-Han et al., 2011). The number of TH positive cell bodies and neurites was reduced at
1 lM, and axonal fragmentation and LC3 dots increased while tubulin density decreased (Kim-
Han et al., 2011).
• Mice treated with MPTP at 20 mg/kg per day i.p. for 5 days showed loss of DA neurons in SN
which was attenuated by the pharmacological block of mitochondrial ﬁssion protein Drp1. Drp1
blockade also promoted mitochondrial fusion and enhanced the release of DA from the striatal
terminals in a PINK1 knockout model showing a defective DA release (Rappold et al., 2014;
Tieu et al., 2014).
• In differentiated (d6) LUHMENS cell system stably expressing eGFP/mito-tRFP, treatment with
MPP+ (5 lM) for 24 h revealed a reduction in the total number of mitochondria in neuritis and
a signiﬁcant reduction in velocity. Partial protection from MPP+ dependent mitochondrial
immobilisation in neuritis as well as from drop in mitochondria numbers in neuritis was detects
following co-treatment with the antioxidant vitamin C (Schildknecht et al., 2013)
Proteasome inhibitors
Intracerebral microinfusion of proteasome inhibitors (lactacystein or epoxomycin at, 100 and
1,000 lM) induced loss of TH and DAT immunostaining and decrease in DA and DOPAC in DA
terminals in the striatum and loss of nigral cells in SN (counting of TH positive cells). Formation of cell
inclusions (positively immunostained for a-synuclein and ubiquitin) and apoptosis were observed after
treatment with proteasome inhibitors (0.1–50 lM) in an in-vitro system (PC 12 cells). The
concentration response curve for apoptosis was shifted to the right compared to the concentration
response curve for cellular inclusions indicating that inclusions occurred earlier and independently of
cell death. A maximum effect was reached between 1 and 10 lM (Fornai et al., 2003).
Rotenone
• Administration of rotenone, via osmotic mini pumps implanted to rats (3 mg/kg per day for
7 days) induced decrease of TH in substantia nigra and striatum and decrease in a-synuclein,
in its native form, in substantia nigra and striatum, while monoubiquitinated alpha-synuclein
increased in the same regions. Valproic acid (VPA) treatment (effective inhibitor of histone
deacetylases) signiﬁcantly counteracted the death of nigral neurons and the 50% drop of
striatal dopamine levels caused by rotenone administration. VPA treatment also counteracted
both type of a-synuclein alterations. Furthermore, monoubiquitinated alpha-synuclein increased
its localisation in nuclei isolated from substantia nigra of rotenone-treated rats, an effect also
prevented by VPA treatment. Nuclear localisation of alpha-synuclein has been recently
described in some models of PD and its neurodegenerative effect has been ascribed to histone
acetylation inhibition (Monti et al., 2010).
• Chronic oral administration of rotenone at 30 mg/kg per day in mice produced neuronal loss
and degeneration of TH positive terminals in the striatum accompanied by an increase in a-
synuclein, ubiquinated proteins and decrease in proteasomal activity. Concomitant treatment
with 4-PBA (a chemical chaperone able to reverse the mislocalisation and/or aggregation of
proteins) inhibited rotenone-induced neuronal death and decreased protein level of a-synuclein
(Inden et al., 2007).
• Treatment of Lewis rat with 2 mg/kg per day of rotenone, administered sc for 8 weeks
impaired autophagic ﬂux, induced lysosomal dysfunction and degeneration of DA neurons
(decrease in number of TH positive cells and decrease in density of TH positive ﬁbres) in SNpc.
The effect of rotenone was paralleled by an increase in LC3 immunopositive dots and
upregulation of the LC3II in DA neurons. A concomitant effect was observed and characterised
by a decrease in LAMP2 and catepsin immunodots with a diffuse morphological pattern,
possibly indicative of decreased lysosomal membrane integrity and leaking to cytosol. In-vitro
(PC12 cells) at 500 nM, rotenone also induced increases in a-synuclein, microtubule associated
protein 1, light chain 3-II, Beclin 1, p62, increased lysosome permeability and induced cell
death. In PC12 cell, the concomitant treatment with trehalose (autophagic inducer) attenuated
the rotenone-induced cell death while in-vivo trehalose treatment decreased the rotenone-
induced dopaminergic neurons loss (Wu et al., 2015).
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• Rotenone LD50 of 10 nM in differentiated SH-SY5Y cells decreased autophagic ﬂux at both 2
and 24 h. Upregulation of autophagy by rapamycin protected against cell death while inhibition
of autophagy by 3-methyladenine exacerbated cell death (Giordano et al., 2014)
• Treatment of embryonic midbrain neuronal cells with 0.1–10 lM rotenone for 30 min induces a
decrease in polymerised tubulin and increased the number of apoptotic TH+ cells. Similar
effects were observed with colchicine treatment, a well-known microtubule-depolarising agent
and prevented by taxol, a well-known microtubule-stabilising agent. The effect was considered
speciﬁc to DA neurons as the effect on apoptosis and cell death was much less evident in
GABAergic and glutamatergic neurons (Ren et al., 2005).
Human evidences
• Inclusion bodies in DA neurons (i.e. Lewy bodies), a pathological hallmark for sporadic PD,
stains speciﬁcally for proteins associated with the UPS (Gai et al., 2000; Mcnaught et al., 2002;
Fornai et al., 2003), including a-synuclein, parkin and ubiquitin; possibly indicating that failure
of the UP system represents a common step in the pathogenesis of PD and impairment of the
proteasome system was found in humans affected by sporadic PD (McNaught et al., 2001,
2003).
• Lysosomal breakdown and autophagosome (AP) accumulation with co-localisation of lysosomal
markers in Lewy Bodies is reported to occur in PD brain samples where Lewy bodies were
strongly immunoreactive for the autophagosome markers (LC3II) (Dehay et al., 2010).
• Postmortem studies on PD patients show axonal pathology that is likely to precede the loss of
neuronal bodies In this investigation, TH immunoreactive ﬁbres had almost entirely
disappeared with preservation of neuronal bodies (Orimo et al., 2005, 2008).
A.4.3. Uncertainties or inconsistencies
• MPTP can induce damage to nigrostriatal neurons without formation of Lewy bodies (hall mark
of PD). Acutely intoxicated humans and primates with MPTP lack LB-like formation (Forno,
1986, 1993; Dauer, 2003). Similarly, discontinuous administration of rotenone, even at high
doses, damages the basal ganglia but produce no inclusions (Heikkila et al., 1985; Ferrante
et al., 1997; Lapontine, 2004). To reproduce the formation of neuronal inclusions, continuous
infusion of MPTP or rotenone is necessary.
• Acute intoxication with rotenone seems to spare dopaminergic neurons (Ferrante, 1997, Dauer
et al., 2003). In addition, in rats chronically infused with rotenone showed a reduction in
striatal DARPP-32-positive, cholinergic and NADPH diaphorase-positive neurons (Hoglinger,
2003) or in other brain regions. These results would suggest that Rotenone can induce a more
widespread neurotoxicity (Aguilar, 2015).
• The vulnerability of the dopaminergic pathway still remains circumstantial. The selectivity of
MPP+ for dopaminergic neurons is due to its selective uptake via dopamine transporter (DAT),
which terminates the synaptic actions of dopamine (Javitch, 1985; Piﬂ, 1993; Gainetdinov,
1997; Hirata, 2008). Selectivity of Rotenone for dopaminergic neurons is not fully understood
(Hirata, 2008).
• Transgenic overexpression of a-synuclein induces neurotoxicity (i.e. neuronal atrophy,
distrophic neuritis, astrocytosis and LB-like formation). However they fail to cause death of
dopaminergic neurons. Nevertheless, injection of the human protein or mutated form
expressing viral vectors into the SN, are able to induce all the pathological changes
characteristic of PD. This discrepancy could be due to the higher expression of a-synuclein in
the viral vector model or because in these models, a-synuclein overexpression would occur
suddenly in adult animals (Dauer et al., 2003). In addition, transgenic expression of C-terminal
truncated a-synuclein also leads to motor symptoms but neuronal degeneration is not reported
(Halls et al., 2015).
• There is conﬂicting literature on whether increased autophagy would be protective or enhances
damage. Similarly, a conﬂicting literature exists on extent of inhibition or activation of different
protein degradation system in PD and a clear threshold of onset is unknown (Fornai et al.,
2005).
• Several mechanisms may affect the axonal transport in neurons showing swelling of neurites
positive for a-synuclein. These include e.g. ROS production, lysosome and mitochondria
membranes depolarisation, increased permeability and microtubule depolymerisation (Borland,
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2008; Choi, 2008; Kim-Ham 2011). As both MPTP and Rotenone could directly trigger these
effects, a clear mechanistic understanding leading to cell death is difﬁcult to identify (Aguilar
et al., 2015).
• Different features of imbalanced proteostasis can trigger one another (e.g. disturbed protein
degradation, pathological protein aggregation, microtubule dysfunction); and each of them can
lead to cell death. Therefore, the ‘single’ triggering event triggering axonal degeneration or
neuronal death is not known. For instance, for a-synuclein aggregation, it is not clear whether
this causes death because some vital function of neurons is lost, or whether some protein
increases e.g. because of inhibited chaperone-mediate autophagy (Kaushik et al., 2008;
Cuervo et al., 2014).
• Real-time changes in DA axons are difﬁcult to assess, accounting for the limitation of testing
models of structural or trafﬁcking impairment in vivo.
A.4.4. Quantitative evaluation of KER
As described in the empirical support, a quantitative relationship has been established between
chemical stressors inducing impaired proteostasis and loss of DA neurons of nigrostriatal pathway. The
response–response relationship was evident in most of the studies and, where possible a relationship
in dose–response could be also observed. A chronic dose regimen for the chemical stressor was
necessary in most of the studies and this is conﬁrming that a long lasting perturbation of the key
event up is necessary to affect neuronal loss consistent with the presence of intracytoplasmatic
inclusions. However, some inconsistency in the measurement of the endpoints relevant for impaired
proteostasis were observed, probably because they also act as compensatory factors (Betarbet et al.,
2006). The acute administration of MPTP (single injection of 30 mg/kg/ or 4 separate injections of
20 mg/kg) induced a transient inhibition of the UPS activity and neuronal loss but no
intracytoplasmatic inclusions i.e. Lewy body were observed, supporting the temporal relationship
among the two events (Fornai et al., 2005).
Table A.3: Quantitative evaluation of the KER
Measured endpoint
relevant for the KEup
(KE3)
Measured endpoint relevant
for the KEdown (KE4)
Model Reference
Approx. 40% inhibition
of UPS
Approx. 38% decrease in TH
density in dorsal striatum
MPTP 1 mg/kg per day IV
infusion for 28 days in mice
Fornai et al. (2005)
Approx. 50% inhibition
of UPS
Approx. 40% decrease in number
of TH positive cells/mm2 in SN and
approx. 25% decrease in TH in
dorsal striatum
MPTP 5 mg/kg per day IV
infusion for 28 days in mice
Approx. 60% inhibition
of UPS
Approx. 86% decrease in number
of TH positive cells/mm2 in SN and
approx. 50% decrease in TH in
dorsal striatum and approx. 50%
in ventral striatum
MPTP 30 mg/kg per day IV
infusion for 28 days in mice
Approx. 40%
proteasome inhibition
Approx. 70% decrease in DA and
50% decrease in DOPAC in
striatum and 30% cell loss in SN
i.c. infusion of lactacystin
(proteasome inhibitors) in
rats 100 lM
Fornai et al. (2003)
Approx. 50% increase in
mRNA expression for
a-synuclein
Decrease in TH immunoreactivity
(approx. 50%), in TH-positive
nerve terminals in the striatum
Transgenic model
overexpressing a-synuclein
Kirk et al. (2002)
Approx. 16–13%
reduction in
proteosomal activity
Degeneration of nigrostriatal
dopaminergic neurons in 50% of
animals
Chronic i.v. treatment (up to
5 weeks) of Lewis rat with
rotenone at 2–3 mg/kg day
(free brain Rotenone
20–30 nM)
Betabret et al.
(2000, 2006)
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Measured endpoint
relevant for the KEup
(KE3)
Measured endpoint relevant
for the KEdown (KE4)
Model Reference
Approx. 50% increase in
a-synuclein
Approx. 57% reduction in TH
immunoreactivity in SNpc neurons
at 30 mg/kg per day
Decrease in TH and DAT in the
striatum (approx. 30% and 70%
respectively) and ventral midbrain
area (approx. 60%) at 30 mg/kg
per day
Oral chronic administration
(28 days) of rotenone (0.25,
1, 2.5, 5, 10 or 30 mg/kg
per day) to mice
Inden et al. (2007)
Increase in LC3 positive
dots in nigral DA
neurons (approx.
380%), upregulation of
LC3II (approx. 40%),
Beclin 1 (approx. 33%)
and P62 (approx. 50%)
autophagic substrate
Approx. 40% decrease in the
number of TH neurons (SNpc) and
density of TH positive ﬁbres
(approx. 50%) (striatum)
2 mg/kg per day for
8 weeks sc of Rotenone in
Levis rats
Wu et al. (2015)
Approx. 8 fold increase
in the number of TH+
neurons with granular
LC3
Approx. 40% decrease in the
number of TH immunoreactive
neurons
Primary dopaminergic
neurons following treatment
with MPP+ (LD50 of 5 lM/L)
Zhu et al. (2007)
Decrease in
mitochondrial speed
(approx. 100% decrease
in anterograde speed
and approx. 28%
increase in retrograde
speed)
Approx. 70% decrease in positive
TH neuronal bodies at 48 h
Treatment with up to 5 lM
(1–5 lM) of MPP+ in TH
positive murine
mesencephalic neurons in an
in-vitro microchamber
segregating system
Kim-Ham et al.
(2011)
Reduction in
mitochondrial movement
was statistically
signiﬁcant from day 8
and was greatest on
day 16 at 50 nM
(approx. day 3 19%,
day 6 7%, day 8 62%,
day 14 37%, day 16
200%)
Approx 60% of cell loss by day 21 In vitro SH-SY5Y neural cells
treated with 50 nM rotenone
for 21 days
Borland et al.
(2008)
30% increase over
control in static
mitochondria and 50
decrease over control in
number of mitochondria
Signiﬁcant decline of intracellular
ATP at 24 h
Differentiated (d6) LUHMENS
stably expressing eGFP/mito-
tRFP, treated with MPP+
(5 lM) for 24 h
Schildknecht et al.
(2013)
PPPs, Parkinson’s disease and childhood leukaemia
www.efsa.europa.eu/efsajournal 149 EFSA Journal 2017;15(3):4691
Figure A.17: Neurotoxicity induced by continuous MPTP administration. (A) Representative tyrosine
hydroxylase (TH)-stained sections of the substantia nigra from mice that were
continuously treated for 28 days with control pump infusions or with infusions of 1, 5,
or 30 mg MPTP/kg daily. (Scale bar, 600 lm) (B and C) TH-positive cell counts in the
substantia nigra (B) and semiquantitative densitometric measurements of the TH signal
in striatum (C) (n = 10 mice per group). (D) Striatal monoamine levels in MPTP-treated
mice (n = 10 mice per group). Asterisks indicate statistically signiﬁcant differences
(p < 0.05) of a sample compared to control (single asterisks) or to both the control and
the lower MPTP dose (double asterisks) (Fornai et al., 2005. ﬁg. 3, copyright The
National Academy of Sciences)
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Evidence Supporting Taxonomic Applicability
Multiple animal models have been used to mimic PD (Johnson et al., 2015). There are no sex
restriction; however, susceptibility to MPTP increases with age in both non-human primates and mice
(Rose et al., 1993, Irwin et al., 1993, Ovadia et al., 1995).
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5th KER: Neuroinﬂammation leads to degeneration of the dopaminergic
neurons of nigrostriatal pathway
A.5.1. How this KER works
Cells of the innate (microglia and astrocytes) and adaptive (inﬁltrating monocytes and lymphocytes)
immune system of the brain have, like other immune cells (in peripheral tissues), various ways to kill
neighbouring cells. This is in part due to evolutionary-conserved mechanisms evolved to kill virus-
infected cells or tumour cells; in part it is a bystander phenomenon due to the release of mediators
that should activate other cells and contribute to the killing of invading microorganisms. An
exaggerated or unbalanced activation of immune cells can thus lead to parenchymal (neuronal) cell
death (Gehrmann et al., 1995). Mediators known to have such effects, and that are also known to be
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produced during inﬂammation in the brain comprise components of the complement system and
cytokines/death receptor ligands triggering programmed cell death (Dong and Benveniste, 2001).
Besides these speciﬁc signals, various secreted proteases (e.g. matrix metalloproteases), lipid
mediators (e.g. ceramide or gangliosides) or reactive oxygen species can contribute to bystander
death of neurons (Chao et al., 1995; Nakajima et al., 2002; Brown and Bal-Price, 2003; Kraft and
Harry, 2011; Taetzsch and Block, 2013). Especially the equimolar production of superoxide and NO
from glial cells can lead to high steady state levels of peroxynitrite, which is a very potent cytotoxicant
(Yuste et al., 2015). Already damaged neurons, with an impaired antioxidant defence system, are
more sensitive to such mediators.
An important role of microglia in the brain is the removal of cell debris (Xu et al., 2015). Healthy
cells continuously display anti-‘eat me’ signals, while damaged and stressed neurons/neurites display
‘eat-me’ signals that may be recognised by microglia as signal to start phagocytosis (Neher et al.,
2012), thus accelerating the loss of DA neurites in the striatum.
Activated microglia surrounding DAergic neurons in PD express the M1 neurodegenerative
phenotype (Hunot et al., 1999), which promote proliferation and function of CD4+ T cells (for review
Appel et al., 2010), which in turn induce DA neuron toxicity, as assessed by experiments with
immunodeﬁcient mice (Brochard et al., 2009). Possible inﬁltration of other myeloid cells, such as
monocytes or macrophages through a compromised blood-brain barrier, may also be involved in
phagocytosis and neurodegeneration (Depboylu et al., 2012; Pey et al., 2014).
A.5.2. Weight of evidence
A.5.2.1. Biological plausibility
Histopathological studies have shown that glial activation is a hallmark of every neurodegenerative
disease, including Parkinson’s disease (Whitton, 2007; Tansey and Goldberg, 2009; Niranjan, 2014;
Verkhratiky et al., 2014). PET studies in PD patients have revealed that microglial activation in the
substantia nigra is an early event in the disease process (Iannaccone et al., 2012), and that it is
extremely persistent. The role of astrocytes is less clear than the one of microglia, but reactive
astrocytes are able to release neurotoxic molecules (Mena and Garcia de Ybenes, 2008; Niranjan,
2014). However, astrocytes may also be protective due to their capacity to quench free radicals and
secrete neurotrophic factors. The activation of astrocytes reduces neurotrophic support to neurons,
and the proportion of astrocytes surrounding dopaminergic neurons in the substantia nigra is the
lowest for any brain area suggesting that dopaminergic neurons are more vulnerable in terms of glial
support (for review, Mena and Garcia de Ybenes, 2008).
In vitro co-culture experiments have demonstrated that reactive glial cells (microglia and
astrocytes) can kill neurons (Chao et al., 1995; Brown and Bal-Price, 2003; Kraft and Harry, 2011;
Taetzsch and Block, 2013), and that interventions with e.g. i-NOS inhibition can rescue the neurons
(Yadav et al., 2012; Brzozowski et al., 2015). Direct activation of glial cells with the inﬂammogen LPS
has also resulted in vivo in the death of DA neurons (Li et al., 2009; Zhou et al., 2012; Sharma and
Nehru, 2015).
Circulating monocytes and lymphocytes
Neuroinﬂammation can disrupt blood-brain barrier integrity (Zhao et al., 2007), facilitating
inﬁltration of circulating monocytes and lymphocytes (Qian et al., 2010; Machado et al., 2011). T cell
inﬁltration has been found in CNS tissue of PD patients (Miklossy et al., 2006; Qian et al., 2010), and
in animal models, in which depletion or inactivation of lymphocytes has been found to protect striatal
DA terminals (for review, Appel et al., 2010).
A.5.2.2. Empirical support for linkage
LPS injections
Lipopolysaccharide (LPS, a known activator of microglia) injected into the substantia nigra
successfully replicated the pathogenic features of Parkinson’s disease in rats. An increase in the mRNA
expression of pro-inﬂammatory cytokines (TNF-alpha, IL-1 beta) was observed 7 days post-injection;
alterations in oxidative stress markers (ROS, lipid peroxidation, NO formation, NADPH oxidase activity,
GSH system, SOD and catalase) became signiﬁcant 14 days post-injection, and this was followed by a
signiﬁcant decline in tyrosine hydroxylase (TH), as marker of dopaminergic neurons (Sharma and
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Nehru, 2015). LPS-induced downregulation of TH expression seemed to depend on the pro-
inﬂammatory cytokine IL-1 beta, since it was not observed in LPS-injected IL-1 knockout mice (Tanaka
et al., 2013).
Progressive hypokinesia, selective loss of dopaminergic neurons in substantia nigra and reduction of
striatal dopamine content, as well as alpha-synuclein aggregation in substantia nigra was also achieved
by unilateral intranasal instillation of LPS every other day for 5 months, mimicking a progressive
inﬂammation-mediated chronic pathogenesis of Parkinson’s disease (He et al., 2013). It is important to
note that LPS administrated either directly in the brain, intraperitoneally or in utero results in a delayed
and progressive loss of nigral DA neurons that persists well after the initial inﬂammatory stimulus (for
review, Taetzsch and Block, 2013).
Rotenone
Chronic systemic rotenone exposure reproduces features of Parkinson’s’ disease with loss of DA
neurons and putative Lewis bodies in substantia nigra, accompanied by neuroinﬂammation and oxidative
stress, and reduction of TH immunoreactivity in striatum together with an increase in reactive astrocytes
(Betarbet et al., 2000; Ferris et al., 2013). In this chronic rotenone model (2–3 mg/kg per day up to
4 weeks), microglia activation precedes neuronal death (Sherer et al., 2003). Several interventions
aiming at blocking several features of microglial activation (NADPH oxidase, myeloperoxidase,
phagocytosis, opening of KATP channels, etc.) protected DA neurons from death (Gao et al., 2003; Zhou
et al., 2007; Chang et al., 2013; Emmrich et al., 2013; Salama et al., 2013; Wang et al., 2014). An
enhanced sensitivity of dopaminergic neurons to rotenone-induced toxicity was observed with aging, in
parallel with the increase of glial cell activation in older rats (Phiney et al., 2006).
In vitro, little neurotoxicity was detected in primary DA neuron cultures (low glia-content) exposed
to rotenone, whereas signiﬁcant and selective dopaminergic neurodegeneration was observed in
neuron/glia cultures (Gao et al., 2002).
MPTP/MPP+
Following MPTP treatment, microglial cells are activated by a mechanism secondary to
dopaminergic neuron injury (Zhou et al., 2005). However, elevation of interferon-gamma and TNFalpha
in substantia nigra was detected before the death of DAergic neurons (Barcia et al., 2011); and serum
levels of INF-gamma and TNFalpha remain elevated for years in monkeys exposed to MPTP (Barcia
et al., 2011). The role of microglia in the progression of DA neurodegeneration is suggested by in vivo
and in vitro experiments in which feature of microglial reactivity (TNF-alpha, i-NOS, NADPH-oxidase,
ROS generation) were blocked (Dehmer et al., 2000; Feng et al., 2002; Sriram et al., 2002; Ferger
et al., 2004; Wang et al., 2006; Chung et al., 2011; Bodea et al., 2014; Borrajo et al., 2014; Wang
et al., 2014; Brzozowski et al., 2015; Liu et al., 2015). Some evidence from above studies also extends
to astrocytes (Sathe et al., 2012; Khan et al., 2014). For instance, systemic administration of nicotine
(stimulating the anti-inﬂammatory role of alpha 7 nicotinic acetylcholine receptors on astrocytes and
microglia) reduced MPTP-induced motor symptoms, and protected against neurodegeneration in the
substantia nigra by (Liu et al., 2012, 2015).
Entrance into the brain of bone marrow-derived cells expressing i-NOS may also play a deleterious
role in neurodegeneration (Kokovay and Cunningham, 2005). Indeed, pharmacological inhibition or
deletion of CD95 in peripheral myeloid cells hampered brain inﬁltration and was protective for MPTP-
induced DA loss in striatum (Chung et al., 2015; Gao et al., 2015). Similarly, therapies aiming at
suppressing immune reactivity, such as administration of Treg cells (CD4+ CD25+ regulatory T cells)
lead in MPTP treated mice, to a robust nigrostriatal protection associated to an inhibition of microglial
reactivity (Reynolds et al., 2010).
Paraquat
Paraquat alone (10 mg/kg, 2x/week, for 4 weeks) or in combination with maneb (30 mg/kg)
induces a loss of DAergic neurons in the substantia nigra paralleled by an increase in microglial
reactivity (Cicchetti et al., 2005; Mitra et al., 2011). In a paraquat rat model, microglial reactivity was
observed 4 weeks post-injection, whereas degeneration of DAergic neurons was only observed
2 weeks later (Sant-Pierre et al., 2006).
Direct treatment of primary microglial cells with paraquat (5–15 lM) showed no morphological
change and no upregulation of IL-10, IL-1beta, IL-2, IL-4, TNF-alpha, GM-CSF or INF-gamma,
suggesting that paraquat cannot activate directly microglial cells (Klintworth et al., 2009), despite
contrasting observations in the microglial cell lines BV2 (Miller et al., 2007) or N9 (Bonneh-Barkay
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et al., 2005). But « priming » of microglial cells by a ﬁrst exposure to paraquat (10 mg/kg) (Purisai
et al., 2007), by LPS (2–4 mg/kg) (Purisai et al., 2007), or by a viral mimic (Bobyn et al., 2012)
increased the vulnerability of DA neurons to further paraquat treatments. Interestingly, if minocycline
(45 mg/kg), an antibiotic known to decrease microglial reactivity, was applied together and after the
ﬁrst priming paraquat treatment, subsequent exposure to paraquat failed to cause DA
neurodegeneration (Purisai et al., 2007). If paraquat treatments were made in mice lacking functional
NADPH oxidase, no DA neurodegeneration was detected (Purisai et al., 2007), identifying again
NADPH-oxidase as a key factor (Wu et al., 2005).
In particular, the NADPH oxidase isoform NOX2 located on microglia plasma membranes transfers
electrons to paraquat inducing the formation of the paraquat radical cation (Rappold et al., 2011).
Radical paraquat may then (i) react with oxygen efﬁciently producing superoxide and regenerating
paraquat, and/or (ii) enter DA neurons being a substrate for the dopamine transporter (DAT) (Rappold
et al., 2011). This second possibility is supported by the observation that cells expressing DAT
efﬁciently uptake paraquat only in the presence of microglia, but not when NOX2 activity is speciﬁcally
abolished (Rappold et al., 2011). Neurodegeneration may be then triggered (i) by the ampliﬁcation of
the extracellular redox signalling (Bonneh-Barkay et al., 2005; Purisai et al., 2007) and/or (ii)
establishing a new round of redox cycling once paraquat is taken up into DA neurons. Accordingly,
expression of DAT sensitise HEK293 cells to paraquat (50 microM) induced intracellular ROS production
and cell death as well as mutant mice with hypomorphic DAT are resistant to paraquat neurotoxicity
(Rappold et al., 2011).
Besides NADPH-oxidase, other inﬂammatory factors are involved in DA neurodegeneration: for
example, iNOS, NF-kappaB or p38 MAPK, since their blockade reverted the 50% decrease of TH
immunoreactivity, as well as IL1-beta and NO increased expression in striatum observed following
paraquat or paraquat and maneb treatments (Yadav et al., 2012). Similarly, IFN-gamma silencing
prevented the paraquat-induced morphological signs of microglial activation, the NADPH-oxidase
expression, as well as the time-dependent changes in the pro-inﬂammatory enzymes i-NOS and COX-2,
of cytokines (IL-1beta, TNF alpha), and of signalling molecules (JNK and p38 MAPK), and protected
against paraquat-induced DA neurodegeneration (Mangano et al., 2012).
Protection against paraquat-induced DA neurodegeneration can also be achieved by providing
trophic support (intranigral or peripheral injection of GDNF or GM-CSF, respectively), which is reduced
upon paraquat treatment (Mangano et al., 2011).
A.5.3 Uncertainties or inconsistencies
• Mice deﬁcient in microglia (depletion by a ganciclovir-thymidine kinase system under the
CD11b promoter) were still susceptible to MPTP toxicity, while mixed cell cultures prepared
from these deﬁcient mice showed partial protection (Kinugawa et al., 2013).
• Although some publications show strong protection by COX-2 inhibition/deletion, others showed
that mice deﬁcient for COX-2 were partly protected against MPTP-induced decrease of DAergic
neurons in substantia nigra, but not against DA terminal loss in striatum (Feng et al., 2000).
• Mice deﬁcient in IL6 (IL6/) showed an increased vulnerability of the nigrostriatal pathway
following MPTP treatment associated to a normal astrogliosis but a transient microgliosis,
suggesting that transient microgliosis and IL6 may have also protective effects (Cardenas and
Bolin, 2003).
• MMTV integration site 1 (Wnt 1) is a key transcript involved in DAergic neurodevelopment, and
is dynamically regulated during MPTP-induced DA degeneration and glial activation. MPTP-
activated astrocytes of the ventral midbrain were identiﬁed as candidate source of Wnt 1 by
in situ hybridisation and RT-PCR in vitro, suggesting that reactive astrocytes may be rather
involved in neuroprotective/neurorescue pathways, as further demonstrated by deletion of Wnt
1 or pharmacological activation of Wnt/catenin signalling pathway (L’Episcopo et al., 2011).
• The role of microglia, NADPH-oxidase and oxidative stress in paraquat-induced
neurodegeneration is well established. Nevertheless, the mechanism connecting these three
elements remain poorly understood since direct evidence for extracellular and/or intracellular
formation of radical paraquat and superoxide is controversial.
• Rotenone (1–3 nM) applied directly on BV2 microglial cells increased their phagocytosis and
the release of pro-inﬂammatory cytokines (TNF-alpha, IL-1 beta), suggesting that microglial
cell can also be a primary target of rotenone (Zhang et al., 2014). However, these results in a
transformed microglial cell line contrast with the experiments performed on isolated primary
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microglial cells, where rotenone (10–50 nM) was not able to trigger a direct activation
(Klintworth et al., 2009).
• The regulation of inducible nitric oxide synthase (for production of peroxynitrite) differs
strongly between rodents and human, and thus, the role of NO in human remains unclear
(Ganster et al., 2001).
• While in human long-term use of anti-inﬂammatory drugs (NSAIDs, aspirin, iboprufen) for
preventing PD onset or for slowing the progression is still controversial, a new strategy is
emerging aiming at targeting microglial cells by modulating their activity, rather than simply
trying to counteract their inﬂammatory neurotoxicity. The advantage of this therapeutic
approach could be to reduce neuroinﬂammation and neurotoxicity, while at the same time
strengthening intrinsic neuroprotective properties (Pena-Altamira et al., 2015)
A.5.4. Quantitative relationship
As it is rather the features and the duration of the inﬂammatory response that determine the extent
of the nigrostriatal pathway neurodegeneration, the best way to propose a quantitative or
semiquantitative evaluation of the links between KEup and KEdown is to use studies where any feature
of neuroinﬂammation is inhibited and to quantify the protection of the Daergic neurons and terminals.
Thus it will give an evaluation of how much neurodegeneration depends on the neuroinﬂammatory
process. Below are some examples for illustration.
Table A.4: Quantitative evaluation of the KER
KE upstream
Neuroinﬂammation
KE downstream
Neurodegeneration of
dopaminergic
nigrostriatal pathway
Reference Type of study Comment
Inhibition of any feature of
neuroinﬂammation
(microglia/astrocyte)
How much nigrostriatal
pathway degeneration
depends on KEup as
assessed by protection when
any KEup feature is inhibited
KATP channel opener
(iptakalim) induced
decrease of TNF-alpha and
COX2 mRNA expression and
TNF-alpha content, as well
as microglial reactivity
(OX42, ED1)
TH immunoreactivity: Total
recovery
Zhou et al. (2007) In vivo
Rotenone
2.5 mg/kg per
day + in vitro
NADPH oxidase
Neuron enriched cultures
Neuron-Glia co-cultures
+apocynin
DA uptake
TH immunoreactivity
About 50% more neuronal
death in the presence of glia
(80% of protection with
apocynin)
Gao et al. (2002) In vitro
Rotenone
5–20 nM
NADPH oxidase
Mice knockout for NADPH
ox gp91/
Co-culture neuron-glia
DA uptake: 40% protection
TH immuno: 20% protection
Gao et al. (2003) In vitro
Rotenone
5–10 nM
Phagocytic signalling
between neuron and
microglia i.e. block of
vitronectin and P2Y6 on
microglia or annexin or
phophatidylserine on
neuron (eat-me signal)
About 20% neuronal
protection
Emmrich et al.
(2013)
In vitro
Co-cultures of
cerebellum
Rotenone
2.5 nM
Decrease in the number
of activated microglia by
L-thyroxin in substantia
nigra, not in striatum
Protection of DA terminals in
striatum, but no effect in
substantia nigra
Salama et al.
(2012)
In vivo
Rotenone
3 mg/kg per
day
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KE upstream
Neuroinﬂammation
KE downstream
Neurodegeneration of
dopaminergic
nigrostriatal pathway
Reference Type of study Comment
Myeloperoxidase
(HOCl from H2O2)
Resveratrol decreased NO,
ROS, phagocytosis in
microglia and astrocytes
Protection of neuron: 40%
cell viability
50–60% TH
immuno + number of
dendrites
Chang et al. (2013) In vitro
Rotenone 30 nM
MPP+ 0.1 lM
NADPH oxidase: NOX2
Diphenyleneiodonium: long
acting NOX2 inhibitor
DA uptake and TH immuno:
30–40% of protection
Wang et al. (2014) In vitro
LPS 20 ng/mL
MPP+ 0.15 lM
Control of microglial and
astrocyte reactivity by
Alpha 7 nicotinic Ach
receptor present on
microglia and astrocyte
Its activation decreased
microglial and astrocyte
reactivity
MPP+ caused 40% decrease
of TH+ neurons
Nicotine induced a 30%
recovery
Liu et al. (2012,
2015)
In vivo
MPTP 20 mg/kg
Nicotine
5 mg/kg
In vitro on
isolated
microglia and
astrocytes
TNF-alpha of microglial
origin
By blocking angiotensin-1
receptors, NADPH-oxidase,
Rho-kinase and NF.kB
20% of recovery of TH
immunoreactivity
Borrajo et al.
(2013)
In vitro + in vivo
MPP+ 0.25 lM
Infusion of the anti-
inﬂammatory cytokine
TGF beta protects from
MPP+-induced cell loss by
decreasing CD11b, i-NOS,
TNFalpha, IL+ beta, and
increasing IGF-1. Silencing
of TGFbR1 gene abolished
the protective effect
MPP+ caused 60% decrease
of TH immuno, and TGFbeta
induced a dose-dependent
recovery (5–20 ng/mL)
Liu et al. (2015) In vitro
Co-cultures
MPP+ 5 lM
Indirect
i-NOS inhibition caused a
decrease of astrocyte and
microglial reactivity as
assessed by GFAP and OX6,
respectively
(n-NOS inhibition had no
effect)
TH immunoreactivity
Dose-dependent recovery
with 1,400 W (0.1–100 lM)
Brzozowski et al.
(2015)
In vitro
MPP+
43 lM
Inhibition of laminin
receptor on microglia
i.e. regulating cell-ECM
interactions induced a
decrease of microglia
phagocytosis and of O2

production
Dose-dependent partial
recovery (about 35% of TH
immunoreactivity
Wang et al. (2006) In vitro
MPP+
0.1–0.5 lM
Inhibition of glial
activation-mediated
oxidative stress by
Fluoxetine, antidepressant)
30% of recovery of TH
immunoreactivity in
Substantia nigra and total
recovery of DA terminals in
striatum
Chung et al. (2011) In vivo
MPTP 20 mg/kg
i.p.
Mice lacking both TNFR
Induced a decrease of GFAP
in striatum
Double KO, if only KO for
TNFR1 or TNFR2, no
protection
TH staining in striatum, DA
content and GFAP staining,
all returned to control level
Sriram et al. (2014) In vivo
MPTP
12.5 mg/kg sc
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KE upstream
Neuroinﬂammation
KE downstream
Neurodegeneration of
dopaminergic
nigrostriatal pathway
Reference Type of study Comment
Mice-deﬁcient for COX2
Microglial cells are the
major cells expressing COX2
MPTP caused in substantia
nigra
40% loss in wild type
45% loss in COX1/
20% loss in COX2/
in striatum
70% loss of DA in all 3 types
of mice
Feng et al. (2002) In vivo
MPTP 20 mg/kg
sc
S100B/ in astrocytes
caused decreased
microgliosis, TNF-alpha and
RAGE
12% of protection for TH+
neuron
30% of protection for Nissl-
labelled neurons
Sathe et al. (2012) In vivo
MPTP 30 mg/kg
i.p.
Glia Maturation Factor
(GMF) overexpression or
GMF/
showed decreased TNF-
alpha, IL-1beta, ROS and
NFkappaB downregulation
Overexpression of GMF
exacerbate DA neuron
degeneration
GMF/ induced a
protection of 40% of TH+
neurons
Khan et al. (2014) In vitro
Mesencephalic
neuron/glia
cultures
MPP+
5, 10, 20 lM
Pharmacological
inhibition or deletion of
CD95 in peripheral
myeloid cells
(monocytes, macrophages,
microglia, leucocytes)
hampered inﬁltration in the
brain of peripheral myeloid
cells
Total preservation of DA
level in striatum
Total protection of TH+
neurons in S. nigra (25%
affected in wild type mice)
Gao et al. (2015) In vivo
MPTP 30 mg/kg
i.p.
Glucocorticoid receptor
(GR) deletion in
microglia
increased their reactivity
and induced a persistent
activation
2X aggravation of TH+
neuronal loss in S. nigra
Ros-Bernal et al.
(2011)
In vivo
MPTP 20 mg/kg
i.p.
TNF/ mice No protection in substantia
nigra
TH density in striatum:
return to control level
Ferger et al. (2004) In vivo
MPTP
20 mg/kg i.p.
Intra-venous
transplantation of
mesenchymal stem cells
Cell migration in substantia
nigra and release of
TGFbeta (anti-inﬂammatory)
Reparation of BBB,
decreased inﬁltration and
microglial activation
About 15% protection of
TH+ neurons in S. nigra
Chao et al. (2009) In vivo
MPTP 20 mg/kg
i.p.
Nrf2/
Increase in microgliosis and
astrogliosis
Microglial M1 phenotype
Nrf2 involved in tuning
microglial activation, switch
M1/M2 phenotypes
40% more DA neurons loss
in substantia nigra (TM
immunostaining)
Rojo et al. (2010) In vivo
MPTP 20 mg/kg
i.p.
Indirect
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Evidence Supporting Taxonomic Applicability
Rodent models have been mainly used to study the impact of neuroinﬂammation on DAergic
nigrostriatal pathway degeneration, without any sex restriction. Neuroinﬂammation preceding neuronal
death was detected in monkeys exposed to MPTP (Barcia et al., 2011); and in human,
neuroinﬂammation is considered as an early event in the disease process (Innaccone et al., 2012).
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6th KER: Degeneration of dopaminergic neurons of the nigrostriatal
pathway directly leads to neuroinﬂammation
A.6.1. How does this KER work?
Several chemokines and chemokines receptors (fraktalkine, CD200) control the neuron-microglia
interactions and a loss of this control on the side of neurons can trigger microglial reactivity without
any further positive signal required (Chapman et al., 2000; Streit et al., 2001; Blank and Prinz, 2013).
Upon neuronal injury, signals termed ‘Damage-Associated Molecular Patterns (DAMPs)’ are released by
damaged neurons to promote microglial reactivity (Marin-Teva et al., 2011; Katsumoto et al., 2014).
These are for instance detected by Toll-like receptors (TLRs) (for review, see Hayward and Lee, 2014).
TLR-2 functions as a master sensing receptor to detect neuronal death and tissue damage in many
different neurological conditions including nerve transection injury, traumatic brain injury and
hippocampal excitotoxicity (Hayward and Lee, 2014). Astrocytes, the other cellular actor of
neuroinﬂammation besides microglia (Ranshoff and Brown, 2012) are also able to sense tissue injury
via e.g. TLR-3 (Farina et al., 2007; Rossi, 2015), and neuronal injury can result in astrocytic activation
(Efremova et al., 2015).
A.6.2. Weight of evidence
A.6.2.1. Biological Plausability
Kreutzberg and co-workers (1995, 1996) showed that neuronal injury generally leads to activation
of microglia and astrocytes. This is a general phenomenon: for instance it is always observed in
ischaemic damage (stroke; often in the form of glial activation following neuronal injury (Villa 2007))
as well as in stab or freeze injuries (Allahyari and Garcia, 2015). It is also observed regularly when
neurons are killed by highly speciﬁc neurotoxicants that do not affect glia directly, such as injection of
quinolinic acid or of 6-hydroxydopamine into the striatum (Hernandez-Baltazar et al., 2013; Arlicot
et al., 2014). The vicious circle of neuronal injury triggering glial activation and glial activation
triggering/enhancing neurodegeneration is often assumed to be a key element in the pathogenesis of
neurodegenerative diseases, not just PD, but also (Alzheimer’s disease, prion disease and many
others) (Grifﬁn et al., 1998; McGeer and McGeer, 1998; Blasko et al., 2004; Cacquevel et al., 2004;
Hirsch and Hunot, 2009; Tansey and Goldberg, 2009; Barbeito et al., 2010; Rubio-Perez and Morillas-
Ruiz, 2012; Thundyil and Lim, 2014).
A.6.2.2. Empirical support for linkage
MPP+
The chemokine fractalkine (regulating neuron-glia interactions) was found to be released by
neurons after unilateral injection of MPP+ in substantia nigra. It induced microglial activation by
binding on the microglial receptor CXCR1 (Shan et al., 2011). Similarly, in chronically MPTP-injected
PPPs, Parkinson’s disease and childhood leukaemia
www.efsa.europa.eu/efsajournal 165 EFSA Journal 2017;15(3):4691
macaques, metalloproteinases-9 (MMP-9) released by injured neurons favour glial activation (Annese
et al., 2015). Advanced glycation endproducts (AGEs), which are endproducts of reactions involving
ROS, colocalised with DAergic neurons 2 days post last MPTP injection, suggesting neuronal injury
(Teismann et al., 2012). In contrast, the receptors for AGEs (RAGEs) were found on microglial cells
and astrocytes (Teismann et al., 2012). RAGE can activate NF-kappaB, the transcription factor involved
in the inﬂammatory response (Abdelsalam and Safar, 2015). Ablation of RAGE proved to be protective
against MPTP-induced decreases of TH+ neurons, by decreasing NF-kappaB p65 nuclear translocation
and by mitigating microglia and astrocyte reactivities (Teismann et al., 2012).
Rotenone
Rotenone-induced neurotoxicity was less pronounced in neuron-enriched cultures, than in neuron-
glia co-cultures (Gao et al., 2002), suggesting that neuron-glia interactions are critical for rotenone-
induced neurodegeneration. Indeed, CD200-CD200R signalling regulates neuron-glia interactions and
holds microglia in a quiescent state (Biber et al., 2007). Therefore, inhibition of CD200R by blocking
antibodies increased rotenone-induced DA neurotoxicity in neuron-glia mesencephalic cocultures
(Wang et al., 2011). Ageing is associated with a decrease of CD200 expression (Wang et al., 2011)
and deﬁcits in neuronal CD200 production is also observed in several animal models of Parkinson’s
disease (Wang et al., 2011; Zhang et al., 2011; Sung et al., 2012). Inhibition of RAGE, which is
upregulated in the striatum following rotenone exposure and in response to neuroinﬂammation,
decreases rotenone-induced apoptosis by decreasing mitochondrial cytochrome c release and caspase-
3 activation and suppresses NF-kappaB activation, as well as the downstream inﬂammatory markers
TNF-alpha, i-NOS and myeloperoxidase (Abdelsalam and Safar, 2015), showing again intermingled links
between neuronal injury/death and neuroinﬂammation.
Paraquat
Non-lethal neuronal damage is sufﬁcient to trigger neuroinﬂammation: in 3D rat brain cell cultures,
repeated treatment with concentrations of paraquat that did not kill the neurons, microglia and
astrocytes were activated (Sandstrom von Tobel et al., 2014). Paraquat alone (10 mg/kg, 2x/week, for
4 weeks) or in combination with maneb (30 mg/kg) induces a loss of DAergic neurons in the
substantia nigra paralleled by microglial activation (Cicchetti et al., 2005; Mitra et al., 2011). Neuronal
injury is facilitated by uptake of paraquat via DA transporters (Rappold et al., 2011). In this model,
paraquat-induced neuronal perturbations are sufﬁcient to induce neuroinﬂammation, but then
neuroinﬂammation exacerbates the neurodegenerative process (Purisai et al., 2007).
A.6.3. Inconsistencies and uncertainties
Triggering of glia by injured neurons may not necessarily be due to the damage of neurons, but it
may also be due to released synuclein (Sanchez-Guajardo, 2010). In a AAV alpha-synucleinopathy
model, it was shown that cytoskeletal perturbation and accumulation of alpha-synuclein were sufﬁcient
to induce microglial reactivity, suggesting that neuroinﬂammation appears early in the disease process
and is not a result triggered by cell death (Chung et al., 2009). Direct effects of toxicants on glia
cannot be completely excluded. They have been reported for most toxicants in one or the other
publication (rotenone, paraquat, MPP+) (Brooks et al., 1989; Rappold et al., 2011; Zhang et al., 2014).
The overwhelming evidence speaks against such effects for rotenone and MPP+ (Klintworth et al.,
2009), but for paraquat there is evidence of direct interaction with microglial membrane NADPH
oxidase (Rappold et al., 2011).As paraquat has several MIE (Rappold et al., 2011; Czerniczyniec et al.,
2015), these may involve both neurons and microglia.
A.6.4. Quantitative relationship
Some examples of quantitative relationships between KEup and KEdown are given below. For KEdown
Neuroinﬂammation, only the features measured are cited, as neuroinﬂammation is a complex KE
involving several cell types and measured by changes in the expression /release of several markers
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Evidence Supporting Taxonomic Applicability
Beside the rodent models, the concept of vicious circle with neuronal injury leading to
neuroinﬂammation and neuroinﬂammation triggering or enhancing neurodegeneration is described in
several neurodegenerative diseases in human, without any sex restriction (Grifﬁn et al., 1998; McGeer
and McGeer, 1998; Blasko et al., 2004; Cacquevel et al., 2004; Hirsch and Hunot, 2009; Tansey and
Goldberg, 2009; Barbeito et al., 2010; Rubio-Perez and Morillas-Ruiz, 2012; Thundyil and Lim, 2014).
Aging is an aggravating factor and increases the risk for developing a neurodegenerative disease
(Kawas et al., 2000; Blasko et al., 2004).
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7th KER: Mitochondrial dysfunction leads to the degeneration of
dopaminergic neurons of the nigrostriatal pathway
A.7.1. How this key event relationship works
Neurons are characterised by the presence of neurites, the formation of action potentials, and the
release and re-uptake of neurotransmitters into the synaptic cleft. The presence of long extensions
implies a signiﬁcant enlargement of total cell surface. In combination with the transmission of action
potentials that require a continuous maintenance of active transport processes across the membrane,
the steady state energy demand of these neurons is signiﬁcantly higher compared with non-neuronal
cells. Dopaminergic (DA) neurons located in the substantia nigra pars compacta (SNpc) that project
into the striatum are unique with respect of the total length of their neurites and the number of
synapses that are signiﬁcantly higher compared with other neuronal cell types (Bolam et al., 2012).
Besides this complex morphology DA neurons have a distinctive physiological phenotype that could
contribute to their vulnerability (Surmeier et al., 2010). Other features such as high energy demand,
high calcium ﬂux, dopamine autoxidation process as well as high content of iron and high content of
microglia makes these DA neurons at vulnerable population of cells to oxidative stress produced by
mitochondrial dysfunction. These architectural features of SNpc DA neurons render this cell type as
particularly vulnerable to impairments in energy supply. Mitochondrial dysfunction, either evoked by
environmental toxins such as the complex I inhibitor rotenone or MPTP, by oxidative modiﬁcations of
components of the mitochondrial respiratory chain, or by genetic impairments of mitochondrial ATP
generation hence have direct inﬂuence on the function and integrity of SNpc DA neurons.
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A.7.2. Weight of evidence for the KER
A.7.2.1. Biological plausibility
Mitochondria are organelles essentials for multiple cellular processes, including production of ATP,
maintenance of calcium homeostasis, management of ROS production and apoptosis. Mitochondrial
dynamics are also critical for the maintenance of cellular homeostasis, which involve multiple factors
controlling mitophagy (Youle et al., 2012). Deregulation of mitochondrial functions may impact any
neuronal population; however, SNpc DA neurons are indeed the most vulnerable population in PD.
Multiple factors are related to their vulnerability: These include autonomous activity, broad action
potentials, low intrinsic calcium buffering capacity, poorly myelinated long highly branched axons and
terminal ﬁelds, and use of a catecholamine neurotransmitter, often with the catecholamine-derived
neuromelanin pigment (Surmeier et al., 2010; Sulzer et al., 2013).
The above mentioned factors imply a signiﬁcantly higher total cell surface and a high energy
requirement in order to maintain the re-distribution of ions across the membrane following an action
potential. In addition, SNpc DA neurons are characterised by signiﬁcantly higher numbers of synapses
compared with other neuronal types or with DA neurons of different anatomical localisations (Anden
et al., 1966; Kawaguchi et al., 1990; Kita et al., 1994; Bevan et al., 1998; Wu et al., 2000; Tepper
et al., 2004). In humans, ca. 10 times higher numbers of synapses compared with rats are expected,
making human DA neurons particularly vulnerable (Matsuda et al., 2009; Bolam et al., 2012). These
extreme bioenergetics demands pose SNpc DA neurons energetically ‘on the edge’. Any stressor that
might perturb energy production would hence lead to conditions under which the energy demand
would exceed energy supply, resulting in cell damage and ultimately to cell death
The mechanistic link between mitochondrial dysfunction and loss of SNpc DA neurons also comes
from evidence of mutated proteins related to mitochondrial function in familial PD, resulting in reduced
calcium capacity, increased ROS production, increase in mitochondrial membrane permeabilisation and
increase in cell vulnerability (Gandhi et al., 2009; Koopman et al., 2012). In addition, excessive ROS
production can damage mitochondrial DNA and activate the intrinsic pathway of apoptosis (Tait et al.,
2010). Additional sources of oxidative stress come from the autoxidation of dopamine and the active
generation of ROS by activated glia cells; however, the mitochondrial respiratory chain itself represents
a source of constant superoxide formation, even under normal conditions (Moosmann et al., 2002).
Furthermore, imbalance of mitochondrial dynamics have been reported in a wide range of
experimental models of PD and inhibition of the mitochondrial ﬁssion proteins (i.e. Drp1) promote
mitochondrial fusion and ﬁssion and enhanced the release of dopamine from the nigrostriatal terminals
(Tieu et al., 2014).
Additional link between mitochondrial dysfunction and the degeneration of DA neurons of the
nigrostriatal pathway comes from studies indicating a reduced activity of mitochondrial complex I in
human idiopathic PD cases in the substantia nigra (Parker et al., 1989, 2008; Swerdlow et al., 1996;
Keeney et al., 2006). The impairment in complex I activity was directly correlated with an elevated
sensitivity of SNpc DA neurons and their demise. Transfer of mitochondria from human platelets
collected from idiopathic PD subjects into ﬁbroblasts or neuronal cells resulted in elevated levels of
basal oxidative stress, a declined supply with ATP, and an elevated vulnerability towards exogenous
stressors such as the complex I inhibitors rotenone or the redox cycler paraquat (Swerdlow et al.,
1996; Gu et al., 1998). Systemic application of complex I inhibitors such as rotenone or MPTP lead to
a preferential loss of nigrostriatal DA neurons, while other brain areas or peripheral cells are not
affected to the same degree (Langston et al., 1983).
A.7.2.2. Empirical support for linkage
The experimental support linking mitochondrial dysfunction with the degeneration of DA neurons of
the nigrostriatal system is based on the analysis of mitochondria from PD patients, from genetic mouse
models, from in vitro knockdown and overexpression systems, and from in vitro and in vivo toxin
models.
• In vitro/rotenone: Prevention of ROS formation protects from cell death. The concept of
mitochondrial dysfunction as a consequence of defects in complex I has been fuelled by
observations of impaired complex I activity in the SNpc, muscle, and in platelets of PD
patients. Human neuroblastoma SK-N-MC cells, exposed to rotenone, displayed a time- and
concentration-dependent decline in viability. Transfection of rotenone-insensitive single subunit
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NADH dehydrogenase (NDI 1) allowed a replacement of endogenous complex I activity. NDI 1
transfected cells showed no oxidative damage, no declined mitochondrial activity, or cell death.
A signiﬁcant amount of endogenously formed ROS at complex I was identiﬁed in SK-N-MC cells
and in a chronic midbrain slice culture exposed to rotenone. Antioxidants such as a-tocopherol
prevented cell death evoked by rotenone, but not the rotenone-induced drop in ATP (Sherer
et al., 2003).
• In vitro/rotenone/MPP+: Antioxidants protect from rotenone/MPP+ cell death. Analysis of post
mortem nigrostriatal material from PD patients regularly revealed the presence of elevated
levels of oxidative modiﬁed proteins, lipids, and DNA. These observations indicate an elevated
formation of ROS in the cells affected by the disease and triggered the concept of antioxidants
as a potential intervention strategy to slow down the progression of PD. In MES23.5 cells, a
reduction in viability, DA content, NADH levels, as well as an increase in ROS formation and
elevated nuclear condensation was observed upon treatment with MPP+. Rosmarinic acid is
well known for its radical scavenging activities and displayed a complete protection from MPP+-
mediated cell death and rescued NADH levels. In addition, it lead to a partial protection from
the loss of DA and resulted in a rate of nuclear condensation that was about half of that
observed with MPP+ alone (Du et al., 2010).
• The ﬂavonoid rutin has been demonstrated to protect from oxidative stress in 6-OHDA induced
motor deﬁcits in rats as well as to inhibit the formation of nitric oxide and proinﬂammatory
cytokines (Khan et al., 2012). In a model of SH-SY5Y cells, exposure to rotenone lead to a
reduction in viability by ca. 50% that was almost completely protected in the presence of rutin.
Rotenone-dependent increase of ROS formation and an elevation of intracellular Ca2+ was
signiﬁcantly dampened by the presence of rutin, similar to its rescue from rotenone-dependent
decrease in mitochondrial membrane potential (Park et al., 2014).
• Comparable observations were made with the quinone triterpene celastrol that protected SH-
SY5Y cells exposed to rotenone almost completely from cell death, from a rotenone-dependent
elevation in ROS levels, and from a rotenone-dependent loss of the mitochondrial membrane
potential (Choi et al., 2014).
• In vitro/different complex I inhibitors: Inhibition of complex I triggers oxidant formation and
cell death. The majority of experimental PD studies were either conducted using rotenone or
MPP+. In order to demonstrate that the concept of complex I inhibition and its ROS-mediated
triggering of mitochondrial dysfunction and cell demise can be regarded as a general principle,
alternative complex I inhibitors were applied to substantiate previous observations made with
rotenone. In human SK-N-MC neuroblastoma cells, rotenone as well as the pesticides
fenazaquin, fenpyroximate, pyridaben, tebufenpyrad, pyridaben were tested. In all cases, a
time- and concentration-dependent decline in intracellular ATP and cell viability was observed.
Expression of the rotenone-insensitive NADH dehydrogenase from Saccharomyces cerevisiae
(NDI 1) prevented from the toxicity of the different complex I inhibitors completely. Rotenone-
and pyridaben-dependent cell death was prevented by ca. 75% by the presence of the
antioxidant a-tocopherol (Sherer et al., 2007).
• In vitro/rotenone: Mitochondrial dysfunction-dependent cell death is prevented by antioxidants.
In a human neuroblastoma SH-SY5Y model, exposed either to the complex I inhibitors MPP+ or
rotenone, the imine antioxidants iminostilbene, phenothiazine, phenoxazine in the low
nanomolar concentration range partially protected from MPP+ or rotenone toxicity. A reduction
in the membrane potential evoked by MPP+ and rotenone was completely prevented by these
antioxidants (Hajteva et al., 2009)
• In vitro/rotenone: Circumvention of dysfunctional mitochondria protects from cell death.
Assuming a direct causal relationship between complex I inhibition, mitochondrial dysfunction,
and the demise of DA neurons, the circumvention of endogenous complex I by expression of
the NADH dehydrogenase of Saccharomyces cerevisiae (NDI 1) provided initial evidence for
the essential role of complex I inhibition in this sequence of events. As an alternative electron
carrier, capable of transferring electrons from NADH to cytochrome c, methylene blue was
identiﬁed. In hippocampal HT-22 cells, a rotenone-mediated reduction in the oxygen
consumption rate was completely reversed by the addition of methylene blue. A rotenone-
mediated decline in cell viability by 70% was almost completely prevented by 0.1 lg/ml
methylene blue. In rats, rotenone-mediated decline in striatal DA was entirely prevented by
methylene blue, the observed elevation of ROS formation evoked by rotenone was reduced to
control levels, and rotarod performance impairments evoked by rotenone were completely
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avoided by administration of methylene blue. These observations illustrate a causal relationship
between dysfunctional mitochondria, the degeneration of nigrostriatal DA neurons, and
impaired motor performance (Wen et al., 2011).
• In vivo/rotenone: Circumvention of dysfunctional mitochondria prevents from nigrostriatal cell
degeneration. Circumvention of a dysfunctional complex I by the rotenone-insensitive NADH
dehydrogenase NDI 1 in vivo and its inﬂuence on nigrostriatal DA neuron integrity was
demonstrated in a rat model with an unilateral injection of a recombinant adeno-associated
virus, carrying the NDI 1 gene into close special vicinity to the SNpc. The animals were treated
with rotenone after the unilateral expression of NDI 1. NDI 1 almost completely prevented
from the rotenone-mediated loss of TH staining in the SNpc and the striatum. Striatal DA levels
that were reduced by ca. 50% by rotenone, in the presence of NDI 1, DA levels were also
almost identical to the values of untreated controls. These observations highlight a causal
relationship between the inhibition of complex I and the degeneration of nigrostriatal DA
neurons (Marella et al., 2008).
• In vitro/DA: Exogenously added oxidants lead to mitochondrial dysfunction and cell death.
Next to an elevated formation of reactive oxygen species evoked by endogenous defects in
complex I or in response to pharmacological inhibitors of complex I, nigrostriatal DA neurons
are characterised by the neurotransmitter dopamine and its tendency to undergo autooxidation
when exposed to physiological pH and oxygen tension conditions. To assess the role of
DA-mediated oxidative stress as a cause of mitochondrial dysfunction and its inﬂuence on cell
viability, PC12 cells were exposed to DA. The observed increase in intracellular ROS was
completely reversed by the presence of the antioxidant N-acetyl-cysteine (NAC). The amount
of oxidative modiﬁed protein increased by DA treatment, its rise was completely prevented by
the presence of NAC, and partially prevented by the presence of exogenously added GSH.
DA-dependent PC12 cell death, decline in the transmembrane potential and in intracellular ATP,
and decline in complex II/III activities were observed and were all completely prevented by
the presence of NAC. (Jana et al., 2011).
• In vitro/ GSH depletion: Oxidative stress causes mitochondrial dysfunction and
neurodegeneration. Several reports indicated a declined activity of complex I in the brain, but
also in muscle and platelets of PD patients. In order to investigate the mutual interaction between
pro-oxidative conditions and complex I activity, a PC12 subclone was generated, allowing the
inducible downregulation of c-glutamyl-cysteine synthase involved in the synthesis of glutathione
(GSH). This system allows a controlled decrease of intracellular GSH by ca. 50% and a decrease
in mitochondrial GSH by ca. 40%. Under these conditions, intracellular and intramitochondrial
ROS increased by ca. one third, mitochondrial complex I activity and ATP levels were reduced by
ca. two thirds. The observed inhibition of complex I was completely reversed by DTT. These
observations indicate that an impairment of complex I activity as a key event in the initiation of
mitochondrial dysfunction and ultimately cell death, can be evoked by elevated levels of oxidants,
respectively by a declined cellular antioxidant capacity (Jha et al., 2000).
• In vitro/ GSH depletion: Oxidative stress causes mitochondrial dysfunction and
neurodegeneration. PD is characterised by the depletion of glutathione (GSH) in the SNpc.
Declined cellular levels of GSH were reported to be associated with morphological changes of
mitochondria (Perry et al., 1982; Jain et al., 1991). To investigate the inﬂuence of declined GSH
levels, N27 cells were exposed to buthionine-S-sulfoximine (BSO), an inhibitor of glutamate
cysteine ligase and hence of de novo GSH synthesis. The BSO concentration chosen allowed a
reduction in intracellular GSH levels by 50% in the absence of cell death. Chronic GSH depletion
resulted in the S-nitrosation of complex I and its inhibition. Both effects were completely reversed
by the addition of DTT (Chinta et al., 2006).
• Isolated mitochondria: Exogenous oxidants cause mitochondrial dysfunction. In order to
further address the aspect on how DA autoxidation contributes to mitochondrial dysfunction
and DA neurodegeneration, isolated rat brain mitochondria were exposed to DA, resulting in an
inhibition of complex I by ca. 30% and in an inhibition of complex IV by ca. 50%. Both
activities of complex I and complex IV were completely protected from DA-dependent
inactivation by the presence of GSH. These observations point to a direct inhibitory action of
endogenous DA and its autoxidation derivatives on the activity of the mitochondrial respiratory
chain. (Khan et al., 2005)
• In vitro/cybrid cells: Sensitisation of neuronal cells for degeneration by transfer of dysfunctional
mitochondria. In a subclone of human neuroblastoma cells (SH-SY5Y), devoid of mitochondrial
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DNA, mitochondria from platelets of PD patients were transplanted. Analysis after 5–6 weeks in
culture after transplantation of mitochondria indicated a 20% reduction in complex I activity, a
twofold increase in the basal formation of reactive oxygen species, and a ca. twofold higher
sensitivity towards the mitochondrial PD toxin MPP+ (Swerdlow et al., 1996)
• In vitro/cybrid cells: Sensitisation of neuronal cells for degeneration by transfer of dysfunctional
mitochondria. In a subclone of the human A549 cell line, devoid of mitochondrial DNA,
mitochondria of platelets from PD patients were transplanted. Complex I activity in platelets of
PD patients displayed a reduction of 25% compared with age-matched controls. After
transplantation into the A549 cells, complex I activity was reduced by 25% in its activity (Gu
et al., 1998)
• In vivo: Induction of mitochondrial dysfunction by Drp1 deletion leads to neuronal cell loss.
Maintenance of functional mitochondria in a cell is regulated by ﬁssion/fusion processes that
allow the elimination of damaged mitochondria and the spreading of intact mitochondria.
Deletion of the central ﬁssion protein dynamin related protein 1 (Drp1) leads to an elimination
in DA neuron terminals in the caudate putamen and to a loss of DA neuron cell bodies in the
midbrain. In Drp1 deﬁcient mice, mitochondrial mass decreases, particularly in axons (Berthet
et al., 2014)
• In vivo: Induction of mitochondrial dysfunction by Tfam knockdown leads to neuronal cell loss.
Mitochondrial transcription factor A (Tfam) is a key regulator of mitochondrial biogenesis.
Conditional knockout mice with a selective disruption of the gene for mitochondrial Tfam in DA
neurons indicated a reduction in mtDNA levels and deﬁciencies in the respiratory chain in
midbrain DA neurons that progressed to DA cell death. The demise of DA neurons in the SNpc
was associated with the onset of PD symptoms such as a reduction in locomotor activity of
these mice by ca. 30%. The decrease in locomotor activity was reversed by L-DOPA treatment
(Ekstrand et al., 2007)
• In vivo: MPTP dependent mitochondrial dysfunction and cell death is protected by PGC-1a
overexpression. Peroxisome proliferator-activated receptor gamma coactivator 1a (PGC-1a) is a
key regulator of mitochondrial biogenesis and metabolism. Transgenic mice overexpressing
PGC-1a show protection against MPTP intoxication (50%). The SNpc in these mice is
characterised by elevated levels of SOD2, Trx2. Resveratrol is a known activator of SIRT1,
leading to enhanced PGC-1a gene transcription. In MPTP mice, resveratrol protected
TH-positve neurons by 80% from cell loss (Mudo et al., 2012)
• In vivo: Prevention of mitochondrial dysfunction protects from nigrostriatal cell loss. In order to
demonstrate the causative connection between complex I-dependent mitochondrial dysfunction
and the degeneration of DA neurons, a series of in vivo experiments were conducted that
indicated partial restoration by antioxidants or by compounds supporting a dysfunctional
mitochondrial ATP generation. In MPTP challenged mice that additionally received Q10
treatment, a 37% higher striatal DA level compared with the MPTP group was detected. TH
positive staining in the striatum dropped by ca. 65% after MPTP. In the MPTP + Q10 group,
the loss in striatal TH staining was reduced to ca. 40% compared with the untreated controls.
(Beal et al., 1998).
• In MPTP challenged marmosets, TH positive cell body numbers were reduced by ca. 60%, co-
administration with ebselen resulted in a reduction of TH staining of only ca. 25% (Moussaoui
et al., 2000).
• In MPTP challenged mice, a reduction of striatal DA by ca. 70% was detected. Cotreatment
with creatine resulted in a reduction of DA levels of only 42%. In the same setup, TH positive
neuron number in the SNpc was reduced by 70% in response to MPTP, in the presence of
creatine, a drop of only 4% was observed (Matthews et al., 1999).
• In vivo/rotenone: Antioxidants prevent from rotenone-dependent nigrostriatal cell death.
Rotenone administered subcutaneously for 5 weeks (2.5 mg/kg per day) caused a selective
increase in oxidative damage in the striatum as compared to the hippocampus and cortex,
accompanied by massive degeneration of dopaminergic neurons in the substantia nigra.
Antioxidant polydatin (Piceid) treatment signiﬁcantly prevented the rotenone-induced changes
in the levels of glutathione, thioredoxin, ATP, malondialdehyde and the manganese superoxide
dismutase (SOD) in the striatum, conﬁrming that rotenone-induced mitochondrial dysfunction
resulted in oxidative stress (Chen et al., 2015).
• In vivo/rotenone: Degeneration of DA neurons depends on oxidative stress evoked by
mitochondrial dysfunction. Many studies have shown that mitochondrial aldehyde dehydrogenase
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2 (ALDH2) functions as a cellular protector against oxidative stress by detoxiﬁcation of cytotoxic
aldehydes. Dopamine is metabolised by monoamine oxidase to yield 3,4-
dihydroxyphenylacetaldehyde (DOPAL) then converts to a less toxic acid product by ALDH. The
highly toxic and reactive DOPAL has been hypothesised to contribute to the selective
neurodegeneration of dopamine (DA) neurons. In this study, the neuroprotective mechanism of
ALDH2 was observed as overexpression of wild-type ALDH2 gene, but not the enzymatically
deﬁcient mutant ALDH2*2 (E504K), reduced rotenone-induced DA neuronal cell death.
Application of a potent activator of ALDH2, Alda-1, was effective in protecting against rotenone-
induced (100 nM, 24 h exposure) apoptotic cell death in both SH-SY5Y cells and primary cultured
substantia nigra (SN) DA neurons. These results were conﬁrmed by in vivo studies.
Intraperitoneal administration of Alda-1 to C57BL/6 mice treated with rotenone (50 mg/kg per
day, oral administration for 14 days) or MPTP (40 mg/kg per day, i.p. for 14 days) signiﬁcantly
reduced death of SN tyrosine hydroxylase-positive dopaminergic neurons. The attenuation of
rotenone-induced apoptosis by Alda-1 resulted from decreasing ROS accumulation, reversal of
mitochondrial membrane potential depolarisation, and inhibition of activation of proteins related
to mitochondrial apoptotic pathway. The present study demonstrates that rotenone or MPP+
induces DA neurotoxicity through oxidative stress. Moreover, Alda-1 is effective in ameliorating
mitochondrial dysfunction by inhibiting rotenone- or MPP+-induced mitochondria-mediated
oxidative stress that leads t0 apoptosis (Chiu et al., 2015).
A.7.3. Uncertainties or inconsistencies
• Several in vitro studies applying rotenone to evoke mitochondrial dysfunction came to the
conclusion that rotenone-dependent ROS formation, and not the rotenone-evoked drop in ATP is
the primary cause for cell degeneration. These observations are largely based on experimental
systems employing the rotenone insensitive NADH dehydrogenase NDI 1. Expression of NDI 1
protected rotenone exposed cells from degeneration. The presence of NDI 1 however results in a
substitution of ATP. Endogenously expressed complex I is still present in these models and it can
be assumed that rotenone exposure would still lead to a complex I-dependent formation of ROS
that precludes the modelling of a precise cause-consequence relationship between either ATP
depletion or elevated ROS levels with the demise of DA neurons.
• Several studies indicate a dominant role of ROS in the degeneration of DA neurons, based on
models in which rotenone/MPP+ mediated mitochondrial dysfunction and cell degeneration was
protected by the presence of exogenously added antioxidants. Maintenance of the endogenous
redox potential however is a highly ATP-dependent process. Clear-cut separations between the
respective contribution of ROS or the role of an inhibited mitochondrial ATP synthesis on the
degeneration of DA neurons is hence difﬁcult to postulate.
• Studies with chronic partial GSH depletions indicated that an experimental reduction of GSH/
GSSG by ca. 50% has no inﬂuence on cell viability. Reports involving rotenone and MPP+
however regularly observe degeneration of DA neurons under conditions of GSH depletion
around 50%. These observations indicate a more prominent role of the intracellular drop of
ATP evoked by the complex I inhibitors in the process of cell degeneration.
• Studies in which oxidative stress is generated e.g. by the application of DA or 6-OHDA not only
observed a challenge of the cellular redox potential, but also reversible and irreversible
inhibitory mechanisms of mitochondrial respiratory chain complexes (nitration, S-nitrosation)
that are accompanied by an inhibition of the respiratory chain in the absence of
pharmacological complex I inhibitors. These observations illustrate the close mutual interaction
between oxidative stress and the inhibition of mitochondrial respiration and point to a
profound role of direct mitochondrial inhibition also under oxidative stress conditions.
• Mitochondrial dysfunction is generally associated with conditions of oxidative stress.
Dysfunctional mitochondria can act as potent source of superoxide. Oxidative stress associated
with PD however not only originates from mitochondrial ROS, but also from DA autoxidation
and the Fenton reaction, as well as from inﬂammatory activated adjacent glia. Interpretations
on the role of oxidative stress in DA neurons and its role in DA neurodegeneration is hence
hampered by the fact that the respective origin of the reactive oxygen species formed
(mitochondria, DA autoxidation, inﬂammation of glia cells) is rather difﬁcult to identify and
often shows overlappings (Starkov et al., 2008; Murphy et al., 2009; Cebrian et al., 2015).
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• In PD patients, a reduction in complex I activity in the SNpc, but also in peripheral tissue and
cells such as platelets, was reported. Studies with isolated mitochondria indicated that for
efﬁcient inhibition of mitochondrial ATP formation, an inhibition of complex I by ca. 70% is
necessary (Davey et al., 1996). Reports on the reduction of complex I activity in PD patients
however repeatedly indicated an inhibition of only 25–30% (Schapira et al., 1989; Schapira
et al., 1990; Janetzky et al., 1994).
• Data available on the respective inhibition of the components of the respiratory chain are
highly dependent on the experimental setup used. Analysis of mitochondrial respiratory chain
complex activities in mitochondrial homogenates provide results different from data obtained
with intact, isolated mitochondria. These aspects need to be considered in the interpretation of
such data (Mizuno et al., 1989; Schapira et al., 1990; Mann et al., 1992; Cardellach et al.,
1993; Parker et al., 2008)
A.7.4. Quantitative understanding
Quantitative understanding for this KE relationship mainly comes from in-vitro and engineered
systems, using rotenone and MPTP as main chemical stressors. A clear response–response effect is
evident as well as temporality was mainly supported by evidence that modulation of the KEup was
attenuating or preventing the KEdown. Evidence of dose relationship was limited, as most of the time a
single, generally high, concentration was used.
Table A.6: Quantitative evaluation of the KER.
KE 2 upstream KE 4 downstream Comments Reference
Rotenone experiments
Mitochondrial membrane potential
reduced by 50% upon rotenone
treatment. Back to 80% compared to
controls in the presence of the
ﬂavonoid rutin
Intracellular Ca2+ elevated by a
factor of 3 by rotenone, reduction to
an increase of 1.5 in the presence of
rutin
ROS increased by a factor of 6.5;
increase of ROS by a factor of 2 in
the presence of rutin
Rotenone (10 lM) resulted
in a reduction of cell
viability by 50%
In the presence of rutin,
cell viability was only
reduced by 10% upon
rotenone treatment
SH-SY5Y cells exposed to
rotenone (10 lM) for 24 h
When applied alone, rutin
displayed no toxic effects,
up to 100 lM
Rutin was added to the
cells 30 min prior rotenone
at concentrations from
0–10 lM
Park et al.
(2014)
Mitochondrial membrane potential
reduced by ca. 66% upon rotenone
treatment; in the presence of
celastrol, reduction by ca. 55%
ROS formation increased by a factor
of 2 in the presence of rotenone;
ROS increase by a factor of 1.5 in the
presence of celastrol
Cell viability was reduced
by 50% by rotenone; In
the presence of the
triterpene celastrol, cell
viability was only reduced
by ca. 10%
SH-SY5Y + rotenone
(10 lM). Celastrol (2.5 nM)
was applied 90 min prior to
rotenone
Cells were incubated with
the two compounds for a
period of 24 h
Choi et al.
(2014)
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KE 2 upstream KE 4 downstream Comments Reference
TH staining in the SNpc in
arbitrary units:
Control (25)
Rotenone (14)
Rotenone + NDI 1(22)
TH staining in the striatum
Control (70)
Rotenone (40)
Rotenone + NDI 1 (65)
DA levels in the striatum:
Control (2.5)
Rotenone (1.3)
Rotenone + NDI 1 (2.2)
5 month old male Sprague
–Dawley rats (ca. 500 g)
received intracerebral
injection of recombinant
adeno-associated virus with
the NADH dehydrogenase
NDI 1 gene
45 days after virus
injection, rats were treated
with rotenone-loaded
microspheres (poly(DL-
lactide-co-glycolide)
100 mg rotenone /kg body
weight s.c
With this method, HPLC
analysis of plasma
rotenone revealed levels of
2 lM 14 days after
microsphere treatment,
and 1 lM 60 days after
microsphere treatment
Behavioural experiments
and brain sample collection
was conducted 30 days
after rotenone treatment
Marella et al.
(2008)
MPP+ experiments
Decline in mitochondrial
transmembrane potential by MPP+;
50% prevention from this decline by
rosmarinic acid
NADH levels were reduced by ca.
50% in the presence of MPP+; loss of
NADH was completely prevented by
the presence of rosmarinic acid
ROS levels increased by 50% in the
presence of MPP+. Rosmarinic acid
lead to a reduced increase of ROS by
only 20% compared with the
untreated control
Cell viability reduced by
MPP+ by 30%, complete
protection by the presence
of the antioxidant
rosmarinic acid
Striatal DA content
reduced by 40% by MPP+
treatment, partially
protected by rosmarinic
acid back to a value of
25% reduction compared
with the untreated control
MES23.5 cells exposed to
MPP+ (200 lM) for 24 h
Rosmarinic acid (1 nM)
was applied 30 min prior to
MPP+ treatment
Du et al. (2010)
Reduction in mitochondrial
membrane potential by 60% (MPP+),
by 50% (rotenone), complete
recovery by the co-incubation with
ISB, PHT, PHO
SH-SY5Y + MPP+:
Cell viability reduced by
66%; ISB, PHT, PHO
partially protected from cell
death with a reduction in
cell viability by ca. 20%
SH-SY5Y + rotenone:
reduction in cell viability by
60%
Partial protection by ISB,
PHT, PHO to a reduction in
cell viability by 25–50%
SH-SY5Y + BSO:
Reduction in cell viability
by 80%
ISB, PHT, PHO partially
protected with a residual
decline in cell viability by
ca. 20%
SH-SY5Y + MPP+ (200 lM)
or rotenone (150 nM) or
BSO (150 lM) for 60 h and
72 h
Antioxidants tested:
Iminostilbene (ISB)
Phenothiazine (PHT)
Phenoxazine (PHO)
The antioxidants were
applied 2 h prior to
rotenone, MPP+, or BSO
treatment
Hajieva et al.
(2009)
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KE 2 upstream KE 4 downstream Comments Reference
Circumvention of endogenous
complex I
Wt cells exposed to rotenone:
increase in carbonyl content as
marker of oxidative stress by 100%;
completely prevented in NDI 1
expressing cells
In midbrain slice cultures exposed to
rotenone: increase in carbonyl
content by 20%
Rats exposed to rotenone: increase
in carbonyl content: 27% in the
striatum, increase by 41% in the
midbrain
SK-N-MC cells: rotenone
evoked cell death
protected by ca. 90% in
NDI 1 expressing cells
Rotenone induced cell
death prevented by 80%
by a-tocopherol (62.5 lM
and 125 lM)
SK-N-MC human
neuroblastoma cells
transfected with the
rotenone insensitive NADH
dehydrogenase NDI 1;
Cells were treated with
rotenone (100 nM) for
48 h or with BSO (10 lM)
for 24 h
When both compound
were used in a combined
experiment, cells were ﬁrst
treated with BSO (10 lM)
for 24 h, then rotenone
(10 nM) was added for
additional 36 h
Sherer et al.
(2003)
Application of the complex I
inhibitors:
Rotenone
Fenazaquin
Fenpyroximate
Pyridaben
Tebufenpyrad
Pyridaben
Time and concentration-
dependent cell death with
rotenone and a series of
other complex I inhibitors
NDI 1 expressing cells
were resistant towards the
different complex I
inhibitors
SK-N-MC human
neuroblastoma cells
expressing the rotenone-
insensitive NADH
dehydrogenase NDI 1 from
Saccharomyces cerevisiae
All complex I inhibitors
applied were added at the
concentrations: 10 nM,
100 nM, 1 lM
Pyridaben was applied at
1 lM, 10 lM, 100 lM
Viability was assessed after
48 h, ATP was detected
after 6 h. Carbonyl content
was detected after 24 h
Sherer et al.
(2007)
Oxygen consumption rate doubled by
MB in the absence of complex I
inhibitor
Oxygen consumption reduced by
50% by rotenone; completely
reversed to control levels by the
presence of MB
Complex I-III activity reduced by
95% by rotenone. Reversed to
control levels by the presence of MB
HT22 cell viability reduced
by 70% by rotenone
In the presence of MB,
reduction by only 10% of
cell viability was observed
In rats treated with
rotenone, rotarod retention
time was reduced by 50%
by rotenone. Completely
reversed to control levels
by the co-administration of
MB
In rats, rotenone evoked a
reduction of striatal DA by
50%; completely reversed
to control levels by MB
Complex I-III activity in
the striatum of rats was
reduced by 50%, residual
inhibition of 10% observed
in rats that were
additionally treated with
MB
The study included:
• Isolated rat heart
mitochondria
exposed to
rotenone (5 lM)
(instant treatment)
• Hippocampal HT-22
cells exposed to
rotenone (2–8 lM)
for 24 h
• Rats receiving
rotenone (5 mg/kg
per day via osmotic
minipumps for
8 days
Test of methylene blue
(MB) (10 and 100 ng/mL in
isolated mitochondria; 1
and 10 µg/ml in HT 22
cells) to circumvent the
complex I/III blockade
Wen et al.
(2011)
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Evidence Supporting Taxonomic Applicability
There are no sex or age restictions for the applicability of this KE and mitochondria are essential for
most of eukaryotic cells. Rotenone and MPTp have been tested successfully in primates and mice. The
mouse C57BL/6 strain is the most frequently used strain in the reported experiments. A difference in
KE 2 upstream KE 4 downstream Comments Reference
Cybrid cells with PD mtDNA display a
reduction in complex I activity by
20%
Cybrid cells: increase in
basal formation of reactive
oxygen species by 80%
2-times higher sensitivity
towards MPP+ as stressor
SH-SY5Y cells devoid of
mtDNA; fused with
platelets from PD patients
for mitochondria transfer:
cybrid cells
Treatment with MPP+ (40
or 80 lM) for 24 h or 48 h
Swedlow et al.
(1996)
Oxidative stress causes
mitochondrial dysfunction
Isolated mitochondria:
Exposure to DA: loss of ca. 50%
membrane potential. Completely
protected by GSH or N-acetyl-cystein
(NAC)
Decline of mitochondrial respiration
capacity by 90%
In the presence of NAC or GSH, only
a reduction by 25–30% was
observed
PC12 cells exposed to DA, then
isolation and analysis of
mitochondria: inhibition of complex I
activity by ca. 50%, prevented by
co-incubation with NAC
Inhibition of complex II and III;
prevented by NAC
Intact PC12 exposed to DA:
Mitochondrial transmembrane
potential reduced by ca. 50%;
prevented by NAC
Intracellular ATP reduced by ca.
50%; Cell death increased by DA by
ca. 30%, caspase 3 activity increased
by a factor of 3; all increases
prevented by the presence of NAC
PC12 cells exposed to DA:
Increase in intracellular
ROS by a factor of 2;
completely reversed by
NAC
Quinoprotein formation
increased by a factor of 3;
completely prevented by
the presence of NAC or
GSH
Cell death increased from
3% (control) to 37% (DA).
Reduced to 10% in the
presence of NAC
PC12 cells and isolated rat
brain mitochondria exposed
to dopamine (100–400 lM)
N-acetyl cysteine or GSH
for protection were added
at a concentration of
2.5 mM
In experiments including
isolated mitochondria, NAC
and GSH were added 2 h
prior to DA. In experiments
including PC12 cells, NAC
and GSH were added 1 h
prior DA
Isolated mitochondria were
exposed to DA for 2 h;
PC12 cells were expose to
DA for 24 h
Jana et al.
(2011)
Reduction of intracellular GSH by
50% and of intramitochondrial GSH
by 60% leads to:
Mitochondrial ROS increased by 30%
ATP levels reduced by 66%
Mitochondrial activity reduced by
66%
State 3 respiration reduced by 60%
Complex I activity inhibited by 60%
Whole cell ROS increased
by 30%
PC12 cells with inducible
knockdown of glutamyl
cysteine synthetase
(inhibition of GSH
synthesis) by addition of
25 lg/mL doxycycline
Treatment for 24 h with
doxycycline resulted in a
GSH decline by ca. 50%
Jha et al.
(2000)
Reduction of GSH levels by ca. 50%
result in:
Complex I inhibition by 40%;
completely reversed by DTT
No cell toxicity under the
applied conditions
N27 cells exposed to BSO
(2.5 lM) for 7 days:
Total glutathione was
declined by ca. 50% by
this chronic treatment;
absence of cell toxicity
under these conditions.
DTT for restoration of
complex I activity was
added at 1 mM
Chinta et al.
(2006)
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vulnerability was observed, particularly for rats, depending on the strain and route of administration.
The Lewis strain gives more consistency in terms of sensitivity when compared to the Sprague–Dawley.
In addition to rodents, the pesticide rotenone has been also studied in Caenorhabditis elegans
(C. elegans), Drosophila, zebraﬁsh and Lymnaea stagnalis (L. stagnalis) (Johnson et al., 2015),
indicating that the system is preserved across species.
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8th KER: Degeneration of DA neurons of nigrostriatal pathway leads to
parkinosnian motor deﬁcits (bradykinesia, rigor, and tremor)
A.8.1. How Does This Key Event Relationship Work
Degeneration of dopaminergic (DA) neuron terminals in the striatum and the degeneration of DA
neurons in the substantia nigra pars compacts (SNpc) are the deﬁning histopathological events
observed in idiopathic, familial, and toxicant-evoked cases of Parkinson’s Disease (PD) (Tolwani et al.,
1999; Bove et al., 2012). The loss of nigrostriatal DA neurons leads to a decline in the levels of DA in
the striatum (Koller et al., 1992). Striatal DA is involved in the modulation of extrapyramidal motor
control circuits. A decline in striatal DA leads to an overactivation of the two principal basal ganglia
output nuclei (GPi/STN). Therefore, the inhibitory GABAergic neurons that project to thalamocortical
structures are overactivated and inhibit cortical pyramidal motor output performance. This inhibited
output activity is responsible for key clinical symptoms of PD such as bradykinesia and rigor.
A.8.2. Weight of Evidence
A.8.2.1. Biological Plausibility
The mechanistic understanding of striatal DA and its regulatory role in the extrapyramidal motor
control system is well established (Alexander et al., 1986; Penney et al., 1986; Albin et al., 1989;
DeLong et al., 1990; Blandini et al., 2000; Obeso et al., 2008). The selective degeneration of DA
neurons in the SNpc (and the subsequent decline in striatal DA levels) have been known to be linked
to PD symptoms for more than 50 years (Ehringer et al., 1960). The reduction of DA in the striatum is
characteristic for all aetiologies of PD (idiopathic, familial, chronic manganese exposure) and related
parkinsonian disorders (Bernheimer et al., 1973), and it is not observed in other neurodegenerative
diseases, such as Alzheimer’s or Huntington’s Diseases (Reynolds et al., 1986). In more progressive
stages of PD, not only a loss of DA neuronal terminals in the striatum, but also a degeneration of the
entire DA neuron cell bodies in the substantia nigra pars compacta (SNpc) was detected (Bernheimer
et al., 1973; Leenders et al., 1986). The different forms of PD exhibit variations in the degradation
pattern of the SNpc DA neurons. In idiopathic PD, for example, the putamen is more severely affected
than the caudate nucleus (Moratalla et al., 1992; Snow et al., 2000). All different PD forms however
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are characterised by the loss in striatal DA that is paralleled by impaired motor output (Bernheimer
et al., 1973). Characteristic clinical symptoms of motor deﬁcit (bradykinesia, tremor, or rigidity) of PD
are observed when more than 80% of striatal DA is depleted (Koller et al., 1992). These ﬁndings on
the correlation of a decline in striatal DA levels as a consequence of SNpc DA neuronal degeneration
with the onset of clinical PD symptoms in man provide the rationale for the current standard therapies
that aim to supplement striatal DA, either by the application of L-DOPA, or by a pharmacological
inhibition of the endogenous DA degradation-enzyme monoamine oxidase B (MAO-B). These
treatments result in an elevation of striatal DA that is correlated with an improvement of motor
performance (Calne et al., 1970). The success of these therapies in man as well as in experimental
animal models clearly conﬁrms the causal role of dopamine depletion for PD motor symptoms.
A.8.2.3. Empirical Support for Linkage
The experimental support linking the degeneration of DA neurons of nigrostriatal pathways with the
manifestation of motor symptoms characteristics of parkinsonian disorders comes from human clinical
observations as well as from primates, mice and rat in vivo models using DA neuron ablation by
toxicants. The levels of striatal DA corrected with the onset of PD symptoms, and dopaminergic
degeneration precede the onset of motor symptoms. The exemplary animal studies selected here are
based on the use of MPTP or rotenone. The efﬁcacy of MPTP or rotenone treatment depends on the
regimen applied (acute, subacute, chronic administration), the age of the animals, and the strains
used. For the interpretation of the studies, it is important that in some animal models the initial
depletion of DA is only partially explained by neurite degeneration. The other contributing factors are
downregulation of TH, and depletion of DA from synaptic terminals. These effects recover after
1–2 weeks. This makes the time point of measurement important for the correlation of effects.
Moreover, the mouse brain has a very high plasticity after damage, so that motor deﬁcits can recover
after several weeks although there is pronounced dopaminergic neurodegeneration.
Rat in vivo models
• Rat/rotenone: Correlation between striatal DA, SNpc DA neurons, and motor deﬁcits. Lewis
rats exposed to systemic rotenone (3 mg/kg per day i.p.) exhibited a loss of TH positive
neurons in the SNpc by 45%. Motor deﬁcits were assessed by the postural instability test and
by the rearing test. While 3 month old animals developed motor symptoms after 12 days of
rotenone exposure, 7 month and 12 month old animals developed motor symptoms already
after 6 days of exposure. Rotenone treatment elicited a progressive development of motor
deﬁcits that was reversible when treated with a DA agonist. Similar to that, the loss of rearing
performance evoked by rotenone was reversed by the DA agonist apomorphine. Rotenone
elicited terminal loss in the dorsolateral structures. While in the dorsolateral striatum, a
signiﬁcant loss of TH-positive neurites was detected, striatal cell bodies were spared from
degeneration. Initial striatal DA levels (75 ng/mg protein) dropped to 45% following rotenone
treatment (Cannon et al., 2009).
• Rat/6-OHDA: Destruction of nigrostriatal DA neurons. Unilateral injection of 6-OHDA into the
dopaminergic nigrostriatal pathway leads to a preferential loss of DA neurons that is correlated
with the onset of rotational motor deﬁcits (Luthman et al., 1989; Perese et al., 1989;
Przedborski et al., 1995).
• Rats/rotenone: Correlation between striatal dopamine and motor symptoms; partial reversibility
by L-DOPA. Rats were exposed to 2.5 mg/kg rotenone, daily, for 48 days. Dopamine detected
in the anterior striatum and posterior striatum was reduced by ca. 50% after rotenone
treatment. Rotenone treatment resulted in a signiﬁcantly prolonged descent latency compared
to control in the bar test and grid test. In the catalepsy test, descent latency dropped from 35
s of the controls to 5 s. In the grid test, a reduction from 30 s (control) down to 4 s
(rotenone) was observed. The average distance travelled within 10 min by the animals was
reduced from 37 m to 17 m in the rotenone group. Average number of rearings declined from
65 to 30; the time of inactive sitting of 270 s in controls was increased to 400 s in the
rotenone group (Alam et al., 2004).
• Rat/rotenone: Correlation between striatal dopamine and motor symptoms. Rats were treated
with rotenone either at doses of 1.5 mg/kg or 2.5 mg/kg over 2 months with daily i.p.
injections. In the 2.5 mg/kg group, striatal DA levels dropped from 6,400 pg/mg in the
controls to 3500 pg/mg in the rotenone group. Rotenone treated animals showed an extended
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descent latency (5 to 50). In a vertical grid test, latency time increased from 9–72 s (Alam
et al., 2002).
• Rats/rotenone: Correlation between nigrostriatal TH intensity and motor symptoms. Rats were
treated with different doses of rotenone for 21 days with daily i.v. or s.c. injections. In the
2.5 mg/kg group, TH intensity in the striatum dropped from 0.2 to 0.12. The average time to
initiate a step increased from 5 s in the controls to 11 s in the rotenone group. Spontaneous
rearing scores dropped from 80% of the vehicle-treated controls to 20% in the rotenone group
(Fleming et al., 2004).
• Rat/rotenone: In middle-aged rats exposed to rotenone (3 mg/kg per day for 6 days), a
reduction of striatal DA levels and TH positive neurons by ca. 50% correlated with impairments
rearing performance and postural instability tests (Cannon et al., 2009).
• Rat/rotenone: In rats, exposed to rotenone (2.5 mg/kg per day), spontaneous locomotor
activity was reduced by ca. 50% after 1 week of rotenone treatment. This impaired motor
performance was correlated with a loss of striatal DA ﬁbres by 54% and a loss of nigral DA
neurons by 28.5% (H€oglinger et al., 2003).
Mouse in vivo models
• Mouse/MPTP: In mice exposed to MPTP in combination with probenecid, both a chronic
treatment scheme (MPTP 25 mg/kg, in 3.5 day intervals for 5 weeks) as well as a subacute
treatment scheme (25 mg/kg, 1x per day for 5 days) resulted in a deletion of striatal DA that
was directly correlated with impairments in motor symptoms (Petroske et al., 2001).
• Mouse/MPTP: In a mouse model exposed to MPTP at 15 day intervals (36 mg/kg), lower
rotarod performance was observed after the fourth injection. The decline in motor
performance was correlated with the decline in TH-immunoreactivity in the striatum
(r2 = 0.87) (Rozas et al., 1998).
Monkey in vivo models
• Monkey/MPTP: Correlation between striatal DA, SNpc DA neuron number and PD symptoms.
Macaca exposed to MPTP (i.v) (0.2 mg/kg, daily) display signs of PD at day 15, including
motor abnormalities. The transition between the presymptomatic and symptomatic period
occurred between day 12 and day 15 of MPTP exposure. At day 15, TH neurons in the SNpc
were reduced by 50%, DAT binding autoradiography studies revealed a decline in binding also
by 50% at day 15. Compared with control values of 150 pg/lg protein, the DA content of the
caudate nucleus dropped to values < 10 pg/lg protein at day 15. In the putamen, DA levels
dropped from 175 pg/lg protein to 20 pg/lg protein at day 15 (Bezard et al., 2001).
• Monkey/MPTP: Correlation between striatal DA, SNpc DA neurons, and PD symptoms. Monkeys
display a motor symptom pattern similar to that observed in humans. In order to optimise a
MPTP intoxication protocol that allows a gradual development of nigral lesion, different states of
PD symptom severity were deﬁned and correlated with the amount of striatal DA and the
number of TH-positive neurons in the SNpc. Asymptomatic monkeys displayed a reduction in
striatal DA by 30%, a neuronal loss in the SNpc by 40%, and a decline in striatal expression of
TH, DAT and VMAT2 by 50–60%. Monkeys that recovered from early PD symptoms displayed a
reduction of striatal DA of 50%, a loss of TH neurons in the SNpc and a loss of DAT and VMAT2
expression up to 60%. In animals with moderate PD symptoms, striatal DA levels as well as TH
positive neurons and DAT and VMAT 2 expression were reduced by 70–80%. Animals with
severe PD symptoms displayed remaining levels of striatal DA and SNpc expression of TH, DAT
and VMAT2 of around 20% compared to untreated controls (Blesa et al., 2012).
• Monkey/MPTP: The established model of basal ganglia wiring received ample experimental
support in recent years. For instance, an increase in the inhibitory output by GPi/STN has been
observed in MPTP treated monkeys, similar to the situation in idiopathic PD patients. These
ﬁndings were corroborated by observations indicating an elevated mitochondrial activity and an
elevated ﬁring rate of the inhibitory output nuclei detected on the level of individual neurons
(Mitchell et al., 1989; Filion et al., 1991). Lesions in the output ganglia of monkeys lead to a
reduction in the output and to an improvement in motor control (Bergman et al., 1990; Aziz
et al., 1991). In analogy to these lesion experiments, deep brain stimulation of these regions
results in a profound improvement of motor performance in PD patients (Ceballos-Baumann
et al., 1994; Limousin et al., 1999).
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Human data
• Human PD: Association of PD phenotype with impaired striatal DA. In the brains of human PD
patients, a signiﬁcant decrease of striatal DA was observed (Lloyd et al., 1975). In the caudate
nucleus, levels of DA dropped from control values of 4 lg/g tissue to levels of 0.2 lg/g. In the
putamen, control values were in the range of 5 lg/g and 0.14 lg/g in the PD patient group.
The levels of DA in the striata of DA patients that received L-DOPA treatment was 9–15 times
higher compared with non-treated PD cases.
• Human PD: Correlation between striatal DA loss and degeneration of DA neurons in the SNpc.
Examinations of the brains of PD patients revealed morphological damage in the SNpc,
accompanied by the degeneration of DA neurons (Earle et al., 1968).
• Human: Association of striatal DA levels and motor performance. In order to substitute
degenerated DA neurons in the SNpc, human fetal tissue from the ventral mesencephalon was
transplanted to the caudate and putamen in idiopathic cases PD as well as in patients that
developed PD-related motor deﬁcits as a consequence to MPTP intoxication. Transplanted cells
led to a reinnervation of the striatum with DA projections (Widner et al., 1992; Kordower
et al., 1995, 1998). In these case studies, patients demonstrated a sustained improvement in
motor function (decline in rigidity score by more than 80%).
• Human PD: correlation between nigrostriatal DA neuron content and motor symptoms.
Imaging of DAT was performed by the use of 123I-FP-CIT SPECT (single photon emission
computed tomography). Clinical PD severity was determined by using the Uniﬁed Parkinson’s
Disease Rating Score (UPDRS). In PD patients, DAT binding in the striatum, caudate, and
putamen correlated with disease severity and duration of disease (Benamer et al., 2000).
• Human PD: correlation between 18F-dopa uptake measured by PET and the onset of motor
symptoms detected according the UPDRS. 18F-dopa inﬂux rate constants (Ki/min) were
reduced in the midbrain from 0.008 to 0.006, in the right putamen from 0.017 to 0.0036, and
in the left putamen from 0.017 to 0.005 (Rakshi et al., 1999).
• Human PD: correlation between putamen inﬂux rate (Ki/min). Ki (control): 0.0123;
asymptomatic PD (no observable motor deﬁcits): 0.0099; symptomatic PD (clinically evident
motor deﬁcits): 0.007. Mean UPDRS value was 15.1  7.5. A correlation coefﬁcient of -0.41
was detected between motor UPDRS and putamen inﬂux (Ki) (Morrish et al., 1995).
• Human PD: Correlation of the degree of monoaminergic degeneration in early PD with motor
symptoms assed by the UPDRS and the Hoehn and Yahr Stage scale. For PET imaging, 18F-9-
ﬂuoropropyl-dihydrotetrabenzazine that targets VMAT2 was used. Uptake of the tracer was
reduced by 20–36% in the caudate, by 45–80% in the putamen, and by 31% in the substantia
nigra. This correlated with a total UPDRS value of 12.1  7.1 in the PD group, respectively
with a HY value of 1.0  0.1 in the PD group compared to controls (Lin et al., 2014).
• Human PD: Correlation between the decline in 18F-dopa rate constant (Ki) and the onset of
motor deﬁcits. The 18F-dopa rate constant Ki was reduced in the caudate nucleus (0.011
down to 0.0043) and inversely correlated with an increase in the UPDRS from 11.9  5.2 to
50  11.6 (Broussolle et al., 1999).
• Human PD: Correlation between striatal DAT binding measured by the use of 123I-CIT SPECT
and motor deﬁcits. A correlation coefﬁcient between 123I-CIT binding and UPDRS motor scale
of -0.56 was detected. A correlation coefﬁcient of -0.64 between 123I-CIT binding and Hoehn
and Yahr stage scale was detected. Motor symptoms in the clinically less affected body side
show a closer correlation with striatal DAT binding (Pirker et al., 2003).
• Human PD: Correlation between the reduction in the putamen uptake of 18F-CFT and the
severity of PD motor symptoms. 18F-CFT uptale was reduced to 18% in the putamen, to 28%
in the anterior putamen, and to 51% in the caudate nucleus (Rinne et al., 1999).
• Human PD: Reduction in 123I-CIT binding in the putamen by 65% correlated with a mean
UPDRS score of 27.1 (Tissingh et al., 1998).
• Association between striatal DA and motor performance. Application of L-DOPA leads to a
substitution of DA in the striatum and improves motor performance (Hutchonson et al., 1997;
Boraud et al., 1998; Papa et al., 1999; Levy et al., 2001; Heimer et al., 2002; Gilmour et al.,
2011).
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A.8.3. Uncertainties or Inconsistencies
• Motor abnormalities observed in PD display large interindividual variations.
• The model of striatal DA loss and its inﬂuence on motor output ganglia does not allow to
explain speciﬁc motor abnormalities observed in PD (e.g. resting tremor vs bradykinesia)
(Obeso et al., 2000). Other neurotransmitters (Ach) may play additional roles
• There are some reports indicating that in subacute rotenone or MPTP models (non-human
primates), a signiﬁcant, sometimes complete, recovery of motor deﬁcits can be observed after
termination of toxicant treatment. While the transient loss of striatal DA can be explained by
an excessive release of DA under acute toxicant treatment, the reported losses of TH-positive
neurons in the SNpc and their corresponding nerve terminals in the striatum are currently not
explained (Petroske et al., 2001).
• In MPTP treated baboons, the ventral region of the pars compacta was observed to be more
severely degenerated that the dorsal region. This pattern is similar to the degeneration pattern
in idiopathic PD in humans. These observations indicate that two subpopulations of
nigrostriatal DA neurons with different vulnerabilities might exist (Varastet et al., 1994).
• According to the classical model of basal ganglia organisation, DA is assumed to have a
dichotomous effect on neurons belonging either to the direct or indirect pathway. More recent
evidence however rather indicates that D1 and D2 receptors are expressed on most striatal
neurons in parallel (Aizman et al., 2000).
A.8.4. Quantitative Understanding of the Linkage
An example of quantitative analysis is reported in Table A.7. The analysis of the empirical data
produced with the chemical toxicants supports a strong response–response relationship between the
KEup and the KEdown which also indicative of the temporal progression and relationship between the
degeneration of striatal terminals of DA neurons, loss of DA neurons in the SNpc and the occurrence
and severity of the motor deﬁcits. This is also quantitatively supported by studies conducted in human
PD patients.
Table A.7: Quantitative evaluation of the KER
Upstream key event
(KE 4)
Downstream key event (AO) References Comments
Rat models
45% loss of TH-positive
SNpc neurons in 7 month
old rats, ca. 40% loss in
12 month old rats
Striatal DA reduced from
90 ng/mg (control) down
to 45 ng/mg
TH pos. neuron number
18,000 (control)
10,000 (rotenone)
Bradykinesia, postural instability,
rigidity observed in 50% of cases:
3 month old rats: after 12 days
of rotenone
7 + 12 month old rats. After 6 days
of rotenone
Postural instability test:
Distance required for the animal
to regain postural stability:
3.5 cm (control)
5 cm (rotenone)
Rearing test (rears/5 min):
10 (control
3 (rotenone)
Loss of rearing performance evoked
by rotenone was reversed by the DA
agonist Apomorphine in 3 month old rats
Cannon et al.
(2009)
Lewis
rats + rotenone
(3 mg/kg per day,
i.p. daily)
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Upstream key event
(KE 4)
Downstream key event (AO) References Comments
Dopamine in the anterior
and posterior striatum
reduced by ca. 50%
Catalepsy test: decline from 35 s to 5 s
Grid test: decline from 30 s to 4 s
Distance travelled in 10 min: reduction
from 37 m to 17 m
Number of rearings: decline from 65 to 30
Inactivity time increased from 270 to 400 s
Partial reversibility by L-DOPA treatment:
L-DOPA: number of rearings increased
from 16 to 30
L-DOPA: inactivity time reduced from
450 to 360 s
L-DOPA: increase in the distance travelled
from 12 to 16 m
Alam et al.
(2004)
Rats + rotenone
(2.5 mg/kg) daily
over the course of
48 days
TH staining intensity
reduced from 0.2 to 0.12
Rearing scores reduced from 80%
(vehicle controls) to 20% (rotenone group)
Increase in the average time to initiate
a step from 5 to 11 s.
Fleming et al.
(2004)
Rats + rotenone
2.5 mg/kg for
21 days i.v. or s.c.
Loss of striatal DA ﬁbres
by 54%
Loss of DA neurons by
28.5%
Spontaneous locomotor activity after 1 week
100% (control)
55% (rotenone)
H€oglinger
et al. (2003)
Rats + rotenone
(2.5 mg/kg per day
for 28 days
Mouse models
Subacute model:
Striatal DA dropped from
11 (control) to 2.5 ng/mg
(MPTP) after 3 days
3H-DA striatal uptake
reduced from 2.9 (control)
to 1.3 pmol/mg after
3 days of MPTP
Total nigrostriatal TH cell
count was not affected
Chronic model:
Striatal DA content
reduced from 13 down to
0.5 ng/mL at 1 week after
MPTP treatment
3H-DA uptake in the
striatum reduced from 3 to
1 pmol/mg 1 week after
start of MPTP treatment
TH staining in the
nigrostriatal system
reduced by ca. 50% 1
week after initiation of
MPTP treatment
Subacute model:
Rotarod performance reduced from
1,800 AUC (control) down to 1,500 AUC (MPTP)
Chronic model:
Rotarod performance reduced from
1,800 AUC (control) to 1,250 AUC
(1 week after initiation of MPTP treatment)
Petroske
et al. (2001)
Mouse + MPTP
Subacute model:
25 mg/kg MPTP 1x
days for 5 days
Chronic model:
MPTP (25 mg/
kg + 250 mg/kg
probenizid) in
3.5 day intervals for
maximal 5 weeks
Reduction in TH staining
intensity of at least 50%
required for detectable
inﬂuence on motor
performance
TH density in the
nigrostriatal system
correlated with the decline
of rotarod performance
(r2 = 0.87)
Rotarod performance reduced
from 1,250 AUC to 200 AUC
Time on rod at a speed of 20 rpm:
125 s in controls, 25 s in MPTP animals
Rozas et al.
(1998)
Mouse + MPTP
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Upstream key event
(KE 4)
Downstream key event (AO) References Comments
Monkey models
Approx. 50% loss of TH
positive neurons in the
SNpc. DA content in the
caudate nucleu reduced to
< 10%; DA content of the
putamen ca. 10%
compared with control
Mean duration in the bradykinesia
test increased from 3 s (day 0)
to 19 s at day 15
Bezard et al.
(2001)
Macaca + MPTP i.v.
0.2 mg/kg daily for
15 days
Human
18F-dopa inﬂux rate
constants (Ki)
Midbrain:
Control: 0.008
Early PD: 0.008
Adv. PD: 0.006
Right putamen:
Control: 0.017
Early PD: 0.006
Adv. PD: 0.0036
Left putamen:
Control: 0.017
Early PD: 0.0096
Adv. PD: 0.005
Early PD:
UPDRS: 9  3
Adv. PD:
UPDRS: 41  15
Rakshi et al.
(1999)
Human PD patients
Putamen inﬂux (Ki/min)
detected by 18F-dopa
control: 0.0123
asympt. PD: 0.0099
symptom. PD: 0.007
Symptom. PD patients: mean
UPDRS: 15.1  7.5
Correlation between total UPDRS
and putamen Ki:
r = 0.41
Morrish et al.
(1995)
Human PD
Uptake of 18F-DTBZ
(VMAT2 tracer) reduced
by:
20–36% (caudate)
45–80% (putamen)
31% (SN)
UPDRS total: 12.1  7.1
Hoehn and Yahr: 1.0  0.1
Lin et al.
(2014)
Human PD
Caudate nucleus Ki/min
Control: 0.011
PD group 3: 0.0067
Putamen Ki/min
Control: 0.011
PD group 3: 0.0043
UPDRS: 50  11.6 in PD group 3 Broussolle
et al. (1999)
Human PD
Reduction in 18F-CFT
uptake in the posterior
putamen (by 18%); in the
anterior putamen (by
28%); in the caudate
nucleus (by 51%)
Correlation between total motor
score of the UPDRS and
18F-CFT uptake:
Posterior putamen:
r = 0.62
Anterior putamen:
r = 0.64
Caudate nucleus:
r = 0.62
Rinne et al.
(1999)
Human PD
123I-CIT SPECT values in
controls and PD cases with
a Hoehn and Yahr rating
of 2–2.5:
Putamen (ipsilateral):
Control: 6.13
Correlation coefﬁcient between striatal
123I-CIT binding and:
Str. (ipsilateral) and Bradykinesia:
r = 0.61
Str. (ipsilateral) and Rigidity:
r = 0.46
Tissingh et al.
(1998)
Human PD
PPPs, Parkinson’s disease and childhood leukaemia
www.efsa.europa.eu/efsajournal 187 EFSA Journal 2017;15(3):4691
A.8.5. Evidence Supporting Taxonomic Applicability
Parkinsonian disorders are generally recognised as progressive age-related human
neurodegenerative diseases more prevalent in males. However, the anatomy and function of the
nigrostriatal pathway is conserved across mammalian species (Barron et al., 2010) and no sex and
species restrictions were evidenced using the chemical stressors rotenone and MPTP. It should be
noted that animal behaviour models can only be considered as surrogates of human motor disorders
as occuring in Parkinson’s disease.
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Overall assessment of the AOP
A.1. Concordance of dose–response relationship
Data from experiments with the stressor compounds rotenone and MPTP (known inhibitors of the
mitochondrial Complex I (CI)) reveal a good concordance of the dose–response relationships between
the MIE and AO and within KEs. Although the different KEs have been measured using different
methodologies, comparison of data from multiple in-vitro/in-vivo studies shows a general agreement in
dose relationship (see Tables 1 and 2). There is a good consistency when comparing data on KE4 and
the AO after exposure to rotenone and MPTP. However, in vivo rodent studies proved that only
exposure to low concentrations of rotenone (rat brain concentration between 20–30 nM of rotenone;
Betrabet et al., 2000) or MPTP (mice striatum concentration of approximately 12–47 lM MPP+; Fornai
et al., 2005; Thomas et al., 2012) after chronic exposure (approximately 5 weeks) reproduced the
anatomical, neurochemical behavioural and neuropathological features similar to the ones observed in
Parkinson’s disease (PD). Because of the variability of experimental protocols used, a clear no-effect
threshold could not be established; nevertheless, these brain concentrations of rotenone (20–30 nM)
and MPP+ (approximately 12–47 lM) could serve as probabilistic thresholds for chronic exposure that
could reproduce features of PD as both concentrations trigger approximately a 50% inhibition of
Complex I (see Table 3). Generally, a strong response–response relationship is observed within studies.
Some exceptions for this rule are observed between KE3/KE5 and KE4, likely because of the all
biological complexity associated with these KEs. In this AOP, neuroinﬂammation was considered to
have a direct effect on degeneration of DA neurons. However, it was not clear at which conditions it
would become a modulatory factor and for practical reasons was not included in Tables 1, 2 and 3 but
considered in the weight of evidence analysis.
A.2. Temporal concordance among the MIE, KEs and AO
There is a strong agreement that loss of DA neurons of the SNpc that project into the putamen is
preceded by reduction in DA and degeneration of DA neuronal terminals in the striatum (Bernheimer
et al., 1973). The clinical symptoms of a motor deﬁcit are observed when 80% of striatal DA is
depleted (Koller et al., 1992) and the sequence of pathological events leading to the adverse outcome
has been well-documented (O’Malley, 2010; Dexter et al., 2013; Fujita et al., 2014). Temporal
concordance (see Tables 1 and 2) among the KEs can be observed in the experimental models of PD
using the chemical stressors rotenone and MPTP (Betarbet, 2000, 2006; Sherer et al., 2003; Fornai
et al., 2005). The acute administration of the chemical stressors can trigger a dose-related change
from the MIE to impaired proteostasis; however, to trigger KE4 (i.e. degeneration of DA neurons in
SNpc with presence of intracytoplasmatic Lewy-like bodies) and motor deﬁcits (AO), proteostasis needs
to be disturbed for a minimum period of time (Fornai et al., 2005).
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A.3. Strength, consistency, and speciﬁcity of association of AO and
MIE
Strength and consistency of the association of the AO with the MIE is strong. There is a large body
of evidence from in-vitro and in-vivo studies with chemical stressors, showing association between the
MIE that triggers an inhibition of CI and the AO (Betarbet et al., 2000, 2006; Sherer et al., 2003;
Fornai et al., 2005; Thomas et al., 2012). Human data also suggest a link between inhibition of CI and
AO (Schapira et al., 1989; Greenamyre et al., 2001; Shults, 2004). Using the two different chemical
stressors, rotenone and MPTP, data are consistent and the pattern of activation of the MIE leading of
the AO is similar. For rotenone and MPTP, speciﬁcity is high; however, there are many inhibitors of the
mitochondrial CI without evidence of triggering the AO. When considering these chemicals speciﬁcity is
low; therefore, kinetic and metabolic considerations should be taken into account to fully demonstrate
speciﬁcity for these compounds.
Table A.8: Response–Response and Temporality concordance table for the tool compound rotenone
(a): Concentration
at the target site
(b): KE1(c)
(c):
Inhibition of
C I
(d): KE2(c)
(e):
Mitochondrial
dysfunction
(f): KE3(c)
(g): Impaired
proteostasis
(h): KE4
(i): Degeneration
of DA neurons of
nigrostriatal
pathway
(j): AO
(k): Parkinsonian
motor symptoms
5–10 nM in-vitro
[1]
+
4–72 h [1]
+
4–72 h [4]
+
24 h [3]
– –
20–30 nM ex-vivo, rat
brain concentration
[4–5–2–6]
++
4–72 h (4–5)
++
4–72 h [4–5]
++
24 h [3–2–6]
++(a)
5 weeks [2–6]
+++(b)
5 weeks [2–6]
100 nM in-vitro
[4]
+++
4–72 h [4]
+++
4–72 h [4]
+++
24 h [3]
Above the maximum
tolerated dose [2–6]
Above the maximum
tolerated dose [2–6]
References: Choi et al., 2008 [1]; Betarbet et al., 2006 [2]; Chou et al., 2010 [3]; Barrientos and Moraes 1999 [4]; Okun et al., 1999 [5];
Betarbet et al., 2000 [6].
–: No data available.
+: Low severity score, ++ intermediate severity score, +++ high severity score.
(a): 50% of treated animals showed loss of DA neurons in SNpc.
(b): All animals affected in KE4 showed impaired motor symptoms.
(c): KE 1, 2 and 3 showed a dose-related severity in the effect and the score ++ was normalised vs. the KE4.
Table A.9: Response–Response and Temporality concordance table for the tool compound MPTP/MPP+
(l): Dose
(m): Brain
concentration
(n): KE1(e)
(o):
Inhibition of
C I
(p): KE2(e)
(q):
Mitochondrial
dysfunction
(r): KE3(d)
(s): Impaired
proteostasis
(t): KE4
(u): Degeneration
of DA neurons of
nigrostriatal
pathway
(v): AO
(w):
Parkinsonian
motor
symptoms
1 mg/kg
infusion
[1]
– – – +
4 weeks [1]
+(c)
4 weeks [1]
No effect
5 mg/kg
infusion
[1]
– – – ++
4 weeks [1]
++(b)
4 weeks [1]
+++
4 weeks [1]
20–30 mg/
kg infusion
[2, 1]
47 lM [2](f)
12 lM [1]
+++
4 h [2]
+++
4 h [2]
+++
4 weeks [1]
+++(a)
1–4 weeks [2, 1]
+++
4 weeks [1]
References: Fornai et al., 2005 [1]; Thomas et al., 2012 [2].
–: No data available.
(a): Approx 50% loss of DA neurons in SNpc.
(b): Approx 30% loss of DA neurons SN pc.
(c): No loss of DA neurons in SN pc. Reduced level of striata DA.
(d): For KE3, a dose response effect was observed.
(e): For KE 1 and 2 the severity of the effect was normalised vs. the KE4.
(f): After single dose MPTP administration, brain concentration was approx. 5.15 lM.
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A.4. Weight of Evidence (WoE)
A.4.1. Biological plausibility, coherence, and consistency of the
experimental evidence
The biological plausibility of this AOP is considered strong overall. When using multiple stressors in
different studies and assays, the coherence and consistency of the experimental data is well
established. Furthermore, in-vivo and in-vitro studies are also in line with the human evidence from PD
patients. In addition, although the mechanistic understanding of parkinsonian disorders (and PD in
particular) are not fully clear, the KEs and KERs described in this AOP are considered critical for the
development of the disease (Dauer et al., 2003; Shulman et al., 2011; Dexter et al., 2013; Fujita et al.,
2015).
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A.5. Uncertainties and Inconsistencies
• There is no strict linear relationship between inhibitor binding and reduced mitochondrial
function. Low doses of rotenone that inhibit CI activity partially do not alter mitochondrial
oxygen consumption. Therefore, bioenergetics defect cannot account alone for rotenone-
induced neurodegeneration. Instead, under such conditions, rotenone neurotoxicity may result
from oxidative stress (Betarbet et al., 2000). Few studies used human brain cells/human brain
mitochondria. Therefore, full quantitative data for humans are not available.
• It is molecularly unclear how rotenone binding alter CI function, switching it to ROS
production. It is still unclear whether the site of superoxide production in CI inhibited
mitochondria is complex I itself or not (Singer and Ramsay, 1994).
• Some studies suggest that rotenone and MPTP may have effects other than CI inhibition, e.g.
MPTP and rotenone can induce microtubule disruption (Brinkley et al., 1974; Cappelletti et al.,
1999, 2001; Ren et al., 2005; Feng, 2006; Aguilar et al., 2015)
• There are additional feedback possible between KEs, e.g. ROS production from KE2 may
damage CI, this leads to enhancement of KE1.
• Some KEs e.g. KE 2, 3, 5 pool molecular processes that may need to be evaluated individually
at a later stage.
• The exact molecular link from mitochondrial dysfunction to disturbed proteostasis is still
unclear (Malkus et al., 2009; Zaltieri et al., 2015).
• The role of ATP depletion vs. other features of mitochondrial dysfunction is not clear.
• The role of a a-synuclein in neuronal degeneration is still unclear as well as the mechanisms
leading to its aggregation.
• It is not clear under which conditions KE3 and KE5 become modulatory factors, and when they
are essential. MPTP can induce damage to nigrostriatal neurons without formation of Lewy
bodies (Forno 1986, 1993; Dauer 2003). Similarly, discontinuous administration of rotenone,
even at high doses, damages the basal ganglia but produce no inclusions (Heikkila et al.,
1985; Ferrante et al., 1997; Lapontine 2004). To reproduce the formation of neuronal
inclusions, continuous infusion of MPTP or rotenone is necessary. Acute intoxication with
rotenone seems to spare dopaminergic neurons (Ferrante 1997; Dauer et al., 2003). In
addition, in rats chronically infused with rotenone showed a reduction in striatal DARPP-32-
positive, cholinergic and NADPH diaphorase-positive neurons (Hoglinger, 2003) or in other
brain regions. These results would suggest that Rotenone can induce a more widespread
neurotoxicity (Aguilar, 2015) or the model is not reproducible in all laboratories.
• Inconsistent effects of MPP+ on autophagy (up or down regulation) are reported (Dauer et al.,
2002, Drolet et al., 2004). There is conﬂicting literature on whether increased autophagy
would be protective or enhances damage. Similarly, a conﬂicting literature exists on extent of
inhibition or activation of different protein degradation system in PD and a clear threshold of
onset is unknown (Fornai et al., 2005; Malkus et al., 2009).
• The selective vulnerability of the SN pc dopaminergic pathway does not have a molecular
explanation.
• Priority of the pattern leading to cell death could depend on concentration, time of exposure
and species sensitivity; these factors have to be taken into consideration for the interpretation
of the study’s result and extrapolation of potential low-dose chronic effect as this AOP refers to
long-time exposure.
• The model of striatal DA loss and its inﬂuence on motor output ganglia does not allow to
explain speciﬁc motor abnormalities observed in PD (e.g. resting tremor vs bradykinesia)
(Obeso et al., 2000). Other neurotransmitters (Ach) may play additional roles. Transfer to
animal models o PD symptoms is also representing an uncertainty.
• There are some reports indicating that in subacute rotenone or MPTP models (non-human
primates), a signiﬁcant, sometimes complete, recovery of motor deﬁcits can be observed after
termination of toxicant treatment. The role of neuronal plasticity in intoxication recovery and
resilience is unclear.
• This AOP is a linear sequence of KEs. However, mitochondrial dysfunction (and oxidative
stress) and impaired proteostasis are inﬂuencing each other and this is considered an
uncertainties (Malkus et al., 2009).
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A.6. Quantitative Considerations
The quantitative understanding of this AOP includes a clear response–response relationship and the
identiﬁcation of a threshold effect. The WoE analysis clearly supports the qualitative AOP as a means
to identify and characterise the potential of a chemical to induce DA neuronal loss and the AO.
Importantly, both the AO and the KE4 are considered relevant regulatory endpoints for this AOP. The
empirical evidence supports existence of a response–response relationship. This response–response is
likely triggered by a the brain concentrations of approximately 20–30 nM and 17–47 lM of rotenone
and MPP+ respectively and both concentrations trigger approx. a 50% inhibition of mitochondrial
complex I and this could be considered as a ‘threshold’. However, a more detailed dose–response
analysis for each KE is lacking as well as it is not clear which temporal relationship exists for lower CI
inhibitory effects. It is clear from the analysis of the AOP that for the identiﬁcation of these AOs, the
design of the in-vivo studies should be tailored as to a MIE which leads to a long-lasting perturbation
of the KEs. This provides the most speciﬁc and deﬁnite context to trigger neuronal death. To observe
KEs relevant for this AOP, new endpoints need to be introduced. Although a dose, response and
temporal relationship is evident for most KEs, the quantitative relationship between impaired
proteostasis and degeneration of DA neurons has yet to be elucidated. Moving from a qualitative AOP
to quantitative AOP would need a clear understanding of effect thresholds and this is still representing
a major hurdle for several KEs of this AOP.
A.7. Applicability of the AOP
This proposed AOP is neither sex-dependent nor associated with certain life stage; however, aged
animals may be more sensitive. The relevance of this AOP during the developmental period has not
been investigated.
In vivo testing has no species restriction. The mouse was the species most commonly used in the
experimental models conducted with the chemical stressors; though experimental studies using
alternative species have been also performed. (Johnson et al., 2015). However, animal models
(rodents in particular) would have limitations as they are poorly representative of the long human life-
time as well as of the human long-time exposure to the potential toxicants. Human cell-based models
would likely have better predictivity for humans than animal cell models. In this case, toxicokinetics
information from in-vivo studies would be essential to test the respective concentrations in-vitro on
human cells.
A.8. Schematic summary of the AOP
Chronic, low level of exposure to environmental chemicals that inhibit complex I could result in
mitochondrial dysfunction and oxidative stress, triggering proteasomal dysfunction strongly implicated
in parkinsonian disorders, including aggregation/modiﬁcations in a-synuclein protein and organelles
trafﬁcking. These cellular key events cause DA terminals degeneration in striatum and progressive cell
Table A.13: Concordance table for the tool compounds rotenone and MPTP/MPP+
Concentration
KE1
Inhibition of
C I
KE2
Mitochondrial
dysfunction
KE3
Impaired
proteostasis
KE4
Degeneration of
DA neurons of
nigrostriatal
pathway
AO
Parkinsonian
motor
symptoms
Rotenone
20–30 nM rat
brain
concentration
[1–2]
Approx. 53%
[4–5]
Approx. 20–53%
(decrease in
respiration rate)
[1–2]
Approx. 20–60%
(decrease in UPS
(26S) activity)
[3]
Neuronal loss
(50% of animal
affected)
[2]
Motor impairment
(100% of animals
with neuronal
loss)
[2]
MPP+ 12–47 lM
rat brain
concentration
[4–5]
Approx.
50–75%
[5]
Approx. 38%
(reduction in
phosphorylating
respiration)
[5]
Approx. 60%
(decrease in UPS
activity)
[4]
Approx. 50% of
neuronal loss
[4–5]
Motor impairment
[4]
References: [1] Okun et al. (1999); [2] Barrientos and Moraes (1999); [3] Borland et al. (2008); [4] Thomas et al. (2012);
[5] Betarbet et al., (2000, 2006).
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death of DA neurons in SNpc. Important to notice that at each step, the effects become regionally
restricted such that systemic complex I inhibition eventually results in highly selective degeneration of
the nigrostriatal pathway.
A.9. Potential application of the AOP
This AOP has been developed in order to evaluate the biological plausibility that the adverse
outcome i.e. parkinsonian motor deﬁcits, is linked to a MIE that can be triggered by chemical
substances i.e. pesticides and chemicals in general. The relevance of the AOP has been documented
by tools compounds known to trigger the described AOP. By means of using a human health outcome
that has been shown in epidemiological studies to be association with pesticide exposure, the authors
intend to draw attention on this AO in the process of hazard identiﬁcation. This AOP can be used to
support the biological plausibility of this association during the process of evaluation and integration of
the epidemiological studies into the risk assessment. It is biologically plausible that a substance
triggering the pathway, can be associated with the AO and ultimately with the human health outcome,
pending the MoA analysis. In addition, this AOP can be used to support identiﬁcation of data gaps that
should be explored when a chemical substance is affecting the pathway. Moreover, the AOP provides a
scaffold for recommendations on the most adequate study design to investigate the apical endpoints.
It is important to note that, although the AO is deﬁned in this AOP as parkinsonian motor deﬁcits,
degeneration of DA neurons is already per se an adverse outcome even in situations where it is not
leading to parkinsonian motor deﬁcits, and this should be taken into consideration for the regulatory
applications of this AOP.
Figure A.19: Schematic summary of the AOP
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The MIE and KEs identiﬁed in this AOP could serve as a basis for assays development that could
contribute to an AOP informed-IATA construction which can be applied for different purposes such as:
screening and prioritisation of chemicals for further testing, hazard characterisation or even risk
assessment when combined with exposure and ADME information.
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AOP 2: Redox-cycling of a chemical initiated by electrons released by the
mitochondrial respiratory chain leading to parkinsonian motor deﬁcits
Abstract
This Adverse Outcome Pathway (AOP) describes the linkage between excessive ROS production at
the level of the mitochondrial respiratory chain and parkinsonian motor deﬁcits, including Parkinson’s
disease (PD). Interaction of a compound with complex I and/or III of the mitochondrial respiratory
chain has been deﬁned as the molecular initiating event (MIE) that triggers mitochondrial dysfunction,
impaired proteostasis, which then cause degeneration of dopaminergic (DA) neurons of the nigra-
striatal pathway. These causatively linked cellular key events result in motor deﬁcit symptoms, typical
of parkinsonian disorders including PD, described in this AOP as an Adverse Outcome (AO). This AOP
also includes neuroinﬂammation as a KE and is intending the KER with degeneration of dopaminergic
neurons as a causative link but the priority of the temporal sequence is not deﬁned as
neurodegeneration can be the cause as well the consequence of the KE neuroinﬂammation.
Since the role DA neurons of the Substantia Nigra pars compacta (SNpc) projecting into the striatum is
essential for motor control, the key events refer to these two brain structures, i.e. SNpc and striatum. The
weight-of-evidence supporting the relationship between the described key events is mainly based on
effects observed after an exposure to the well-known pesticide paraquat which will be used as a tool
chemical to support this AOP.
Schematic representation of the proposed AOP:
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MIE: Redox cycling of a chemical initiated by electrons released by the
mitochondrial respiratory chain
How this Key Event works:
Redox cycling is a process of alternate reduction and reoxidation steps. It is triggered in the
presence of chemicals able to accept an electron from a reductant to form free radicals (Figure A.21).
These radicals due to their high reactivity may undergo electron transfer to molecular oxygen
generating superoxide anion radical (O2
°) (Kappus, 1986). As a result of electron transfer, the parent
compound is regenerated and able to catalyse further O2
. production. Extent and direction of this
reaction depend on both the concentration of the reactants and their reduction potentials relative to
the O2/ O2
. (E0= 160 mV at pH7 for a standard state of 1M O2; Sawer and Valentine, 1981).
Compounds with more negative electron reduction potential will react faster being thus effective redox
cycler. In addition, very negative E0 limit the pool of possible reductants, which have a sufﬁciently low
reduction potential to donate an electron.
Chemicals radicalisation appears to be the consequence of one electron reduction often catalysed
by a ﬂavoprotein (Cohen and Doherty, 1987). A number of different enzymes are involved, including
mitochondrial reductases.
Electron transport through the mitochondrial respiratory chain (oxidative phosphorylation) is
mediated by ﬁve multimeric complexes (I–V) that are embedded in the mitochondrial inner membrane
(Figure A.22).
e-
O2
-
O2
NAD(P)H
NAD(P)+
Figure A.21: Schematic representation of the mechanism of chemicals redox cycling. (Adapted by
permission from Macmilllan Publishers Ltd, Cohen and Doherty, 1987, copyright (1987))
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Under physiological conditions 1–5% of the oxygen is converted to O2
. by mitochondria due to
electron leakage from the respiratory chain (Wei et al., 2001). Although different respiratory complexes
and individual mitochondrial enzymes are sources of O2
. (Figure A.23), leaking electron are primarily
produced at two discrete points in the electron-transport chain namely at CI (NADH) and CIII
(ubiquinone-cytochrome c reductase) (Selivanov et al., 2011).
Figure A.22: The electron transport chain in the mitochondrion. Complex I (NADH-coenzyme Q
reductase or NADH dehydrogenase) accepts electrons from NADH and serves as the
link between glycolysis, the citric acid cycle, fatty acid oxidation and the electron
transport chain. Complex II also known as succinate-coenzyme Q reductase or
succinate dehydrogenase, includes succinate dehydrogenase and serves as a direct link
between the citric acid cycle and the electron transport chain. The coenzyme Q
reductase or Complex III transfers the electrons from CoQH2 to reduce cytochrome c
which is the substrate for Complex IV (cytochrome c reductase). Complex IV transfers
the electrons from cytochrome c to reduce molecular oxygen into water. Finally, this
gradient is used by the ATP synthase complex (Complex V) to make ATP via oxidative
phosphorylation
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NADH-ubiquinone oxidoreductase is the Complex I (CI) of electron transport chain (ETC). It is a
large assembly of proteins that spans the inner mitochondrial membrane. In mammals, it is composed
of about 45–47 protein subunits (human 45) of which 7 are encoded by the mitochondrial genome
(ND1, ND2, ND3, ND4, ND4L, ND5, and ND6) and the remainder by the nuclear genome
(Greenamyre, 2001). Complex I oxidises NADH elevating the NAD+/NADH ratio by transferring
electrons via a ﬂavin mononucleotide (FMN) cofactor and several iron-sulfur centres to ubiquinone
(Friedrich et al., 1994).
Complex III (CIII) of the ETC is the ubiquinol cytochrome C oxidoreductase, or coenzyme Q
reductase. Like CI, CIII is also an assembly of multiple proteins spanning the inner mitochondrial
membrane. One of the 11 CIII subunits is encoded by mtDNA, while nuclear DNA codes the remaining
10 proteins. CIII transfers electrons from CoQH2 to reduce cytochrome C, which is the substrate for
Complex IV (Figure A.1).
In the presence of a redox cycling chemical, the leaking electrons from these complexes are readily
accepted and transferred to molecular oxygen starting the redox cycling and boosting O2
. production.
How it is measured or detected
Redox cycling of a chemical can be measured directly or indirectly by different methods.
A.1. Direct detection of redox cycling by electron paramagnetic
resonance (EPR):
A radical with an unpaired electron, like the PQ•+ radical, has a distinctive EPR spectrum because of
the delocalisation of the unpaired electron across the conjugated ring system. Thus, it can be
measured by EPR, which is a sensitive, speciﬁc method for studying radicals formed in chemical
reactions and the reactions themselves (Schweiger and Jeschke, 2001 Principles of Pulse Electron
Paramagnetic Resonance, Oxford University Press). An example of an EPR spectrum of the PQ•+ radical
is shown in Figure A.24.
Figure A.23: Chemical redox cycling in mitochondria. Complex I and Complex III start PQ redox cycle in
bovine heart and brain mitochondria respectively, while the involvement of outer
mitochondrial membrane NADH-oxidoreductase is controversial. OMM: outer
mitochondrial membrane, IMM: inner mitochondrial membrane
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A.2. Direct detection of chemical radical formation by
spectrophotometry:
Each chemical radical with a distinct absorbance spectrum than the parent compound can be
measured spectrophotometrically in isolated mitochondria. However, due to the fast reaction of the
chemical radical with oxygen, these measures have to be performed under anaerobic conditions
(Cocheme and Murphy, 2009).
A.3. Direct detection of chemical radical formation (aromatic cations)
by selective electrodes:
Selective electrodes were constructed and used for measuring the concentration of lipophilic cations
in real time in mitochondrial incubations (Brand, 1995; Murphy and Smith, 2007; Cocheme and
Murphy, 2009).
A.4. Direct detection of superoxide anione formation
The methods for superoxide detection are described by Grivennikova and Vinogradov (2013). A
range of different methods is also described by BioTek (http://www.biotek.com/resources/articles/
reactive-oxygen-species.html). The reduction of ferricytochrome c to ferrocytochrome c may be used
to assess the rate of superoxide formation (McCord, 1968). Like in other superoxide assays, speciﬁcity
can only be obtained by measurements in the absence and presence of superoxide dismutase.
Oxidation of hydroethidine (HE) to 2-OH-E+, together with non speciﬁc oxidation to ethidium and
dimeric ethidium products to exclude the formation of oxidants other than superoxide, is also used as
an indicator of superoxide anion formation (Dranka et al., 2012). Chemiluminescent reactions have
been used for their increased sensitivity with lucigenin or coelenterazine as substrates. Hydrocyanine
dyes are ﬂuorogenic sensors for superoxide and hydroxyl radical, and they become membrane
impermeable after oxidation (trapping at sit of formation). The best characterised of these probes are
Hydro-Cy3 and Hydro-Cy5. Generation of superoxide in mitochondria can be visualised using
ﬂuorescence microscopy with MitoSOXTM Red reagent (Life Technologies). MitoSOXTM Red reagent is a
cationic derivative of dihydroethidium that permeates live cells and accumulates in mitochondria.
A.5. Indirect detection of superoxide anione formation
The enzyme aconitase contains an iron-sulfur cluster at its active site, which is highly sensitive to
inactivation by O2
. (Gardner, 2002). Levels of O2
. production can, therefore, be inferred from the
rate of aconitase inactivation during mitochondrial incubations. Aconitase activity is measured
spectrophotometrically by a coupled enzyme assay, linking isocitrate production by aconitase to NADPH
formation by isocitrate dehydrogenase (Gardner, 2002; Cocheme and Murphy, 2009).
Figure A.24: Detection and quantiﬁcation of the PQþ radical by EPR spectroscopy. (A) Typical EPR
spectrum of the PQþ radical (100 mM; trace (a)) generated in vitro by reduction of PQ2þ
with a twofold excess of sodium dithionite. EPR signal of the SO 2 radical present in the
dithionite solution (10 mM; trace (b)). Modiﬁed after Cocheme and Murphy, 2009
Methods in Enzymology, Copyright (2009)) Cocheme and Murphy, 2009
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Evidence supporting taxonomic applicability (tissue type, taxa, life stage, sex)
Isolated mitochondria, cultured cells and whole organisms like yeast, worms, ﬂies, rodents and
plants generate O2
° in the presence of redox chemicals like Paraquat mostly increasing mitochondrial
oxidative damage (Mason, 1990; Vanﬂeteren, 1993, Sturz and Culotta, 2002; Van Remmen et al.,
2004; Bonilla et al., 2006).
Mitochondria as a major site of mitochondrial superoxide production by PQ are supported in
rodents, ﬂies and yeast. Thus, mice heterozygous for MnSOD (the isoform of superoxide dismutase
locate in the mitochondrial matrix) (Van Remmen et al., 2004) and ﬂies silenced for MnSOD (Kirby
et al., 2002) show greater sensitivity to PQ than the control; ﬂies overexpressing catalase in
mitochondria are resistant to PQ, whereas enhancement of cytosolic catalase was not protective
(Mockett et al., 2003); human peroxiredoxin 5 in mitochondria protects yeast more efﬁciently against
PQ than expression in the cytosol (Tien Nguten-nhu et al., 2003).
Complex I has a highly conserved subunit composition in eukaryotes (Cardol, 2011). Fourteen
subunits are considered to be the minimal structural requirement for physiological functionality of the
enzyme. These units are well conserved between bacterial (E. coli), human (H. sapiens), and bovine
(B. Taurus) (Ferguson, 1994; Vogel et al., 2007). However, the complete structure of Complex I is
reported to contain between 40 to 46 subunits and the number of subunits differs, depending on the
species (Gabaldon 2005; Choi et al., 2008).
Complex I is well-conserved across species, from lower organism to mammals. In vertebrates it
consists of at least 46 subunits (Hassinen, 2007), including human in which 45 subunits were found
(Vogel et al., 2007). Moreover, enzymatic and immunochemical evidence indicate a high degree of
similarity between mammalian and fungal counterparts (Lummen, 1998). Mammalian complex I
structure (Vogel et al., 2007) and activity is characterised in detail, referring to different human organs
including brain. There is also substantial amount of studies performed on human muscles, brain, liver
as well as bovine heart (Okun et al., 1999).
Yeasts lack Complex I but reduce PQ in dependence on NADPH by intramitochondrial NADPH
dehydrogenases (Cocheme and Murphy, 2008).
Cytochrome bc1 complexes (Complex III) are found in the plasma membranes of photosynthetic
and respiring bacteria and in the inner mitochondrial membrane of all eukaryotic cells (Trumpower,
1990). In all of these species the bc1 complex contain three electron transfer proteins and transfer
electrons from a low-potential quinol to a higher-potential c-type cytochrome (Trumpower, 1990). The
number of subunits in the bc1 varies between 3 catalytic subunits in some bacteria and 11 subunits in
the mitochondrial bc1 (Trumpower, 1990).
Evidence for Chemical Initiation of this Molecular Initiating Event (MIE)
The most studied examples of chemicals that accept an electron from the mitochondrial respiratory
chain and undergo redox cycling in dopaminergic neurons are the three bipyridyl herbicides paraquat,
diquat and benzyl viologen. Substantial evidence has accumulated in the existing literature suggesting
a role for these chemical, and paraquat in particular, and this AOP. Therefore, the redox cycler parquat
will be discussed in the context of all KEs identiﬁed in this AOP.
A.1. Paraquat as a mitochondrial electron acceptor
The cellular toxicity of PQ is essentially due to its redox cycling abilities. Mitochondria are a major
source of PQ-induced ROS production in brain (Castello et al., 2007; Figure A.25).
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The early involvement of mitochondria in PQ-induced oxidative stress has been also demonstrated
in whole cells overexpressing reduction-oxidation sensitive ﬂuorescent proteins targeted to
mitochondria or the cytosol (Rodriguez-Rocha, 2013; Filograna et al., 2016). PQ (0.1–1 mM) dose-
dependently increases oxidative stress in SK-N-SH cells mitochondrial matrix at 24 h with no changes
in the cytosol (Figure A.26) (Rodriguez-Rocha et al., 2013). Accordingly, PQ 0.5 mM increases
mitochondrial ROS production in SH-SY5Y after 6 and 12 h with no evidence in the cytosol (Filograna
et al., 2016). Signiﬁcant cytoplasmic oxidative stress is evident only after 48 h starting from PQ
0.5 mM, but not for lower concentrations (Figure A.26) (Rodriguez-Rocha et al.,, 2013). A selective
involvement of mitochondria is thus dose- and time-dependent.
Figure A.25: PQ2 -induced H2O2 production in cellular fractions from the brain. Fluorometric (A) and
polarographic (B) assays were used to measure H2O2 in the presence of malate and
glutmate following the addition of 250 mM PQ2 to equal amounts of protein from each rat
brain fraction: mitochondria (solid line), cytosol (dotted line), and homogenate (dashed
line) (from: Castello et al. 2007, ﬁg. 2)
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In addition, higher protection against PQ toxicity is reached with mitochondrial, rather than
cytosolic, expression of antioxidant enzymes (Mockett et al., 2003; Tien Nguyen-nhu and Knoops,
2003; Rodriguez-Rocha et al., 2013; Filograna et al., 2016). Accordingly, the deﬁciency of the isoform
of mitochondrial superoxide dismutase (MnSOD) or mitochondrial thioredoxin reductase (necessary to
maintain the H2O2 detoxifying thioreduxin/peroxiredoxin system) increases sensitivity to PQ (Kirby
et al., 2002; Van remmen et al., 2004; Lopert et al., 2012).
Both Complex I (Cocheme and Murphy, 2008) and Complex III (Castello et al., 2007; Drechsel and
Patel, 2009) have been involved in PQ radicalisation. In Castello et al. (2007), the redox cycle-initiating
electrons are accepted from complex III and to a minor part by complex I as inhibition of complex I by
rotenone only partially inhibited PQ-induced ROS formation in isolated brain mitochondria or rat
midbrain cultures, while PQ-induced ROS formation in these systems was completely blocked after
inhibition of complex III by using antimycin A (Castello et al., 2007; Drechsel and Patel, 2009). That
complex I is not the major source of electrons triggering PQ toxicity is supported by Choi et al., (2008)
who demonstrated that silencing a major component of complex I abolishing its activity does not
protect against PQ-dependent dopaminergic cell death. On the other hand, Cocheme and Murphy
(2008) demonstrated that PQ accumulates into yeast and bovine heart mitochondrial matrix in
dependence on mitochondrial membrane potential. In heart mitochondria, PQ is then reduced mainly
by Complex I forming the radical which rapidly react with O2 to give O2
.. The Authors explain this
discrepancy with differences existing between brain and heart mitochondria (Cocheme and Murphy,
2008; Drechsel and Patel, 2009). The involvement of mitochondrial enzymes other than Complex I and
III (VDAC and Cytb5, located at the external mitochondrial membrane) remains controvertial (Shimada
et al., 2009; Nikiforova et al., 2014) and potentially excluded by the recent observation that the main
site of PQ reduction is inside mitochondria (Nikiforova et al., 2014).
A.2. General characteristics of other mitochondrial redox cyclers
Other mitochondrial redox cyclers include two other bipyridyl herbicides, diquat and benzyl viologen
(Figure A.27A and B). These share common structural features with paraquat (Figure A.27C): all
compounds are composed of two aromatic rings containing a positively charged nitrogen and are thus
good electron acceptors and redox cyclers (Drechsel and Patel, 2009; Sandy et al., 1986).
Figure A.26: Alterations of mitochondrial and cytosol redox state following exposure to PQ of cells
expressing ﬂuorescent redox probe targeted to mitochondria (Mito-roGFP) or cytosol
(roGFP). Cells were co-stained with PI and only viable cells were analysed. Alteration in
the redox state were determined by ratiometric analyses of changes in (Mito-)roGFP
ﬂuorescence at 407/488 ex and 530 em normalised with respect to control values. Data
represents means + SE of at least ﬁve independent experiments. *p < 0.05 vs control
values (Reprinted from Rodriguez-Rocha et al., 2013, copyright (2013) with permission
from Elsevier)
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Quinones (i.e. menadione, Adriamycin) and nitroaromatic compounds (i.e. nitrofurantoin) also
radicalise following one electron reduction by mitochondrial reductases (complex I and III and external
mitochondria NADH-oxidoreductase) establishing a redox cycle (Frei et al., 1986; Nikiforova et al.,
2014). Intriguingly, free cytosolic dopamine spontaneously oxidises to produce different quinones like
dopamine-o-quinone and aminochrome. Aminochrome can undergo a one-electron reduction by NAD
(P)H ﬂavoproteins generating a leukoaminochrome-o-semiquinone radical and giving rise to redox
cycle with production of superoxide anion (Figure A.28) (Zoccarato et al., 2005; Mu~noz et al., 2012).
Aminochrome has been recently suggested to play a role in the death of dopaminergic neurons
containing neuromelanin triggering oxidative stress/mitochondrial dysfunction, the formation of
a-synuclein and impaired protein degradation (Sandy et al., 1986; Drechsel and Patel, 2009).
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KE1: Mitochondrial reactive oxygen species (ROS) formation and
dysfunction
How this Key Event works:
O2, generated by redox cycling drives a cascade of active oxygen species (ROS). O2 may:
• spontaneously or in a reaction catalysed by mitochondrial superoxide dismutase (MnSOD) and
CuZnSOD (primarily cytoplasmic but also present in the peroxisome, lysosome, nucleus and
mitochondrial intermembrane space) lead to the production of hydrogen peroxide (H2O2),
which in turn will favour the formation of hydroxyl anion and hydroxyl radical through the
Fenton reaction (Figure 1; Turrens, 2003).
• react with nitric oxide (NO), which can be simultaneously produced in mitochondria by a
unique form of nitric oxide synthase located at the mitochondrial matrix (Turrens 2003), to
form peroxynitrite which may further convert to peroxynitrous acid and may yield nitrogen
dioxide and hydroxyl radical (Pryor et al., 1995).
Other possible reactions triggered by free radicals originating from redox-cycle are: hydrogen atom
abstraction and covalent binding to tissue macromolecules by radical addition to carbon-carbon double
bonds or by radical combination.
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ROS amount can be counter-balanced by natural antioxidants under physiological conditions. As such,
mitochondria are equipped with several ontioxidants systems (vitamin E, phospholipid hydroperoxide
glutathione peroxide, MnSOD, cytochrome C, catalase, glutathione, glutathion-S-transferase, glutathione
reductase, glutathione peroxidase, peroxiredoxins) (Andreyev et al., 2004). Nevertheless, antioxidant
response might be overwhelmed by aberrant augmented levels of ROS that react with mitochondrial
macromolecules such as lipids, proteins, nucleic acids and carbohydrates (Murphy, 2009) leading to
mitochondrial dysfunction, cell death and subsequently to organ pathogenesis. Indeed, oxidative stress is
considered as a contributor to the pathogenesis of chronic health problems among which
neurodegenerative conditions (Halliwell and Gutteridge, 2007).
It is well established in the existing literature that mitochondrial dysfunction may result in: (a) an
increased ROS production and a decreased ATP level, (b) the loss of mitochondrial protein import and
protein biosynthesis, (c) the reduced activities of enzymes of the mitochondrial respiratory chain and the
Krebs cycle, (d) the loss of the mitochondrial membrane potential, (e) the loss of mitochondrial motility,
causing a failure to re-localise to the sites with increased energy demands, (f) the destruction of the
mitochondrial network, (g) increased mitochondrial Ca2+ uptake, causing Ca2+ overload (reviewed in Lin
and Beal, 2006; Graier et al., 2007), (h) the rupture of the mitochondrial inner and outer membranes,
leading to the release of mitochondrial pro-death factors, including cytochrome c (Cyt. c), apoptosis-
inducing factor, or endonuclease G (Martin, 2011; Braun, 2012; Correia et al., 2012; Cozzolino et al.,
2013), which eventually leads to apoptotic, necrotic or autophagic cell death (Wang and Qin, 2010). Due to
their structural and functional complexity, mitochondria present multiple targets for various compounds.
How it is measured or detected
A.I. Reactive oxygen species production
Different ROS including hydrogen peroxide and the hydroxyl radical or the consumption of the ROS
detoxifying substance glutathione as well as ROS-dependent cellular damage like lipid peroxidation or
oxidation of protein or DNA can be measured by a variety of assays. Direct assays are based on the
chemical modiﬁcation of ﬂuorescent or luminescent reporters by ROS species. Indirect assays assess
cellular metabolites, the concentration of which is changed in the presence of ROS (e.g. glutathione,
malondialdehyde, 4-hydroxynonenal, isoprostanes, etc.). The assays described below are not
comprehensive.
A.1. Detection of hydrogen peroxide (H2O2) production
There are a number of ﬂuorogenic substrates, which serve as hydrogen donors that have been
used in conjunction with horseradish peroxidase (HRP) enzyme to produce intensely ﬂuorescent
products in the presence of hydrogen peroxide (Ruch et al., 1983; Zhou et al., 1997). The more
Figure A.29: Reactive oxygen species. Two molecules of superoxide can react to generate hydrogen
peroxide (H2O2) in a reaction known as dismutation, which is accelerated by the enzyme
superoxide dismutase (SOD). In the presence of iron, superoxide and H2O2 react to
generate hydroxyl radicals. In addition to superoxide, H2O2 and hydroxyl radicals, other
reactive oxygen species (ROS) occur in biological systems., which can be generated from
singlet oxygen by antibody molecules 65,66. The colour coding indicates the reactivity of
individual molecules (yellow, limited reactivity; orange, moderate reactivity; red, high
reactivity and non-speciﬁcity) (Adapted by permission from Macmillan Publishers Ltd,
Lambeth, 2004, copyright (2004))
PPPs, Parkinson’s disease and childhood leukaemia
www.efsa.europa.eu/efsajournal 225 EFSA Journal 2017;15(3):4691
commonly used substrates include diacetyldichloro-ﬂuorescein, homovanillic acid, and Amplex Red
(https://www.thermofisher.com/order/catalog/product/A22188). In these assays, increasing amounts of
H2O2 leads to increasing amounts of ﬂuorescent product (Tarpley et al., 2004).
A.2. Measurement of the cellular glutathione (GSH) status
GSH is regenerated from its oxidised form (GSSH) by the action of a NADPH-dependent reductase
(GSSH + NADPH + H+ ? 2 GSH + NADP+). The ratio of GSH/GSSG is therefore a good indicator for the
cellular NADP+/NADPH ratio (i.e. the redox potential). GSH and GSSH levels can be determined by HPLC,
capillary electrophoresis, biochemically with DTNB (Ellman’s reagent, 5,5’-dithio-bis-[2-nitrobenzoic
acid]) or by mean of luminescence-based assays (for example, GSH-GloTM Glutathione Assay, https://
www.promega.co.uk/resources/protocols/technical-bulletins/101/gsh-glo-glutathione-assay-protocol/).
As excess GSSG is rapidly exported from most cells to maintain a constant GSH/GSSG ratio, a reduction
of total glutathione levels is often considered a good surrogate measure for oxidative stress.
A.3. Measurement of ROS-scavenging enzymes activity
Increased activity of scavenging enzymes like catalase, superoxide dismutase (SOD) and
glutathione-S-transferase activity (GST) is indicative of ROS-production. The enzymes are recovered
both in cells and tissues homogenates, thus providing a tool to measure the occurrence of ROS ex-vivo
(Mitra et al., 2011) as an alternative to the measurement of lipid peroxidation. Measurements are
based on the detection of chromogen, sensitive to the ROS speciﬁcally produced by the investigated
enzyme, by spectroﬂuorimetric methods as described by Shina et al. (1972; for catalase); Pabst et al.
(1974, for GST) and Kakkar et al. (1984, for SOD).
A.4. Quantiﬁcation of lipid peroxidation
Measurement of lipid peroxidation has historically relied on the detection of thiobarbituric acid
(TBA)-reactive compounds, such as malondialdehyde generated from the decomposition of cellular
membrane lipid under oxidative stress (Pryor et al., 1976). This method is quite sensitive, but not
highly speciﬁc. A number of commercial assay kits are available for this assay using absorbance or
ﬂuorescence detection technologies. The formation of F2-like prostanoid derivatives of arachidonic
acid, termed F2-isoprostanes (IsoPs) has been shown to be more speciﬁc for lipid peroxidation. A
number of commercial ELISA kits have been developed for IsoPs, but interfering agents in samples
requires partial puriﬁcation before analysis. Alternatively, gas chromatography–mass spectrometry (GC-
MS) may be used as a robust, speciﬁc and sensitive method.
A.5. Detection of peroxynitrite
There are three major approaches for peroxynitrite detection, including electrochemical sensors,
detection of nitrotyrosine formation, and ﬂuorescent probes (Chen X, Biomed J. 2014).
A.II. Mitochondrial dysfunction assays assessing a loss-of function
A.1. Cellular oxygen consumption
Electrons, fed into the mitochondrial respiratory chain either by complex I or complex II, ultimately
reduce molecular oxygen to water at complex IV. In a closed system, this consumption of oxygen
leads to a drop of the overall O2 concentration, and this can serve as parameter for mitochondrial
respiratory activity. Measurements are traditionally done with a Clark electrode, or with more
sophisticated optical methods. At the cathode of a Clark electrode, oxygen is electrolytically reduced,
which initiates a current in the electrode, causing a potential difference that is ultimately recorded.
Clark electrodes however have the disadvantage that oxygen is consumed. Furthermore, interferences
with nitrogen oxides, ozone, or chlorine is observed (Stetter et al., 2008). To circumvent these
limitations, optical sensors have been developed that have the advantage that no oxygen is consumed,
combined with a high accuracy and reversibility. Optical oxygen sensors work according to the principle
of dynamic ﬂuorescence quenching. The response of the respective ﬂuorescence dye is proportional to
the amount of oxygen in the sample investigated (Wang et al., 2014). In a model of isolated
mitochondria in the absence of complex II substrates, oxygen consumption can serve as surrogate
readout for the assessment of the degree of complex I inhibition. It is however essential to realise that
also complex III and complex IV activities are involved and their inhibition also results in a decline in
O2 consumption. In addition to that, CI inhibitors can lead to a one-electron reduction of molecular
oxygen at the site of CI to yield superoxide. The amount of superoxide formed hence contributes to
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the consumption of oxygen, but must not be interpreted as oxygen consumption as a result of
controlled and coupled electron ﬂux through the complexes of the mitochondrial respiratory chain. A
modern convenient method to measure oxygen consumption is provided by the Seahorse technology
of extracellular ﬂux (XF) analysis, in which cells are kept in a very small volume, so that changes of
oxygen levels can be detected very sensitively by an oxygen sensor. To allow manipulation of the
mitochondria in cells, the cell membrane can be permeabilised with saponin (SAP), digitonin (DIG) or
recombinant perfringolysin O (rPFO) (XF-plasma membrane permeabiliser (PMP) reagent), to allow
addition of speciﬁc substrates to measure activity of different respiratory chain complexes, including
complex I. (Salabei et al., 2014).
The oxygen consumption parameter can be combined with other endpoints to derive more speciﬁc
information on the efﬁcacy of mitochondrial function. One approach measures the ADP-to-O ratio (the
number of ADP molecules phosphorylated per oxygen atom reduced (Hinkle, 1995 and Hafner et al.,
1990). The related Phosphate/Oxygen (P/O) ratio is calculated from the amount of ADP added, divided
by the amount of O consumed while phosphorylating the added ADP (Ciapaite et al., 2005).
A.2. Mitochondrial membrane potential (Dwm)
The mitochondrial membrane potential (Dwm) is the electric potential difference across the inner
mitochondrial membrane. It requires a functioning respiratory chain in the absence of mechanisms
that dissipate the proton gradient without coupling it to ATP production. The classical, and still most
quantitative method uses a tetraphenylphosphonium ion (TPP+)-sensitive electrode on suspensions of
isolated mitochondria.
The Dwm can also be measured in live cells by ﬂuorimetric methods. These are based on dyes which
accumulate in mitochondria because of Dwm. Frequently used are tetramethylrhodamineethylester
(TMRE), tetramethylrhodamine, methyl ester (TMRM) (Petronilli et al., 1999) or 5,50,6,60-tetrachloro-1,
10,3,30-tetraethylbenzimidazole carbocyanide iodide (JC-1). In particular, mitochondria with intact
membrane potential concentrate JC-1, so that it forms red ﬂuorescent aggregates, whereas de-
energised mitochondria cannot concentrate JC-1 and the dilute dye ﬂuoresces green (Barrientos et al.,
1999). Assays using TMRE or TMRM measure only at one wavelength (red ﬂuorescence), and
depending on the assay setup, de-energised mitochondria become either less ﬂuorescent (loss of the
dye) or more ﬂuorescent (attenuated dye quenching).
A.3. Enzymatic activity of the electron transport system (ETS)
Determination of ETS activity can be determined following Owens and King’s assay (1975). The
technique is based on a cell-free homogenate that is incubated with NADH to saturate the mitochondrial
ETS and an artiﬁcial electron acceptor [l-(4-iodophenyl)-3-(4-nitrophenyl)-5-phenyltetrazolium chloride
(INT)] to register the electron transmission rate. The oxygen consumption rate is calculated from the
molar production rate of INT-formazan which is determined spectrophotometrically (Cammen et al.,
1990).
A.4. ATP content
For the evaluation of ATP levels, various commercially available ATP assay kits are offered (e.g.
Sigma, http://www.abcam.com/atp-assay-kit-colorimetricfluorometric-ab83355.html), based on luciferin
and luciferase activity. For isolated mitochondria various methods are available to continuously
measure ATP with electrodes (Llaudet et al., 2005), with luminometric methods, or for obtaining more
information on different nucleotide phosphate pools (e.g. Ciapaite et al., 2005).
A.III. Mitochondrial dysfunction assays assessing a gain-of function
A.1. Mitochondrial permeability transition pore (PTP) opening
The opening of the PTP leads to the permeabilisation of mitochondrial membranes (Fiskum, 2000;
Lemasters et al., 2009), so that different compounds and cellular constituents can change intracellular
localisation. This can be measured by assessment of the translocation of cytochrome c, adenylate
kinase or the apoptosis-inducing factor (AIF) from mitochondria to the cytosol or nucleus. The
translocation can be assessed biochemically in cell fractions, by imaging approaches in ﬁxed cells or
tissues, or by life-cell imaging of GFP fusion proteins (Single et al., 1998; Modjtahedi et al., 2006). An
alternative approach is to measure the accessibility of cobalt to the mitochondrial matrix in a calcein
ﬂuorescence quenching assay in live permeabilised cells (Petronilli et al., 1999).
PPPs, Parkinson’s disease and childhood leukaemia
www.efsa.europa.eu/efsajournal 227 EFSA Journal 2017;15(3):4691
A.2. mtDNA damage as a biomarker of mitochondrial dysfunction
Various quantitative polymerase chain reaction (QPCR)-based assays have been developed to
detect changes of DNA structure and sequence in the mitochondrial genome (mtDNA). mtDNA damage
can be detected in blood after low-level rotenone exposure, and the damage persists even after CI
activity has returned to normal. With a more sustained rotenone exposure, mtDNA damage can be
also detected in skeletal muscle. These data support the idea that mtDNA damage in peripheral tissues
in the rotenone model may provide a biomarker of past or ongoing mitochondrial toxin exposure
(Sanders et al., 2014).
Evidence Supporting Taxonomic Applicability
Redox cycling is a universal event occurring in any cells of any species as well as in bacteria and
yeast (Cocheme and Murphy, 2008).
Mitochondrial dysfunction is a universal event occurring in cells of any species (Farooqui and
Farooqui, 2012). Many invertebrate species (e.g. D. melanogaster and C. elegans) are considered as
potential models to study mitochondrial functionality. New data on marine invertebrates, such as
molluscs and crustaceans and non-Drosophila species, are emerging (Martinez-Cruz et al., 2012).
Mitochondrial dysfunction can be measured in animal models used for toxicity testing (Waerzeggers
et al., 2010; Winklhofer and Haass, 2010) as well as in humans (Winklhofer and Haass, 2010).
However, there seem to be different susceptibilities towards mitochondrial toxins between
mitochondria of different organs. For example, rotenone (complex I inhibitor) severely damage brain
mitochondria, whereas liver mitochondria remained virtually unaffected (Panov et al., 2005). Moreover,
liver mitochondria have much lower Ca2 + capacities, they evidently undergo mitochondrial
permeability transition (mPT), followed by apoptosis much easier than brain mitochondria, which can
withstand much higher Ca2 + concentrations than liver (Panov et al., 2007). Not only do mitochondria
differ between organs, but also between brain regions. Work from Dubinsky’s group found that striatal
mitochondria isolated from rats were more sensitive than cortical mitochondria in their response to
calcium, perhaps due to increased amounts of cyclophilin D, a mitochondrial permeability transition
pore component (Brustovetsky et al., 2003; LaFrance et al., 2005). Independent of the mitochondrial
transition pore, brain region-speciﬁc mitochondrial membrane potential and susceptibility towards
dysfunction of mitochondrial oxidative phosphorylation (OXPHOS) was also observed by Pickrell et al.
(2011). Here the striatum was found to be especially sensitive towards disturbance of OXPHOS due to
the high striatal mitochondrial OXPHOS and membrane potential, which is prone to collapse when
OXPHOS activity is reduced. This instance becomes important when studies on compound effects on
isolated mitochondria are not of the correct origin, which would – for studying Parkinsonism – be the
brain, and here the nigrostriatal area. In addition to mitochondrial differences between organs and
intra-organ regions, species-speciﬁc mitochondrial activity was also measured. For example, inhibition
of complex III with Antimycin A causes signiﬁcantly higher ROS formation in mouse than rat brain
mitochondria suggesting a species-speciﬁc susceptibility to compounds interfering with complex III
across species (Panov et al., 2007). If human brain mitochondria are more similar to mouse or rat
mitochondria remains so far enigmatic.
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KE2: Impaired proteostasis
See AOP 1 (p. 87) for) for the description of this KE
KE3: Neuroinﬂammation
See AOP 1 (p. 95) for the description of this KE
KE4: Degeneration of dopaminergic neurons of nigrostriatal pathway
See AOP 1 (p. 90) for the description of this KE
Adverse Outcome: Parkinsonian motor deﬁcits
See AOP 1 (p. 98) for the description of the AO
KEY EVENTS RELATIONSHIPS (KERs)
1st KER: Chemical redox cycling in mitochondria leads to mitochondrial
reactive oxygen species (ROS) production and dysfunction
How this Key Event Relationship works
Chemical redox cycling is triggered in the presence of chemicals able to accept an electron from a
reductant to form a mono-cation free radical. Compounds with a lower electron reduction potential
than O2 will react fastest and the newly formed free radical, in the presence of oxygen, will re-oxidise
generating the superoxide radical O2°
 (Kappus, 1986). The radical species may then be reformed
from the parent compound reacting with oxygen again and establish a futile redox cycle boosting O2°

production (Cohen and Doherty, 1987). Mitochondria may represent the major site of chemical redox
cycling, although several membrane and cytosolic enzymes may trigger this reaction. This has been
demonstrated for PQ where alterations of mitochondrial redox state occurs earlier in mitochondria than
in the cytosol (Castello et al., 2007; Rodriguez-Roche et al., 2013; Filograna et al., 2016) and higher
protection from its toxicity is reached with mitochondrial, rather than cytosolic, expression of
antioxidant enzymes (Mockett et al., 2003; Tien Nguyen-nhu and Knoops, 2003; Rodriguez-Roche
et al., 2013; Filograna et al., 2016). Excessive generation of superoxide within mitochondria, as it
occur in the presence of a chemical redox cycler like PQ, will start a cascade of active oxygen species
that will overwhelm antioxidant response and damage DNA, proteins, lipids and other mitochondrial
components and function (Turrens, 2003; Murphy, 2009; Andreyev et al., 2014) (Figure A.30).
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Weight of Evidence
That PQ-dependent superoxide anion formation causes H2O2 in mitochondria is promoted by
concentration-response relationships, e.g. in Cocheme and Murphy, 2009 (Figure A.4). In addition, the
observation that higher protection against PQ toxicity is reached with mitochondrial, rather than
cytosolic, expression of antioxidant enzymes (Mockett et al., 2003; Tien Nguyen-nhu and Knoops,
2003; Rodriguez-Rocha et al., 2013; Filograna et al., 2016), supports the evidence as these enzymes
are involved in mitochondrial ROS detoxiﬁcation, which occurs e.g. after paraquat exposure.
Figure A.30: Schematic representation of the mechanism of paraquat toxicity. A, cellular diaphorases;
SOD, superoxide dismutase; CAT, catalase; GPX, glutathione peroxidase; Gred,
glutathione reductase; PQ2+ , paraquat; PQ+, paraquat cation radical; HMP, hexose
monophosphate pathway; FR, Fenton reaction; HWR, Haber–Weiss reaction (Reprinted
from Dinis-Oliveira et al., 2006, copyright (2006), with permission from Elsevier)
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Biological Plausibility
The biological plausibility evolves from the measured that (i) PQ is reaching the brain (Prasad,
2007; Yin, 2011; Breckenridge, 2013, 2014; Liang, 2013), (ii) PQ is taken up into nigrostriatal neurons
(Rappold, 2011) and mitochondria (Castello et al., 2007; Cocheme and Murphy, 2009) (iii) PQ is a
redox cycler inducing O2°
 production and a cascade of ROS in isolated rat brain mitochondria
(Castello et al., 2007; Cocheme and Murphy, 2008) brain homogenates (Castello et al., 2007), yeast
(Cocheme and Murphy, 2008) and brain cell cultures mitochondria (Castello et al., 2007; Cantu et al.,
2011; Dranka et al., 2012; Huang et al., 2012; Rodriguez-Rocha et al., 2013) (iv) Uncontrolled O2°

production and oxidative stress, due to chemical redox-cycling or endogenous O2°
 overproduction,
results in mitochondrial dysfunction, namely decreased activity of enzymes of the respiratory chain
(Hinerfeld et al., 2014; De Oliveira et al., 2016), diminished ATP production (De Oliveira et al., 2016),
decrease in mitochondrial membrane potential (Huang et al., 2012; De Oliveira et al., 2016),
mitochondrial DNA damage (Murphy, 2009). (v) This ROS formation can be blocked by inhibition of
complex III activity (and to a lesser extent by complex I inhibition; Castello et al., 2007; Drechsel &
Figure A.31: Production of H2O2 and O2 by PQ in mammalian mitochondria – effect of respiratory
substrate, uncoupler, and respiratory inhibitors. (A–B) Example traces from the Amplex
Red assay. Rat heart mitochondria (0.2 mgprotein/mL) were incubated at 37 in KCl buffer
supplemented with 0.01% [w/v] BSA. Substrate (5 mM succinate or 5 mM glutamate/
malate), PQ (0.1 or 1 mM), the uncoupler FCCP (1 mM), and the complex I inhibitor
rotenone (4 mg/mL) were added as indicated. (C) Rates of H2O2 efﬂux determined from
the above traces. Data are the means SD of three-four determinations. (D) O2 production
in rat heart mitochondria determined by the aconitase inactivation assay. Heart
mitochondria (2 mg protein/mL) were incubated for 10 min at 37 in KCl buffer
supplemented with 0.1% [w/v] BSA. Substrate (5 mM succinate or 5 mM glutamate/
malate) and PQ (0.1 or 1 mM) were present as indicated. Data are the means SD of
three determinations (Cocheme and Murphy, 2009. Copyright (2009) Cocheme and
Murphy, 2009)
PPPs, Parkinson’s disease and childhood leukaemia
www.efsa.europa.eu/efsajournal 232 EFSA Journal 2017;15(3):4691
Patel 2009), (v) the deﬁciency of the isoform of mitochondrial superoxide dismutase (MnSOD) or
mitochondrial thioredoxin reductase (necessary to maintain the H2O2 detoxifying thioreduxin/
peroxiredoxin system) increases sensitivity to PQ (Kirby et al., 2002; Van Remmen et al., 2004; Lopert
et al., 2012). Mitochondrial oxidative stress and mitochondrial dysfunction is a contributing factor in
the aetiology of PD.
Empirical support for linkage
Existing in vitro and in vivo data shows that compound-induced mitochondrial redox cycling causes
mitochondrial ROS formation and dysfunction. PQ dose-dependently increases mitochondrial O2°

production both in isolated mitochondria and brain cells. The effect occurs within minutes in isolated
mitochondria exposed to PQ and hours in cell cultures. In any biological context the effect is dose
dependent and cumulative in time. In vivo evidence supporting PQ-induced oxidative stress exists and
is mainly based on the occurrence of lipoperoxidation. It has been demonstrated that PQ induces an
early increase in oxidative stress in the mitochondrial matrix due to O2°
 formation that is followed by
subsequent oxidative stress in the cytosol (Rodiriguez-Rocha et al., 2013). In both in vivo and in vitro
studies mitochondrial dysfunction and cell death is reduced/prevented by overexpression.
Paraquat redox cycling with superoxide anion formation causes ROS formation and mitochondrial
dysfunction.
In Vitro
• Incubation of rat primary mesencephalic cells or a dopaminergic cell line, N27, with PQ 0.250–
1 mM for 3 or 4 h resulted in a dose-dependent reduction of aconitase activity signiﬁcant for
all the tested doses (Tab. 1) (Cantu et al., 2009, 2011). Aconitase is uniquely sensitive to O2°

mediated oxidative inactivation thus being an indirect marker of O2°
 production. O2°

formation was coupled to a dose dependent H2O2 production after 2–6 h exposure of both cell
type to PQ. The effect was signiﬁcant only for PQ 1mM at 2 h (Tab.1, 17%), 0.5 and 1 mM at
4 h (Tab. 1) and 0.25–1 mM at 6 h (Tab. 1) (Cantu et al., 2009, 2011). Cell death occurred
only 18 h after PQ exposure (i.e. after 4–6 h) (Cantu et al., 2009, 2011). Mitochondrial
aconitase has also been shown to be a source of °OH, probably Via Fenton chemistry initiated
by the co-released Fe2+ and H2O2 (Vasquez-Vivar et al., 2000). 60–70% reduction of
mitochondrial aconitase expression in N27 cells resulted in a decreased H2O2 production,
attenuation of respiratory capacity deﬁciency and death after PQ exposure (Cantu et al., 2011).
On the contrary, overexpression of m-aconitase resulted in exacerbation of H2O2 production
and increased primary mesencepahlic neuron death (Cantu et al., 2009). Aconitase inhibition
by PQ (0.1 and 1 mM) has been reported also in yeast and bovine heart mitochondrial within
minutes from the exposure (Cocheme and Murphy, 2008). This effect is coupled as well to a
dose dependent (PQ 0.1, 0.5 and 1 mM) mitochondrial H2O2 formation and is a consequence
of a mitochondrial membrane potential-dependent uptake of PQ dication (Cocheme and
Murphy, 2008).
• In another study performed on primary mesencephalic neurons (Cantu et al., 2009) exposure
to PQ 0.25 and 0.5 mM reduced aconitase activity of 43% and 58% respectively. A dose– and
time–response increase in H2O2
• Exposure of human neuroblastoma SK-N-SH cells to PQ dose (0.2–1 mM) and time (6–72 h)
dependently increases the production of O2°
, as measured by mitosox and electron
paramagnetic resonance. PQ (0.5 mM)-induced O2°
 production up to 48 h was due to
mitochondria, being prevented by MnSOD (located in the mitochondrial matrix) but not by
CuZnSOD (primarily localised in the cytosol). In addition PQ dose-dependently increases
oxidative stress in the mitochondrial matrix at 24 h and both in mitochondrial matrix and
cytosol at 48 h. A mitochondrial restricted ROS production after SH-SY5Y cell exposure to PQ
0.5 mM for 6 and 12 h was also observed in another study (Filograna et al., 2016). MnSOD
pretreatment signiﬁcantly reduced mitochondrial oxidative stress and neuronal cell death
induced by PQ 0.5 mM at 48 h, while CuZnSOD had no effect (Rodriguez-Rocha et al., 2013).
Similar results were obtained by Filograna et al. (2016) in SH-SY5Y after 24 h exposure to PQ.
All together these data shows that PQ induces an early increase in oxidative stress in the
mitochondrial matrix associated with O2°
 production, which is followed by subsequent
oxidative stress in the cytosol and is a trigger to neural cell death (Rodriguez-Rocha et al.,
2013).
PPPs, Parkinson’s disease and childhood leukaemia
www.efsa.europa.eu/efsajournal 233 EFSA Journal 2017;15(3):4691
• Paraquat (250 lM) induced H2O2 in the mitochondrial, but not in the cytosolic fraction of rat
brain homogenates (Castello et al., 2007). These data indicate again that the mitochondrion is
the primary place of PQ-induced ROS production in the cell.
• Redox cycling of Paraquat (250 lM) involves complex III of the MRC as PQ-dependent H2O2
production of isolated rat brain mitochondria (2–3 min) or primary mid brain cell cultures (6 h)
is antagonised by co-treatment with the complex III inhibitor Antimycin A and to a lesser
extent by rotenone (inhibitor of complex I; Castello et al., 2007). These data are supported by
Drechsel and Patel (2009), who conﬁrmed that complex III of the MRC is the major player in
PQ-induced ROS production in Malate and Glutamate-stimulated rat brain mitochondria (100
and 300 lM; measurements over 15 min) and primary midbrain cultures (300 lM, 8 h) by co-
treatment with Antimycin A, while this group measured involvement of MRC complex I in PQ-
induced ROS formation in isolated rat brain mitochondria only after exposure to 1 or 3 mM PQ
(15 min measurement).
• A neurotoxic concentration of PQ 0.1 mM induces production of O2°,H2O2 and NO after 24 h
in SH-SY5Y. Oxidative stress is coupled to impairment of complex I and complex V activity, to a
decrease mitochondrial potential and ATP production. All these effects are prevented by a 12 h
pretreatment with carnosic acid, a diterpene with antioxidant properties (de Oliveira, 2016).
ROS production coupled to reduced ATP production and lipid peroxidation were also observed
in SH-SY5Y differentiated cells exposed to PQ 10 lM for 48 h (McCarthy et al., 2004),
indicating that PQ ability to trigger an oxidative damage is function of dose and time of
exposure.
• In vitro, PQ toxicity both in terms of ROS production, mitochondrial dysfunction and neuronal
death is rescued by several antioxidants namely EUK 134 and 189 (synthetic SOD/catalase
mimetics) (Peng et al., 2005; Hinerfeld et al., 2014), Coenzyme Q10 (McCarthy et al., 2004),
rasagiline and cabergoline through their ability to increase the expression of gluthatione (Chau
et al., 2009, 2010), carnosic acid through the increased expression of both mitochondrial and
total glutathione and several other antioxidant enzymes (de Oliveira, 2016). Similar results are
obtained by decreasing the expression of mitochondrial enzymes involved in ROS production
(i.e. mitochondrial aconitase) prior to PQ exposure (Cantu et al., 2011) or by overexpressing
enzymes involved in O2°
 dismutation (i.e. mitochondrial superoxide dismutase) (Choi et al.,
2006; Rodriguez-Rocha et al., 2013). Accordingly, decreased expression or inhibition of
detoxifying enzymes like thioredoxin reductase (involved in the conversion of H2O2 in H2O)
potentiates synergistically increase H2O2 levels and decreased maximal and reserve respiratory
capacity following incubation with PQ oxidative stress and mitochondrial dysfunction in
dopaminergic cells (Lopert et al., 2012).
Ex Vivo
• Mitochondria isolated from the striatum of Sprague Dawley rats 24 h after exposure to PQ
25 mg/kg produce a signiﬁcant higher amount of H2O2 compared to controls (+150%) and
display decreased complex I and IV activity (37 and 21%), increased mitochondrial
membrane potential, increased lipid peroxidation (+42%) and increased cardiolipin oxidation/
depletion (+12%). No changes were observed in cortical mitochondria from PQ treated
animals. (Czerniczyniec et al., 2015). Increased O2°
 production (50% and 20% for cortical
and striatal mitochondria respectively), decreased aconitase activity (30% Cx, 50% Str),
increased lipid peroxidation (20% Cx, 30% Str) and release of cytochrome c and AIF were also
observed in mitochondria isolated from the cortex and the striatum of Sprague Dawley
exposed to PQ (10 mg/kg) over 4 weeks (one injection weekly) (Czerniczyniec et al., 2013).
These results show that both acute and prolonged in vivo exposure to PQ promotes
mitochondrial O2°
and ROS production coupled to mitochondrial dysfunction with the striatum
more sensitive than the cortex.
In Vivo
• Paraquat (10 mg/kg i.p.) once a week for 3 weeks causes loss of dopaminergic neurons (TH+)
after 2 weeks in mice in vivo. In parallel, 4-hydroxynonenal (4-HNE, time course) and
nitrotyrosine proteins (single time point) (as markers of PQ-induced oxidative stress) were
measured in TH+ cells of these animals. Lipid peroxidation at TH+ neurons is already
signiﬁcant after the 1st PQ injection (+200%) and increases up to 600% on the 2nd PQ
injection. No nigral dopaminergic cell loss occurs after the 1st PQ injection, while a signiﬁcant
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reduction of neurons is triggered by the 2nd injection (30%), suggesting a relationship with
lipid peroxidation. That ROS was involved in the dopaminergic cell death was not only shown
by these markers of peroxidation, but also shown by transgenic, human ferritin overexpressing
mice (characterised by a decreased susceptibility to oxidative stress), which were protected
against PQ-induced dopaminergic cell death and 4-HNE generation (McCormack et al., 2005).
• Mice exposed to PQ (5, 10, 20, 40, 80 mg/kg, twice a week for 4 weeks, i.p.) displayed a
dose-dependent increase in superoxide, catalase and glutathione s-transferase activity as
measured in homogenate obtained from substantia nigra, (SN) frontal cortex and the
hippocampus. ROS-scavenging activity dose dependently increased in all the three areas both
at sublethal (PQ 5–10 mg/kg) and lethal doses (PQ 20–80 mg/kg) (Tab.1, data referred only to
SN and non lethal doses). At PQ 5 and 10 mg/kg, ROS scavenging enzyme activity was speciﬁc
for the brain since no increase was observed in peripheral organs. Part of the mice exposed to
PQ 10/mg kg were also supplemented with a-tocopherol (20 mg/kg, after the last dose of PQ
for ﬁve consecutive days, i.p.), which decreased SOD, catalase and GST activity in all three
brain areas. All the animals displayed signiﬁcant DA neuronal death, microglia activation and
motor dysfunction at PQ 10 mg/kg (Mitra et al., 2011).
• In vivo administration of synthetic superoxide dismutase/catalase mimetics like EUK-134, 189,
(mice, PQ 7 mg/kg, i.p. every 2 days for 10 times; Peng et al., 2005), M40401 (rats, PQ 50 g
infused in the SN); PEP-SOD (mice, PQ 10 mg/kg, i.p.,once; Choi 2006) fusion protein protects
against PQ neurotoxicity. On the other hand, depletion of antioxidants systems exacerbates PQ
toxicity.
• Subcutaneous administration of PQ (10 mg/kg, twice/week, 3 weeks) to null mice for
glutathione (major antioxidant to maintain redox equilibrium in cells) signiﬁcantly decreased
aconitase activity (20%) and complex I activity (20%) in the striatum but not in the cortex. PQ
has no effect in wild type mice (Liang et al., 2013).
Quantitative Understanding of the Linkage
PQ ability to trigger mitochondrial ROS production (O2°
 and correlated species) by redox cycling
has been demonstrated in vitro, both in isolated mitochondria, mitochondrial brain homogenates and
cells and ex-vivo from brain mitochondria isolated from PQ-treated rats. In vivo evidence of oxidative
stress, as a consequence of PQ exposure, is mainly supported by the occurrence of lipoperoxidation,
accumulation of oxidised protein or by mean of sodium salicylate molecular trap.
PQ (0.1–1 mM) induces ROS production within minutes in isolated mitochondria and mitochondrial
brain fraction (Castello et al., 2007; Cocheme and Murphy, 2008), while in cells this process is
detectable after 2–6 h from the exposure in dependence on the dose (Cantu et al., 2011, Dranka
et al., 2012; Huang et al., 2012; Rodriguez-Rocha et al., 2013). Based on the work of Cantu et al.
(2009), which compare O2 and H2O2 production by PQ (0.25–0.5 mM) along different time points, O2
formation slightly precedes H2O2 production at the lowest PQ concentrations (Tab.1). In addition, at
these time points no death is usually detected in cells exposed to PQ up to 1 mM, pointing at ROS
production as an early event preceding cell death.
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Uncertainties or inconsistencies
• Besides mitochondria, NADPH-oxidase 1 (NOX1) (Cristovao et al., 2012) and plasma membrane
microglia NOX (Rappold et al., 2011) also contribute to PQ-induced ROS production.
Furthermore, in vitro data suggest that for time points of exposure longer than 48 h oxidative
stress occurs both at mitochondria and cytosol in dependence to the dose. Thus it is difﬁcult to
discriminate the source of PQ-induced ROS and the early involvement of mitochondria in vivo
due to the extensive treatments and to the indirect detection of oxidative stress mainly by
Table A.14: Quantitative evaluation of the KER
Treatment
PQ redox cycling with
superoxide formation
ROS formation (KE1) Reference
Rat primary
mesencephalic cell
culture PQ at
0.25–1 mM
Inhibition of aconitase after
3:
43% at 0.25 mM
58% at 0.5 mM
Increase in H2O2
At 2 h 17% at 1 mM
At 4 h 28% at 0.5 mM and 64% at
1 mM
At 6 h 31% at 0.25 mM, 59% at
0.5 mM and 119% at 1 mM
Cantu (2009)
N27 cell culture, PQ
at 0.3–1 mM
Inhibition of aconitase, 80%
at 0.5 mM, 98% at 1 mM at
4 h
Increase in H2O2 at 4–6 h
25% at 0.3 mM and 33% at 1 mM
Cantu (2011)
Dose-dependent neuronal cell
death occurring at 18 h but not
at 4–6 h
SK-N-SH human
neuroblastoma cells
treated with PQ
0.2 mM up to 1 mM.
6–62 h sampling
Dose and time related
increase of O2 by electro
paramagnetic resonance
spectroscopy. 50% at
0.2 mM, 80% at 0.5 mM
and 150% at 1 mM at 24 h
Increase in DHE
ROS production 800% at 0.5 mM at
48 h
Rodriguez Rocha (2013)
SD rat treated at
25 mg/kg and
observed 24 h later
H2O2 increase of 150% in isolated
mitochondria from SN neurons
corresponding to 42% mitochondrial
lipid peroxidation
Decrease in Complex I 33% and
Complex IV 21%
Increase mitochondrial membrane
potential
Czerniczyniec (2015)
SD rat treated at
10 mg/kg weekly for
4 weeks
Increase in O2 production in
isolated mitochondrial of
20%
Decrease in aconitase
activity in mitochondrial of
50% in striatum
Increase in lipid peroxidation in
isolated mitochondria of 30%
Czerniczyniec (2015)
C57BL/6 mice treated
with 10 mg/kg PQ i.p.
once a week for
3 weeks
Increased neuronal lipid peroxidation
measured 1 day after weekly injection
each:
10 mg kg i.p.
200% increase in lipid peroxidation at
2 and 4 days post-inj
500–600% in lipid peroxidation after
2nd injection 2/4 days after
After third injection limited response
due to signiﬁcant neuronal cell loss
McCormack et al. (2005)
Neuronal cell loss up to 30% in
mid brain sections
Swiss albino mice i.p.
at 5 and 10 mg kg
twice a week for
4 weeks
SOD activity ex vivo
At 5 mg/kg increase of 42%
At 10 mg/kg increase of
75%
Glutatathione s transferase activity
ex vivo
At 5 mg/kg increase of 25%
At 10 mg/kg increase of 75%
Catalase activity ex vivo
At 5 increase of 17%
At 10 increase of 50%
Mitra (2011)
Neuronal cell loss of 40% TH
positive and Fox 3 positive and
motor dysfunction symptoms at
10 mg/kg and 10% at 5 mg/kg.
Motor symptoms only at
5 mg/kg
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mean of lipoperoxidation, protein oxidation. Mitochondrial involvement is suggested by ex-vivo
studies (Czerniczyniec et al., 2013, 2015).
• Mitochondrial loss of function (i.e. decrease in mitochondrial membrane) might sometimes be
the consequence of cell death rather than directly resulting from oxidative stress. This is due
to the estimation of this parameter at time points already characterised by a signiﬁcant cell
death without a double staining, which allow discriminating between alive and dead cells. The
observation that loss of mitochondrial membrane potential on PQ exposure is only detected in
the population of dead cells when cells are double stained for mitochondrial membrane
potential and plasma membrane integrity (Rodriguez-Rocha, 2013) support this uncertainty.
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2nd KER: Mitochondrial dysfunction results in an impaired proteostasis
How this Key Event Relationship work
See AOP 1 (p. 124)
Weight of Evidence
See AOP 1 (p. 124)
Biological Plausibility
See AOP 1 (p. 124)
Empirical support for linkage
Based on the existing in vitro and in vivo data it is suggested that mitochondrial dysfunction impairs
protein homoeostasis through oxidative and nitrosative stress resulting in protein aggregation,
damaged intracellular transport of proteins and cell organelles.
• Paraquat 0.5 mM decreases mitochondrial complex V activity, ATP production and proteasome
activity in SH-SY5Y cells. All these effects increase in time (from 6 to 48 h) and are signiﬁcant
at 24 and 48 h of treatment. In addition, PQ signiﬁcantly decreases proteasome 19S subunit –
but not 20S – only at 48 h. However, since this 19S subunit drops later than proteasome
activity decrease, it could not have caused proteasome dysfunction. Signiﬁcant increased levels
of a-syn and ubiquitinated proteins are also evident at 24 and 48 h following PQ exposure.
SH-SY5Y death occurred only at 48 h. Cell death is dose dependent (PQ 0.05 – 1 mM) and is
signiﬁcant at 0.5 and 1 mM (57 and 75% respectively). PQ induces mitochondrial dysfunction
and proteasome impairments leading to neuronal death (Yang and Tiffany-Castiglioni, 2007).
• Reduced mitochondrial membrane potential and proteasome inhibition has been also observed
for 0.2 mM PQ as early as 3 h after exposure in SH-SY5Y cells. A slight but signiﬁcant effect
also occurs at 0.02 mM PQ at longer time (6 h). 0.2 mM PQ-induced effects precede neuronal
death (12 h; no death observed at 0.02 mM). Transfection of the heat shock protein HDJ-1
(that attenuate protein aggregation without altering ROS production, as measured by DCF) in
SH-SY5Y cells attenuates 0.2 mM PQ-induced mitochondrial membrane potential decrease at
6 h (from 50% to 80%). This suggests that protein aggregation also contribute to the loss of
mitochondrial membrane potential (Ding and Keller, 2001).
• Paraquat (10 mg/kg, once a week for 3 weeks) in combination with DJ-1 deﬁciency decreases
ATP levels, proteasome activities, proteasome subunits levels and increases ubiquitinated
proteins in the ventral midbrain including SNpc. None of these effects is observed at the
striatum (Yang et al., 2007). DJ-1 has been suggested to contribute to mitochondrial integrity
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due to its localisation in the mitochondrial matrix and inter-membrane space (Zhang et al.,
2005) and its antioxidant action (Taira et al., 2004). Likewise, exposure to PQ and deﬁciency of
DJ-1 might cooperatively induce mitochondrial dysfunction resulting in ATP depletion and
contribute to proteasome dysfunction in the brain.
• Paraquat (10 mg/kg i.p.) induced signiﬁcant increase in lipid peroxides (LPO) in ventral midbrain
(VM), striatum (STR) and frontal cortex (FCtx), maximum in VM after 5 doses (2.4 times the
control). An elevated LPO level was still present in VM after 28 days. Moreover, the activity of 20S
proteasome in STR was altered (increased 40–50%) after a single dose and slightly reduced after
5 doses (Prasad et al., 2007). The temporal activation of proteasomal activity at 1 and 24 h after
single dose was explained by the fact that carbonylated proteins moderately undergo
degradation by UPS (Poppek and Grune, 2006). Sublethal proteasome inhibition induces neurons
to increase proteasome activity and promotes resistance to oxidative injury (Lee et al., 2004).
Quantitative evaluation of KERs
Table A.15: Quantitative evaluation of the KER
Treatment
Mitochondrial
dysfunction (KE2)
Impaired protein degradation
(KE3a)
Reference
SHSY5Y cells, PQ
0.5 mM, 12, 24 and
48 h
Decreased activity of
complex V (% of control;
signiﬁcant):
12 h ne
24 h 70%
48 h 50%
decreased ATP levels (% of
control):
12 h ne
24 h 76%
48 h 39%
Decreased proteasome activity (%
of control):
12 h ne
24 h 40%
48 h 23%
Decreased protein level of 19S
subunit (% of control):
12 h ne
24 h ne
48 h 32%
ne on 20S a and b at any time
Increased level of ubiquitinated
proteins (% of control):
12 h ne
24 h 154.5%
48 h 167%
Increased protein level of a-syn:
12 h ns
24 h 236%
48 h 305%
Yang and Tiffany-Castiglioni (2007)
Comments:
PQ induced signiﬁcant SHSY5Y
cells death only at 48 h thus
mitochondrial dysfunction and
impaired protein degradation
occurs before neurons die.
Furthermore, the lack of effect on
20S subunits suggests that the
observed paraquat effects were
not nonspeciﬁc cytotoxic events
Levels of 19S dropped at 48 but
not 24 h after paraquat treatment,
and therefore could not have
caused the proteasome
dysfunction observed
SHSY5Y cells, PQ 20
and 200 lM, different
time points
SHSY5Y transfected
with HDJ-1 (member of
the Hsp40 family,
attenuate protein
aggregation), PQ
200 lM for 6 h
Reduced mitochondrial
membrane potential (% of
control):
20 lM-
6 h approx. 80%? Reduced
of 20% vs control
200 lM-
3 h approx. 60%? Reduced
40% vs control
6 h approx 40% reduced
60% vs control
Partial signiﬁcant (20% vs
PQ treated only) recovery of
mitochondrial membrane
potential
Reduced proteasome activity
(% of control)
20 lM-
6 h 85% signiﬁcant reduced of
15% vs control
200 lM-
1 h approx. 80% reduced of 20%
vs control
3 h approx 60% reduced of 40%
vs control
6 h approx. 55% reduced of 65%
vs control
Partial signiﬁcant (25% vs PQ
treated only) recovery of
proteasome activity
Ding and Keller (2001)
Comments:
Death at 6 h not measured,
signiﬁcant death at 24 h for 20 lM
and 12 h for 200 lM
Co-treatment with 20 lM PQ +
epoxomycin 1 lM (proteasome
inhibitor) exacerbate PQ-induced
mitochondrial membrane potential
decrease (to 75% vs control or
60% vs 20 nM PQ treated only)
and cell death.
The ability of increased levels of
HDJ-1 to attenuate proteasome
inhibition did not appear to be due
to a decrease in ROS levels, or
altered levels of proteasome
subunits
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Uncertainties or inconsistencies
• The exact molecular link from mitochondrial dysfunction to disturbed proteostasis is not
known. It is not clear which is the oxidative modiﬁcation that drives the process.
• Proteostasis incidence is higher than mitochondrial dysfunction at PQ 0.5 mM (Yang and
Tiffany-Castiglioni, 2007) but not at PQ 0.2 mM (Ding and Keller, 2001) at the same time point
in SH-SY5Y cells. These results suggest that, in vitro, at doses higher than 0.2 mM PQ might
involve mechanisms other than mitochondrial dysfunction.
• The sequence of events that link mitochondrial dysfunction to proteases inhibition is not
entirely clear, proteosomal dysfunction might contribute to mitochondrial dysfunction (Ding and
Keller, 2001). On the other side, sublethal proteasome inhibition induces neurons to increase
pretoasome activity and promotes resistance to oxidative injury (Lee et al., 2004), whereas
oxidative stress can increase proteasome activity early in the sequence leading to cell death
in vitro (Holtz et al., 2006).
• A vicious circle is observed that make it difﬁcult to establish an exact quantitative relationship
between mitochondrial and proteosomal dysfunction. This task needs a better dose- and time-
related deﬁnition of PQ effect on those two events that is actually lacking.
• Lack of evidences of the link between mitochondrial dysfunction and disturbed proteostasis in
WT animals exposed to PQ.
• Distinct unfolded protein response (UPR) signalling branches could have speciﬁc and even
opposite consequences on neuronal survival depending on the disease input (Hetz and
Mollereau, 2014). Proteostasis impairment at the level of the endoplasmic reticulum (ER) is
Treatment
Mitochondrial
dysfunction (KE2)
Impaired protein degradation
(KE3a)
Reference
Mice WT and DJ-
deﬁcient, 10 mg/kg PQ,
once a week for
3 weeks
ATP levels in VMB decreased
of 30% in DJ deﬁcient (vs
control)
• Proteasome activity in VMB
reduced approx. 30% (vs
control)
• Ubiquitinated proteins
increased levels in VMB 1.5
times the control
• Proteasomal subunits (18S
and 20S) levels decreased in
VMB of approx. 30% (vs
control)
Yang et al. (2007)
Effects evident only in VMB
(include SNpC) and not in striatum
and only in DJ-deﬁcient mice. DJ-
deﬁcient as WT for all the
parameters.
Additional measurements:
• Motor symptoms decreased
of 40%(vs control) in DJ-
deﬁc only;
• Dopamine levels decreased
30% (vs control)in DJ-deﬁc
only (BUT dopamine level in
DJ mice not treated is higher
than in WT control);
• TH+ neurons stereol count:
NO effects
Thus concordance motor
symptoms and decreased
dopamine, but not effect on
neurons: authors suggested that
behavioural and neurochemical
consequences manifest before
dopamine neuron degeneration
PQ 10 mg/kg i.p.
(administered 3 times/
week for a total of 1, 3
or 5 doses) in C57BL/6J
mice
Increased tissue level of lipid
peroxides (LPO) after a
single (and persistent up to
28 days) and repeated
doses, maximum in VM after
5 doses (2.4 times the
control, lower in STR (80%)
and least (66%) in FrCtx
Increased activity 20S proteasome
in STR (not quant in other tissues)
at 1 (40%) and 24 h (50%) after
single i.p. dose
20S activity was reduced in STR
after 5 doses (15%)
Prasad et al. (2007)
ne: negative.
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emerging as a driving factor of dopaminergic neuron loss in PD. ER stress engages the
activation of the UPR adaptive reaction to recover proteostasis or trigger apoptosis of damaged
cells. PQ may induce ER stress (Huang et al., 2012).
• A genetic screening in yeast revealed that one of the major physical targets of a-Synuclein is
Rab1, an essential component of the ER-to-Golgi trafﬁcking machinery (Cooper et al., 2006;
Gitler et al., 2008). Overexpression of Rab1 in animal models of PD reduced stress levels and
protected dopaminergic neurons against degeneration (Coune et al., 2011).
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3rd KER: Impaired proteostasis leads to degeneration of DA neurons of the
nigrostriatal pathway
How this key event relationship works
See AOP 1 (p.143)
Weight of evidence for the KER
1. Biological plausibility
See AOP 1 (p.143)
2. Empirical support for linkage
Large part of the empirical evidence supporting this KEs relationship comes from observational
studies conducted in human affected by PD, from in in-vitro and in-vivo studies conducted with the
chemical stressors MPTP and rotenone or from experiments conducted with proteasome inhibitors.
With the chemical stressor paraquat, used for the empirical support of this AOP, most of the studies
where providing evidence that in the same experiments impaired proteostasis and neuronal
degeneration where co-existing. Although different concentrations of paraquat wher used in the in-
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vitro assays, in-vivo studies where generally conducted at ﬁxed dose though different doses scheduling
could have been applied.
Paraquat is an herbicide for which a unique sensitivity of dopaminergic neuronal cells was also
observed (Brooks et al., 1999; McCormack et al., 2002; Uversky, 2004). Similarly to MPTP and
Rotenone, also in paraquat treated mice, an up regulation and aggregation of a synuclein and
inhibition of the proteosomal pathway was demonstrated in DA neurons in SN (Manning-Bog et al.,
2002; Wills et al., 2012). Additionally, paraquat is able to reduce proteosomal function in DJ-I deﬁcient
mice with an impaired clearance of altered proteins (Yang et al., 2007). Paraquat is clearly more toxic
in aged animal or when co-administered with the fungicide maneb (McCormack et al., 2002;
Thiruchelvam et al., 2003). Duration of treatment could also impact neuronal loss (Ossowska et al.,
2005).
Human evidences
• Human data from PD patients are indicative of an overall inhibition of axonal autophagy with
an increased level of mTor (a major protein involved in autophagy) which was accompanied
with an impairment to form autophagosome. The observed increase in m TOR levels was of
63% (Willis et al., 2012).
• Inclusion bodies in DA neurons (i.e. Lewy bodies), a pathological hallmark for sporadic PD,
stains speciﬁcally for proteins associated with the UPS (McNaught et al., 2002; Fornai et al.,
2005), including a-synuclein, parkin and ubiquitin; possibly indicating that failure of the UP
system represents a common step in the pathogenesis of PD and impairment of the
proteasome system was found in humans affected by sporadic PD (McNaught et al., 2001,
2003).
• Lysosomal breakdown and autophagosome (AP) accumulation with co-localisation of lysosomal
markers in Lewy Bodies is reported to occur in PD brain samples where Lewy bodies were
strongly immunoreactive for the autophagosome markers (LC3II) (Dehay et al., 2010).
• Postmortem studies on PD patients show axonal pathology that is likely to precede the loss of
neuronal bodies In this investigation, TH immunoreactive ﬁbres had almost entirely
disappeared with preservation of neuronal bodies (Orimo et al., 2005, 2008).
Paraquat
• Paraquat (10 mg/kg i.p. once a week for 3 consecutive weeks) exposure in male mice (control
mice and transgenic mice expressing either wild type human a-synuclein or mutant form of the
human protein) induced in control mice accumulation of intracellular a-synuclein-
immunoreactive deposits in 30% of dopaminergic neurons and decreases by 25–35% the
number of TH positive and Nissl-stained neurons in SNpc following stereological evaluation. A
protective effect (presence of intracellular protein positive deposits –36% with lack of
neurodegeneration) was observed in animal overexpressing the wild as well as a mutated form
of a-synuclein. In these animals a concomitant increase of HSP70 chaperone protein was
observed (Manning-Bog et al., 2003). Heat shock proteins has been reported to play a
protective role against PQ toxicity (Ding and Keller, 2001; Minois et al., 2001) and its increase
may represent an adaptive change to high intraneuronal a-synuclein concentrations.
• Weekly i.p. injection of 10 mg/kg of paraquat for 3 weeks in male mice overexpressing a-
synuclein induced loss of dopaminergic neurons in SNpc and decrease in TH optical density
(slight) in the striatum which was accompanied by an increase of intracytoplasmic insoluble a-
synuclein (Fernagut et al., 2007). (Similar decrease in dopaminergic neurons, without a-
synuclein accumulation, was observed also in PQ-treated WT animals.)
• Administration of 10 mg/kg i.p. twice a week for 4 weeks to adult Swiss albino mice induced
dopaminergic neuronal loss (ca. 40% reduction) in SN (also in FC and hippocampus) which
was associated with a decrease in a-synuclein expression (ca. 50% reduction) (increased in
hippocampus) and reduction of TH levels (ca. 50% reduction) in SN (and hippocampus) (Mitra
et al., 2011). The reduced a-synuclein expression in SN, increased expression in hippocampus,
and aggregated forms in FC might correlate with a-synuclein gene polymorphism associated
with PQ-mediated neurotoxicity and the differential time frames necessary to initiate
neurodegeneration in the different regions.
• In male Wistar rat receiving four i.p. injections, separated by 1 day, of paraquat at 10 mg/kg
per day, showed a 50% increase of a-synuclein immunoreactivity and protein level (by Western
blot) in SN. The stereological count of TH-positive neurons showed that Nox 1 knockdown
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animals (stereotaxically injected with a viral constructed expressing Nox 1 or ablated for it)
treated with Paraquat, signiﬁcantly reduced PQ-elicited dopaminergic neuronal loss from 37%
in the group treated with vector and PQ to 13% in the Nox 1 KO treated with PQ. Nox 1
knockdown reduced by 37% the PQ-mediated a-synuclein levels, compared to vector plus PQ,
as well as a-synuclein aggregation and it was accompanied by a reduction in a-synuclein
immunoreactivity and protein level as well as a decrease in a-synuclein aggregation (Cristovao
et al., 2012).
• Proteasome activity was investigated in dopaminergic SH-SY5Y cells treated with paraquat.
Results showed that at a concentration of paraquat that reduced viability by about 60% at
48 h (0.5 mM) loss of proteasome activity occurred. Furthermore, paraquat-treated cells
showed decreased protein levels of proteasome 19S subunits, but not 20S alpha or beta
subunits, suggesting that the effects observed were not the result of general cytotoxicity.
Paraquat also increased levels of alpha-synuclein and ubiquitinated proteins, suggesting that
paraquat-induced proteasome dysfunction leads to aberrant protein accumulation (Yang et al.,
2007).
• Low concentration of paraquat (10 lM) induced autophagy in human neuroblastoma cells line
(SH-SY5Y). Paraquat induced autophagic vacuoles (AV) and recruitment of LC3-GFP fusion
protein to AV. Finally, cell death with hallmarks of apoptosis was observed. Paraquat also
increased long-lived protein degradation which was blocked by the autophagy inhibitor 3-
methyladenine (3-MA). While caspase inhibition retarded cell death, autophagy inhibition
accelerated the apoptotic cell death induced by paraquat (Gonzalez-Polo et al., 2007).
• SH-SY5Y cell transfected with DJ-1-speciﬁc siRNA and exposed to paraquat showed additive
effect on apoptotic cell death, inhibition of the cytoplasmic accumulation of autophagic
vacuoles as well as recruitment of LC3 fusion protein to the vacuoles. The effect was time and
dose related (25–500 lM) (Gonzalez-Polo et al., 2009). Apoptotic cell death was accelerated by
treatment with the autophagy inhibitor 3-methyladenine (3-MA). Findings suggest an active
role for DJ-1 in the autophagic response produced by Paraquat, providing evidence for the role
of PD-related proteins in the autophagic degradation pathway.
• Paraquat (500 lM) triggers endoplasmic reticulum stress and cell death (70% reduction in cell
survival) and inhibits proteosomal activity (60–70% reduction) in a rat N27 mesencephalic
dopaminergic cells system (Shankar et al., 2008).
• Males C57BL/6NCrlVr mice received i.p. injections of 10 mg/kg of paraquat twice a week for
4 weeks showed a decrease in TH+ neurons of approximately 43%. This was accompanied by:
increased of 133% of a-synuclein, increased by 13% (not statistically signiﬁcant) in 19S
proteasome function and decrease of 5% 20S proteasome function (not stat signiﬁcant),
increase by 43% in mTOR (autophagy inhibitor), increase by 81% of beclin-1 (autophagy
inducer) and increase in Atg12 of 36% (Su et al., 2015).
Quantiﬁable understanding
A quantitative relationship has been established between the chemical stressor paraquat inducing
impaired proteostasis and loss of DA neurons of nigrostriatal pathway. A response concordance was
observed for the quoted studies; however dose and time relationship could be only established in a
limited number of in-vitro studies as the in-vivo studies were conducted at single dose and single
evaluation time-point.
Impaired proteostasis DA neurons degeneration Treatment References
Intracellular deposit of in a-synuclein
observed in 30% of DA neurons
Approx. 30 (25–35%) % of cell
loss (TH positive cells) in SNpc
C57BL/6 mice treated with
Paraquat once a week for 3 weeks
at 10 mg/kg i.p.
Manning –Bog
et al. (2003)
Fernagut (2007)
Increase of approx. 91% of
a-synuclein inclusion (proteinase-K-
resistant a-syn aggregates) only
observed in a-synuclein
overexpressing animals
Approx. 25% loss of DA neurons
(stereological analysis TH-positive
neurons) in both WT as well as
a-synuclein overexpressing animals
Weekly i.p. administration of
10 mg/kg paraquat for 3 weeks in
mice WT and overexpressing
a-synuclein
Approx. 50% reduction in a-synuclein
expression in SN
Approx. 40% loss of DA neurons
(TH+ and FOX3 + neurons)
Paraquat 10 mg/kg i.p. twice a
week for 4 weeks to adult Swiss
albino mice
Mitra et al.
(2011)
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Impaired proteostasis DA neurons degeneration Treatment References
Approx. 50% increase of a-synuclein
expression (immunoreactivity and
protein)
Paraquat signiﬁcantly reduced PQ-
elicited dopaminergic neuronal loss
from 37%
Wistar rat receiving four i.p.
injections, separated by 1 day, of
paraquat at 10 mg/kg per day
Cristovao et al.
(2012)
Proteasome inhibition (approx. 60%
at 24 h and 80% at 48 h)
Increased protein levels of a-
synuclein (2.3-fold at 24 h and 3-fold
at 48 h)
Increased ubiquinated protein levels
(1.5-fold at 24 h and 1.7-fold at
48 h)
Reduction of 60% in cell viability
at 48 h
DA SH-SY5Y cells treated with
paraquat 0.5 mM
Yang et al.
(2007)
Accumulation of AV (%vacuolated
cell volume) at 6, 15 and 24 h was
20, 40 and 45% respectively.
Inhibition of PQ-induced autophagic
vacuolisation and protein degradation
after treatment with 3-MA
25% of nuclear apoptosis at 24 h
(caspase-3 maximum level)
Apoptosis cell death was
accelerated and caspase-3
activation increased after 3-MA
treatment
DA SH-SY5Y cells treated with
paraquat 10 lM
DA SH-SY5Y cells treated with
paraquat 10 lM were then treated
with prototypic autophagy inhibitor
3-MA 10 mM
Gonzalez-Polo
et al. (2007)
SiRNA knockdown of DJ-1 has no
effect alone on the formation of
autophagic vacuoles.
In the presence of PQ (250 lM), DJ-
1 knockdown signiﬁcantly inhibited
cytoplasmic accumulation of
autophagic vacuoles, with an additive
increase in apoptotic chromatin
condensation
SiRNA knockdown of DJ-1 induces
apoptotic death (25–30%)
The combination of DJ-1 si RNA
and Paraquat induces additive
apoptotic death (more signiﬁcant
in the range 250–500 lM PQ) and
caspase-3 activation.
Apoptosis cell death was
accelerated after 3-MA treatment
DA SH-SY5Y cells transfected with
DJ-1 si RNAs and exposed to
paraquat 250–500 lM
DA SH-SY5Y cells transfected with
DJ-1 si RNAs exposed to paraquat
250–500 lM treated with
prototypic autophagy inhibitor
3-MA 10 mM
Gonzalez-Polo
et al. (2009)
Increased expression of ER stress
proteins and inhibition proteosomal
activity (60–70% reduction at
500 lM)
Time and concentration-dependent
cell death (70% with 500 lM of
PQ for 48 h) reduction in cell
survival
Rat N27 mesencephalic
dopaminergic cells treated with
Paraquat (100–500 lM) for
12–48 h
Chinta et al.
(2010)
Increased 133% of a-synuclein
Increased by 13% (not statistically
signiﬁcant) in 19S proteasome
function and decrease of 5% 20S
proteasome function (not stat signif)
Increase by 43% in mTOR
(autophagy inhib)
Increase 81% beclin-1 (autophagy
inducer)
Increased in Atg 12 of 36%
Decrease of appr 24% in LC3 II to
LC3 I ratio
C57BL/6 mice treated with
Paraquat twice a week for 6 weeks
at 10 mg/kg i.p. (12 doses)
Wills et al.
(2012)
Increase 115% a-synuclein in
striatum
10% decrease in 19S proteasome
function and 5% in 20S proteasome
function (both not statist signiﬁcant)
Increase 47% in mTOR and stat sig
in beclin-1(81–95%)
Increase in Atg12 (40%)
LC3 II to LC3 I ratio decreased up to
25%
TH neuronal loss 43% C57BL/6NC mice treated with
Paraquat twice a week for 4 weeks
at 10 mg/kg i.p.
Su et al. (2015)
Uncertainties or inconsistencies
• The ability of paraquat to induce loss of DA neurons in SN in vivo is sometime equivocal. Loss
of 60% of DA neurons in SN and 90% of their striatal terminals are reported (Brooks et al.,
1999) following repeated treatment with paraquat but less signiﬁcant evidence, or no
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evidence, has been reported in later studies (Thiruchelvam et al., 2000; McCormack et al.,
2002). No effect of paraquat on dopaminergic neurons has been reported by some authors
(Widdowson et al., 1996; Breckenridge et al., 2013; Minnema et al., 2014). However, the
applied dose, the treatment scheduling, the route of administration as well as the animal age,
species and strain (McCormack et al., 2002; Thiruchelvam et al., 2003; Yin et al., 2011; Jiao
et al., 2012; Tieu, 2016) are all important factor to be considered in the evaluation of the
study’s outcome.
• Dopaminergic neurons in SN and VTA seem to have a different susceptibility to the damage
induced by paraquat (McCormack et al., 2006). However, whether impaired proteostasis and
protein aggregation would cause the selective death of DA neurons in the SN still remain an
uncertainties.
• Selectivity of paraquat-induced DA neuronal cell death still remains uncertain. Similar effect on
other brain region i.e. frontal cortex and hippocampus) are also affected (Mitra et al., 2011).
• The vulnerability of the dopaminergic pathway still remains circumstantial. Paraquat has been
proposed to pass the blood-brain-barrier by mediation of neutral amino acid transportation
(Shimizu et al., 2001; McCormack et al., 2003). Accumulation of paraquat in the brain is
reported to be age dependent, possibly indicating a role for the blood-brain-barrier
permeability (Corasaniti et al., 1991); however, paraquat is not a substrate for dopamine
transporter (Richardson et al., 2005), and hence how the toxicant enters into dopaminergic
neurons still remain uncertain.
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4th KER: Neuroinﬂammation leads to degeneration of the dopaminergic
neurons of nigrostriatal pathway
See AOP1 (p. 154)
5th KER: Degeneration of dopaminergic neurons of the nigrostriatal
pathway directly leads to neuroinﬂammation
See AOP1 (p. 165)
6th KER: Degeneration of DA neurons of nigrostriatal pathway leads to
motor symptoms of PD
How this key event relationship works
See AOP1 (p. 169)
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Weight of evidence for the KER
Biological plausibility
See AOP 1 (p. 170)
Empirical support for linkage
• Paraquat treatment (10 mg/kg twice a week for 4 weeks) of young adult Sprague-Dawley rats
(2 months old) induced a signiﬁcant loss of nigral dopaminergic neurons (by Nissl staining and
TH immunostaining) in SNpc of 15% and a mixed pattern of motor impairments (postural
deﬁcit, decrease in speed and mobility), which may have been related to early effects of nigral
dopaminergic neuronal loss (Cicchetti et al., 2005).
• Adult C57 BL/6 mice treated i.p. with paraquat (5 and 10 mg/kg) showed a dose-dependent
decrease in substantia nigra dopaminergic neurons (36% and 61%, respectively, assessed by
Fluoro-gold prelabelling method), a decline in striatal dopamine nerve terminal density (87%
and 94%, respectively, assessed by TH immunoreactivity) and neurobehavioural syndrome
characterised by reduced ambulatory (locomotor) activity (Brooks et al., 1999).
• Paraquat treatment (i.p. 10 mg/kg twice a week for 4 weeks) of male Swiss Albino mice, 22–
14 weeks old, induced progressive motor dysfunction with severe postural instability and gait
impairment. A concomitant decrease in the expression levels of TH in SN (approximately 60%),
FC (frontal cortex) and hippocampus and a decrease (approx. 40%) in TH+ and FOX3+
neurons in SN were observed (stereological evaluation). As part of the toxicological evaluation
of the most suitable sublethal dose, mice were also treated at 5 mg/kg by i.p. twice a week for
4 weeks. In addition, a decrease in DOPA-decarboxylase was observed in the SN and FC. The
only endpoint measured (in addition to the general toxicity endpoints) was the neuronal count
in the SN. A statistical signiﬁcant decrease (approximately 15%) in TH+ and FOX3+ neurons
was observed (Mitra et al., 2011).
• Male C57BL/6 mice, 6 weeks, 5 months and 18 months old, were i.p. treated with paraquat at
10 mg/kg twice a week for 3 weeks (6 injections in total). Age-dependent reduction in
locomotor activity and motor coordination was observed. The 18-month old mice were the
most severely affected and failed to recover 24 h post treatment. Progressive reduction in
dopamine metabolites and turnover were greatest in the 18-month old group of animals.
Increased in striatal TH activity was observed in the 6-week-old and 5-month-old animals but
not in 18-month-old mice. The number of nigrostriatal dopaminergic neurons was reduced in
all age group animals but these losses, along with the decreases in striatal TH protein levels,
were progressive in 18-month-old paraquat groups between 2 weeks and 3 months post-
exposure. (Thiruchelvam et al., 2003).
• Intracerebral injection of 1–5 lg paraquat in male Wistar rats (3 months old) for 16 weeks
caused dose-dependent depletion DOPA in the ipsilateral striatum starting 2 weeks after
treatment (long-lasting and irreversible) up to 91.5% at 3 lg paraquat. Paraquat induced
marked loss of Nissl substances and severe loss of neurons at 3 lg. PQ caused dose-
dependent rotational behaviour in rats, contralateral to the lesion side, in response to
apomorphine administration (inducing circling behaviour) (Liou et al., 1996).
• Male Wistar rats were injected with 10 mg/kg paraquat i.p. for 4–24 weeks. Paraquat induced
reduction in TH+ neurons of the SN (17% at 4-week mainly in the rostral region, up to 37% at
24 weeks expanding to the whole length of SN; evaluated by stereology). DOPA levels
increased in the caudate-putamen (4–8 weeks) then returned to control values and dropped
(25–30%) after 24 weeks. This seems to result from degeneration of DA neurons. TH level
(Western blot) decreased in the caudate-putament after 24 weeks (55%) but this effect was
not reﬂected by the loss in TH-ir neurons (being already dropped in the rostral part of SN after
4 weeks) (Ossowska et al., 2005). Clinical signs were not recorded in this study; however the
study design was considered of relevance for the evaluation of the progression of the ﬁnding
associated with neuronal loss.
• Paraquat treatment (i.p. injection 10 mg/kg bw every 5 days over 20 days) of Long Evans
Hooded rats induced progressive (TH positive neurons stereology counted) loss in
dopaminergic neurons up to 47% (end of week 8 post PQ exposure) and deﬁciency in
behavioural motor function (horizontal beam walking test) (after 4 and 8 weeks). Ubisol-Q10
(6 mg/bw) administration after completion of paraquat injections (when the degenerative
process had already began (20% TH positive neurons lost)) was effective in blocking the
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progression of neurodegeneration and improved motor skills. To maintain this neuroprotection,
continuous Ubisol-Q10 supplementation was required. Discontinuation of treatment resulted in
neuronal death, suggesting that the presence of the antioxidant was essential for blocking the
pathway (Muthukumaran et al., 2014).
• In Fernagut (2007) experiment, male mice overexpressing human a-syn under the Thy 1
promoter (Thy 1-aSYN) and WT were i.p. injected PQ 10 mg/kg once a week for 3 weeks.
Despite degeneration of dopaminergic neurons (densitometric measurement and stereological
analysis for counting TH+ neurons) in both Thy 1-aSYN mice and WT PQ-treated mice,
behavioural impaired sensimotor performance was observed in non-treated Thy 1-aSYN mice
only, remaining unchanged after PQ administration. The sensimotor abnormalities in Thy
1-aSYN were observed in a previous work (Fleming et al., 2004) and the lack of behavioural
deﬁcits after PQ administration was commented by the author as not surprising in the view of
small magnitude neuronal loss TH-positive terminals in striatum (25%).
Quantiﬁable understanding
Table A.16: Quantitative understanding of the KER
DA neurons degeneration Parkinsonian motor symptoms Treatment References
15% DA neuronal loss (Nissl
staining and TH immunostaining) in
SNpc
Mixed pattern of motor impairment
observed for testing posture and
speed but not for mobility (approx.
3 times the control, as average for
total score-from Figure A.5)
Young adult Sprague-Dawley
rats (2 months old) i.p.
injected with PQ 10 mg/kg,
twice a week for 4 weeks
Cicchetti et al.
(2005)
Decrease in SN dopaminergic
neurons of 36% and 61%,
respectively (assessed by Fluoro-
gold prelabelling method)
Decline in striatal dopamine nerve
terminal density of 87% and 94%,
respectively (assessed by TH
immunoreactivity)
Neurobehavioural syndrome
characterised by reduced
ambulatory (locomotor) activity 48 h
after ﬁnal treatment (during the
course of 60 min experimental
session) observed at both doses
(reduction approx. 45% after
60 min. Figure A.5A)
Adult C57 BL/6J mice i.p.
injected with PQ 5 and
10 mg/kg, 3 doses
separated by 1 week each
Brooks et al.
(1999)
Differential immunolocalisation and
decreased expression levels of TH
in SN (60%), FC (50%) and
hippocampus (30%) (only
measured at 10 mg/kg)
Decrease in TH+ and
FOX3+ neurons in SN (stereological
count) of approximately 40% at
10 mg/kg and of approximately
10–15% at 5 mg/kg
Motor dysfunction (only observed at
10 mg/kg) after 2 weeks of
treatment (progressive over the
next days) with severe postural
instability and gait impairment
consistent with a unilateral lesion:
• Curling test (qualitative
asymmetry evaluation):
ipsilateral
• Gait impairment: walking
footprint pathway
(qualitative assessment),
stride length of consecutive
steps and step frequency
Adult male Swiss Albino mice
i.p. treated with 5 and
10 mg/kg PQ twice a week
for 4 weeks
Mitra et al.
(2011)
Dose-dependent DA depletion in
ipsilateral striatum 2 weeks after
treatment. 26. 7, 60.3 and 91.5%
at 1, 2 and 3 lg PQ respectively.
The effect lasted up to 16 weeks
Marked loss of Nissl substances and
severe loss of neurons at 3 lg PQ
(2 weeks after injection). The effect
was considered moderate at 2 lg
PQ (2 weeks after injection)
Circling behaviour (direction of the
lesioned side) due to the imbalance
of dopaminergic activity in striata
(unilateral lesion) at 3 lg PQ
Dose-dependent rotational
behaviour in rats contralateral to the
lesion side in response to
apomorphine s.c. administration
0.5 mg/kg (inducing circling
behaviour) at 3 lg PQ (2 weeks
after injection)
Intracerebral (unilateral
intranigral) injection of 1, 2
and 3 lg PQ in male Wistar
rats for 16 weeks
Liou et al.
(1996)
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Uncertainties or inconsistencies
• Exposure to paraquat may decrease the number of nigral neurons without triggering motor
impairment (Fernagut, 2007). This can be consequent to the low level of DA reduction or
limited neuronal loss observed following the treatment.
• The impact of paraquat upon the striatum appears to be somewhat less pronounced than the
effects of the pesticide upon SNc DA neuronal soma (Mangano et al., 2012). As well, some
authors have failed to ﬁnd changes in striatal DA levels or behavioural impairment, even in the
presence of loss of DA soma (Thiruchelvam et al., 2003). It is conceivable that compensatory/
buffer downstream processes provoked by soma loss, variations in experimental design (e.g.
route of administration, dosing regimen, sacriﬁce interval, striatal subregions tested, age of
mice) can possibly contribute to some of the inconsistency observed across studies (Rojo
et al., 2007; Prasad et al., 2009; Kang et al., 2010; Rappold et al., 2010).
• The effects on nigral dopaminergic neurons appear to be speciﬁc (Tieu et al., 2011). However,
damage in dopaminergic cell bodies and terminal has not been consistently observed
(Thiruchelvam et al., 2000b; Cicchetti et al., 2005). In addition, even in studies in which a loss
of nigral dopaminergic neurons is detected, PQ does not have an effect on striatal dopamine
level (Thiruchelvam et al., 2000b; McCormack et al., 2002). This lack of dopamine reduction
might be related to the compensatory upregulation of tyrosine hydroxylase activity in the
striatum after PQ injection (Thiruchelvam et al., 2000b; McCormack et al., 2002; Ossowska
et al., 2005; Tieu 2011).
• The repeat dose administration of 10 mg/kg i.p. is likely representing the maximum tolerated
dose of the chemical stressor. The observed movement disorders can, at least in part, come
from systemic illness and the contribution of systemic pathological changes to the observed
movement disorders cannot ruled out (Cicchetti et al., 2005).
• In-vivo, experimental reproducibility of the estimated mean number of TH positive neurons in
the SNpc or TH positive axons and terminals in the striatum is weak and representing an
uncertainty. In particular, Breckenridge et al. (2013) and Smyne et al. (2016) conducted in vivo
experiments where the administration of the chemical stressor Paraquat at an expected
neurotoxic dose and treatment schedule showed no effect. The experiments were conducted
following a very thorough and comprehensive protocol. In addition, Smyne et al. (2016),
conducted a systematic review of the published literature that has evaluated the effects of
paraquat on the SNpc and striatum in male mice. In order to evaluate potential sources of
variability, multiple information was extracted and evaluated. A number of experimental
limitations were identiﬁed which can reduce the strength of positive outcomes observed with
paraquat. Nevertheless, some positive studies could not be dismissed and the differences in
host susceptibility (e.g. dose, timing of treatment, species or strain, age of animal, iron
accumulation, strain speciﬁc gene ontology) can explain contradictory effects observed
following treatment with the chemical stressor paraquat in mice.
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DA neurons degeneration Parkinsonian motor symptoms Treatment References
Progressive TH positive neurons
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Overall assessment of the AOP
A.1. Response–response and incidence concordance (Table 1)
Toxicity mediated by redox cycling is based on acceptance of an electron by a chemical from a
reductant, formation of a radical, and transfer of an electron to molecular oxygen. The process is
leading to the generation of superoxide and mitochondria are one of the presumed sites where the
chemical is initially reduced within the cell to form superoxide. This is the chemical based mechanism
of action of the herbicide paraquat (PQ), which is therefore considered a suitable chemical tool/
stressor for exploring the link between the MIE and the AO. In animal models, PQ susceptibility is
known to act synergistically with microglia leading to its activation (Purisai et al., 2007; Mitra et al.,
2011). Microglia through plasma-membrane NADPH-oxidase may also activate the extracellular redox
cycling of PQ favouring its transport within dopaminergic neurons (Rappold et al., 2011). The kinetic
and metabolism of PQ is complex and the amount of PQ entering and accumulating into the brain is
dependent on dose, route of administration, expression of transporters, animal age and strain.
Multiple genetic factors are also involved in host susceptibility which is likely to represent an
important source of variability (Corasaniti et al., 1991; Youdim, 2003; Li et al., 2005; Tieu, 2011; Yin
et al., 2011; Jiao et al., 2012). These elements are the possible/likely reason of lack of reproducibility
of apical endpoints as observed in some studies conducted with this stressor (Breckenridge et al.,
2013; Smyne et al., 2016).
In-vivo, the commonly used dose of 10 mg/kg administered i.p. leads to a brain concentration of
around 3 lM after 6 doses (Prasad et al., 2009; Smeyne et al., 2016) and around 6–10 lM in striatum
after 24 doses (Prasad et al., 2009). A single s.c. administration of 10 mg/kg leads to 3.88  0.79 lM
serum concentration after 3 h reaching 0.36  0.09 lM in the extracellular space of the striatum
(Shimizu et al., 2001). At this dose level (10 mg/kg i.p.), ambiguous results in terms of neuronal loss
and occurrence of parkinsonian motor symptoms are reported in C57BL/6J mice (Thiruchelvam et al.,
2000b; McCormack et al., 2002; Barlow et al., 2004; Li et al., 2005, 2012; Khwaja et al., 2007; Prasad
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et al., 2007, 2009; Fei et al., 2008; Cristovao et al., 2009; Fernagut et al., 2009; Mangano et al., 2009,
2011, 2012; Breckenridge et al., 2013; Watson, 2013; Minnema, 2014; Smeyne et al., 2016).
In order to integrate data on paraquat toxicity from widely different experimental models, ranging
from cell cultures to repeat dose animal studies, the concentrations close to the target site were
compared by classical approaches of in vitro in vivo extrapolation (IVIVE) based on the available
publications. The lowest observed effect concentrations in vitro were in the range of 20 lM.
Concentrations up to 200 lM have been used for some studies. A variability of observed
concentrations is expected from the fact that PQ needs a transporter to cross cell membranes, and
that different oxidation states of PQ have different afﬁnities for transporters (Rappold et al., 2011).
Thus, the levels of transporter expression, the presence of microglia and the oxidation state of PQ
determine its intracellular concentration. This may explain variations of effective in vitro concentrations
by at least 10-fold.
For the in vivo situation, different sets of data are available to estimate the PQ concentration in DA
neurons. A study on average brain concentrations after 6 doses found an average brain concentration
of 0.54 lg/g brain tissue, corresponding to an average brain tissue concentration of 3 lM (Smeyne
et al., 2016). It needs to be assumed that some cells accumulate PQ, while others do not. Thus,
intracellular concentrations in DA neurons may be considerably higher than 3 lM, considering the
uptake of PQ. In another study, plasma concentrations and extracellular brain concentrations were
measured 3 h after a single dose. Extracellular concentrations of 0.4 lM were reached in the brain
(Shimizu et al., 2001). It needs to be assumed that this would be higher after multiple dosing. Indeed
a study by Prasad et al., 2009 showed that the extracellular concentration in the striatum was around
3.3 lM after 6 doses and around 10 lM after 24 doses of 10 mg/kg i.p.
These data suggest that the brain concentration at the target site (inside DA neurons) is in the 1–2
digit lM range. This range overlaps well with the effective in vitro concentrations of 20–50 lM. Within
the limits of accuracy possible (the intracellular concentrations have not been measured within DA
neurons) this IVIVE shows that in vitro and in vivo active concentrations are within the same order of
magnitude and thus aligned.
In a conservative approach, the range of brain concentration expected to represent the steady
state (3–10 lM) of PQ can be considered only indicative and will be used in this AOP to deﬁne a
possible probabilistic threshold of activation of the MIE leading to the AO. With the limited number of
doses known from in-vivo studies, an intra (in the same) and inter (between) KE response–response
relationship can be observed. A response–response relationship in the increase in activity of ROS
scavenging enzymes can be observed (KE 1) in-vivo; however, the KE degeneration of dopaminergic
neurons and the AO can only be seen at the threshold concentration in the brain of about 3–10 lM
reached after repeated exposure to PQ 10 mg/kg bw, and not for higher doses due to the marked
general toxicity (Mitra et al., 2011). The frequency of the KE degeneration of dopaminergic neurons
and the AO were less than for the other key events. In this AOP, neuroinﬂammation was considered to
have a direct effect on paraquat activation and on loss of DA neurons (Purisai et al., 2007; Rappold
et al., 2011). However, in addition to neurodegenerative consequences, neuroinﬂammation can have
also protective effects. Therefore, due to this complexity this key events was not included in Tables 1
and 2.
In vitro, an intra KEs response–response is evident, with some evidences of inter KEs response–
response concordance. However, when multiple time of sampling are applied to the experimental
design, the inter KEs response–response concordance is stronger. In-vitro, a strong response–response
concordance between KE1 and cell death (KE 3) is evident (Figure A.32). Overall, the response–
response and incidence concordance was considered moderate.
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A.2. Temporal concordance among the MIE, KEs and AO
There is a strong agreement on the sequence of pathological events linking the MIE to the adverse
outcome (Fujita et al., 2014). The temporal concordance is strong when considering the chronicity and
progressive nature of the pathology of parkinsonian disorders. Temporal concordance among the KE 1,
2, 3 and AO can be observed in the experimental models of PD using the chemical stressors rotenone
and MPTP (Betarbet, 2000, 2006; Sherer et al., 2003, Fornai et al., 2005) which are sharing the same
KEs with this AOP but are caused by a different MIE. With the chemical stressor MPTP, to trigger the
KE3 (i.e. degeneration of DA neurons in SNpc with presence of intracytoplasmic Lewy-like bodies) and
motor deﬁcits (AO), proteostasis needs to be disturbed for a minimum period of time (Fornai et al.,
2005) and this is similarly expected with chemicals inducing redox cycling like PQ (Ossowska et al.,
2005). In vivo, with the chemical stressor PQ, evidence of temporal concordance is limited by the
study design using single time-point descriptive assessment. In vitro, evidence of temporal
concordance is limited by the fact that 24 and 48 h were the most investigated time points.
Nevertheless, those papers taking into account shorter time points show that a good temporal
concordance exist between MIE (4 h), KE2 (6 h) and KE3 (12–24 h) (Ding, 2001; Gonzalez-Polo, 2007;
Cantu, 2011; de Oliveira, 2016). Based on the established knowledge on chronicity and progression of
parkinsonian disorders, the temporal concordance is considered strong for this AOP up to the KE 3
(degeneration of DA neurons of nigrostriatal pathway). The occurrence of the AO outcome is strongly
linked to the amount of DA in the striatum and to the loss of DA neurons in the SNpc. Following
treatment with the chemical stressor/s the key events are observed in the proposed order in this AOP.
Figure A.32: PQ-induced ROS and Cell death (% over controls) at 24 h in neuronal cells. Points in the
ﬁgure derive from the listed papers, targeted by the number associated to each symbol
(1-de Oliveira 2016, 2-Gonzalez-Polo 2007, 3-Lopert 2012, 4-Rodriguez-Rocha 2013, 5-
Huang 2012, 6-Ding 2001, 7-Yang and Tiffany Castiglioni 2007) Data refers to different
neuronal cell lines and primary cultures, and to different methods of detection. As such,
single results have been calculated over their control to allow comparison between
different studies
PPPs, Parkinson’s disease and childhood leukaemia
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A.3. Strength, reproducibility of the experimental evidence, and
speciﬁcity of association of AO and MIE
There is a strong agreement that ROS production and mitochondrial dysfunction can lead to
neurodegeneration and motor symptoms of parkinsonian disorders and familial PD genes are also
implicated in ROS production by mitochondria (Gandhi et al., 2009; Yao et al., 2011; Sanders et al.,
2013; Fujita et al., 2014). The chemical stressor used for the empirical support, PQ, is a well-known
substance with a toxicity primarily mediated by redox cycling (Day et al., 1999; Tieu, 2011). With PQ,
ROS production and oxidative stress, impaired proteostasis, and loss of nigral dopaminergic neurons
are reported (Brooks et al., 1999; McCormack et al., 2002; Mitra et al., 2011; Su et al., 2015). Some
uncertainties on the initial mitochondrial involvement in triggering PQ redox-cycle in vivo exists due to
the prolonged (consistent with a generalised oxidative stress) and repeated exposure and the use of
general indicators of oxidative stress like lipid and protein oxidation. Degeneration of dopaminergic
neurons (KE3) was tested in-vivo in many studies conducted in rat and mice with an higher prevalence
of testing in mice. The estimated mean number of TH+ neurons in the SNpc or TH+ axons and
terminals in the striatum was the common endpoint measured, with detailed neuropathology,
neurochemistry and behavioural evaluation conducted more seldomly. Reproducibility of the effect of
PQ on these parameters in mice was questioned by some authors (Thiruchelvam et al., 2000b;
Cicchetti et al., 2005; Breckenridge et al., 2013; Minnema et al., 2014; Smeyne et al., 2016). For
studies conducted in mice, a systematic review of the published literature that has evaluated the
effects of PQ on the SNpc and striatum was included in Smeyne et al. (2016). The potential impact of
animal, dose variables, stereological and methodological factors was evaluated. Despite the thorough
evaluation conducted and the identiﬁcation of some methodological biases potentially affecting a
number of studies, a signiﬁcant controversy remains regarding the reproducibility of the ﬁnding using
PQ as a chemical stressor and a clear methodological bias affecting it cannot be fully established.
In addition in a number of studies performed with the chemical stressor PQ, loss of dopaminergic
neurons (KE3)was not associated with an effect on striatal dopamine levels (Thiruchelvam et al.,
2000b; McCormack et al., 2002). Although this can be due to the activation of compensatory effects or
compensatory upregulation of TH activity in the striatum following PQ treatment (Thiruchelvam et al.,
2000b; McCormack et al., 2002; Ossowska et al., 2005), this effect is known to be quantitatively linked
to the loss of DA neurons and a threshold is likely to exists. The role and inﬂuence of the animal
species, strain, age, route of administration, dose scheduling and susceptibility of neuronal population
to the noxa on the outcome of the studies cannot be completely ruled out.
The occurrence of parkinsonian motor symptoms was not consistently reported for the chemical
stressor PQ. Evidence on the occurrence of the AO can however be observed with PQ following
unilateral intranigral administration where loss of neuronal cells was marked (ca. 90%). For most of
the studies conducted with the tool chemical PQ administered by i.p. the amount of DA neuronal loss
was relatively limited (e.g. 20–30%) and the AO i.e. parkinsonian motor symptoms, was therefore not
consistently reported. These observations are in line with the human evidence that parkinsonian motor
symptoms are only evident in PD when striatal DA drops approximately 80% (corresponding to a 60%
DA neuronal cells loss (Jellinger et al., 2009). Indeed, the variability observed in the latest KE and in
the AO, not clearly associated with methodological biases in some cases, could be well reﬂecting the
variability in host susceptibility. This is particularly true when considering the complexity of the factors
inﬂuencing the local disposition i.e. concentration at the target site of the chemical stressor.
Considering the relevance of ROS production and oxidative damage in Parkinson’s models, it is
expected that the speciﬁcity of this AOP would be high. However, with the use of PQ as a unique
chemical stressor supporting the empirical evidence, judging speciﬁcity was not possible. Overall, the
strength linking the MIE to the AO was considered high for this AOP; however, using PQ as a chemical
tool, the reproducibility of some experimental evidence and the speciﬁcity of the association was
considered moderate.
A.4. Weight of Evidence (WoE)
A.4.1. Biological plausibility, analogy between chemical stressors, and
species consistency of the experimental evidence
ROS generation and deregulation of ROS management by dysfunctional mitochondria is known to
be a crucial event in neurodegeneration in general and for dopaminergic neurons in SNpc in particular
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when considering the unique susceptibility of these neurons (Fujita et al., 2014; Sanders et al., 2013).
Familial forms of PD include genes (i.e. PINK1 and DJI) that are implicated in ROS management by
mitochondria resulting in mitochondrial DNA damage and inﬂammation as a downstream effect
(Gandhi et al., 2009; Horowitz et al., 2010; Yao et al., 2011; Fujita et al., 2014). The biological
plausibility for the KEs relationship linking the MIE to the AO is strong based on the existing knowledge
of PD pathogenesis and parkinsonian syndrome. As PQ is the only tool compound so far analysed and
comprehensively studied, analogy is considered moderate as the KE relationship is only plausible based
on the supporting analogy with PD, but a scientiﬁc understanding on the relationship between a
chemically induced redox cycler and parkinsonian motor deﬁcits is not completely established. ROS
generation is mechanistically recognised as a cause of PD and parkinsonian syndrome. Mouse and rat
are the most frequently used animal models to support this AOP using the tool compound PQ. Strain
differences in susceptibility are reported for the experiments conducted with the chemical stressor PQ
(Prasad et al., 2009; Smyne et al., 2016). The same pattern of effects has been observed in a different
test species i.e. drosophila. Overall the consistency of this AOP was considered moderate to high.
PPPs, Parkinson’s disease and childhood leukaemia
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A.5. Uncertainties and Inconsistencies
• No direct evidence exists in the literature of PQ-induced O2° production in vivo. The
involvement of O2°
 production is deduced by the efﬁcacy of superoxide dismutase analogues
to prevent/reduce PQ neurotoxicity.
• Besides mitochondria, cellular NADPH-oxidases (Rappold et al., 2011; Cristov~ao et al., 2012)
also contribute to PQ-induced ROS production. Furthermore, in vitro data suggest that for time
points of exposure longer than 48 h oxidative stress occurs both at mitochondria and cytosol.
This makes it difﬁcult to discriminate the source of PQ-induced ROS and the early involvement
of mitochondria in vivo due to the extensive treatments and to the indirect detection of
oxidative stress mainly by mean of lipid peroxidation and/or protein oxidation. Mitochondrial
involvement is suggested by ex-vivo studies (Czerniczyniec et al., 2013, 2015).
• The exact molecular link from mitochondrial dysfunction to disturbed proteostasis is still
unclear (Malkus et al., 2009; Zaltieri et al., 2015). Furthermore, whether impaired proteostasis
and protein aggregation would cause the selective death of DA neurons in the SN still remains
an uncertainty.
• The role of a-synuclein in neuronal degeneration is still unclear as well as the mechanisms
leading to its aggregation.
• Priority of the pattern leading to cell death could depend on concentration, time of exposure
and species/strain sensitivity; these factors have to be taken into consideration for the
interpretation of the study’s result and extrapolation of potential low-dose chronic effect as this
AOP refers to chronic exposure.
• Animal studies, conducted with the chemical stressor PQ, show little consistency in dose,
timing of treatment, species, strain and age of animals. All these factors are included in the
host susceptibility, possibly contributing to the variability observed. In particular, age and iron
accumulation in SNpc are additional putative risk factors for reproducing degeneration of
dopaminergic neurons in SNpc (Youdim et al., 2003; Li et al., 2005; Yin et al., 2011; Jiao et al.,
2012).
• The ability of PQ to induce loss of DA neurons in SNpc in vivo is sometime equivocal and
reproducibility of the ﬁnding is representing an uncertainty (Smyne et al., 2016). Some
methodological biases could account for the lack of reproducibility observed in some studies
(Smeyne et al., 2016); however, the same cannot be applied to all studies and the a signiﬁcant
controversy still remains. The role of host susceptibility factors as a matter of variability should
be therefore considered.
• The model of striatal DA loss and its inﬂuence on motor output ganglia does not explain
speciﬁc motor abnormalities observed in PD (e.g. resting tremor vs bradykinesia) (Obeso et al.,
2000). Other neurotransmitters (ACh) may play additional roles in other brain areas like the
olfactory bulb. Transfer to animal models of PD symptoms also represents an uncertainty.
• The role of neuronal plasticity in intoxication recovery and resilience is unclear.
• This AOP is a linear sequence of KEs. However, ROS production, mitochondrial dysfunction and
impaired proteostasis are inﬂuencing each other and these are considered as uncertainties
(Malkus et al., 2009).
• When measurement of loss of mitochondrial membrane potential is performed together with
cell viability, the former is detected only in dead cells in PQ treated cells (on the contrary for
MPTP and Rotenone is detected in alive cells suggesting this event precedes cell death). It is
suggested that decrease PQ-induced neuronal death is independent on mitochondrial
membrane potential (mmp) decrease. As such overexpression of Mn SOD (in mitochondria)
prevents PQ-induced cell death but not mmp decrease (Rodriguez-Rocha, 2013).
• Paraquat-induced neurotoxicity could affect a subpopulation of DA neurons. This might explain
why, once the maximum effect is reached, no further neuronal death occurs after
supplementary exposures (McCormack et al., 2005). Another possibility is the development of
defensive mechanisms, which preserve neurons from further toxicity. This hypothesis is
consistent with the in vitro observation of an increased transcriptional activation of redox-
sensitive antioxidant response elements and NF-jB, speciﬁcally induced from paraquat but not
from rotenone and MPTP (Rodriguez-Rocha et al., 2013).
• The impact of paraquat upon the striatum appears to be somewhat less pronounced than the
effects upon SN dopaminergic neuronal soma (Mangano et al., 2012). In addition, some
authors have failed to ﬁnd changes in striatal DA levels or behavioural impairment, even in the
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presence of loss of dopaminergic soma (Thiruchelvam et al., 2003). It is conceivable that
compensatory/buffer downstream processes provoked by soma loss or variations in
experimental design can possibly contribute to some of the inconsistencies observed across
studies (Rojo et al., 2007; Prasad et al., 2009; Kang et al., 2010; Rappold et al., 2011).
• Dopaminergic neurons in SN and VTA seem to have a different susceptibility to the damage
induced by paraquat (McCormack et al., 2006).
• Few hypothesis have been put forward to explain the selective vulnerability of the SN pc
dopaminergic pathway, although a deﬁned molecular mechanism remains elusive. Elevated iron
content in this region, that increase sensitivity to redox-damage catalysing the generation of
ROS (Liddell et al., 2013) and regional distribution of transporters able to uptake PQ (i.e. DAT
and Oct3) in combination with a high microglia population in the nigra (Rappold et al., 2011)
have been evoked.
• The vulnerability of the dopaminergic pathway still remains circumstantial. Paraquat has been
proposed to pass the blood-brain-barrier by mediation of neutral amino acid transportation
(Shimizu et al., 2001; McCormack and DiMonte 2003). Accumulation of paraquat in the brain is
reported to be age dependent, possibly indicating a role for the blood-brain-barrier
permeability (Corasaniti et al., 1991); Dication paraquat has been reported not to be a
substrate for dopamine transporter (Richardson et al., 2005). Nevertheless, Rappold et al.
(2011) demonstrated that radical paraquat is transported by DAT and hence how the toxicant
enters into dopaminergic neurons is still unclear. One possibility is extracellular paraquat
reduction by membrane-bound NADPH oxidase with the formed paraquat monocation radical
entering DA neurons by neuronal DAT (Rappold et al., 2011).
• Exposure to paraquat may decrease the number of nigral neurons without triggering motor
impairment (Fernagut, 2007). This can be consequent to the low level of DA reduction or
limited neuronal loss observed following the treatment.
• The repeat dose administration of 10 mg/kg i.p. is likely representing the maximum tolerated
dose of the chemical stressor. The observed movement disorders can, at least in part, come
from systemic illness and the contribution of systemic pathological changes to the observed
movement disorders cannot ruled out (Cicchetti et al., 2005).
• There is uncertainty concerning the real brain concentration that is triggering this AOP. In
addition, because of the complexity of the kinetic e metabolism, including local disposition of
PQ in the SNpc, extrapolation of the in vitro concentration to in vivo scenario is an uncertainty.
A.6. Quantitative Considerations
The quantitative understanding of this AOP includes evidence of response–response relationship
and the identiﬁcation of a putative threshold effect. This is because the triggering effect at MIE level
was explored in only few studies and the reproducibility of the KE 3 is likely depending by multiple
host susceptibility factors. More evidence exists that an increase from 200% to 600% of lipid
peroxidation (endpoint of KE1) in DA neuronal cells can be used as a probabilistic threshold triggering
the degeneration of DA neurons of the nigrostriatal pathway. In line with others chemical tools that
can induce DA neuronal loss through different MIE (i.e. rotenone and MPTP), for the identiﬁcation of
the AO the design of the in-vivo studies should be tailored as to a MIE which leads to a long-lasting
perturbation of the KEs. This provides the most speciﬁc and deﬁnite context to trigger neuronal death
in vivo. A major hurdle for this AOP is represented by the AO. With PQ, the low level of reported DA
neuronal loss (ca. 20–30%) is not expected to induce parkinsonian motor symptoms and essentiality
data (i.e. recovery of motor symptoms following treatment with DA) is limited. Moving from a
qualitative AOP to quantitative AOP would need a clear understanding of effect thresholds for the
different KEs.
PPPs, Parkinson’s disease and childhood leukaemia
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A.7. Applicability of the AOP
This proposed AOP is neither sex-dependent nor associated with certain life stage; however, male
aged animals are considered more sensitive. The relevance of this AOP during the developmental
period has not been investigated.
In vivo testing has no species restriction. However, host susceptibility is likely to have a relevant
impact on the outcome of the studies and in this context, elements of stress and animal strain could
have a profound impact on the outcome of the studies (Youdim et al., 2003; Li et al., 2005; Yin et al.,
2011; Jiao et al., 2012; Jones et al., 2014). The mouse was the species most commonly used in the
experimental models conducted with the chemical stressor paraquat and the C57BL/6J is considered
the most sensitive mouse strain (Jiao et al., 2012; Smeyne et al., 2016). However, animal models
(rodents in particular) would have limitations as they are poorly representative of the long human life-
time as well as of the human long-time exposure to the potential toxicants. Human cell-based models
would likely have better predictivity for humans than animal cell models if biologically relevant by
means of being able of recapitulate the key events in the toxicology and pathology pathway providing
robust and repeatable results predictive of the chemical concentration that lead to a particular
outcome. In this case, toxicokinetics information from in-vivo studies would be essential to test the
respective concentrations in-vitro on human cells.
A.8. Regulatory considerations
The AOP is a conceptual framework to mechanistically understand apical hazards. The AO,
parkinsonian motor symptoms, is an apical endpoint that can be explored and quantiﬁed in the
regulatory toxicology studies conducted in experimental laboratory animals. Motor deﬁcit endpoints,
and their relevance to parkinsonian disorders and PD are a matter of intensive discussion in the
scientiﬁc community. The use of rodent models for assessment of parkinsonian/PD-associated motor
deﬁcits was even put into question. Although rodent motor output can only hardly be correlated with
the human motor output repertoire, the adverse outcome of the present AOP was explicitly focused on
alterations in motor output associated with parkinsonian conditions. Indeed, this AOP does not claim
that motor deﬁcits included herein reﬂect the complexity of the human disease.
It is also noteworthy that decrease in neuronal cell count is also an apical regulatory endpoint
explorable and quantiﬁable in experimental studies conducted in vivo; if the appropriate areas of the
brain are sampled and properly evaluated. A statistically signiﬁcant decrease in DA neuronal cell count
is considered an adverse event, regardless of the concomitant presence of motor symptoms. This has
to be taken into consideration for the potential regulatory applications of this AOP and for the
sensibility of the method applied to capture the KE/apical endpoint/hazard. If the intention is to use
Table A.21: Concordance table for the tool compound paraquat
Dose/concentration at
the target site
MIE
KE1
Mitochondrial
dysfunction (ROS
production)
KE2
Impaired
proteostasis
KE3
Degeneration of
DA neurons of
nigrostriatal
pathway
AO
Parkinsonian
motor
symptoms
0.78 lM brain
concentration [1 and 2]
No data 200% increase in
lipid peroxidation [4]
No data No effect [4] No data
Below 3 lM (intended as
a cumulative
concentration; 8 doses)
[8]
42% increase
in SOD
activity [8]
No data 10% decrease in TH+
neurons [8]
No data
3–10 lM (cumulative
concentration after
multiple doses) [1 and 2]
75% increase
in SOD
activity [8]
500–600%
(cumulative effect)
lipid peroxidation
[2, 4]
50% increase in 20S
proteasome fraction at
24 h [2]
Intracellular deposits of
a-synuclein in 30% of
DA neurons [6]
50% increase in a-
synuclein expression [8]
30–50% (cumulative
effect) decrease in
TH+ neurons
[2,4, 6, 7, 8]
Motor
impairment
[2, 8, 10]
References: Breckenridge 2013 [1]; Prasad 2007 and 2009 [2]; Castello 2007 [3]; Mc Cormack 2005 [4]; Cantu 2011 [5]; Manning-Bog 2003 [6];
Fernagut 2007 [7]; Mitra 2011 [8]; Yang 2007 [9]; Brooks 1999 [10].
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this AOP for deﬁning the link between the MIE and the degeneration of DA neuronal cells of the
nigrostriatal pathway, the WoE is considered strong; however, in the case of deﬁning the link between
the MIE and parkinsonian motor symptoms, the WoE should account for the biology and complexity
linking disruption of the nigrostriatal pathway and occurrence of motor symptoms. Because of the
potential different uses of this AOP, keeping the parkinsonian motor symptoms as AO was considered
relevant. It is also foreseen that for potential additional uses, like deﬁning a testing strategy or
properly design an in-vitro or an in-vivo study, or evaluation of mixture of chemicals, degeneration of
DA neuronal cells of nigrostriatal pathway should be considered as AO.
A.9. Potential application of this AOP
This AOP was developed in order to evaluate the biological plausibility that the adverse outcome
i.e.parkinsonian motor deﬁcits, is linked to the selected MIE. By means of using a human health
outcome from epidemiological studies and meta-analysis, the authors intend to embed the AO in the
process of hazard identiﬁcation and identiﬁcation of risk factors.
In addition, this AOP can be used to support identiﬁcation of data gap that can be required or
explored when a chemical substance is affecting the pathway or provide recommendation on the most
adequate study design that can be applied to investigate the apical endpoints. It is important to note
that, although the AO is deﬁned in this AOP as parkinsonian motor deﬁcits, degeneration of DA
neurons is already per se an adverse event even in situations where is not leading to parkinsonian
motor deﬁcits or clinical signs indicative of a central effect, and this should be taken into consideration
for the regulatory applications of this AOP. In addition, this AOP can inform on the identiﬁcations of
in vitro methods that can be developed for an integrated approach to testing and assessment (IATA)
based on in vitro neurotoxicity assays complementary to in vivo assays.
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Appendix B – AOPs developed for Infant Leukaemia and Childhood
Leukaemia
Adverse Outcome Pathway (AOP) 3: In utero DNA topoisomerase II
poisons leading to infant leukaemia
Introduction
Infant leukaemia is a rare haematological disease (1 in 106 newborns, accounting for 10% of all
childhood acute lymphoblastic leukaemias (ALL)) manifesting soon after birth (< 1 year) and having a
poor prognosis (Sanjuan-Pla et al., 2015). Compared to the more frequent childhood leukaemia, infant
leukaemia show distinct features:
• an early neonatal onset linked to its plausible origin as a ‘intrauterine developmental disease’
(Greaves, 2015; Sanjuan-Pla et al., 2015);
• rearrangements of the mixed-lineage leukaemia (MLL; KMT2A) gene on the q23 band of
chromosome 11, as the hallmark genetic abnormality (Joannides and Grimwade, 2010);
• however, MLL is not the only translocation gene; for infant ALL, about 60–80% carry an MLL
rearrangement (Jansen et al., 2007; Sam et al., 2012) and the percentage for infant acute
myeloid leukaemia (AML) is about 40%;
• the MLL rearrangement at an early stage of development; the likely target cells (still
unidentiﬁed) are the haematopoietic stem and progenitor cells (HSPC) in fetal liver and/or
earlier (mesenchymal) stem cells in embryonic mesoderm (Bueno et al., 2009; Menendez
et al., 2009);
• the infant MLL-rearranged leukaemia carries less somatic mutations (1.3 vs 6.5/case) than the
childhood disease (Dobbins et al., 2013; Andersson et al., 2015), pointing to the lack of a
‘second hit’ and suggesting a ‘one big hit’ origin.
Overall, based on the available evidence, infant leukaemia pathogenesis originates from a single,
severe hit to a target cell during early intrauterine development. Whereas the limited epidemiological
studies do not allow any ﬁrm conclusion on a possible role for chemicals in infant leukaemia (Pombo-
de-Oliveira et al., 2006; Ferreira et al., 2013), exposures to chemicals able to induce MLL
rearrangements through topoisomerase II (TopoII) ‘poison’, particularly etoposide and other TopoII
‘poisons’, including some bioﬂavonoids, have been suggested as agents promoting the driver genetic
oncogenic event. Experimental models for infant leukaemia have been developed, but a wholly
satisfactory model reproducing the phenotype and latency is not yet available.
Nevertheless, the anticancer drug etoposide can be considered as a model chemical for DNA
topoisomerase ‘poison’. Acute leukaemia is an adverse effect recorded in etoposide-treated patients,
showing MLL rearrangements that are in many ways analogous to those in infant leukaemia (Bueno
et al., 2009; Joannides et al., 2010, 2011). Therefore the proposed AOP is supported by a number of
convincing inferential evidences by means of using etoposide as a tool compound to empirically
support the linkage between the proposed molecular initiating event (MIE) and the adverse outcome
(AO). In the meanwhile, this AOP identiﬁes several knowledge gaps, the main ones being the
identiﬁcation of the initiating cell and the investigation of TopoII poisons in a robust model; thus, the
present AOP may be modiﬁed in future on the basis of new evidence.
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Adverse Outcome Pathway (AOP): In utero DNA topoisomerase II
inhibition leading to infant leukaemia
MIE: In utero exposure to DNA topoisomerase II ‘poisons’
How this MIE works
DNA topoisomerase (Top) II enzyme ‘poisons’ disturb the normal TopoII enzyme function and cause
a ‘hanging double strand break (DSB)’ at a speciﬁed DNA sequence. The above description of the MIE
is of signiﬁcance because there are 3 different kinds of ‘poisons’ of TopoII enzyme, out of which
competitive inhibitors prevent the function of the enzyme and cause cell death, whereas other
interfacial and covalent inhibitors may cause – depending on the situation – other consequences of
DNA damage response including chromosomal rearrangements (Pendleton et al., 2014; Lu et al.,
2015). A further prerequisite for the speciﬁc outcome, i.e. creation of chromosomal rearrangement, is
that TopoII ‘poison’ has to occur in an especially vulnerable and correct hot spot in the MLL locus in
the right target cell vulnerable to transformation.
TopoII enzymes have several crucial functions in DNA replication, transcription, repair and
chromatin remodelling, i.e. TopoII enzymes take care of DNA integrity and topology. Because the
enzyme functions by passing an intact double helix through a transient double-stranded break, any
disturbances in its function, e.g. by chemical inhibitors, could have a profound effect on genomic
stability, resulting in DNA repair response, gene and chromosomal damage, initiation of apoptosis and
ultimate cell death. A double-strand break and error-prone non-homologous end-joining (NHEJ) DNA
repair mechanism may lead to gene rearrangements; chromosomal translocations and consequently
fusion genes (see Figure B.2). A comprehensive description of TopoII enzymes and their functions and
derangements could be found in recent review articles (Cowell and Austin, 2012; Ketron and Osheroff,
2014; Pendleton et al., 2014).
Figure B.1: AOP scheme
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How it is measured or detected
The identiﬁcation and measurement of the inhibition of TopoII enzymes is made more difﬁcult by
the presence of different molecular mechanisms (see above). However, some assays are used in
pharmacological research to screen TopoII ‘poisons’, including cell-free decatenation assay (Schroeter
et al., 2015). The most important mode, the cleavage activity of TopoII can be studied in vitro, by
using a human recombinant enzyme and an appropriate double-stranded plasmid as a target to
quantitate double-strand breaks (Fortune and Osheroff, 1998). A cleavage can also be indirectly
detected by measuring various indicators of DNA damage response, such as ATM activity, p53
expression, cH2AX or Comet assay (Li et al., 2014; Schroeter et al., 2015; Castano et al., 2016).
It is useful to note that several chemicals identiﬁed as TopoII ‘poisons’ do require metabolic
oxidation to become active inhibitors. Etoposide itself is converted via the catechol metabolite to
etoposide 3-quinone, which is a covalent TopoII poison (Smith et al., 2014), whereas etoposide and its
catechol are interfacial inhibitors. Curcumin is also an active TopoII poison due to its oxidised
metabolites (Gordon et al., 2015). This fact deserves consideration if a screening for TopoII inhibition
is envisaged.
Evidence supporting taxonomic applicability (tissue type, taxa, life stage, sex)
DNA topoisomerases are ubiquitous enzymes, which control the integrity of double-stranded DNA.
They are thus key enzymes at all levels of living organisms. The available evidence suggest that
important differences in sensitivity to topoisomerase inhibition might exist among different cell types,
depending on the amount of proliferative burden, of the TopoII enzymes and on physiological repair
processes. Mesodermal precursor or haematopoietic stem and progenitor cells (HSPCs) are rapidly
dividing cells with a high content of TopoII and for these reasons they can be a sensitive target during
a critical developmental window (Hernandez and Menendez, 2016). In addition, evidence from
micronuclei assay studies conducted in untreated and chemical-treated foetuses and newborns show
that both the baseline and chemically induced micronuclei frequencies are higher in the foetuses and
infants than in adults (Udroiu et al., 2016). This is possibly indicating a greater sensitivity to genotoxic
insult during development which can be due to the higher proliferation rate and lower ability of DNA
repair of the haematopoietic stem cells. However, the role that the different microenvironments (fetal
liver, infant bone marrow and adult bone marrow) during ontogenesis can exert on cell sensitivity
cannot be ruled out (Udroiu et al., 2016). The existence of relevant interspecies differences is
unknown, but it cannot be ruled out presently.
Figure B.2: TOP2 Poisons, downstream events. TOP2 poisons inhibit the religation step of the TOP2
reaction cycle, leading to accumulation of covalent TOP2-DNA cleavage complexes. These
lesions are cytotoxic and lead to activation of the DNA damage response and potentially
apoptosis. Alternatively these lesions are repaired, largely through the non-homologous
end-joining pathway. Translocations observed in therapy-related leukaemia are presumed
to occur as a result of misrepair, joining two heterologous ends. (from Cowell and Austin,
2012, ﬁg. 3, CC BY 3.0)
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Evidence for Chemical Initiation of this Molecular Initiating Event (MIE)
A number of drugs, environmental chemicals and natural substances are identiﬁed as TopoII
‘poisons’ (Pendleton et al., 2014) (Table B.1). A well investigated example is the anticancer drug
etoposide; also bioﬂavonoids, e.g. genistein (Barjesteh van Waalwijk van Doorn-Khosrovani et al.,
2007; Azarova et al., 2010) bind to TopoII enzymes, induce cleavage in the MLL gene and produce a
fusion gene (and its product) in human cells. The organophosphate pesticide chlorpyrifos has been
shown to inhibit (‘poison’) the enzyme in vitro (Lu et al., 2015).
Etoposide
Much of the relevant, albeit indirect, evidence to support this AOP come from the studies on
etoposide, an anticancer drug TopoII ‘poison’, which is known to induce therapy-associated acute
leukaemia (t-AL) in adults (Cowell and Austin, 2012; Pendleton et al., 2014). It is of interest that the
latency of t-AL is < 2 years between the treatment of the primary malignancy and the clinical diagnosis
of the secondary disease and that the prognosis of t-AL is poor (Pendleton et al., 2014). t-AL is
characterised by the MLL rearrangements and it is practically certain that these fusion genes are
caused by etoposide or anthracyclines treatment, because MLL rearrangements have not been
detected in bone marrow samples banked before the start of the treatment of the ﬁrst malignancy.
Also the breakpoints in MLL or partner genes fall within a few base pairs of a drug-induced enzyme-
mediated DNA cleavage site (Pendleton et al., 2014).
Etoposide can induce MLL rearrangements in different cell types; interestingly, embryonic stem cells
and their haematopoietic derivatives are much more sensitive than cord blood-derived CD34+ cells to
etoposide-induced MLL rearrangements; in addition, undifferentiated human embryonic stem cells
(hESCs) were concurrently liable to acute cell death (Bueno et al., 2009). These ﬁndings suggest that
the MIE should be put into evidence in target cell models with appropriate sensitivity.
Bioﬂavonoids
Bioﬂavonoids are natural polyphenolic compounds in a large variety of plant-derived food items.
TopoII-mediated DNA cleavage has been linked to genistein, kaempferol, luteolin, myricetin and
apigenin (Strick et al., 2000; Bandele and Osheroff, 2007; Azarova et al., 2010; Lopez-Lazaro et al.,
2010), although the concentrations in in vitro studies have been quite high. It has also been
demonstrated that several bioﬂavonoids are capable of inducing the cleavage of the MLL gene in
human cell lines (Strick et al., 2000; van Doorn-Khosrovani et al., 2007). The in vitro effects of
bioﬂavonoids suggested a possible link between dietary intake and infant leukaemia (e.g. Azarova
Table B.1: TopoII poisons
Chemical class Examples References
Anticancer agents
Epipodophyllotoxins Etoposide, teniposide Montecucco et al. (2015)
Anthracyclines Doxorubicin, epirubicin, daunorubicin, idarubicin,
aclarubicin
Cowell and Austin (2012)
Anthacenedione Mitoxantrone Cowell and Austin (2012)
Acridines Amsacrine Cowell and Austin (2012)
Bioﬂavonoids
Flavones Luteolin, apigenin, diosmetin Ketron and Osheroff (2014)
Flavonols Myricetin, quercetin, kaempferol, ﬁsetin Ketron and Osheroff (2014)
Isoﬂavones Genistein Ketron and Osheroff (2014)
Catechins EGCG, ECG, EGC, EC Ketron and Osheroff (2014)
Isothiocyanates Benzyl-isothiocyanate, phenethyl-isothiocyanate,
sulforaphane
Ketron and Osheroff (2014)
Other phytochemicals Curcumin Ketron and Osheroff (2014)
Environmental chemicals
Aromatic compounds Benzene, PAHs
Nitrosamines Diethylnitrosamine Thys et al. (2015)
Organophosphates Chlorpyrifos Lu et al. (2015)
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et al., 2010; Lanoue et al., 2010); however until now, epidemiological evidence existing to support or
refute such a hypothesis is based on small studies (Ross et al., 1996; Spector et al., 2005).
Chlorpyrifos
Chlorpyrifos is a widely used organophosphate insecticide, which has been suspected as a risk
factor for infant and childhood leukaemia after the house-hold exposure of pregnant women.
According to Lu et al. (2015), chlorpyrifos and its metabolite chlorpyrifos oxon exhibit an inhibitory
effect on in vitro TopoII activity. Chlorpyrifos causes DNA double strand breaks as measured by the
neutral Comet assay and induces MLL gene rearrangements in human fetal liver-derived CD34+
haematopoietic stem cells via TopoII ‘poisoning’ as detected by the FISH assay and in vitro isolated
TopoII inhibition assay, respectively (Lu et al., 2015). Chlorpyrifos also stabilises the TopoII-DNA
cleavage complex. Etoposide was used a positive reference compound in these studies and it
performed as expected. The lowest concentration of chlorpyrifos used was 1 lM and it gave a
statistically signiﬁcant effect in many in vitro assays. The point of departure of etoposide, which was
calculated to be 0.01 to 0.1 lM (Li et al., 2014), is at least 10-fold lower than that of chlorpyrifos.
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KE1: In utero MLL chromosomal translocation
How this key event works
Chromosomal rearrangements of the mixed-lineage leukaemia (MLL) gene, located on the q23 band
of chromosome 11 (11q23), are the genetic hallmark of most infant leukaemias (Meyer et al., 2013;
Sanjuan-Pla et al., 2015). MLL is located within the fragile site FRA11G; chromosomal fragile sites are
regions of the genome susceptible to breakage under conditions of replication stress; interference with
TopoII may promote fragile site instability. MLL encodes a protein homologous to the Drosophila
trithorax gene, which has relevant functions in embryogenesis and haematopoiesis (Hess et al., 1997;
Ernest et al., 2004).
There are many translocation and fusion partners for MLL; DNA breakage within MLL can lead to
rearrangement with over 120 partner genes (Meyer et al., 2013). In principle all MLL fusion genes are
potential initiating drivers, although clinical studies have shown a preponderance with infant leukaemia
for only a few of these rearrangements. For infants diagnosed with ALL, approximately 60–80% carry
an MLL rearrangement (Jansen et al., 2007; Sam et al., 2012), with predominant fusion partners being
AF4 (41%), ENL (18%), AF9 (11%) or another partner gene (10%). In particular, the fusion gene MLL-
AF4 shows a speciﬁc and consistent relationship with the disease (Menendez et al., 2009): however, it
has been difﬁcult to reproduce a manifest disease resulting from this rearrangement in in vivo animal
models. For AML, about 30% of the patients carry an MLL rearrangement.
The occurrence of MLL rearrangements at a very early fetal development is highly probable on the
basis of neonatal blood spot analysis and by the high concordance rate of infant leukaemia in
monozygotic twins (Ford et al., 1993; Gale et al., 1997; Sanjuan-Pla, 2015). Menendez et al. (2009)
showed that MLL-AF4 fusion gene is present in bone marrow mesenchymal stem cells in infant
leukaemia patients, but not in patients of childhood leukaemia, suggesting that the origin of the fusion
gene is probably prehaematopoietic. Consequently, the affected cell, the so called leukaemia-initiating
cell, may be an early prehaematopoietic mesodermal precursor, a haematopoietic stem cell or
haematopoietic progenitor cell residing mainly in the liver (Greaves, 2015; Sanjuan-Pla et al., 2015).
MLL protein (complexed with a large number of other protein factors) serves as a transcriptional
activator or repressor via the binding to promoter regions of active genes, marking these regions by
covalent histone modiﬁcations (Sanjuan-Pla et al., 2015). Translocation and creation of fusion genes
and products destroys the intrinsic control mechanisms of the MLL protein. The resulting ‘ectopic’
functions involve promoter hyper-activation and re-acquiring stem cell features (Sanjuan-Pla et al.,
2015). A schematic presentation of the drastic changes of the MLL product is depicted in Figure B.3.
PPPs, Parkinson’s disease and childhood leukaemia
www.efsa.europa.eu/efsajournal 279 EFSA Journal 2017;15(3):4691
MLL translocation sites (breakpoint sequences) in the therapy-related leukaemia fall within a few
base pairs of etoposide-induced enzyme-mediated DNA cleavage site (r). Although rearrangements
associated with infant leukaemias are often more complex than those observed in treatment-related
leukaemias, many are nevertheless associated with stable TopoII-mediated DNA cut sites. Although all
these ﬁndings are indirect regarding infant leukaemia, they are nevertheless rather persuasive in this
respect.
Growing scientiﬁc evidence, including the stable genome of the patients, suggests that infant
leukaemia originates from one ‘big-hit’ occurring during a critical developmental window of stem cell
vulnerability (Andersson et al., 2013; Greaves 2015). Therefore, the totality of evidence suggests the
essential role of the formation of MLL-AF4 (and other partner) fusion gene and product in causing
pleiotropic effects in the affected cell and directing it to the obligatory pathway to the adverse
outcome of leukaemia (see KER2).
How it is measured
The presence and structure of a fusion gene can be identiﬁed with PCR or related techniques.
Mapping of cleavage sites in the gene needs genomic DNA. In cells or tissues, the detection of a fusion
gene is possible by appropriate immunoﬂuorescent techniques.
Assays measuring chromosomal aberrations, micronuclei or DNA and chromosome damage (Comet
assay) may indirectly identify the KE through its consequences in experimental systems in vitro and
in vivo; the degree of accuracy of such identiﬁcation cannot be evaluated presently.
Taxonomic applicability
Although the KE deals with the general process of DNA integrity, the available evidence do not
allow for evaluating whether any signiﬁcant difference occurs among cell types or species. It has been
shown that the mouse has an analogous fusion gene mll-af4. A recent study has shown that in utero
exposure to etoposide induces mll translocations in Atm-knockout mice, which are defective in the DNA
damage response, albeit not in wild-type mice; moreover, fetal liver haematopoietic stem cells were
more susceptible to etoposide than maternal bone marrow mononuclear cells, pointing out the life
stage-related susceptibility in regard to TopoII ‘poison’ also in the mouse (Nanya et al., 2015).
Figure B.3: Proposed model for the oncogenic conversion of MLL fusions: (A) Physiological situation and
(B) A chromosomal translocation, which leads to the intrinsic regulatory mechanism of MLL
being destroyed (Republished with permission of American Society of Hematology, from
Sanjuan-Pla et al., 2015; permission conveyed through Copyright Clearance Center, Inc.)
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Adverse Outcome (AO) Infant leukaemia
How this key event works
Symptoms of leukaemia – thrombocytopenia resulting in sensitivity to bruising and bleeding,
anaemia with pallor and fatigue, neutropaenia associated with increased susceptibility to infections –
are principally due to the displacement of the normal haematopoiesis by expansion of leukaemia cells.
Leukaemic inﬁltration of the brain is common at diagnosis of the infant leukaemia (Hunger and
Mulligham, 2015).
How it is measured
Haematological methods – identiﬁcation of leukaemia cells and routine blood cell counts;
observations of clinical symptoms.
Following clinical diagnosis, methods for reﬁned diagnosis include bone marrow aspirates for
immunophenotypic analyses and cytogenetic assays for molecular stratiﬁcation.
The carcinogenicity assays and the extended one generation test (OECD 443) include endpoints
that can potentially explore the AO; however, considerations should be made on the speciﬁcity of the
disease to humans.
Taxonomic applicability
Infant leukaemia is a paediatric leukaemia likely resulting from gene-environmental interactions.
The limited data available suggest that dietary and environmental exposure to substances targeting
topoisomerases together with reduced ability of the fetus or their mother to detoxify such compounds
because of the polymorphic variants of given genes could contribute to the development of this AO
(Hernadez et al., 2016).
In animals the disease is not known and artiﬁcial animal models able to reproduce the disease have
limitations. Bardini et al. (2015) have however developed a xenograft mouse model with patient MLL-
AF4-involving leukoblasts transplanted.
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Regulatory relevance of the AO
Genotoxicity in general and carcinogenicity are apical endpoints in established regulatory guideline
studies. TopoII poisoning has been listed as one of the potential mechanisms of genotoxicity and
carcinogenicity in the ICH M7 guideline for human medicines. It is also known that some
manifestations of genotoxicity in tests measuring chromosomal aberrations, micronuclei or DNA and
chromosome damage (Comet assay) are partially due to double-strand breaks created by the disturbed
action of TopoII enzymes.
The extended one generation test (OECD 443) includes a developmental immunotoxicity cohort. At
present the cohort may identify postnatal effects of prenatal and neonatal exposures on the immune
tissues and white blood cells population. However, each regulatory guideline study has potential
limitations e.g. no speciﬁc parameters are in place to identify a pattern relevant to infant leukaemia in
humans in the extended one generation test, no treatment is occurring during the early in-utero
development phase in the carcinogenicity assay and no considerations on the possible higher
sensitivity of the HSC are in place for the genotoxicity assays.
Epidemiological evidence linking pesticide exposure to infant leukaemia, also suggests that pesticide
exposure may have a greater impact on children than adults; though, almost all of the available
evidence does not make a distinction between infant and childhood leukaemia. However, most
epidemiological studies are limited because no speciﬁc pesticides have been directly associated with
the risk of leukaemia, but rather the broad term ‘pesticide exposure’ (Hernandez and Menendez,
2016). In this perspective, this AOP would provide a regulatory relevant support for understanding the
potential of a chemical to be involved in this toxicological pathway.
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1st KER: In utero DNA topoisomerase II inhibition (KEup) leading to In
utero MLL chromosomal translocation (KEdown)
How this Key Event Relationship works
Certain TopoII poisons stabilise the intermediate cleavage complex and prevent the religation with
appropriate DNA strands. Covalently DNA end-bound TopoII protein is digested and a hanging end is
created. The same process happens in the translocation partner gene. Hanging ends of both genes are
processed and subsequently joined by non-homologous end joining (Cowell and Austin, 2012). There
is evidence that this inappropriate joining of ‘hanging ends’ happens in the same transcriptional factory
(hub), and the result is a fusion gene and ultimately protein product (Cowell and Austin, 2012;
Pendleton et al., 2014; Sanjuan-Pla et al., 2015). The ﬁrst part of this description has not been shown
in the putative target cell, which is still not unequivocally identiﬁed, but for the second part there is
ample evidence of formation of MLL-AF4 fusion product that has been a result of a very early
chromosomal translocation and rejoining. It is of interest that the simultaneously induced speciﬁc DSBs
in the MLL gene and two different translocation partners (AF4 and AF9) by engineered nucleases in
human HSPCs resulted in speciﬁc ‘patient-like’ chromosomal translocations (Breese et al., 2016).
Weight of Evidence
Evidence supporting the causal relationship between etoposide-induced TopoII inhibition and the
MLL rearrangement leading to the fusion gene is strong regarding treatment-related acute leukaemia
(Cowell and Austin, 2012; Pendleton et al., 2014). The bioﬂavonoid-rich diet in pregnant women has
been suggested to initiate infant leukaemia by an analogous causality between in utero inhibition of
TopoII enzymes and creation of the fusion gene. However, there is no direct evidence in humans and
it is also difﬁcult or impossible to study. Power of epidemiological studies is relatively weak in the case
of a very rare disease and case-control or spatiotemporal cluster studies have barely suggested a
causal relationship between exposures and disease.
PPPs, Parkinson’s disease and childhood leukaemia
www.efsa.europa.eu/efsajournal 282 EFSA Journal 2017;15(3):4691
Biological plausibility
The KER as such is biologically plausible. Type II topoisomerases are ubiquitous enzymes which are
essential for a number of fundamental DNA processes. As they generate DNA strand breaks, they can
potentially fragment the genome. Indeed, while these enzymes are essential for the survival of
proliferating cells they can also have signiﬁcant genotoxic effects by means of accumulation of DNA
strand breaks that, if not resulting in cell death may lead to chromosomal translocation in the surviving
cell population (McClendon et al., 2007). DNA breaks and MLL rearrangements by etoposide and
bioﬂavonoids have been demonstrated in human fetal liver haematopoietic stem cells, in human
embryonic stem cells and in human prehaematopoietic mesenchymal stem cells as well as in cord
blood mononuclear cells (Ishii et al., 2002; Blanco et al., 2004; Moneypenny et al., 2006; Bueno et al.,
2009; Menendez et al., 2009), which clearly shows that TopoII-associated MLL rearrangements are
produced in appropriate human cells in utero.
Empirical support for linkage
There are animal models for infant leukaemia which recapitulate at least some salient aspects of
the disease (Sanjuan-Pla et al., 2015). However, for example the MLL-AF4 knock-in mice develop
leukaemia only after a prolonged latency (Chen et al., 2006), thus not recapitulating the
‘pathognomonic’ feature of infant leukaemia.
Etoposide treatment in vivo in mice at day 13.5 of pregnancy induces MLL breakage in fetal liver
haematopoietic stem cells in utero, but MLL-rearranged fusion mRNAs were detected only in mice
which were defective in the DNA damage response, i.e. atm knockout mice. A fusion gene analogous
to MLL-AF4 was not detectable in the wild type mice. In this study, an intraperitoneal injection of
10 mg/kg of etoposide into pregnant mice at day 13.5 of pregnancy resulted in a maximum fetal liver
concentration of about 5 lM. A dose of 0.5 mg/kg did not result in a measurable concentration. A
statistically signiﬁcant increase (about sixfold) in DSBs in the MLL gene of isolated fetal liver
haematopoietic stem cells was observed after a single dose of 1 mg/kg to pregnant mice.4 A clear
activation of DNA damage response was observed at the dose of 10 mg/kg (Nanya et al., 2016).
There is a lot of information about the interaction of etoposide with TopoII enzymes and MLL
chromosomal translocation at the cell culture level and in connection with treatment-related leukaemia.
Molecular dose–response modelling of etoposide-induced DNA damage response, based on
comprehensive in vitro high content imaging in the HT1080 cell model, was developed by Li et al.,
(2014). The model was based on the hypothesis that cells are capable of clearing low-level DNA
damage with existing repair capacity, but when the number of DSBs exceeds a certain value; ATM and
p53 become fully activated through reversible mechanism, leading to elevated repair capacity. The
model was able to capture quantitatively the dose–response relationships of a number of markers
observed with etoposide. Especially interesting are the dose–response relationships for activation of
p53 and the formation of micronuclei in the target cell model, which indicate point-of-departure
concentrations of etoposide in the range of 0.01 to 0.1 lM (Li et al., 2014). This range is in agreement
with the ﬁnding that in human fetal liver CD34+ cells an increase in DSBs was observed at a
concentration of 0.14 lM and MLL translocations were detectable by FISH or ﬂow cytometry at higher
concentrations (Moneypenny et al., 2006).
Uncertainties and Inconsistencies
• A prerequisite for the speciﬁc outcome, i.e. creation of chromosomal rearrangement, is that
TopoII inhibition has to occur in an especially vulnerable and correct hot spot in the MLL locus;
however, details of this process and how it happens are not clear.
• A target cell, i.e. leukaemia-initiating cell, has not been identiﬁed with sufﬁcient conﬁdence and
consequently there is no target cell model to recapitulate the linkage between TopoII inhibition
(‘poisoning’) and the production of DSB in an appropriate target. Recently, by the expression
of engineered nucleases (TALENs) to induce simultaneous patient speciﬁc double strand breaks
in the MLL gene and two different known translocation partners (AF4 and AF9), Breese et al.
(2015) were able to produce speciﬁc chromosomal translocations in K562 cells and in primary
HSPCs.
• In-utero etoposide-treatment failed to induce leukaemogenesis (Nanya et al., 2015).
Consequently, the envisaged linkage has not been empirically supported or rejected. However,
4 Hypothetically, based on linear extrapolation from the dose of 10 mg/kg, the concentration would be of the order of 0.5 µM.
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it should be kept in mind that, whereas etoposide does induce a large number of MLL
rearrangements, most of them occur within non-coding regions, therefore not eliciting any
direct oncogenic consequence. A MLL-AF4 in frame fusion is a rare event that needs to occur in
a target cell within a relatively small and spatially restricted cell population during the
appropriate, epigenetically plastic, developmental window; thus it may be difﬁcult to
empirically support this process.
• Dose–response relationships between etoposide and treatment-related leukaemia are difﬁcult
to unravel, but risk of leukaemia seems to increase with larger total exposure to etoposide.
However, comparison of exposures or kinetics of etoposide between leukaemia patients and
non-leukaemic treated subjects did not reveal any signiﬁcant differences (Relling et al., 1998).
Also, it is not known whether the etoposide (or metabolite) concentrations during the
treatment are of signiﬁcance. In child and adult chemotherapy, concentrations are extremely
variable between individuals; the lowest through plasma concentrations of etoposide have
been of the order of 1 lM and peak concentrations very much higher. For example, in a study
of Relling et al. (1998), the maximum plasma concentration of etoposide was about 90 lM and
that of etoposide catechol about 100-times less, below 1 lM. In another high dose
chemotherapy study (Stremetzne et al., 1997), the etoposide concentration was 170 lM and
that of the catechol metabolite 5.8 lM maximally. However, it is not straightforward to
juxtapose plasma concentrations and the tissue or cell concentration which TopoII enzyme
‘sees’. Penetration of etoposide or its metabolite through plasma membrane is probably rather
slow and it has been shown that the brain cancer tissue (metastasis or glioma) to plasma ratio
for etoposide is only 0.1 (Pitz et al., 2011). Blood–brain barrier is not necessarily a good model
for cross-membrane distribution, but may give some idea about the general distributional
behaviour of a drug. Even if the active target concentration of etoposide is only 10% of the
plasma concentration, it is still in the same range as the effective concentrations in cellular
studies (see above). A ﬁnal note on relevant concentrations: etoposide concentrations resulting
in DSB and fusion gene are probably within a relatively restricted range. The concentration
resulting in a proper fusion gene should be in a range which gives rise to a partially repaired
insult and cells bypassing death and accumulating the abnormality.
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2nd KER: In utero MLL chromosomal translocation (KEup) leading to Infant
leukaemia (KEdown)
How this Key Event Relationship works
Propagation of a leukaemic cell clone is based on both blockage of differentiation to more mature
cells and ability to expand in an uncontrolled way. Formation of the MLL-rearranged fusion genes and
their protein products are intimately involved in both the blocked differentiation of HSPCs and the
expansion of the fusion gene-carrying clone. It is believed that the fusion gene product block cell
differentiation by inhibiting the normal transcriptional programs and recruiting repressor molecules
such as histone deacetylase enzymes (Greaves, 2002; Teitell and Pandolﬁ, 2009). Furthermore, the
fusion gene product activates other key target genes, which ultimately lead to the propagation of
transformed cell lines without normal restrictions (Greaves, 2015; Sanjuan-Pla et al., 2015). Therefore,
the potential of both differentiation blockage and clonal expansion are inherent properties of the MLL-
rearranged fusion product, based on the preservation of some original functions, even if in a modiﬁed
form, and on the gain of some other functions due to the sequences from the new fusion partner gene
(Marschalek, 2010; Sanjuan-Pla et al., 2015).
Molecular mechanisms
The MLL is the most common translocation gene in infant leukaemia. The N-terminal part of MLL
becomes fused in frame to one of a large number of fusion partners, but in most cases, this fusion
occurs between the N-terminal MLL and either AF4, AF6, AF9, AF10 or ENL (Krivtsov and Armstrong,
2007). Due to the DNA-binding properties of the N-terminal MLL motif, these fusion proteins are
always nuclear and bind to target genes controlled by MLL irrespective of the normal location of the
C-terminal partner.
Many fusion proteins have been shown to recruit DOT1L (catalysing methylation of histone H3K79)
to the promoters of MLL target genes and this recruitment seems to be a common feature of many
oncogenic MLL fusion proteins. Although DOT1L is not genetically altered in the disease per se, its
mislocated enzymatic activity is a direct consequence of the chromosomal translocation. Thus, DOT1L
has been proposed to be a catalytic driver of leukaemogenesis (Chen and Armstrong, 2015). The
enzymatic activity of DOT1L is critical to the pathogenesis of MLL, because methyltransferase-deﬁcient
Dot1L is capable of suppressing growth of MLL-rearranged cells. A small-molecule inhibitor of DOT1L
inhibits cellular H3K79 methylation, blocks leukaemogenic gene expression, and selectively kills
cultured cells bearing MLL translocations (Chen and Armstrong, 2015). One of the target gene of
DOT1L is BCL-2, belonging to a family of antiapoptotic genes, which maintains the survival of the MLL-
rearranged cells (Benito et al., 2015). Expression of BCL-2 is high in human MLL-AF4 leukaemia cells
from a large number of patients. A speciﬁc BCL-2 inhibitor, ABT-199 is capable of killing MLL-AF4
leukaemia cells and prevents cell proliferation in xenograft mouse leukaemia models (Benito et al.,
2015). Furthermore, a MLL-AF4 cell line is sensitive to a combination of ABT-199 and DOT1L inhibitors.
Figure B.4 provides a schematic representation of the molecular pathway.
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Possible facilitating mutated genes
Recurrent activating mutations in the components of the PI3K-RAS signalling pathway have been
detected in almost half of the tested MLL-rearranged ALLs in one study (Andersson et al., 2015).
Prenatal origin of RAS mutations have been demonstrated also in other studies of infant leukaemia
with frequencies of about 15–25% of cases (Driessen et al., 2013; Prelle et al., 2013; Emerenciano
et al. 2015). Emerenciano et al. (2015) are of the opinion that RAS mutations seem not to be driver
mutations, but may aid disease onset by accelerating the initial expansion of cells.
Overall the activation of the RAS pathway could support the extremely rapid progression of the
infant leukaemia. Under this view the mechanism may represent a factor modulating (i.e. increasing)
the progression and severity of the adverse outcome, rather than a necessary key event (second hit)
for infant leukaemia. In the transgenic MLL-AF4 mouse model, activated K-RAS accelerated disease
onset with a short latency (Tamai et al., 2011), possibly by augmenting the upregulation of HoxA9. In
a recent study of Prieto et al. (2016), the activated K-RAS enhanced extramedullary haematopoiesis of
MLL-AF4 expressing cell lines and cord blood-derived CD34+ haematopoietic stem/progenitor cells that
was associated with leucocytosis and central nervous system inﬁltration, both hallmarks of infant MLL-
AF4 leukaemia. However, K-RAS activation was insufﬁcient to initiate leukaemia, supporting that the
involvement of RAS pathway is an important modifying factor in infant leukaemia. It has also been
demonstrated that MLL-AF6 fusion product sequesters AF6 into the nucleus to trigger RAS activation in
myeloid leukaemia cells and it is possible to attenuate the activation by tipifarnib, a RAS inhibitor
(Manara et al., 2014).
A possibility that MLL fusions render cells susceptible to additional chromosomal damage upon
exposure to etoposide was studied by introducing MLL-AF4 and AF4-MLL via CRISPR/Cas9-genome
editing in HEK293 cells as a model to study MLL fusion-mediated DNA-DSB formation/repair (Castano
et al., 2016). In short, the expression of fusion genes does neither inﬂuence DNA signalling nor DNA-
DSB repair.
Weight of Evidence
The overall scientiﬁc evidence, including the stable genome of patients, suggests that infant
leukaemia originates from one ‘big-hit’ occurring during a critical developmental window of stem cell
vulnerability (Andersson et al., 2013; Greaves, 2015). Different from the ‘two-hit’ model of the adult
leukaemias, the infant leukaemia is a developmental disorder where the clonal expansion is a direct
consequence of in utero MLL translocation.
Biological plausibility
The biological plausibility linking the MLL translocation to infant leukaemia is strong. Rearrangement
in the MLL gene is commonly associated with infant acute leukaemia and the disease has unique
clinical and biological feature (Ernst et al., 2002). An in utero initiation, an extremely rapid progression,
and a silent mutational landscape of infant leukaemia suggest that the MLL-translocation-associated
gene fusion product is itself sufﬁcient to spawn leukaemia and no ‘second hit’ is required. Therapy-
related leukaemias following exposure to the topo II poisons such as etoposide are characterised by
the MLL chromosomal translocation (Super et al., 1993; Libura et al., 2006) and translocations
involving MLL are associated with a gain of function and leukaemogenic effect (Yu et al., 1998). A
critical developmentally early window of stem cell vulnerability, involving perhaps lesions based on
Figure B.4: MLL-rearranged acute lymphoblastic leukaemias activate BCL-2 through H3K79
methylation and are sensitive to the BCL-2-speciﬁc antagonist ABT-199 (Benito et al.,
2015, CC-BY)
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epigenetically controlled regulatory factors, has been suggested to explain a rare occurrence and an
exceptionally short latency of infant leukaemia (Greaves, 2015; Sanjuan-Pla et al., 2015). In primary
HSPCs genome engineered for patient speciﬁc MLL translocations it was possible to show that this
speciﬁc ‘artiﬁcial’ initiation can induce a selective advantage in survival in extended culturing and a
higher clonogenic potential in colony forming assay (Breese et al., 2015).
Empirical support
A number of MLL-fusion products, such as MLL-AF9 and MLL-ENL, have shown leukaemogenic
potential in cord-blood stem cells. Although the MLL rearrangement is essential to develop leukaemia,
it alone may not be sufﬁcient and activation of cellular proliferation might be necessary for overt
leukaemia (Nanya et al., 2015).
There are several animal models, in which MLL-AF4 fusion gene has been expressed (Chen et al.,
2006; Metzler et al., 2006; Bursen et al., 2008; Krivtsov et al., 2008; Tamai et al., 2011). In all these
models leukaemia is ultimately developed, but latency has been very protracted. In any case, one
could conclude that the expression of the MLL-AF4 fusion gene is capable of developing leukaemia, but
it is unknown whether facilitating or necessary changes are required during the long latency in mouse.
Gene engineered human HSPCs carrying MLL rearrangements showed that a subset of cells
persisted over time and demonstrated a higher clonogenic potential in colony forming assay (Breese
et al., 2015).
Transcription activator-like effector nuclease (TALEN)-mediated genome editing generated
endogenous MLL-AF9 and MLL-ENL oncogenes in primary human HSPCs derived from human umbilical
cord plasma (Buechele et al., 2015). Engineered HSPCs displayed altered in vitro growth potential and
induced acute leukaemias following transplantation in immunocompromised mice at a mean latency of
16 weeks. The leukaemias displayed phenotypic and morphologic similarities with patient leukaemia
blasts, expressed elevated levels of crucial MLL-fusion partner target genes, displayed heightened
sensitivity to DOT1L inhibition, and demonstrated increased oncogenic potential ex vivo and in
secondary transplant assays.
Uncertainties and Inconsistencies
• The MLL-AF4 knock-in mice develop leukaemia only after a prolonged latency (Chen et al.,
2006), thus not recapitulating the ‘pathognomonic’ feature of infant leukaemia. Also other
animal models have been developed with similar results. Thus, an adequate experimental
model for infant leukaemia is still in need.
• The role of a reciprocal fusion gene AF4-MLL in leukaemias is controversial: it has a
transformation potential in animal model (Bursen et al., 2010), but it is not expressed in all
MLL-AF4 patients (Andersson et al., 2015). The potential role of other reciprocal fusion genes
has not been studied.
• Beyond MLL rearrangements, activation of cellular proliferation by mutation or other
(epi)genetic insults might be necessary for overt leukaemia. Further studies are necessary to
fully understand which factors would contribute to convey a proliferative advantage, as
observed in cells with MLL translocation, to leukaemia.
Quantiﬁable understanding
Relationships between different fusion genes and subsequent leukaemia types are incompletely
understood. Although roughly 70–80% of infant B-ALL leukaemias carry MLL rearrangements, in 20–
30% of the cases there are no MLL rearrangements. In AML and T-ALL leukaemia cases MLL
rearrangements are even rarer.
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Overall assessment of the AOP
Infant leukaemia is a ‘hidden’ disease quite concretely: initiation occurs in utero at an early phase
of fetal development. Studies both in identical twins (Ford et al., 1993) and in neonatal blood samples
retrospectively (Gale et al., 1997) strongly indicate in utero origin of the disease. Consequently, direct
studies in pregnant humans are difﬁcult or impossible and one has to resort to surrogate in vitro or
ex vivo studies or to animal models which necessarily are associated with difﬁculties in interpretation
and extrapolation. Thus, what is described in this overall assessment is based largely on inferences
from analogous diseases using tool chemicals able to reproduce the biological basis of the disease
(especially etoposide (a Topoisomerases II poison)-caused acute leukaemia in children or adults) or
from cellular and animal models.
B.1. Concordance of dose–response relationship
The only in utero study in mice (Nanya et al., 2016) has shown that the dose of 0.5 mg/kg (day
13.5 of pregnancy) does not result in measurable etoposide concentration in fetal liver HSCs whereas
the dose of 10 mg/kg leads to a maximal concentration of 5 lM. A statistically signiﬁcant increase in
double strand break (DSBs) in MLL gene was observed at a dose of 1 mg/kg, which would result in a
concentration of 0.5 lM by linear extrapolation. In treatment-related acute human leukaemia, various
treatment schedules in adults and children give rise to etoposide concentrations between (roughly)
< 1 lM (through) to > 150 lM (peak). There are no adequate experimental systems to study dose–
response and response–response relationships across MIE, KEs and AO in a single model.
B.2. Temporal concordance among the MIE, KEs and AO
There are no serious doubts about temporal concordance among MIE, KEs and AO. It is very
difﬁcult to see any other sequence of events (among this AOP), which would bring the AO into effect.
Another matter is that it has never been shown in human pregnancy (or will be reliably or robustly
demonstrated in the foreseeable future). In this respect, it is difﬁcult to envisage whether
epidemiological studies that are possible in humans, would ever be able to demonstrate the link
without a direct biomarker for the MIE and KE1. Available experimental models (Sanjuan-Pla et al.,
2015) are in conformation with the AOP, except that in experimental in vivo models a very protracted
appearance of leukaemia is not in line with a very short latency of infant leukaemia in human.
It is obvious that there exists a vast gap between wide exposure to potential TopII poisons and the
rarity of infant leukaemia. On the basis of studies in human adult and childhood leukaemias, there are
a large number of genetic, epigenetic and host factors potentially modifying the link between topII
poisons and leukaemia. Because of the rarity of the disease, it is difﬁcult to envisage an even partial
prooﬁng these factors as of importance for the infant leukaemia.
Table B.2: Response–Response and temporality concordance for the tool compound etoposide
Concentration of etoposide
MIE
In utero DNA
topoisomerase II
inhibition
KE1
In utero MLL
chromosomal
rearrangement
AO
Infant
leukaemia
0.01–0.1 lM, in vitro (TopII
enzymes and cells in culture)
+++
(DNA damage response in
various cells)
–
0.1–1 lM, in vitro cell cultures +++
(haematopoietic progenitor
and stem cells)
+
0.5–5 lM, ex vivo, mouse fetal
liver HSC concentration(a)
+++
(inference from MLL
cleavage)
+
(only MLL cleavage)
–
(no leukaemia
development)
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B.3. Strength, consistency of the experimental evidence, and
speciﬁcity of association of AO and MIE
Regarding the treatment-related acute leukaemia, strength, consistency and speciﬁcity of
association of AO and MIE is strong, because only etoposide and a few other TopII-poison anticancer
agents (Mention!) have strong evidence for causing acute leukaemia in human via the general process
of the AOP described here. Although direct observations on the initial in utero MIE in infant leukaemia
are not possible, there is a lot of inferential evidence from animal and in vitro cellular studies
suggesting strongly that infant leukaemia recapitulates at least at an apparent process level the
treatment-related leukaemia. It is important to recognise that in therapy-related AML this has been
clearly demonstrated with abnormalities affecting MLL locus. Chlorpyrifos is reported to be a Topo II
poison and to induce MLL translocation in the human liver haematopoietic stem cells (Lu et al., 2015).
However, it is probable that the dose dependence of the formation of DSBs and fusion genes is linear
only in a very restricted ‘window’ of dose range. Considering the rarity of IFL and the common
exposure to Topo II poisons like bioﬂavonoids, speciﬁcity is low. However, this consideration is limited
by lack of experimental studies conducted with other than anticancer drugs on the sensitive target
cells i.e. the liver haematopoietic stem cell.
B.4. Weight of Evidence (WoE)
B.4.1. Biological plausibility
The biological plausibility for this AOP is strong. The relationship between DNA double strand
breaks, MLL chromosomal translocation and infant leukaemia is well established. The same pathway is
reproducible in chemotherapy-induced acute leukaemia in patients following treatment with etoposide,
a known Topo II poison.
Concentration of etoposide
MIE
In utero DNA
topoisomerase II
inhibition
KE1
In utero MLL
chromosomal
rearrangement
AO
Infant
leukaemia
Max 5 lM, ex vivo, mouse fetal
liver HSC concentration(a)
+++
(inference from MLL
cleavage)
+
MLL fusions detected only in
DNA repair deﬁcient mice
–
(no leukaemia
development)
Max > 150 lM, plasma concs in
etoposide-treated patients(b)
+++
(inference from MLL
cleavage)
++
MLL-AF4 fusion gene and
protein
+
treatment-related
acute leukaemia
(a): A range of concentrations is linearly extrapolated on the basis of the concentration of 5 lM after the dose of 10 mg/kg.
(b): Plasma concentration of etoposide cannot be directly extrapolated to the concentration at the active site. Probably the actual
active cellular concentrations of etoposide is much lower, perhaps 10% or less of the plasma concentration.
PPPs, Parkinson’s disease and childhood leukaemia
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B.5. Uncertainties and Inconsistencies
• In utero evidence of the disease is difﬁcult to obtain in humans and one has to resort to
in vitro cellular systems, which may be inadequate to take into consideration the potential
effects of proposed microenvironments, rapidly changing developmental stages and facilitating
and modifying factors.
• Animal models are a possibility (e.g. Nanya et al., 2015), but are naturally prone to species-
speciﬁc factors.
• An important problem is to provide a convincing and experimentally justiﬁed explanation for
the dilemma between the rarities of disease in the face of pervasive exposure to topoII
inhibitors.
• The treatment-related AML apparently is a true surrogate for the infant leukaemia, at least
mechanistically. Is it only because of etoposide as a principal chemical initiator has provided
many crucial ﬁndings for understanding the infant leukaemia.
• The ‘poisoning’ of the TopoII-DNA cleavage complex has not been shown in the putative target
cell, which is still not unequivocally identiﬁed.
• MLL-AF4 knock-in mice develop leukaemia only after a prolonged latency (e.g. Chen et al.,
2006), thus not recapitulating the ‘pathognomonic’ feature of infant leukaemia.
• The inability of available in vivo models to recapitulate the whole AOP process is due to a
crucial factor which has not yet been found, or to model-speciﬁc peculiarities.
• In the face of the rarity of the disease, epidemiological studies especially concerning aetiology
and risk factors are not powerful enough to provide robust answers. For instance, investigating
the hypothesised relationship of bioﬂavonoids with infant leukaemia will have to consider the
gap between the widespread intake of these phytochemicals and the very rare occurrence of
the disease.
• The biology of the disease (i.e. IFL) and the experimental studies conducted with etoposide,
indicate in-utero exposure of haematopoietic stem cells (HSC) as the most critical, if not
essential, factor for the development of the A. However, a clear comparative quantiﬁcation in
terms of dose response vs different time of exposure and cell systems is lacking.
• The very early embryonic structure and the liver haematopoietic stem cells in particular, are
representing the target cell for this AOP. A clear understanding of a higher sensitivity of HSC
vs, mature haematopoietic cells, particularly in the standard genotoxicity test battery is lacking
and more chemicals and comparative assays should be tested to scientiﬁcally validate this cell
system..
• What would be consequences if we say that the AOP is biologically possible, feasible, even
probable, and then say that most of the evidence is impossible to get directly and has to be
based on surrogates?
B.6. Quantitative Considerations
The WOE analysis indicates that many KEs and KERs lack especially experimental evidence, but
overall the analysis supports the qualitative AOP. The strong element in the development of the
qualitative AOP is the biological plausibility of the overall pathway that it can partially be based on
studies in human treatment-related disease recapitulating many crucial features of the infant
leukaemia. The lack of sufﬁcient experimental data and uncertainties in quantitative information from
treatment-related acute leukaemia makes it problematic to build convincing dose (concentration)-
response and response–response relationships and to identify possible practical thresholds for
stressors. The MIE is expected to show a dose response relationship to a certain extent. However, it is
probable that the dose dependence of the formation of DSBs and fusion genes is linear only in a very
restricted ‘window’. In too-low concentrations the outcome of the stressor is a successful repair of the
break, in too-high concentrations the outcome is cell death. It should be kept in mind additionally that
the quantiﬁcation of dose–responses should also consider the different sensitivity of cell systems that
should be also representative of the speciﬁc time-window of exposure (i.e. in-utero).
The most pressing future need is an adequate and robust experimental model system for the
evaluation of relationships between doses, concentrations and responses within a temporal framework
of the AOP.
PPPs, Parkinson’s disease and childhood leukaemia
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B.7. Applicability of the AOP
The proposed AOP is strictly life stage-dependent, being linked with in utero exposure and early
embryogenesis. However, the surrogate disease (i.e. chemotherapy-related acute leukaemia) is not life
stage restricted as well as the genotoxic hazard is not expected to be life stage related.
B.8. Potential regulatory applications of the AOP
This AOP was initiated with the intention to use an epidemiologically proposed human health
outcome as AO and build back an AOP leading to this. Infant childhood leukaemia is a human disease
and consequently apical regulatory endpoints can only explore the hazard by means of surrogate
testing. These include carcinogenesis assays and blood cell analyses in the in vivo toxicology
assessment. Considering the unique biology of this AO, these tests show some technical limitations
and also the sensitivity and speciﬁcity of the available tests for the AO is limited. Additionally,
experimental animal models replicating the AO are limited. Technical limitations of the standard
regulatory tests include: Standard carcinogenesis studies do not include an early in-utero exposure
time, blood cell analysis is not a standard requirement in the extended multi-generation reproductive
toxicity study and no cancer-related endpoints are included in this study. In addition, considering the
rarity and the complexity of the disease, the sensitivity and speciﬁcity of these tests to capture this
hazard is likely to represent a big hurdle and the regulatory tests are unlikely to represent the best
way to explore this AO.
This AOP is however indicating that the MIE and the KE1 can be measured in scientiﬁc and/or
regulatory validated test assays.
With these premises, the authors support the use of this AOP during the process of assessment of
epidemiological studies and the use of the AOP framework to support the biological plausibility of the
effects observed in the epidemiological studies when experimental and toxicological studies are
indicative that the AOP is affected and this should guide on which additional studies should be
performed, if the case, to integrate the AOP framework into the MOA framework for speciﬁc chemical
entities.
In addition, this AOP should serve in guiding testing strategy. This include the exploration of Topo
II poison characteristics of a chemical and, if the genotoxicity standard regulatory testing battery is
negative, considerations should be made on the sensitivity of the cell system used in the assay (i.e.
liver HSPC).
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AOP4: In utero induction of chromosomal rearrangements/translocations
in haematopoietic stem/progenitor cells (HSPCs) followed by postnatal
mutations and an aberrant immune response leads to childhood leukaemia
Introduction
Leukaemia is the most common cancer in children under 15 years of age, with an annual incidence
of up to 40 cases per million children in developed countries and an incidence peak between 3 and
5 years of age (ENHIS, 2009; Hunger and Mullingan, 2015). Childhood leukaemia (also termed
paediatric leukaemia) is a biologically heterogeneous disease of immature haematopoietic progenitors
that consists of multiple subtypes depending on the cell type and lineage involved (lymphoid or
myeloid progenitors). Seventy per cent of cases are comprised by acute lymphoblastic leukaemia (ALL)
and the remaining 30% by acute myeloid leukaemia (AML). ALL may be of B–cell lineage (85%) or
T-cell lineage (15%). However, there are some cases of biphenotypic acute leukaemias commonly
harbouring Mixed Leukaemia Lineage (MLL) rearrangements, in which myeloid and lymphoid markers
have been shared by the blast population (Hunger and Mullighan, 2015).
Childhood leukaemia should be distinguished from infant leukaemia, a more rare disease that
manifests soon after birth (< 1 year of life) and has a poorer prognosis. Infant leukaemia is considered
as a ‘developmental disease’ showing different features and pathogenesis than childhood leukaemia,
with more immature precursors being involved (Sanjuan-Pla et al., 2015). A remarkable difference
between the two entities is that childhood leukaemia may arise as a consequence of a ‘2-hit’ model
producing two independent (epi)-genetic insults, the ﬁrst one occurring in utero and the second one
either before, or more often, after birth. In contrast, the natural history and genome-wide sequencing
studies on infant leukaemia suggest that only a single hit occurring in utero is needed. A common
initiating pathogenic event for both types of leukaemias is the occurrence of chromosomal
rearrangements (i.e. chromosomal translocations) that create fusion genes encoding transcriptional
factors involved in the regulation of early haematopoiesis. Chimeric fusion proteins encoded by
chromosomal translocations lead to differentiation arrest of HSPCs, which represents a hallmark in
childhood leukaemia. Almost half of the B-cell ALL cases exhibit aneuploidy, either hyperdiploidy or
hypodiploidy with non-random chromosomal gain or loss, respectively, affecting different
chromosomes. Hyperdiploidy causes chromosomal instability as a result of chromosomal translocations,
duplications and deletions (Paulsson et al., 2006).
The genetic basis of ALL consists of recurrent genetic alterations, such as loss-of-function mutations
involving genes regulating lymphoid development that contribute to the maturation arrest
characteristic of B-ALL, mutations that inactivate tumour suppressor and cell cycle regulatory proteins,
and mutations in genes encoding cytokine receptor and/or protein kinases regulating cell signalling
pathways (Mullighan, 2012). For T-cell ALL, the main drivers are chromosomal translocations resulting
from aberrant recombination between T-cell receptor genes and oncogenes (Mullighan, 2012),
together with activating Notch mutations, a protein involved in T-cell differentiation and thymocyte
development (Weng et al., 2004). For AML leukaemias to occur, cooperation is required between gene
rearrangements involving haematopoietic transcription factors (i.e. AML1/ETO, MLL-related fusion
genes, etc.) and activating mutations (i.e. in apical regulators of intracellular signalling cascades)
(Mullighan, 2012).
Despite the rather comprehensive epidemiologic evidence linking pesticide exposures during
different reproductive stages (preconception, pregnancy and early postnatal) with childhood
leukaemia, no robust mechanisms supporting these associations have been reported so far. Pesticide
exposure has not been directly linked to the development of childhood leukaemia in animal models.
Although negative results for genotoxicity tests have been observed in regulatory studies on individual
pesticides, there is limited experimental evidence in the open literature about the genotoxic or cancer-
promoting capacities of some pesticides in cells, suggesting a potential leukaemogenic effect. However,
the target cells used in these experiments are not the most appropriate for this purpose and the role
played by some pesticide metabolites cannot be ruled out.
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Regardless of the extensive gap in our understanding, particularly on how pesticides mechanistically
interact with biological targets to trigger childhood leukaemia, the AOP proposed for this disease is
supported by experimental evidence and cellular models, with the exception of the molecular initiating
event. However, as knowledge increases, the present AOP may be modiﬁed on the basis of novel
supporting evidence.
AOP: In utero induction of chromosomal translocations in haematopoietic
stem/progenitor cells (HSPCs) leads to childhood leukaemia
The MIE is a specialised type of KE representing the starting point of chemical interaction with a
biological target leading to disruption at the molecular (including genetic) level and subsequent disease
progression. Expectation is that perturbation of the MIE, if quantitatively enough, will lead to tha AO.
In the case of childhood leukaemia, early in utero interaction of a chemical with DNA (or DNA-related
proteins/enzymes) might lead to double strand DNA breaks, which if non-repaired or misrepaired, may
result in genomic instability, leukaemic transformation or cell death.
HSPCs exposed to ionising radiation, environmental chemicals or chemotherapeutic agents are
prone to DNA breakage at sites with the potential to form leukaemia-causing gene rearrangements.
Exposure to non-cytotoxic levels of environmental chemicals and chemotherapeutic agents can induce
DNA damage in HSPCs without causing cell death (Thys et al., 2015). Several studies investigating the
role of DNA repair systems in response to DNA damage found that human fetal liver CD34+ HSPCs are
more sensitive to DNA damage than other haematopoietic precursors at different ontogeny stages
(Bracker et al., 2006). Human fetal liver CD34+ HSPCs are more sensitive to oxidative stress induced
by certain environmental chemicals, including many classes of pesticides than neonatal or adult CD34+
cells (Bueno et al., 2009). Among environmental chemicals, the organophosphate (OP) insecticide
chlorpyrifos has been reported to cause DNA double-strand breaks (DSB) and further chromosome
rearrangements in human fetal liver HSPCs (Lu et al., 2015) in part through oxidative stress (Gupta
et al., 2010).
Chemical exposure may result, either directly or indirectly, in DNA damage. Three potential
mechanisms are involved in this process: generation of DNA DSB, improper repair of these DNA lesions
and erroneous V(D)J recombination (Hernandez and Menendez, 2016).
a) DNA double strand break. Exposures to ionising radiation and numerous chemicals are capable
of inducing oxidative DNA damage through the generation of reactive oxygen or nitrogen species (ROS
and RNS, respectively). These highly reactive species may produce DNA base or sugar damage leading
to single-strand break formation. However, under some circumstances DNA DSBs can arise, for
instance: (a) when two single strand breaks form close to each other on opposite strands, (b) when
topoisomerases cleave next to a single strand breaks on the opposite strand, and (c) when either DNA
replication or transcription takes place at unrepaired DNA damage.
b) Improper DNA repair. ROS-induced DNA DSBs in human fetal liver-derived HSPCs following
maternal exposure to chemicals triggers recombination/repair pathways by non-homologous
end-joining (NHEJ), the main repair pathway for DSBs. The majority of damaged HSPCs may either
successfully repair the break or fail and die through secondary activation of apoptotic pathways. In a
Figure B.5: AOP scheme
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fraction of cells, the attempt to repair the DNA DSBs within particular breakpoints cluster regions is not
completed properly, so that chromosomal translocations or deletions may occur (Wiemels and Greaves,
1999). Translocation breakpoints harbour evidence of NHEJ mechanisms, but in only a few examples
are the causative mechanisms of breakage evident, such as V(D)J recombinase gene activation
(Wiemels, 2008).
c) Erroneous V(D)J recombination. V(D)J recombination is a process occurring in developing
lymphocytes during cell maturation, where gene segments of immunoglobulin chains or T-cell receptor,
known as variable (V), diversity (D) or joining (J), are rearranged to yield a wide range of
immunoglobulins and T-cell receptors. The process entails the cleavage of the V(D)J gene at the
ﬂanking recombination signal sequences (RSS) by lymphocyte-speciﬁc recombination-activating gene
(RAG) endonucleases and subsequent ligation of the segments via the classical NHEJ pathway
(Meissner et al., 2014). In the case of childhood leukaemia, chromosomal translocations as well as
gene deletions often arise as result of mistakes in V(D)J recombination, e.g. RAG can erroneously
recognise and target RSS-like sequences. There is growing evidence that in vivo exposure to DNA-
damaging agents can increase the frequency of V(D)J rearrangements at RSS-like sequences that are
widely distributed throughout the genome (ref). However, the mechanism by which exposure to those
agents increase the frequency of V(D)J-recombinase-mediated genomic rearrangements is still
unknown (Pinsoneault et al., 2007). The lack of site-speciﬁc clustering of translocations (which show a
dispersed breakpoint distribution) suggests that chromosomal translocation arise in HSPCs before the
expression of recombinase-activating genes (Wiemels, 2008).
Although all the above reported mechanisms can be chemically induced, a chemical tool able to
initiate the triggering cascade of the proposed pathway was not identiﬁed. For this reason this AOP
was considered putative and the KE 1 was used as initiator of the pathway.
However, the potential initiating events speculated above can be measured. For this reason,
technologies able to do it are reported here. Oxidative stress can be measured by a number of
biomarkers such as plasma antioxidant status, lipid peroxidation products, reduced-to-oxidised
glutathione (GSH:GSSG) ratio, and levels of 4-hydroxynonenal (4-HNE) and nitrotyrosine products.
However, these biomarkers may only provide an indirect assessment of an increased risk of oxidative
DNA damage in vivo (Badham and Winn, 2010). There is a variety of techniques and methods useful
for the detection of single oxidatively generated DNA lesions like 8-oxodG, thymine glycol (Tg) and
abasic (AP) sites such as high performance liquid chromatography (HPLC), liquid chromatography/
tandem mass spectrometry (LC-MS/MS), alkaline ﬁlter elution, single cell gel electrophoresis (SCGE or
Comet assay) and adaptations of agarose gel electrophoresis (Kryston et al., 2011).
DNA damage can be assessed by the single cell gel electrophoresis (SCGE or Comet assay), which
is a simple sensitive and rapid method for the detection and quantiﬁcation of DNA damage (Singh
et al., 1988) and provides a direct microscopic measure of DNA single and double strand breaks.
DNA breakpoints can be determined by Southern blot, polymerase chain reaction (PCR) and DNA
sequencing. Gene mutations can be comprehensively searched for by array-comparative genome
hybridisation (array-CGH) or whole-genome/exome sequencing. Allele-speciﬁc restriction assay, single
strand conformation polymorphism and/or direct sequencing are valid methodologies for point
mutation analysis.
Increased DNA damage in leukaemia cells can be demonstrated by the formation of phosphorylated
histone H2AX (c-H2AX), a marker of DNA DSBs (Graillot et al., 2012).
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KE1: In utero chromosomal translocations
How this key event works
Early in utero interaction of a chemical with DNA (or DNA-related proteins/enzymes) might lead to
permanent DNA damage and further chromosomal translocations. Other chromosomal insults can
occur as well, such as intrachromosmal rearrangements, genetic deletions or activating mutations.
Altogether, these chromosomal lesions are considered initiating events in leukaemogenesis, and most
likely occur prenatally as common leukaemia fusion genes have been detected in cord blood, neonatal
Guthrie cards and shared by monozygotic twins (Greaves et al., 2003).
There are two functional classes of translocations; the ﬁrst one relocates a proto-oncogene (or
genes encoding for transcription factors or non-antigen receptors) into regulatory regions of actively
transcribed genes (such as those encoding for immunoglobulin chains or T-cell receptors), causing
dysregulated expression of an intact protein. The second class juxtaposes two genes to encode a
chimeric protein that has distinct functions from the proteins from which it is derived (Hunger and
Mulligham, 2015).
TEL-AML1 is the most common chromosomal translocation associated with B-ALL, which affects
haematopoietic stem/progenitor cells (HSPCs). TEL-AML1 is a fusion gene involving AML1 (also known
as RUNX1), which controls the emergence of deﬁnitive haematopoietic stem cells in fetal haemogenic
sites, and TEL (ETV6), responsible for adult haematopoietic stem cells survival (Teitell and Pandolﬁ,
2009).
It is not known to what extent chromosomal translocations/rearrangements are caused by errors in
normal DNA processing or by external factors (chemicals, viruses), but translocations are 100-fold
more common in the population than leukaemia, indicating that most translocations are not sufﬁcient
for disease (Wiemels, 2008).
The ﬁnding that most common translocations found in childhood leukaemia (TEL-AML1 and AML1-
ETO) occur at a rate of 1% in the normal population suggests that a signiﬁcant proportion of the
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population carries preleukaemic clones. However, most of these clones are self-limiting and do not
result in disease. During the progression of the disease multiple genetic alterations accumulate over
time being selected by their potential to give ﬁtness advantage to the new clones.
How it is measured
Conventional cytogenetics, ﬂuorescence in situ hybridisation (FISH, using commercially available
dual colour translocation probes) and reverse transcription polymerase chain reaction (RT-PCR)
methods allow the identiﬁcation of speciﬁc chromosome abnormalities (fusion genes, translocations,
etc.), which can be further identiﬁed by subsequent cloning and sequencing (Soszynska et al., 2008).
Cytokinesis-block micronuclei assay also allows to assess chromosome damage.
Gene expression proﬁling deﬁnes distinct oncogenic groups in ALL related to the presence of
different fusion oncogenes.
Taxonomic applicability
Chromosomal translocations can occur at all levels of living organisms and they have been created
in murine and zebraﬁsh models. These models can be useful for the in vivo study of leukaemogenic
potential of chemicals in immature organisms as they may recapitulate human childhood leukaemia.
Bone marrow and fetal liver cells from mice have been retrovirally transduced to express TEL-AML1
protein in an attempt to model human ALL.
Regulatory examples using this KE
The extended one generation test (OECD 443) includes a developmental immunotoxicity cohort. At
present the cohort may identify postnatal effects resulting from prenatal or neonatal exposures on the
immune tissues and white blood cells population. However, no speciﬁc parameters are in place to
identify a pattern relevant to human childhood leukaemia in the extended one generation test.
Besides, no treatment is administered in utero during the early developmental phase in the
carcinogenicity assay and no considerations on the possible higher sensitivity of the HSPCs are in place
for the genotoxicity assays. Thus, regulatory studies following OECD test guidelines may have potential
limitations and experimental gaps eventually leading to false negative results.
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KE2: Differentiation arrest of HSPCs
How this key event works
Chromosomal translocations create fusion genes encoding active kinases and altered transcription
factors as well as hyperdiploidy. The genetic changes alter key regulatory processes by maintaining or
enhancing an unlimited capacity for self-renewal, subverting the controls of normal proliferation,
blocking differentiation and promoting resistance to death signals (i.e. apoptosis).
Altered self-renewal and differentiation of HSPCs can result from chimeric transcription factors,
which arise from chromosome translocations that fuse portions of two different transcription factors.
The aberrant proteins produced by fusion genes inhibit the normal transcriptional program and block
the differentiation of B-cell and myeloid precursors by recruiting repressor molecules such as histone
deacetylase enzymes, resulting in aberrant cell proliferation and survival (Greaves, 2002; Pui et al.,
2004; Teitell and Pandolﬁ, 2009; Papaemmannil et al., 2014). For instance, TEL-AML1 and MLL fusions
in undifferentiated progenitor cells can block the differentiation phase between pro-B to pre-B cells.
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Most of paediatric B-ALL with BCR-ABL fusion genes exhibits IKZF1 deletions. The gene IKZF1
encodes a transcription factor that belongs to the family of zinc-ﬁnger DNA-binding proteins associated
with chromatin remodelling. The expression of this protein is restricted to the fetal and adult
haemolymphopoietic system, and it functions as a key regulator of lymphocyte differentiation. Mice
with reduced Ikaros expression exhibited partial inhibition in precursor B-cell maturation, which might
be relevant in leukaemogenesis (Teitell and Pandolﬁ, 2009).
How it is measured
Arrest of B-cell differentiation can be observed by histological assessment (Sabaawy et al., 2006).
Methods for detecting suppression of haematopoiesis include the assessment of cell-speciﬁc
markers via immunolabelling followed by ﬂow cytometry and/or microscopy (e.g. CD34, CD19 and IgM
for stages of B-cell differentiation).
Methods for detecting epigenetic modiﬁcations include:
• DNA methylation: Combined bisulﬁte restriction analysis (COBRA) and bisulﬁte sequencing for
methylation; methylation-speciﬁc PCR.
• miRNA/non-coding RNAs: miRNA/non-coding RNA isolation followed by ampliﬁcation using
reverse transcription-PCR; miRNA/non-coding RNA microarray proﬁling/analysis
Taxonomic applicability
Mice have been transplanted with TEL-AML1-transduced bone marrow stem cells (Tsuzuki et al.,
2004). There are also zebraﬁsh models of TEL-AML1-positive ALL (Sabaawy et al., 2006).
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KE3: Clonal expansion as a result of secondary oncogenic insults
(activating mutations) and delayed infections
How this key event works
ALL is mainly a disease of childhood that arises from recurrent genetic insults that block precursor
B and T cell differentiation and drive aberrant cell proliferation and survival. A preleukaemic clone with
self-renewal stem cell activity may acquire progressive mutations in proliferative genes (activated
signalling) resulting in a frank leukaemic clone. Cancer genome re-sequencing studies have determined
that most leukaemia cases harbour multiple mutations that have sequentially occurred in a single cell
lineage to generate a dominant leukaemic clone (Jan and Majeti, 2013).
• (Epi)genetic modiﬁcations:
Epigenetic modiﬁcations, in particular DNA methylation leading to reduced expressions of tumour
suppressor genes contribute to the pathogenesis of childhood leukaemia. The inactivation or silencing
of tumour suppressor genes can result in the sustained proliferation or reduced cell death response
(e.g. apoptosis) of leukaemic cells. In childhood ALL, extensive hypermethylation of tumour suppressor
genes such as FHIT, DLX3, p16 and p15 resulting in gene silencing has been observed. Furthermore,
epigenetic silencing of proapoptotic genes (e.g. BIM), or blockage of apoptotic activation via
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deregulated expression of antiapoptotic genes (e.g. Bcl2 and BAX), inhibits activation of apoptosis and
enhances survival of leukaemic cells, enabling the progression of leukaemogenesis (Sabaawy et al.,
2006; Bachmann et al., 2010). Exposure to a variety of environmental agents can alter DNA
methylation pattern inducing destabilising changes in gene expression potentially leading to cell
transformation and tumorigenesis. There is some evidence suggesting that epigenetic modiﬁcations
may be one of the mechanisms by which pesticides may exert adverse effects on human health
(Collota et al., 2013).
The inhibition or aberrant regulation of apoptosis due to gene/protein dysfunction also plays a role
in the pathogenesis of childhood leukaemia. Increased expression of Ikaros isoform 6 in murine
myeloid precursor cell line appears to upregulate the expression of the antiapoptotic protein Bcl-XL,
preventing apoptosis and potentially leading to the pathogenesis of AML (Yagi et al., 2002).
• Delayed infections
The delayed-infection hypothesis of Greaves is based on a minimal two-hit model and suggests that
some susceptible children with a prenatally acquired preleukaemic clone had limited exposure to
common infections early in life because they lived in a very hygienic environment. Such infectious
insulation results in an immune system improperly developed that further predisposes these children to
develop exacerbated aberrant responses after subsequent or delayed exposure to common infections
later on in life, at an age commensurate with increased lymphoid-cell proliferation (Gilham et al., 2005;
Kamper-Jørgensen et al., 2008; Pui et al., 2008). This untimely and excessive inﬂammatory response
abolishes normal haematopoiesis such that lymphocytes or myeloid progenitor cells cannot mature.
Thus, the innate and adaptive immune system is not fully functional upon an immune response and
promotes selective expansion of a preleukaemic clone because of proliferative advantage and an
increased opportunity for the acquisition of secondary genetic changes or mutations ultimately
resulting in overt leukaemic phenotype (Greaves, 2006; Ford et al., 2009; Swaminathan et al., 2015).
• Potential targets of chemical exposures
The immune system may be a target of the toxic effect of several chemicals. Chemically induced
immune alteration through altering well-regulated immune responses to tumour antigens, allergens,
self-antigens and microbial antigens can contribute to predisposition to different types of disorders,
including cancers (Mokarizadeh et al., 2015). Evidence suggests that children may be particularly
susceptible to adverse effects from exposure to pesticides, thus rendering them susceptible to
infections and other immune mediated disorders (Corsini et al., 2013). Some evidence of effects of
environmental exposures to pesticides during prenatal and early postnatal development on childhood
leukaemia has been reported, raising the importance of studying the effects of toxicants on the
developing immune system (Duramad et al., 2007). Xenobiotics may initiate, facilitate or exacerbate
aberrant immune processes by inducing mutations in genes coding for immunoregulatory factors,
modifying immune tolerance and activation pathways. Besides, various general or immune speciﬁc
signalling pathways can be interfered by chemicals, resulting in changes in cytokine production,
surface markers expression, cell differentiation and activation (Corsini et al., 2013).
Immunosuppression induced by pesticides may explain the relation with increased infections in
humans observed in several studies. Particularly susceptible to immunotoxicity are children, as the
vulnerable period for toxic insults to the developing immune system extends from early gestation to
adolescence (Dietert, 2008). Background exposure to some pesticides early in life (pre- and postnatal
exposure) may modulate the immune system development, increasing infection risks (Weselak et al.,
2007). Furthermore, pesticides may interfere with immune surveillance, which in turn can affect
recognition and destruction of abnormal cells, increasing the risk of cancer (Corsini et al., 2013).
How it is measured
Methods of detecting leukaemic cell proliferation include ﬂow cytometry using cell-speciﬁc markers
followed by quantitative analysis, and incorporation and detection of bromodeoxyuridine (BrdU) by
proliferating cells.
Multicolour ﬂuorescence in situ hybridisation (FISH) may be used to track multiple genetic
abnormalities identiﬁed in bulk ALL cells, yielding quantitative single cell resolution of the relative
frequency of genetically distinct leukaemia subclones.
A novel experimental and computational single-cell sequencing approach has been used to directly
measure the clonal structures of childhood ALL samples at diagnosis (Gawad et al., 2011).
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Apoptosis can be measured by using plasma membrane assays, mitochondrial assays, caspase
assays, nuclear apoptosis assays and ﬂow cytometry.
Taxonomic applicability
Mechanisms relevant to clonal expansion may not show signiﬁcant interspecies differences and
potential mechanisms remain currently unclear.
Murine models with human precursor cells harbouring the TEL-AML1 fusion have been developed.
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Adverse Outcome (AO): Overt childhood leukaemia
How this key event works
Symptoms of childhood leukaemia include sensitivity to bruising and bleeding due to
thrombocytopenia, pallor and fatigue from anaemia, and increased susceptibility to infections caused
by neutropenia. These symptoms result from the displacement of the normal haematopoiesis by
expansion of leukaemia cells. Leukaemic inﬁltration of the liver, spleen, lymph nodes, and mediastinum
is common at diagnosis (Hunger and Mulligham, 2015).
How it is measured
Haematological methods: observations of clinical symptoms, routine blood cell count and
identiﬁcation of leukaemia cells (i.e. immunophenotyping by ﬂow cytometry) in peripheral blood and
bone marrow. Diagnosis stratiﬁcation relies on molecular cytogenetics (FISH and karyotype).
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Immunophenotyping allows the identiﬁcation of pathologic cells and phenotype characterisation
based on speciﬁc pattern-identiﬁcation of surface as well as intracellular antigen expressions in unique
cell populations.
Flow cytometry is a laser-based technology that uses monoclonal antibodies for the detection of
expression of a number of antigens on the cell surface, thus distinguishing between healthy and
diseased cells. Flow cytometry allows the identiﬁcation and quantiﬁcation of subsets of the major
leukocyte populations and even further subdivisions that differ in biologic function, maturation stage,
and activation (Adin-Cinar, 2013).
Taxonomic applicability
The following animal models have been developed for childhood leukaemia:
a) MLL-ENL and MLL-AF9 fusions have been proven to be oncogenic by themselves in human cord
blood progenitor cells (Barebe et al., 2007).
b) TEL-AML1 and hyperdiploid primary blasts recapitulate the disease phenotype in
immunodeﬁcient mice (Rehe et al., 2014, le Viseur et al., 2008).
Regulatory relevance of the AO
Genotoxicity and carcinogenicity are standard endpoints measured in the regulatory studies
performed for the risk assessment of chemicals and they are mandatory for pesticide substances.
However, no treatment is occurring during the early in-utero development phase in the carcinogenicity
study.
The extended one generation test (OECD 443) assesses parental fertility and reproductive function
and the development of offspring to sexual maturity and also includes a developmental immunotoxicity
cohort. A second generation can be triggered if any effects requiring further evaluation are identiﬁed in
the ﬁrst generation (OECD, 2011). The study design provides the opportunity to evaluate life stages
not covered by other study types and represents a highly integrated study design that includes an
assessment of developmental immunotoxicity. While the developmental immunotoxicity cohort may
identify postnatal effects resulting from prenatal or neonatal exposures on the immune tissues and
white blood cells population; however, no speciﬁc parameters are in place to identify a pattern relevant
to human childhood leukaemia.
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1st KER: In utero chemical exposure (KEup) leading to
unrepaired/misrepaired double DNA damage and further chromosomal
translocations (KEdown)
How this Key Event Relationship works
DNA is highly susceptible to oxidative damage, which can result in single strand breaks (SSBs) and
DSBs, base and sugar-moiety oxidation, strand crosslinks and the generation of abasic sites. DSBs are
the most serious type of DNA damage because a small number of these lesions are sufﬁcient to induce
gene mutations or chromosomal aberrations (Sedelnikova et al., 2001; Woodbine et al., 2011).
Oxidative molecules may either enhance the likelihood of DSB in HSPCs or interact with biological
molecules disrupting the normal synthesis and repair of DNA. This disruption is primarily associated
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with inhibition or inactivation of antioxidant proteins as well as DNA repair enzymes (Kryston et al.,
2011).
Upon DNA damage or genotoxic stress, haematopoietic stem cells differentiate to lineage-
committed progenitors, which can be considered as a method to escape propagating damaged genetic
information. This escape mechanism fails when haematopoietic stem cells chose DNA repair by NHEJ
over differentiation, in order to maintain their self-renewal, thus thriving haematological malignancies
(Weiss and Ito, 2015).
Defects in NHEJ can create chromosomal deletions and translocations. The accumulation of genetic
damage through misrepair or incomplete repair of DNA may lead to mutagenesis and eventually cell
transformation, particularly if combined with a deﬁcient apoptotic pathway (Kryston et al., 2011). An
impaired repair of oxidatively modiﬁed DNA, documented in children with ALL, may contribute to the
genetic instability of precursor-B cells which may be linked with the development of the disease
(Olinski et al., 2014).
For fusion genes to be effective in promoting leukaemogenesis, DNA DSB must occur
simultaneously in two chromosomes in a single HSPC that does not undergo cell death, and must also
be situated in the coding region of the genes to generate a functional chimeric gene product. The
resulting chromosomal recombination must take place in a HSPC with a sustainable lifespan and clonal
potential to propagate the chimeric gene product (Greaves and Wiemels, 2003).
A massive parallel sequencing approach performed in a cohort of twins concordant for ALL
indicated that the TEL-AML1 fusion gene arises as a consequence of NHEJ as no binding motifs
indicative of RAG1/2 or terminal deoxynucleotidyl transferase (TdT) activity were found. The TEL-AML1
fusion arises in a fetal HSPCs that lies upstream of B-cell lineage-restricted RAG1/2 active precursors.
The preleukaemic clone arises and expands in the pro- or pre-B-lineage compartment in the fetal liver
and then undergoes V(D)J rearrangements (Alpar et al., 2015).
Biological plausibility
In the last decades the occurrence of childhood leukaemia showed a rise that was in part attributed
to an increased exposure to risk factors. Although the aetiology of ALL remains elusive, ionising
radiation, congenital genetic syndromes and in utero exposure to speciﬁc genotoxic chemicals,
including household pesticides, are considered the major risk factors (Pui et al., 2008). Despite the
mounting epidemiologic evidence linking pesticide exposure during pre- and postnatal life with
childhood leukaemia, robust underlying pathological mechanisms remain unknown. The initiating event
at the molecular level might be generation of oxidative stress by environmental exposures (including
pesticides) leading directly or indirectly to DNA damage and further chromosomal damage (Hernandez
and Menendez, 2016); however this still remains hypothetical.
A massive parallel sequencing approach performed in a cohort of twins concordant for ALL
indicated that the TEL-AML1 fusion gene arises as a consequence of NHEJ as no binding motifs
indicative of RAG1/2 or terminal deoxynucleotidyl transferase (TdT) activity were found. The TEL-AML1
fusion arises in a fetal HSPCs that lies upstream of B-cell lineage-restricted RAG1/2 active precursors.
The preleukaemic clone arises and expands in the pro- or pre-B-lineage compartment in the fetal liver
and then undergoes V(D)J rearrangements (Alpar et al., 2015).
Investigation of the DNA damage in steady state, as well as after exposure to UV light, conﬁrmed
increased DNA damage in pro-B cells lacking a functional allele of Ebf1 (a transcription factor critical
for the activation of B-lineage restricted genes in the earliest B-lineage progenitors that also controls
DNA repair). Reduced Ebf1 levels may contribute to malignant transformation by a combination of
impaired DNA repair and increased cell survival rather than simply by a differentiation block (Prassad
et al., 2015). Since Rad 51 is one of the central components of the DNA DSB repair gene, whose
expression can be induced by DNA damage, a drop in leukaemic potential after Rad51 re-expression
would conclusively demonstrate that loss in HR DNA repair was the main driving force of leukaemic
transformation of the Ebf1+/ Pax5+/ B-cell precursors (Georgopoulos, 2015).
Uncertainties and Inconsistencies
Despite the sound epidemiological evidence linking pesticide exposure and childhood leukaemia, the
ﬁrst initiating molecular event(s) has not been identiﬁed yet. In contrast to MLL-rearranged infant
leukaemia, there is no evidence at all regarding the molecular basis of how some individual pesticide
or pesticide class (or functional group) can interact with biological targets to elicit DNA damage. We
can speculate only with potential mechanisms, such as induction of oxidative stress in HSPCs, as DNA
is highly susceptible to oxidative damage and can result in single and double strand breaks. Besides, it
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not clearly understood what drives damaged HSPCs to initiate DNA repair systems and when to enter
the cell cycle or to keep quiescent accumulating genotoxic stress (Weiss and Ito, 2015). While,
regulatory studies have consistently found lack of genotoxic effects of pesticides in many test systems,
there are studies in the open literature supporting genotoxicity by using different biomarkers. In
addition, some epidemiological studies on agricultural workers exposed to pesticides have reported
DNA damage. These uncertainties and inconsistencies warrant further research to delineate how
pesticides interact with DNA and produce genetic lesions.
References
Alpar D, Wren D, Ermini L, Mansur MB, van Delft FW, Bateman CM, Titley I, Kearney L, Szczepanski T, Gonzalez D,
Ford AM, Potter NE, Greaves M, 2015. Clonal origins of ETV6-RUNX1+ acute lymphoblastic leukemia: studies in
monozygotic twins. Leukemia, 29, 839–846.
Edwards TM, Myers JP, 2007. Environmental exposures and gene regulation in disease etiology. Environmental
Health Perspectives, 115, 1264–1270.
Georgopoulos K, 2015. Ebf1 in DNA repair and leukemogenesis. Blood, 125, 3969–3971.
Greaves M, 2002. Childhood leukaemia. British Medical Journal, 324, 283–287.
Greaves MF, Maia AT, Wiemels JL, Ford AM, 2003. Leukemia in twins: lessons in natural history. Blood, 102, 2321–
2333.
Greaves MF, Wiemels J, 2003. Origins of chromosome translocations in childhood leukaemia. Nature Reviews
Cancer, 3, 639–649.
Hauer J, Borkhardt A, Sanchez-Garcıa I, Cobaleda C, 2014. Genetically engineered mouse models of human B-cell
precursor leukemias. Cell Cycle, 13, 2836–2846.
Hernandez AF, Lacasa~na M, Gil F, Rodrıguez-Barranco M, Pla A, Lopez-Guarnido O, 2013. Evaluation of pesticide-
induced oxidative stress from a gene-environment interaction perspective. Toxicology, 307, 95–102.
Hernandez AF, Menendez P, 2016. Linking pesticide exposure with pediatric leukemia: potential underlying
mechanisms. International Journal of Molecular Sciences, 17. pii: E461.
Jaruga P, Zastawny TH, Skokowski J, Dizdaroglu M. Olinski R, 1994. Oxidative DNA base damage and antioxidant
enzyme activities in human lung cancer. Federation of the European Biochemical Societies’s Letters (FEBS),
341, 59–64.
Knapp GW, Setzer RW, Fuscoe JC, 2003. Quantitation of aberrant interlocus T-cell receptor rearrangements in
mouse thymocytes and the effect of the herbicide 2,4-dichlorophenoxyacetic acid. Environmental and Molecular
Mutagenesis, 42, 37–43.
Linn S, 1998. DNA damage by iron and hydrogen peroxide in vitro and in vivo. Drug Metabolism Reviews, 30,
313–326.
Lu C, Liu X, Liu C, Wang J, Li C, Liu Q, Li Y, Li S, Sun S, Yan J, Shao J, 2015. Chlorpyrifos induces MLL
Translocations through caspase 3-dependent genomic instability and topoisomerase II inhibition in human fetal
liver hematopoietic stem cells. Journal of Toxicological Sciences, 147, 588–606.
Mostafalou S, Abdollahi M, 2013. Pesticides and human chronic diseases: Evidences, mechanisms, and
perspectives. Toxicology and Applied Pharmacology, 268, 157–177.
Muniz JF, McCauley L, Scherer J, Lasarev M, Koshy M, Kow, Nazar-Stewart V, Kisby GE, 2008. Biomarkers of
oxidative stress and DNA damage in agricultural workers: a pilot study. Toxicology and Applied Pharmacology,
227, 97–107.
Pui CH, Robison LL, Look AT, 2008. Acute lymphoblastic leukemia. Lancet, 371, 1030–1043.
Sedelnikova OA, Redon CE, Dickey JS, Nakamura AJ, Georgakilas AG, Bonner WM, 2010. Role of oxidatively
induced DNA lesions in human pathogenesis. Mutation Research, 704, 152–159.
Sent€urker S, Karahalil B, Inal M, Yilmaz H, M€usl€umanoglu H, Gedikoglu G, Dizdaroglu M, 1997. Oxidative DNA base
damage and antioxidant enzyme levels in childhood acute lymphoblastic leukemia. Federation of the European
Biochemical Societies’s Letters (FEBS), 416, 286–290.
Weiss CN, Ito K, 2015. DNA damage: a sensible mediator of the differentiation decision in hematopoietic stem
cells and in leukemia. International Journal of Molecular Sciences, 16, 6183–6201.
Woodbine L, Brunton H, Goodarzi AA, Shibata A, Jeggo PA, 2011. Endogenously induced DNA double strand
breaks arise in heterochromatic DNA regions and require ataxia telangiectasia mutated and Artemis for their
repair. Nucleic Acids Research, 39, 6986–6997.
2nd KER: Title: In utero chromosomal translocations (KEup) leading to
differentiation arrest of HSPCs (KEdown)
How this Key Event Relationship works
There are many potential chromosomal translocations associated to childhood leukaemia,
suggesting that multiple mechanisms underlie the development of the disease. Nevertheless, the major
fusion genes generated by chromosome translocations are TEL-/AML1 in ALL and AML1-/ETO in AML.
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The chimeric (aberrant) proteins produced by these genes inhibit gene activity and block cell
differentiation by recruiting repressor molecules such as histone deacetylase enzymes (Greaves, 2002).
TEL-AML1 and MLL fusions in undifferentiated progenitor cells can block the differentiation phase
from pro-B to pre-B cells. By stalling B-cell development, subsequent recombination-activating gene
(RAG)–mediated genomic rearrangements become drivers of the creation of polyclonal structures
(Papaemmanuil, et al., 2014). A study using whole-genome sequencing in ALL has suggested that the
aberrant activity of RAG recombinases, which are highly expressed in cells harbouring TEL-AML1, can
result in various oligoclonal V(D)J recombination events and further inactivation of genes required for
B-lineage differentiation (Papaemmanuil et al., 2014).
Weight of evidence
The block of differentiation of HSPCs provides proliferative advantage because of conferring self-
renewal properties to lymphoid progenitors. Enhanced self-renewal would promote the extended
longevity of B-cell precursors to acquire and accumulate additional genomic aberrations and secondary
mutations, which collaborate to fully transform these B-cell precursors into leukaemia cells (Duque-
Afonso et al., 2015).
The preleukaemic transformation conferring the in utero clonal expansion of TEL-AML1 cells occurs
in an early B-cell lineage committed progenitor, most likely at the pro-B or pre-B-cell stage in the fetal
liver (Alpar et al., 2015).
Biological plausibility
Under the current paradigm, the ﬁrst initiating oncogenic mutation usually involves structural or
numerical chromosomal alterations impairing normal cell differentiation, while secondary hits more
commonly comprise mutations affecting developmentally regulated master transcription factors or
membrane-proximal signalling pathways conferring proliferation and survival advantages to the
differentiation-blocked clone. The development of leukaemia requires activation of cell proliferation in
addition to differentiation blockage (reviewed in Hernandez and Menendez, 2016).
As a result of chromosomal translocations, aberrant chimeric proteins alter the normal
transcriptional program and block normal B-cell and/or myeloid differentiation. Childhood leukaemia
arises from recurrent genetic insults that block differentiation of haematopoietic stem and/or
progenitor cells (HSPCs), and drives uncontrolled proliferation and survival of the differentiation-
blocked clone.
Epigenetic modiﬁcations to DNA affect the activity of genes and their cellular expression and
include DNA methylation, histone modiﬁcation, and alterations in non-coding microRNAs (miRNAs).
Each of these mechanisms alters how genes are expressed or silenced without modifying the DNA
sequence. Epigenetic control of transcriptional activation also plays an essential role in regulating gene
expression during early development and haematopoiesis. Besides, epigenetic modiﬁcations can
inﬂuence leukaemogenesis if they lead to silencing of tumor suppressor genes or activation of
oncogenes (Burke and Bhatla, 2014).
Non-coding RNAs have been implicated in the pathogenesis of childhood leukaemia as their altered
expression can regulate various physiological processes such as cell differentiation, proliferation and
immune responses. Expression of miRNAs is triggered by epigenetic modiﬁcations, e.g. hyper/
hypomethylation of CpG islands in the promoter region of genes, or by fusion proteins.
In a zebraﬁsh model of TEL-AML1+ B-ALL, arrest of B-cell differentiation has been observed by
histological assessment (Sabaawy et al., 2006). An accumulation of early pro-B cells and a
differentiation deﬁcit after pro-B-cell formation has been reported in mice transplanted with TEL-AML1-
transduced bone marrow stem cells (Tsuzuki et al., 2004).
De Laurentiis et al. (2015) generated an experimental model using the murine haematopoietic stem
progenitor cell line EML1 expressing the TEL-AML1 fusion protein, and analysed its differentiation and
global gene expression properties. Upon TEL-AML1 expression, EML1 cells lost the capacity to
differentiate into B-cells and underwent apoptosis. TEL-AML1 expression impaired the activation of
IFNa/b signalling pathway in primary murine and human HSPCs with a dramatic inhibition of IRF3
phosphorylation, a member of the IFN-regulatory transcription factor family (de Laurentiis et al.,
2015). This ﬁnding is consistent with the downregulation of genes involved in IRF3-IFN signalling as
shown in gene expression data derived from blasts of ALL patients expressing TEL-AML1 (Linka et al.,
2013). These data suggest that IRF3-IFNa/b signalling is involved in the block of B-cell maturation
elicited by TEL-AML1 expression. Furthermore, differentiation of cells expressing the TEL-AML1 protein
can be restored by treatment with IFNb (de Laurentiis et al., 2015).
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Mice with reduced Ikaros expression (a master transcription factor that regulates lymphocyte
differentiation) have a partial block at the pro-B-cell stage in development, suggesting a tumorigenic
role by blocking B-cell maturation (Teitell and Pandolﬁ, 2009). In the case of T-cell ALL, aberrant
regulation or genetic mutations of cell-speciﬁc transcription factors inhibit cell maturation/development,
leading to increased expansion of leukaemic cells. More than 50% of T-cell ALL have activating
mutations involving NOTCH1, a gene encoding a transmembrane receptor that regulates normal T-cell
development by enhancing the transcription of diverse responder genes in developing thymocytes,
such as cyclin D1 and c-MYC (Pui et al., 2008).
The Pax5 gene encodes the B-cell lineage speciﬁc activator protein that is expressed at early, but
not late stages of B-cell differentiation. The developmental block observed in Pax5-deﬁcient leukaemia
cells can be reversed on restoration of Pax5 expression, suggesting that the reduction in Pax5 function
results in a reversible disruption of differentiation. Transgenic RNAi can reversibly suppress
endogenous Pax5 expression in the haematopoietic compartment of mice, which cooperates with
activated signal transducer and activator of transcription 5 (STAT5) to induce B-ALL (Liu et al., 2016).
Although the Ebf1 dose-dependent events in B-cell precursors are not overtly leukaemogenic, the
combination with Pax5 haploinsufﬁciency dramatically increases leukaemic potential by stalling B-cell
differentiation at a highly proliferative and recombination active stage, which allows the selection and
expansion of precursors carrying appropriate DNA mutations (Georgopoulos, 2015).
Epigenetic activation (i.e. hypomethylation) of ZNF423, a protein that interferes with B-cell
differentiation, interacts with the early B-cell factor 1 (EBF-1) to inhibit transcription of EBF-1-targeted
genes and subsequently trigger B-cell maturation arrest (Harder et al., 2013). Silencing of some
miRNAs (e.g. miR-34b) or increased level of other miRNAs (e.g. miR-155) may lead to enhanced cell
proliferation of leukaemic cells and/or inhibition of cell differentiation.
Uncertainties and inconsistencies
A prerequisite for the speciﬁc AOP is the occurrence of genetic damage (i.e. chromosomal
translocations) in a particularly vulnerable genetic locus, within the proper cell and in a speciﬁc time
window. However, details of this entire process and how it happens are not clear.
The target leukaemia-initiating cell(s) have not been identiﬁed so far with sufﬁcient conﬁdence and
consequently there is no faithful cell model that recapitulates the pathogenesis in humans at the
molecular level.
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3rd KER: Differentiation arrest of HSPCs (KEup) leading to clonal expansion
of leukaemogenic cells (KEdown)
How this Key Event Relationship works
In the ‘two-hit model’ widely accepted for leukaemogenesis two types of genetic aberrations and/or
mutations are required. The ﬁrst one is associated with a block in differentiation/maturation through
chromosomal translocations affecting transcription factors that normally promote cellular differentiation
at crucial steps during early haematopoiesis (see KER2). Further mutations affect genes controlling
cellular proliferation and apoptosis, classically intracellular signalling pathways (i.e. tyrosine kinases),
which lead to increased proliferation and/or inhibition of apoptosis (such as FLT3, RAS, KIT, and BCR–
ABL) (Eriksson et al., 2014).
Dysregulation of immune responses to common infections might promote the malignant evolution
of TEL-AML1-expressing preleukaemic clones. Ford et al. (2009) linked paediatric ALL with signalling
pathways involved in infection and inﬂammation.
The major histocompatibility genes might play a role in the linkage between patterns of infection
and leukaemia risk as several HLA haplotypes have been associated with childhood leukaemia
(Wiemels, 2012). However, it is possible that exposure to infections promote B-ALL in children
harbouring an intrinsic genetic susceptibility (Hauer et al., 2015).
Weight of evidence
Fusion gene products may sufﬁce to initiate but not to fully complete leukaemogenesis, and other
secondary genetic lesions must occur for developing childhood leukaemia. For instance, the
concordance rate for ALL in monozygotic twin children is around 5–10%, and transgenic mice
expressing fusion gene products (e.g. TEL-AML1 or AML1-ETO) did not exhibit overt signs of leukaemia
(Mori et al., 2002). Also, some fusion genes associated with childhood leukaemia can be detected in
the blood of normal individuals, indicating that they occur ubiquitously in humans and do not
necessarily lead to the disease (Greaves and Wiemels, 2003).
After the occurrence of oncogenic fusion proteins resulting from chromosomal translocations,
subsequent cooperating hits deﬁne the disease latency and occur after birth, and may be of genetic,
epigenetic or immune nature (i.e. delayed infection-mediated immune deregulation).
Transgenic mice expressing TEL-AML1 failed to develop leukaemia and this ﬁnding was
corroborated in subsequent reports where no leukaemia was observed despite the use of differing
gene promoters to express the translocation. These experiments support the need of a second genetic
event is necessary for the development of leukaemia (Jacoby et al., 2014).
Biological plausibility
Dysfunctions of the immune system and delayed infections have been linked to childhood
leukaemia (Greaves, 2006; Swaminathan et al., 2015). Two factors might explain this association: a) a
lower repertoire of infections during early immune development, and b) an altered congenital
responder status to infection resulting in functionally aberrant clinical presentation of occasional
infections. Thus, an untimely and excessive inﬂammatory response abolishes normal haematopoiesis,
promoting selective expansion of a preleukaemic clone because of proliferative advantage and
increased likelihood for a second mutation required for the development of the disease to occur
PPPs, Parkinson’s disease and childhood leukaemia
www.efsa.europa.eu/efsajournal 310 EFSA Journal 2017;15(3):4691
(Sanjuan-Pla et al., 2015). Additional support is provided by studies showing that an increased
opportunity for early childhood infections as well as normal childhood vaccinations protects against
leukaemia indicating that vaccination reduces risk to leukaemia (Ma et al., 2005).
The IFNa/b cytokines, whose production is impaired by TEL-AML1 expression, have been long
known to modulate resistance to viral infections and enhance innate and acquired immune responses.
IFNs also inﬂuence tumour growth by directly inducing the expression of genes involved in apoptosis,
or indirectly by inhibiting angiogenesis and modulating immune response (reviewed in de Laurentiis
et al., 2015).
Murine models with human precursor cells harbouring the TEL-AML1 fusion gene generated a
preleukaemic state that only resulted in an overt leukaemic phenotype upon the acquisition of
additional genetic abnormalities (Alpar et al., 2015).
• Genetic alterations
Genetic alterations that impair cell differentiation probably cooperate with a second class of
mutations that alter the proliferation and survival of HSPCs. One of these mutations affects the RAS-
RAF-MEK-ERK signalling cascade, important for the HSPC development, leading to enhanced cell
survival/proliferation (Case et al., 2008). Mutations of the receptor tyrosine kinase (RTK)-Ras signalling
pathway have been associated with the pathogenesis of childhood (and perhaps infant) leukaemia
(Driessen et al., 2013; Prelle et al., 2013; Paulsson et al., 2015). Also, the lack of degradation of cell
signalling proteins enhances survival and proliferation of leukaemic cells as occurs either with
inactivation of E3 ubiquitin ligase (Makishima et al., 2009; Aranaz et al., 2012), or with constitutive
activation of MAP kinase (e.g. JNK), leading to proteasomal degradation of proapoptotic proteins
(Leung et al., 2008).
Multiple secondary changes have been proposed to cooperate with TEL-AML1 fusion for overt B-cell
ALL. Gene deletions of non-antigen receptor or cell cycle regulatory proteins can further promote the
proliferation and survival of leukaemic cells (Aplan, 2006; Novara et al., 2009; Meissner et al., 2014).
TEL-AML1-positive preleukaemic clones trigger an increase in ROS, which promotes the
accumulation of secondary genetic lesions by increasing genetic instability and DNA DSBs, therefore
enabling these preleukaemic clones to develop into leukaemic cells (Kantner et al., 2013).
Gawad et al. (2014) sequenced a panel of single nucleotide variants (SNVs), deletions, and IgH
sequences in 1,479 single tumour cells from six ALL patients. By accurately segregating groups of co-
occurring mutations into distinct clonal populations, co-dominant clones were found in the majority of
patients. Evaluation of intraclonal mutation patterns (a) identiﬁed clone-speciﬁc cytosine mutagenesis
events, (b) showed that most structural variants are acquired before SNVs, (c) determined that KRAS
mutations occur late in disease development but are not sufﬁcient for clonal dominance, and (d)
identiﬁed within the same patient clones arrested at varied stages in B-cell development. Most large
deletions occurred before cytosine mutagenesis-driven SNV acquisition, thus providing further evidence
that the majority of the SNVs were caused by an APOBEC protein. Ongoing V(D)J recombination can
occur in the most evolved clones, which can have variable magnitude between clones in the same
patient. The development of leukaemic cells can be promoted by rearrangement of T-cell acute
lymphoblastic leukaemia 1 gene (TAL1, which encodes a transcription factor that regulates both
embryonic and adult haematopoiesis) along with the inactivation of phosphatase and tensin
homologue gene (PTEN, encoding a tumour suppressor dual-speciﬁcity phosphatase that antagonises
the PI3K signalling pathway) via microdeletions due to illegitimate RAG activity (Mendes et al., 2014).
• Role of infections and immunity
Infection can trigger a series of events that are directly involved in genome instability. Olinski et al.
(2014) proposed that viral infections may result in aberrant expression of the AID (activation-induced
deaminase)/APOBEC (apolipoprotein B editing complex) family of DNA cytosine deaminases, which are
able to insert mutations in DNA and RNA by deaminating cytidine to uridine. AID is essential for the
antigen-driven diversiﬁcation of already rearranged immunoglobulin genes in the adaptive immune
system. Since these enzymes also participate in active DNA demethylation process, changes in DNA
methylation status or aberrant methylation can occur (Olinski et al., 2014). Altogether, these processes
may lead to genome instability in prenatally generated preleukaemic cells and the emergence of ALL.
The inﬂammatory cytokine TGFb has been involved in TEL-AML1-mediated leukaemogenesis since B
cell progenitor cell line and human cord blood progenitor cells expressing TEL-AML1 inhibit
downstream activation of TGF-b by binding to Smad3, the main TGF-b signalling target, thus
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preventing the activation of target promoters. As a result, TEL-AML1-expressing cells might propagate
by inhibiting the tumour-suppressive properties of TGF-b.
Wild type mice kept in a speciﬁc-pathogen-free environment from birth and then moved to
common infectious environment did not develop B-ALL (Martın-Lorenzo et al., 2015). Pax5+/ mice
also failed to develop leukaemia under non-infection exposure conditions; however, when these mice
were exposed to infection they acquired point mutations in the second allele, which triggered the
development of pB-ALL recapitulating the clinical, histopathological and molecular features of human
B-ALL (Hauer et al., 2015). These data provide evidence that delayed exposure to infection can induce
human-like B-ALL in mice on the basis of inherited genetic predisposition (see Figure B.6 from Hauer
et al., 2015).
Monoallelic loss of Pax5 promotes leukaemogenesis by creating an aberrant IL7-sensitive progenitor
compartment, a preleukaemic pre-B cell population susceptible to malignant transformation through
accumulation of secondary Jak3 mutations, which depicts a rescue mechanism of the IL7/IL7R/STAT5
signalling. Transplantation experiments demonstrate that the activating Jak3 mutations per se are
sufﬁcient to drive leukaemia (Martın-Lorenzo et al., 2015).
The mechanisms underlying the conversion of the preleukaemic clone carrying the inherited PAX5
mutations into B-ALL are not understood yet; however, the B cell-speciﬁc enzyme AID might be the
predominant driver of clonal evolution in human TEL-AML1 pB-ALL (Swaminathan et al., 2015).
Besides AID, RAG1-RAG2 also drives leukaemic clonal evolution after repeated exposure to
inﬂammatory stimuli, paralleling chronic infections in childhood. Abnormal cytokine signalling and
repetitive inﬂammatory stimuli exacerbated susceptibility to genetic lesions during B lymphopoiesis at
the transition from the large pre-BII cell stage to the small pre-BII cell stage (Swaminathan et al.,
2015).
Uncertainties and inconsistencies
One important question in leukaemia genomics is the identity of leukaemia-initiating mutations that
result in preleukaemic clones. Owing to the technical challenge of distinguishing and isolating distinct
cancer subclones, many aspects of clonal evolution are poorly understood, including the diversity of
different subclones in an individual cancer, the nature of the subclones contributing to relapse, and the
identity of precancerous mutations. Studies of paediatric ALL demonstrated that in individual patients
there are multiple genetic subclones of leukaemia-initiating cells, with a complex clonal architecture
which limits to build a consistent AOP.
It remains to be demonstrated that subpopulations of acute leukaemia cells exhibit epigenetic
heterogeneity, but it seems very likely that epigenetic diversity contributes to subclonal heterogeneity
in acute leukaemia. Such epigenetic subclones likely differ in their proliferation, self-renewal,
differentiation and response to therapy, adding an additional dimension to the functional heterogeneity
of leukaemia subclones (Jan and Majety, 2013).
A number of questions arise from the Pax5 promoted leukaemogenesis: how relevant is the timing
and pattern of infectious exposure for B-ALL development, how the second hit impacts on the target
Figure B.6: Exposure to infection is a causal factor in B-precursor acute lymphoblastic leukaemia as a
result of Pax5 inherited susceptibility (Hauer et al., 2015, CC-BY)
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cell, and what makes Pax5+/ stem/progenitor target cells more vulnerable to malignancy (Hauer
et al., 2015).
On the other hand, the adverse effect of pesticides can be produced not only at the MIE level but
also by promoting the accumulation of cooperating mutations in the quiescent preleukaemic clones
based on a potential oxidative damage in rapidly dividing cells during DNA replications. Additionally,
pesticides can exert a developmental immunotoxic effect by the interference of the normal
development of the immune cells and their strictly regulated function (Corsini et al., 2013). However,
the precise nature of these potential effects is lacking and would impact the current paradigm as
pesticides might act at different events of the AOP by means of different toxicological pathways.
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4th KER: Clonal expansion of leukaemogenic cells (KEup) leading to overt
childhood leukaemia (KEdown – AO)
How this Key Event Relationship works
Children with ALL often present with signs and symptoms that reﬂect bone marrow inﬁltration with
leukaemic blasts and the extent of extramedullary disease spread. The initial manifestations of the
disease are based on the expansion of leukaemogenic cells replacing normal blood cells, and involve
anaemia, thrombocytopenia and neutropenia with apparent clinical signs and symptoms.
The majority of ALL cases have multiple clones with distinct genetic alterations that inﬂuence the
response to treatment and the risk of recurrence. Genome-wide association studies comparing
diagnosis versus relapse specimens have shown that both of them share common origin at
prediagnosis or clonal ancestry, but show differences in the nature of genetic alterations (Lo Nigro
et al., 2013).
Biological stress from postnatal infection in combination with a dysregulated immune response may
confer a growth advantage for a preleukaemic clone leading to its rapid expansion and an increased
opportunity for the occurrence of a second mutation required for the development of childhood
leukaemia (Greaves, 2006).
Childhood leukaemia is a biologically heterogeneous disease represented by distinct clinical and
biological subtypes. The disease consists of a multistep process requiring the acquisition of multiple
somatic lesions, and the deﬁnition of such pathways is being elucidated.
Weight of evidence
Although there is scarce scientiﬁc evidence on how leukaemic clones grow and expand, the
pathobiology of the disease along with the evolutionary genetic landscape, response to treatment and
relapse clearly indicate a causal linkage between the expansion of leukaemic clones and the onset of
clinical features.
Biological plausibility
Sequential cooperating mutations in several signalling pathways (i.e., RAS) and cellular processes
are selectively produced in any of the in utero subclones and originated from the same preleukaemic
clone. Later on, an aberrant inﬂammatory response abolishes normal haematopoiesis promoting
selective expansion of a preleukaemic clone, resulting in stochastic or microenvironment-derived
cooperating drivers towards overt leukaemia.
In the cord blood of healthy newborns the prevalence of a TEL/AML1 translocation is about 1 in
100, while only 1 in 10,000 will later in life develop ALL with this translocation. This clearly indicates a
multistep pathogenesis: since at least 99% of the children with this ‘ﬁrst hit’ will not develop
leukaemia, more hits are necessary to develop leukaemia.
Only few children who are born with a chromosomal translocation will develop ALL, proving that
these are preleukaemic changes and that leukaemogenesis is multifactorial and depending on multiple
consecutive events. The ‘ﬁrst hit’, most likely acquired during pregnancy, will give rise to preleukaemic
cells and clones being more susceptible to additional oncogenic events, the ‘second hit’. Most children
with ALL carry 6 up to ~20 different genetic abnormalities in their leukaemia cells.
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Biological stress from postnatal infection in combination with a dysregulated immune response may
confer a growth advantage for a preleukaemic clone leading to its rapid expansion and an increased
opportunity for the occurrence of a second mutation required for the development of childhood
leukaemia (Greaves, 2006).
Uncertainties and inconsistencies
The main challenge of developing AOPs for childhood leukaemia is the complex nature of the
disease. For example, a tumour suppressor gene could be mutated or transcriptionally inactivated to
trigger leukaemogenesis. Different genetic aberrations affect different subtypes of childhood leukaemia
(even between cell-speciﬁc B-cell and T-cell ALL) as almost all of the evaluated human studies report
percentages of a speciﬁc mutation found in cohorts, meaning there is no single mutation responsible
for the disease.
Whole genome and transcriptome sequencing of three B-cell precursor patients (of which one
carried the TEL-AML1 translocation and two lacked a known primary genetic aberration and one T-ALL
patient) found that each patient had a unique genome, with a combination of well-known and
previously undetected genomic aberrations (Lindqvist et al., 2015).
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Overall assessment of the AOP
Childhood leukaemia, the most common cancer affecting children, ﬁts a ‘two-hit’ cancer model.
While the ﬁrst ‘hit’ occurs in utero during fetal haematopoiesis (chromosomal translocation in a HSPC
with a sustainable lifespan and clonal potential to propagate the chimeric gene product), the second
hit takes place postnatally and is related to aberrant immune response to delayed infections or other
secondary activating mutations both leading to clonal expansion. Studies in archived Guthrie cards
suggests the presence of several common chromosomal translocations on neonatal blood spots in
children who contract leukaemia later, which retrospectively indicate clearly an in utero origin of the
disease (Wiemels et al., 1999). However, chromosomal translocations are insufﬁcient by themselves to
cause disease as they are found in approximately 1% of the normal population, a frequency 100 times
higher than the prevalence of acute lymphoblastic leukaemia (ALL) (Mori et al., 2002). This fact
suggests that the vast majority of preleukaemic clones are self-limiting and do not result in disease
(Pui et al., 2008; Wiemels, 2012). In fact, transgenic mice expressing fusion gene products did not
exhibit overt signs of leukaemia (Mori et al., 2002). The variable incubation period and clinical outcome
of the disease, and the 10% concordance rate of leukaemia in identical twins harbouring the same
genetic abnormalities indicates that additional postnatal events are needed for the development of full-
blown childhood leukaemia (Greaves and Wiemels, 2003).
The Greaves’ multi-stage model for childhood ALL suggests that there are three critical windows –
preconceptional, prenatal, and postnatal–during which exposure to exogenous agents could, but not
necessarily, inﬂuence leukaemogenesis. Although information is limited, the principal toxic mechanisms
of potential leukaemogenic agents (e.g. some pesticides) include excessive generation of oxidative free
radicals, which may induce DNA single- and double-strand breaks (DNA-DSBs) in fetal liver HSPCs.
Chromosomal rearrangements (duplications, deletions and translocations) may further occur if genetic
lesions are not properly repaired by non-homologous end-joining (NHEJ). Although the mechanisms
underlying the generation of chromosomal translocations leading to fusion genes are not known,
alternative sources of DNA breaks are V(D)J recombination, topoisomerase II cleavable complex
formation and abortive apoptosis.
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The initiating hit usually occurs in utero and commonly leads to the expression of oncogenic fusion
proteins. Subsequent cooperating hits occurring after birth deﬁne the disease latency and may be of a
genetic, epigenetic or immune nature (i.e. delayed infection-mediated immune deregulation). However,
currently available information does not suggest a strong association of an exogenous agent(s) with a
particular exposure window for childhood ALL. Although prenatal initiation of ALL might be a result of
spontaneous developmental errors normally occurring through endogenous oxidative stress in the
absence of an exogenous DNA-damaging exposure, the likelihood of this formation may be modiﬁed
by other factors including exogenous ones. Different mechanisms of cellular responses pertinent to ALL
induction are expected for the different classes of agents (e.g. chemicals, radiation and infection) (Kim
et al., 2006). The effect of infection is postulated to be caused by a delayed immunological challenge
associated with dysregulated proliferative and/or apoptotic stress to the ‘preleukaemic’ bone marrow,
indicating a promotional effect of infection on childhood ALL, which could be considered a ‘classical’
second hit, i.e. tumour promotion.
More recently, a 3-step model of leukaemia pathogenesis has been suggested, which postulates
that an initiating genetic lesion (diverse chromosomal translocations leading to gene fusions) confers
self-renewal properties to fetal liver HSPCs. A second lesion, normally affecting essential transcription
factors for lymphoid cell development, causes differentiation block at the progenitor cell level. A third
class of cooperating mutations accumulate and are needed to fully transform leukaemia cells. These
secondary mutations affect pathways such as cell cycle, cytokine receptors and associated kinases,
RAS signalling or several other transcription factors or epigenetic regulators (Duque-Afonso et al.,
2015). While mutations of RAS in HSPCs have been demonstrated, K-RAS mutations are not sufﬁcient
to produce overt leukaemia, but requires additional genetic mutation(s) in most likely lineage-
committed progenitors (Zhang et al., 2009). Besides, NOD/SCID mice with transplanted human bone
marrow leukaemic blasts at different maturation stages isolated from paediatric ALL patients developed
the complete leukaemic phenotype in vivo. This suggests that B precursor blasts at different
maturation stages have capability of self-renewal as a means of maintaining their malignancies in vivo
(le Viseur et al., 2008).
Pediatric leukaemia is phenotypically and genetically heterogeneous with an obscure aetiology. The
interaction between genetic factors and environmental agents represents a potential aetiological driver.
Despite the multifactorial causal mechanism and a heterogeneous biological composition, the timing of
environmental exposures and genetic changes associated with childhood leukaemia must be
considered (Bufﬂer et al., 2005). However, its genetic diversity limits investigation into the molecular
pathogenesis of disease. As a result of the peculiar natural history of childhood leukaemia, direct
studies in pregnant women are not possible and there is a need to rely on surrogate in vitro or ex vivo
studies or on animal models which entail difﬁculties in the interpretation and extrapolation of results.
Over the last 3 decades, signiﬁcant progress has been made through the identiﬁcation of recurrent
genetic alterations and translocations in leukaemic blast populations, and their subsequent functional
characterisation in cell lines and/or mouse models. Recently, primary human haematopoietic cells have
emerged as a complementary means to characterise leukaemic oncogenes (Kennedy and Barabe,
2008). Accordingly, this overall assessment is based largely on empirical evidence found in cases of
childhood leukaemia or from cellular and animal models.
B.1. Concordance of dose–response relationship
In contrast to infant leukaemia, the lack of a known aetiological (chemical) agent directly related to
the onset of the disease has prevented the conduct of experimental studies in animals, so a dose–
response relationship is lacking so far. In addition, there are no adequate experimental systems in
which dose–response and response–response relationships can be studied across MIE, KEs and AO.
Conversely, models of radiation-induced leukaemia risk derived from leukaemia mortality among
Japanese survivors of atomic bombs adopted a linear dose–response relationship in the low-dose
(< 100 mGy) region (Wakeford et al., 2010). A dose–response relationship was demonstrated for
childhood leukaemia based on number of X-ray ﬁlms taken and from the observation that the excess
risk was greater among twins for whom X-ray pelvimetry was far more frequent than among singletons
(Boice, 2006).
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B.2. Temporal concordance among the MIE, KEs and AO
There is no doubt about temporal concordance among MIE, KEs and AO for childhood leukaemia.
Key molecular events leading to childhood leukaemia are chromosomal translocations, and mis-
repaired DNA DSBs are prerequisites for their occurrence. Most of the DNA lesions in fetal liver HSPCs
are properly repaired and only persist in case of a failure in the DNA repairing system. Chromosomal
translocations ultimately result in the deregulation of key cellular proteins, especially those encoded by
proto-oncogenes and tumour suppressor genes, which are critical functional regulators of cells.
Recurrent genetic insults leading to differentiation arrest of HSPCs are needed to drive uncontrolled
proliferation and survival of the differentiation-blocked clone. A study using transgenic mice with the
TEL-AML1 transgene has demonstrated that expression of the fusion gene alone is not sufﬁcient to
induce leukaemia, but following prenatal initiation a postnatal second event is necessary for ALL to be
manifested (Andreasson et al., 2001).
Regardless of the knowledge gap on the chemical(s) involved in the MIE, and the molecular
mechanisms underlying this interaction, it is clear that chromosomal aberrations represent a necessary
but not sufﬁcient cause occurring in utero. A second-hit is required for the expansion of quiescent
leukaemic clones and this occurs during postnatal life in a subset of vulnerable children because of an
immunological system improperly developed owing to low exposure to common infections early in life.
The separation of a clonal antecedent preleukaemic cell population from frank leukaemic cells has
been identiﬁed in a monochorionic twin pair with one ‘leukaemic’ and one ‘healthy’ twin (Hong et al.,
2008). The ‘healthy’ twin shared TEL-AML1 fusion transcripts and clonotypic DJ recombination
sequences with the ‘leukaemic’ twin. Moreover, modelling the effect of TEL-AML1 by retroviral
transduction in normal cord blood suggested that the founding chromosomal translocation was likely
sufﬁcient to induce the preleukaemic population found in the ‘healthy’ twin. A follow-up study in the
same twin pair used genome-wide copy number alterations (CNA) proﬁling to identify three potential
‘driver’ CNA in the leukaemic cells. FISH analysis did not detect these three CNA in the ‘healthy’ twin’s
preleukaemic cells, supporting the hypothesis that the preleukaemic cells diverged genetically after the
initiating chromosomal translocation, with subsequent events leading to the clonal evolution of the
affected twin’s leukaemia (Bateman et al., 2010). A further whole genome sequencing study assessed
the genomic proﬁles of monozygotic twins with ALL, and found that while twins share the ﬁrst
initiating lesion (occurring in utero), each twin then acquire distinct non-coding mutational changes
postnatally that drive leukaemogenesis (Ma et al., 2013).
Current epidemiological studies have limitations for the demonstration of the AOP in pregnant
women even in the absence of a clear characterisation of exposure. While experimental models are in
accordance with the AOP, the available evidence shows a large number of (epi)genetic and host
factors potentially modifying the pathogenesis of childhood leukaemia. The translational biology of B
cell precursor ALL has been investigated using comparative genomics and functional approaches
(Duque-Afonso et al., 2015), which has allowed to recapitulate experimentally the multistep
pathogenesis of ALL previously inferred from genomic analyses and highlight key cooperating
oncogenic pathways.
When known mutations occur in non-stem cells, they will quickly be lost from the haematopoietic
pool due to the natural course of differentiation and cell death. In contrast, a mutation in a stem cell
may persist, and the mutated clone may expand, facilitating further clonal progression until a
leukaemic stem cell with extensive self-renewal ability develops (Jan and Majeti, 2013).
Table B.6: Temporality concordance table
Model
(concentration)
MIE
Unknown
KE1
In utero
induction of
chromosomal
translocations
KE2
Differentiation
blockage
KE3
Clonal
expansion
AO
Childhood
leukaemia
Conditional activation of
E2A-PBX1 in the B cell
compartment of mice(a)
+ + + ALL development
(similar to
human
E2A-PBX1+
leukaemias)
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Model
(concentration)
MIE
Unknown
KE1
In utero
induction of
chromosomal
translocations
KE2
Differentiation
blockage
KE3
Clonal
expansion
AO
Childhood
leukaemia
Transplantation of TEL-
AML1 transduced human
cord blood cells into NOD/
SCID mice(b)
+ +
Mice exhibited
features of
preleukaemic
phase of pre-B
cell ALL(b)
-
Human peripheral
lymphocytes exposed to
0.1–10 lg/mL isofenphos
for 1 h
Dose-dependent damage
to chromosomal DNA
could lead to genomic
instability and
leukaemogenesis(c)
+ - - -
Human K562 cells exposed
to 0.1 lM of diazinon
Hypermethylation of genes
involved in cell cycle arrest
(cyclin-dependent kinase
inhibitor 1A and CDKN1C)
as well as tumour
suppressor genes (p53
and PTEN)(d)
- - - -
1–100 lM chlorpyrifos for
up to 24 h
Dose- and time-dependent
double-strand DNA breaks
in HSCs (and MLL
rearrangements)(e)
+ - - -
Human T-cell leukaemia
Jurkat cells exposed to
methyl-pyrazole
insecticides for 1 h
Increased double DNA
breaks (possibly due to
oxidative stress)(f)
- - - -
CEM x 174 cell line, (a
hybrid of human T and B
cells), exposed to 50 lM
heptachlor, chlordane or
toxaphene for 24–36 h
Decrease in levels of the
tumour suppressors p53
and Rb(g),(h)
? - - -
Human peripheral
lymphocytes exposed to a
commercial fungicide
karathane (dinocap) at
20 lg/mL for 24 h
Increased
chromosomal
aberrations,
formation of sister
chromatid
exchanges and
decreased mitotic
index(i)
- - -
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B.3. Strength, consistency, and speciﬁcity of association of AO and
MIE
Regarding the experimental models and genome-wide association studies on childhood leukaemia,
strength, consistency and speciﬁcity of association of AO and MIE is rather strong in spite of the gap
of knowledge on the aetiological factors involved. Although direct observations on the initial in utero
MIE are not possible, there is inferential evidence from animal and in vitro cellular studies suggesting
strongly that childhood leukaemia recapitulates to a large extent the development of the human
disease.
Under the current paradigm, the ﬁrst initiating oncogenic mutation usually involves structural or
numerical chromosomal alterations, impairing normal cell differentiation, while secondary hits more
commonly comprise mutations affecting developmentally regulated master transcription factors or
membrane-proximal signalling pathways conferring proliferation and survival advantages to the
differentiation-blocked clone. The development of leukaemia requires the activation of cell proliferation
in addition to differentiation blockage.
The consistent ﬁnding of a number of chromosomal translocations across studies indicates that they
are needed for the development of the disease, although not enough by themselves. There is no
alternative explanation for this ﬁnding because a reasonable conﬁdence for chance or confounding is
lacking. Besides, the identiﬁed chromosomal damage (and no other) has to occur in a particular cell
(fetal liver HSPCs) and in a particular time window, as otherwise the disease will not develop.
Model
(concentration)
MIE
Unknown
KE1
In utero
induction of
chromosomal
translocations
KE2
Differentiation
blockage
KE3
Clonal
expansion
AO
Childhood
leukaemia
Studies on the Kasumi-1
cell line, which harbours
an AML1–ETO
translocation
The
differentiation
block induced by
AML1–ETO is
due in part to its
ability to
physically bind
to and inactivate
the master
myeloid
transcription
factor PU.1(j)
- -
(a): A conditional E2A-PBX1 allele was engineered to recombine human PBX1a cDNA into the mouse E2A locus to create an E2A-PBX1 fusion gene
(Duque-Afonso et al., 2015).
(b): Hong D, Gupta R, Ancliff P, Atzberger A, Brown J, Soneji S, Green J, Colman S, Piacibello W, Buckle V, Tsuzuki S, Greaves M and Enver T, 2008.
Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia. Science, 319, 336–339.
(c): Williams RD, Boros LG, Kolanko CJ, Jackman SM and Eggers TR, 2004. Chromosomal aberrations in human lymphocytes exposed to the
anticholinesterase pesticide isofenphos with mechanisms of leukemogenesis. Leukemia Research, 28, 947–958.
(d): Zhang X, Wallace AD, Du P, Lin S, Baccarelli AA, Jiang H, Jafari N, Zheng Y, Xie H, Soares MB, Kibbe WA and Hou L, 2012. Genome-wide study
of DNA methylation alterations in response to diazinon exposure in vitro. Environmental Toxicology and Pharmacology, 34, 959–968.
(e): Lu C, Liu X, Liu C, Wang J, Li C, Liu Q, Li Y, Li S, Sun S, Yan J and Shao J, 2015. Chlorpyrifos Induces MLL Translocations Through Caspase 3-
Dependent Genomic Instability and Topoisomerase II Inhibition in Human Fetal Liver Hematopoietic Stem Cells. Toxicological Sciences, 147,
588–606.
(f): Graillot V, Tomasetig F, Cravedi JP and Audebert M, 2012. Evidence of the in vitro genotoxicity of methyl-pyrazole pesticides in human cells.
Mutation Research-Genetic Toxicol Environ Mutag, 748, 8–16.
(g): Rought SE, Yau PM, Chuang LF, Doi RH and Chuang RY, 1999. Effect of the chlorinated hydrocarbons heptachlor, chlordane, and toxaphene on
retinoblastoma tumor suppressor in human lymphocytes. Toxicology Letters, 104, 127–135.
(h): Rought SE, Yau PM, Schnier JB, Chuang LF and Chuang RY, 1998. The effect of heptachlor, a chlorinated hydrocarbon insecticide on p53 tumor
suppressor in human lymphocytes. Toxicology Letters, 94, 29–36.
(i): Celik M, Unal F, Yuzbasioglu D, Ergun MA, Arslan O and Kasap R, 2005. In vitro effect of karathane LC (dinocap) on human lymphocytes.
Mutagenesis, 20, 101–104.
(j): Vangala RK, Heiss-Neumann MS, Rangatia JS, Singh SM, Schoch C, Tenen DG, Hiddemann W and Behre G, 2003. The myeloid master regulator
transcription factor PU.1 is inactivated by AML1–ETO in t(8;21) myeloid leukemia. Blood, 101, 270–277.
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B.5. Uncertainties and Inconsistencies
• Although the causes of the speciﬁc genetic events leading to ALL formation are not known,
numerous exposure-dependent risk factors for childhood ALL have been proposed, including
pesticide exposure. These risk factors can be classiﬁed based on their relationship to potentially
critical exposure windows (i.e. preconceptional, prenatal, and postnatal stages). [KER1]
• As in utero evidence is difﬁcult to obtain in humans, mouse models are used instead.
• Limitations of transgenic animal models faithfully recapitulating all the aspects of human pB-
ALL need to be recognised. The reproducibility and accuracy of these models for human
responses have yet to be validated, so their application to elucidate postnatal exposure effects
of exogenous agents on childhood ALL should be cautiously approached. Mouse models in
which the initiating oncogenic alteration(s) is not directed to the right cell-of-origin are unlikely
to accurately recapitulate the aetiology of the human disease and will originate an inaccurate
model of human leukaemia (Hauer et al., 2014).
• One important question in leukaemia genomics is the identity of leukaemia-initiating mutations
that result in preleukaemic clones. Owing to the technical challenge of distinguishing and
isolating distinct cancer subclones, many aspects of clonal evolution are poorly understood,
including the diversity of different subclones in an individual cancer, the nature of the
subclones contributing to relapse, and the identity of precancerous mutations. Studies of
paediatric ALL demonstrated that in individual patients there are multiple genetic subclones of
leukaemia-initiating cells, with a complex clonal architecture which limits development of a
consistent AOP. [KER3]
• The main challenge in developing AOPs for childhood leukaemia is the complex nature of the
disease. For example, a tumour suppressor gene could be mutated or transcriptionally
inactivated to trigger leukaemogenesis. Different genetic aberrations affect different subtypes
of childhood leukaemia (even between cell-speciﬁc B-cell and T-cell ALL) as almost all of the
evaluated human studies report percentages of a speciﬁc mutation found in cohorts, meaning
there is no single mutation responsible for the disease.
• It remains to be demonstrated whether subpopulations of acute leukaemia cells exhibit epigenetic
heterogeneity, but it seems very likely that epigenetic diversity contributes to subclonal
heterogeneity in acute leukaemia. Such epigenetic subclones likely differ in their proliferation,
self-renewal, differentiation and response to therapy, adding an additional dimension to the
functional heterogeneity of leukaemia subclones (Jand and Majety, 2013). [Clones]
• While there are emerging studies implicating epigenetics as an inﬂuential factor in childhood
leukaemia, it is not clear at which point epigenetics inﬂuences childhood leukaemia
pathogenesis, i.e. as a MIE or later as an intermediate event. For example, DNA
hypermethylation of tumour suppressor genes leading to their decreased expressions can
occur early in childhood leukaemia pathogenesis to facilitate the growth of leukaemic cells, or
altered expressions of microRNAs might be inﬂuenced by earlier events (e.g.), resulting in
alterations in haematopoiesis or inhibition of apoptosis. Therefore, the putative relevance of
epigenetics needs to be further evaluated before it can be considered in the AOP development
for childhood leukaemia. [Epigenetics]
• A detailed understanding of leukaemogenesis requires the development of experimental
models that can accurately model this process. As a complement to work in cell lines and in
mice, there is a need for oncogenes and chromosomal translocations to be studied in the
appropriate cellular context, that of primary human haematopoietic cells. Retroviral-mediated
transduction of primary human haematopoietic cells followed by their transplantation in vivo
has emerged as a feasible approach to study the process of human leukaemogenesis (Kennedy
and Barabe, 2008). [Experimental models]
B.6. Quantitative Considerations
The WOE analysis indicates that some KEs and KERs lack especially experimental evidence, but
overall the analysis supports the qualitative AOP. The strong element in the development of the
qualitative AOP is that it can partially be based on animal models recapitulating many crucial features
of childhood leukaemia and genome-wide association studies. The absence of a MIE clearly deﬁned is
a major limitation. The lack of sufﬁcient experimental data and uncertainties in quantitative information
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from available studies makes it difﬁcult to build convincing dose (concentration)-response and
response–response relationships and to identify possible practical thresholds for stressors.
There is a need for an adequate and robust experimental model system where relationships
between doses, concentrations and responses can be evaluated within a temporal framework of the
AOP.
B.7. Applicability of the AOP
Even in the absence of a mechanistic understanding in regard to the MIE, the proposed AOP might
be applied to pesticide-related leukaemia not only in children but also in adults, although in the latter
case chromosomal translocations are acquired in the postnatal life (the persistence of prenatal
chromosomal translocations does not play a role in adult leukaemogenesis). Based on the rather
consistent epidemiological evidence on human exposure to pesticides and the risk of childhood
leukaemia, it is possible that at least a subset of acute childhood leukaemias may be caused by
environmental exposure to pesticides. Consequently, the proposed AOP may be partially applicable to
these situations, but should be supported with an understanding of the mechanistic processes
underlying the direct or indirect interaction of pesticides (or their metabolites) with DNA.
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